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Study of Maintenance Olaparib Monotherapy in Patients with gBRCA 
Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed 




      
Study centre(s) and number of patients planned: Approximately 80 centres worldwide will 
be initiated to randomise approximately 145 patients with germline BRCA1/2 mutations and 
metastatic adenocarcinoma of the pancreas (hereafter referred to as pancreas cancer).  
Additional countries and centres may be added dependent on recruitment rates. 
Study period  Phase of development 
Estimated date of first patient enrolled Q2 2014 III 
Estimated date of last patient completed Q2 2017  
 
Besides the main study, an exploratory study looking at the feasibility of assaying for and 
determining the prevalence of tumour tissue biomarkers (including but not limited to somatic 
BRCA1/2 mutations, methylation and/or other HRD biomarkers) will be done on tissue 
samples submitted by patients screened for gBRCA. The information from this exploratory 
analysis may potentially guide future pancreas cancer Olaparib studies. 
 
Objectives 
Primary Objective: Outcome Measure: 
• To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo by progression free survival 
(PFS) 
• Progression Free Survival (PFS) by BICR 
using modified RECIST 1.1 
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Secondary Objective: Outcome Measure: 
• To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo 
• Overall Survival (observed and predicted 
using observed PFS and OS data) 
• Time from randomisation to second 
progression (PFS2) 
• Time from randomisation to first subsequent 
therapy or death (TFST) 
• Time from randomisation to second 
subsequent therapy or death (TSST). 
• Time from randomisation to study treatment 
discontinuation or death (TDT) 
• Objective Response Rate by BICR using 
modified RECIST 1.1 criteria for evaluable 
patients 
• Disease Control Rate at 16 weeks by BICR 
using modified RECIST 1.1 criteria 
• To assess the effect of Olaparib on the 
Health-related Quality of Life 
(HRQoL) as measured by EORTC 
QLQ-C30 global QoL scale. 
• Adjusted mean change from baseline in 
global QoL score from the EORTC-QLQ-
C30 questionnaire 
 
Safety Objective: Outcome Measure: 
• To assess the safety and tolerability of 
Olaparib maintenance monotherapy 
• Adverse event (AE), physical examination, 
vital signs including blood pressure (BP), 
pulse, electrocardiogram (ECG) and 
laboratory findings including clinical 
chemistry and haematology 
 
Exploratory Objective: Outcome Measure: 
• To assess the effect of Olaparib on 
functioning as measured by the EORTC 
QLQ-C30 functioning domains (physical, 
• Adjusted mean change from baseline on 
EORTC-QLQ-C30 functioning domains 
(physical, role, cognitive, emotional, 
social), on EORTC-QLQ-C30 + PAN26 
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role, cognitive, emotional and social). 
• To assess the effect of Olaparib on 
pancreas cancer symptoms as measured 
by the EORTC QLQ-PAN26 items and 
scales. 
• To assess clinically relevant symptoms as 
measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, 
weight loss (or difficulty gaining 
weight/loss of appetite), jaundice 
• To assess change in performance status as 
measured by the ECOG Performance 
Status scale 
symptom scales and items (pain, fatigue, 
nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice and on 
performance status measured by the 
ECOG Performance Status scale 
• To investigate the health economic 
impact of treatment and the disease on 
hospital related resource use and health 
state utility 
• Number, type and reason of 
hospitalisations and hospital attendances, 
procedures undertaken and hospital 
length of stay.  
• Health state utility derived from the 
HRQL instrument, the EuroQoL EQ5D 
• To explore methods of estimating overall 
survival (OS) adjusting for the impact of 
the control arm receiving subsequent 
Polyadenosine 5’diphosphoribose [poly 
(ADP ribose)] polymerise (PARP) 
inhibitors or imbalances between the 
treatment arms for other potentially 
active agents.  
• Overall survival adjusted for impact of 
subsequent PARP inhibitors (or other 
potentially active investigational agents 
(if appropriate, to support reimbursement 
appraisals) 
• To determine the frequency of and 
describe the nature of BRCA mutation/s 
in tumour samples and to compare this 
with germline BRCA mutation status. 
• BRCA1 and/or BRCA2 mutation status 
in tumour 
• To identify tumour tissue based 
biomarkers (including but not limited to 
somatic BRCA1/2 mutations, BRCA 
methylation and/or other HRD 
biomarkers) that could be used to guide 
future patient segmentation approaches 
• Potential tissue biomarkers identified 
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for development 
• Future exploratory research into factors 
that may influence development of cancer 
and/or response to treatment (where 
response is defined broadly to include 
efficacy, tolerability or safety) may be 
performed on the collected and stored 
archival tumour samples (if available), 
blood samples at day 1 and on disease 
progression or on residual tissue material 
collected as part of the study. 
 
The exploratory analyses may not be reported in the clinical study report (CSR).  If not, they 
will be reported separately. 
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Study Flow Chart  
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Target Patient population 
All patients randomised in the study will be selected based on the following 2 principles:  
• Genetic selection:  Documented germline mutation in BRCA1 or BRCA2 that is 
predicted to be deleterious or suspected deleterious (known or predicted to be 
detrimental/lead to loss of function).  Patients with gBRCA1 and/or gBRCA2 mutations 
that are considered to be non detrimental (eg, “Variants of uncertain clinical 
significance” or “Variant of unknown significance” or “Variant, favor polymorphism” 
or “benign polymorphism,” etc) will not be eligible for the study.  
• Treatment setting: All eligible patients must have metastatic gBRCAm pancreas 
cancer, must have received a minimum of 16 weeks of platinum based treatment and 
must have no evidence of progression based on investigator’s opinion. Study treatment 
will be started after randomisation as soon as possible but no less than 4 and no more 
than 8 weeks after last dose of first line chemotherapy. Tumour response during study 
treatment will be assessed using modified RECIST 1.1.  Baseline assessments will be 
performed using CT or MRI scans of the chest, abdomen and pelvis and should be 
performed no more than 28 days prior to start of study treatment, and as close as 
possible to randomisation. Follow-up assessments should be performed every 8 weeks 
(±1 week) for 40 weeks and then every 12 weeks ± 1 week relative to date of 
randomisation, until objective disease progression as defined by modified RECIST 1.1. 
An exploratory study looking at the feasibility of assaying for and determining the prevalence 
of tumour tissue biomarkers (including but not limited to somatic BRCA1/2 mutations, 
methylation and/or other HRD biomarkers) will be done on tissue samples submitted by 
patients screened for gBRCA. The information from this exploratory analysis may potentially 
guide future pancreas cancer Olaparib studies. 
After confirmation of eligibility, patients will be randomised (using an IVRS) in a 3:2 ratio 
(Olaparib:placebo) to the treatments as specified below: 
• Olaparib tablets po. 300 mg twice daily 
• Placebo tablets twice daily 
Investigational product, dosage and mode of administration 
Olaparib is available as a green film-coated tablet containing 150 mg or 100 mg of Olaparib.  
Patients will be administered study treatment orally at a dose of 300 mg twice daily (bid). The 
planned dose of 300 mg bid will be made up of two x 150 mg tablets bid with 100 mg tablets 
used to manage dose reductions.  
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Comparator, dosage and mode of administration 
Placebo will be available as green film-coated tablets matching the Olaparib tablets. These 
should be taken as per instructions for Olaparib tablets. 
Duration of treatment 
Patients should continue to receive study treatment until objective radiological disease 
progression per modified RECIST 1.1 as assessed by the investigator or unacceptable toxicity 
and they do not meet any other discontinuation criteria.  Patients who are determined to have 
progressed according to modified RECIST 1.1 criteria by the Investigator will have scans 
centrally reviewed for confirmation of objective disease progression. If disease progression is 
not confirmed at central review one additional RECIST assessment will be requested 
preferably at the next scheduled RECIST visit. Once patients have been discontinued from 
study treatment, other treatment options will be at the discretion of the investigator. Patients 
and investigators will not be routinely unblinded to study treatment prior to the final OS 
analysis. It is expected that many if not most patients will be restarted on a platinum based 
regimen at progression on study therapy. Whatever the regimen, they will be assessed for 
PFS2 and followed for survival.   
Statistical methods 
Approximately 145 patients will be randomised (3:2 ratio of Olaparib:placebo) and the 
primary PFS analysis will occur once approximately 89 PFS events (confirmed via a central 
review) have occurred.   A single interim PFS analysis for superiority and futility will be 
performed when 50% of the final number of progressions has been reached (approximately 45 
PFS events).  The interim analysis will be performed by an Independent Data Management 
Committee (IDMC) and full details will be provided in the IDMC charter.   
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.26% alpha (1-sided) (accounting for a single interim PFS 
analysis), with 3:2 randomisation (Olaparib:placebo). Assuming PFS is exponentially 
distributed, a PFS HR of 0.54 equates to a 3.4 month improvement in median PFS over an 
assumed 4 month median PFS for placebo.  At the interim analyses, 0.5% of alpha (1-sided) 
will be spent, and controlling the type I error across the two time points, 89 PFS events will be 
required at the final analyses.   
Statistical significance will be declared at the interim analysis if the 1-sided p<0.005.  
Assuming 45 PFS events at the interim, a HR ≤ 0.46 would equate to a 1-sided p<0.005.  If 
the null hypothesis for PFS is not rejected at the interim analyses time point then PFS will be 
tested again when approximately 89 PFS events have occurred.  The final significance level 
will be determined accounting for the actual correlation between the interim and final PFS 
analyses. To ensure that the type I error will be controlled at 2.5% 1-sided level, if the interim 
occurs at exactly 50% of events and the number of PFS events at the final analysis is as 
expected then the 1-sided significance level to be applied for the final analysis would be 
2.26% (Stone 2010).  Assuming 89 PFS events, a HR ≤ 0.65 would equate to a 1-sided p-
value <0.0226. 
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Assuming that the study accrual period will be approximately 15 months, 89 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study.  It is estimated that 45 PFS events will occur approximately 13 to 14 
months after the first patient enters the trial. 
Patients are to be followed for the final analysis of OS (when approximately 106 death events 
have occurred).  With 106 OS events the study has 80% power to show a statistically 
significant difference in OS at the 2.5% level (1-sided) if the assumed true treatment effect is a 
HR 0.57; this translates to an approximate 6 month improvement in median OS over an 
assumed 8 month median OS on placebo, assuming OS is exponentially distributed. 
The primary statistical analysis of the efficacy of Olaparib will include all randomised patients 
(Full Analysis Set; FAS) and will compare the treatment groups on the basis of randomised 
treatment, regardless of the treatment actually received. In addition, key sensitivity analyses of 
efficacy endpoints will be performed in the subgroup of patients in the FAS that have a 
gBRCA mutation confirmed by the Myriad test. When assessing safety and tolerability, 
summaries will be produced based on the Safety Analysis Set.  This will include all patients 
who receive at least one dose of randomised treatment (Olaparib or placebo).  The safety data 
will be summarised descriptively and will not be formally analysed. 
PFS will be analysed using a log rank test.  The HR together with its 95% confidence interval 
(CI) and p-value will be presented (a HR less than 1 will favour Olaparib).  The primary 
analysis will be based on a blinded independent central review (BICR) of disease progression 
by modified RECIST 1.1; however, a sensitivity analysis will be performed using the 
investigator-recorded assessment. 
Subgroup analyses will be conducted to assess consistency of treatment effect across potential 
prognostic factors (see Section 8.8.2 for all predefined subgroups).  An analysis will not be 
performed if there are too few events available for a meaningful analysis of a particular 
subgroup (ie, if there are less than 20 events in a subgroup). 
OS analyses will be performed at the same time as the interim (if PFS null hypothesis 
rejected) and final analysis of PFS and will use the same methodology and model as PFS.  A 
final analysis of OS will be performed when approximately 106 death events have occurred 
and a multiplicity adjustment will be made to account for the different analyses. At the time of 
the PFS analysis, a predicted treatment effect for OS at the final analysis will be derived using 
a weighted sum of the observed OS data and the predicted OS value using PFS data.  
Exploratory analyses of OS which attempt to adjust for any potential confounding impact of 
subsequent use of PARP inhibitors on the control arm may be performed if an appropriate 
proportion of patient’s on the control arm receive such treatments and sufficient information is 
collected on subsequent therapy use. 
PFS2 analyses will be performed at the same time as the interim and final analyses of PFS, 
and at the time of the final analysis of OS.  PFS2 will be analysed using the same 
methodology and model as PFS.  
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In order to describe the nature of the benefits of Olaparib maintenance treatment, PFS, PFS2 
and OS will be tested at a 1-sided significance level of 2.5%. However, in order to strongly 
control the type I error, a multiple testing procedure will also be employed where PFS is tested 
first using the full test mass and OS will be tested if the null hypothesis for PFS is rejected. 
Secondary analyses of time to treatment discontinuation, time to first subsequent therapy or 
death, and time to second subsequent therapy or death will be provided, using the same 
methodology as specified for the primary analyses of PFS; however no multiplicity 
adjustment will be applied as these are viewed as supportive endpoints. 
Objective tumour response rates and disease control rates (based on central review) will be 
summarised for the two treatment arms.  In addition, the investigator reported response rates 
will also be summarised.  
Patient Reported Outcomes 
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data. 
The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales.  
Time to global QoL and pancreatic pain scale deterioration will be analysed using the same 
methodology and model as described for the primary analysis of PFS.  Global QoL and PAN-
26 pain scale improvement rate will be analysed using a logistic regression model.   
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group. 
As supportive analyses, change from baseline in global QoL and pancreatic pain scale scores 
will be analysed using a mixed model for repeated measures (MMRM) analysis of all of the 
post-baseline scores for each visit. 
Health Economics 
An exploratory health economic analysis of resource use will be estimated, including 
descriptive statistics relating frequency of hospitalisations and hospital admission, type of 
attendance, length of stay and procedures undertaken, and the primary symptom/reason for the 
attendance.  For utility, descriptive statistics, graphs and listings will be reported for health 
state utility by visit as well as change in these scores from baseline. To support future 
economic evaluations of Olaparib, additional appropriate analyses may be undertaken, for 
example, mean health state utility pre and post treatment and pre and post progression. 
Biomarkers 
The most important biomarker research will be done on non-randomised and 
randomised patients.  Screened patients will submit tumour samples for tBRCA/BRCA 
methylation/ HRD analyses.  A combination of evaluability, prevalence and sensitivity for 
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known gBRCA will be used to determine the feasibility of investigating Olaparib in future 
studies. 
Appropriate summaries of exploratory outcome variables and data listings will be produced 
and compared across the two treatment arms. Graphical methods will be widely used in 
exploring the characteristics and relationships of outcome variables. 
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LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 




AE Adverse event (see definition in Section 6.1) 
ALP Alkaline phophatase 
ALT Alanine aminotransferase 
AML Acute myeloid leukaemia 
ANC Absolute neutrophil count 
APTT Activated partial thromboblastin time 
AST Aspartate aminotransferase 
AUC Area under the plasma concentration-time curve 
Baseline Refers to the most recent assessment of any variable prior to dosing with 
study treatment 
BICR Blinded Independent Central Review 
bid Bis in die (twice daily) 
BoR Best Overall RECIST Response 
BP Blood pressure 
gBRCA germline Breast Cancer susceptibility gene 
BRCA mutation or 
BRCAm 
Breast Cancer susceptibility gene mutation (see gBRCA mutation or 
gBRCAm) 
BUN Blood urea nitrogen 
CHO Chinese hamster ovary 
CI Confidence Interval  
CR Complete Response 
CRF Case Report Form (electronic/paper) 
CRO Clinical Research Organisation 
CSA Clinical Study Agreement 
CSR Clinical Study Report 
CT Computed Tomography 
CTCAE Common Terminology Criteria for Adverse Event 
DAE Discontinuation of Investigational Product due to Adverse Event 
DCIS ductal carcinoma in situ 
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DCO Data Cut Off 
DCR Disease control rate 
DNA Deoxyribonucleic acid  
DSB Double strand break 
ECG Electrocardiogram 
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC) 
E-code Enrolment code (allocated by IVRS/IWRS) 
ECOG Eastern Cooperative Oncology Group: A performance status using scales 
and criteria to assess how a patient’s disease is progressing 
eCRF Electronic Case Report form 
EORTC QLQ-C30 The EORTC QLQ-C30 is a questionnaire developed to assess the quality of 
life of cancer patients 
EORTC QLQ-PAN26 The EORTC QLQ-PAN26 module comprises 26 questions assessing pain, 
dietary changes, jaundice, altered bowel habit, emotional problems related 
to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, 
dry mouth, taste changes) 
EQ-5D-5L/ EQ-5D EuroQoL five dimensions, five level (EQ-5D-5L) health state utility index 
FAS Full Analysis Set 
FDA Food and Drug Administration 
FFPE Formalin Fixed Paraffin Embedded 
FSH Follicle stimulating hormone 
gBRCA mutation or 
gBRCAm 
The term "gBRCA mutation" is used to refer to a germline BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 
recommendations for standards for interpretation and reporting of sequence 
variants  
gBRCA wt gBRCA wildtype (patients without evidence of BRCA1 or BRCA2 
deleterious or suspected deleterious mutations) 
GCP Good Clinical Practice 
G-CSF Granulocyte colony-stimulating factor 
GGT Gamma glutamyl transferase 
GMP Good Manufacturing Practice 
GRand AZ Global Randomisation system 
Hb Haemoglobin  
HDPE High-density polyethylene 
HIV Human Immunodeficiency Virus 
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HR Hazard Ratio 
HRD Homologous recombination repair deficiencies 
HRQoL Health-related Quality of Life 
IATA International Air Transport Association  
IB Investigator’s brochure 




If a study is conducted in several countries the International Co-ordinating 
Investigator is the Investigator co-ordinating the investigators and/or 
activities internationally.  
IDMC    Independent Data Monitoring Committee 
INR International Normalised Ratio 
IPCW Inverse Probability of Censoring Weighting 
IRB Institutional Review Board 
IVRS Interactive Voice Response System 
IWRS Interactive Web Response System 
KM Kaplan Meier 
LDH Lactic dehydrogenase 
LH Luteinizing hormone 
LIMS Laboratory Information Management System 
m Metre 
MCH Mean cell haemoglobin 
MCHC Mean cell haemoglobin concentration 
MCV Mean cell volume 
MDS Myelodysplastic syndrome 
mg Milli-gram 
MRI Magnetic resonance imaging 
nab nanoparticle albumen bound 
NCI National Cancer Institute 
NE Not evaluable 
NTL Non-target lesions 
OAE Other Significant Adverse Event (see definition in Section 8.4.1) 
ORR Objective response rates 
OS Overall survival 
PARP Polyadenosine 5’diphosphoribose [poly (ADP ribose)] polymerisation 
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PD Progressive disease 
PFS Progression Free Survival 
p.o. Per os (by mouth, orally) 
PR Partial response 
QoL Quality of Life 
RECIST Response Evaluation Criteria In Solid Tumours.  This study will use 
modified RECIST version 1.1 
RPSFT Rank Preserving Structural Failure Time 
SAE Serious adverse event (see definition in Section 6.2). 
SAP Statistical Analysis Plan 
SD Stable disease 
SSB Single strand break 
SUSARs Suspected Unexpected Serious Adverse Reactions 
Study treatment Olaparib or control arm chemotherapy 
tBRCA mutation or 
tBRCAm 
The term "tBRCA mutation" is used to refer to a somatic tumour BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 
recommendations for standards for interpretation and reporting of sequence 
variants  
TL Target lesions 
US United States 
WBC White blood cells 
WBDC Web Based Data Capture 
wt Wildtype (patients without evidence of BRCA1 or BRCA2 deleterious or 
suspected deleterious mutations) 
 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1 
Date 31 March 2014 
24(121) 
1. INTRODUCTION 
1.1 Background and rationale for conducting this study 
1.1.1 Pancreas cancer and its treatment  
Pancreas cancer is a life-threatening disease and is the fourth leading cause of cancer death in 
the West.  In 2013, it is estimated that there were 45,220 newly diagnosed pancreas cancer 
cases in the US, and approximately 38,460 people deaths from pancreas cancer (American 
Cancer Society 2013).  Worldwide, it was estimated that 266,000 people died of pancreas 
cancer in 2008 (Jemal A et al 2011). 
The poor prognosis of pancreas cancer (~90% of patients who are diagnosed will die of the 
disease) is a function of late presentation of the disease when inoperable/ locally advanced or 
metastatic. Furthermore treatment of metastatic pancreas cancer even with the most “active” 
regimens such as FOLFIRINOX (Conroy et al 2011) or gemcitabine + nab paclitaxel (Von 
Hoff et al 2013) is associated with median survivals of less than one year, and for single agent 
treatments at best only 6 months. Unfortunately the toxicity of the most active combination 
chemotherapy regimens limits the duration of exposure to patients even if benefiting from the 
treatment. The neurotoxicity of both FOLFIRINOX and gemcitabine + nab paclitaxel in the 
former case generally leads to discontinuation of some or all of the drugs at or before 6 
months of treatment and in the later case dose attenuation.  The FOLFIRINOX study 
recommended no more than a total of 6 months of chemotherapy for patients who had a 
response (Conroy et al 2011).Furthermore there are few if any established second line 
regimens available (American Cancer Society 2013) and benefit if any, is at most a few 
months of survival (Rahma et al 2013). Despite the development of more “active” regimens 
for first treatment of metastatic pancreatic cancer in the last decade, their limited absolute 
benefit and significant toxicity strongly suggest that improving the results of initial therapy of 
metastatic pancreas cancer constitutes an unmet medical need. Furthermore to date there has 
been no marker, clinical or molecular that would predict for increased likelihood of benefit 
from systemic therapies for pancreas cancer.  
Although carriers of deleterious germline mutations of the BRCA1 and particularly BRCA2 
gene are known to have an increased risk of developing pancreas cancer (The Breast Cancer 
Linkage Consortium 1999, Goggins M. et al 1996), the prevalence of  gBRCAm in the 
unselected cases of pancreas cancer is unclear but likely less than 5 % In a tissue based study, 
7% of patients with resected pancreas cancer or human xenografts had “germline” mutations 
in their tumour (Goggins M. et al 1996) but this cohort may not represent the typical 
unselected cases and the prevalence is likely somewhat lower.  There are specific populations, 
however, where the association is much stronger. In Ashkenazi Jewish patients with pancreas 
cancer, the prevalence of gBRCAm is 6-10% in unselected patients (Ferrone CR et al 2009, 
Ozcelik et al 1997,) and 15% in patients with a family history of the disease (Sadler ZK. 
2012). In pancreas cancer patients with a family history of the disease, reported prevalence of 
carrying a germline BRCA2 mutation may be as high as 17-19% (Murphy KM et al 2002, 
Hahn et al 2003).Given the small size of the gBRCAm subpopulation in pancreas cancer, 
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information comparing the natural history of this group with the overall pancreas cancer 
population is minimal. One study of the natural history of Ashkenazi Jews with pancreas 
cancer treated with surgery (most of whom eventually died of the disease) could find no 
difference in survival between those who had germline BRCAm (n=8) vs. those who did not 
(n=137). The study however did not extend beyond 2004 and did not include patients treated 
with more modern chemotherapies (Ferrone CR et al 2009). In a large study of the natural 
history of BRCAm associated pancreas cancer,  the median all–stage overall survival (OS) for 
58 patients was 14 months (95% CI 10-23 months). Median OS for patients with stage 1-2 
disease has not been reached at 60 months. Median OS for stage 3-4 was 12 months (95% CI 
6-15). Superior OS was observed for patients with stage III and IV disease treated with 
platinum versus those treated with non-platinum chemotherapies (22 vs 9 months; p=0.039 
(Golan et al unpublished data). There are no approved treatments for patients with germline 
BRCA1/2 mutations and these patients are treated with regimens used for standard advanced 
pancreas (Lowery M et al 2011). 
Recent data suggest there may also be a number of pancreas cancer patients’ tumours with 
ATM defects or a gBRCA-like or HRD phenotype (Cowley et al 2013).  The development of a 
test to identify such tumours may broaden the patient population which could benefit from 
PARP inhibitors. Obtaining tumour tissue to look for the prevalence these other potential 
markers of drug sensitivity is another unmet need in advancing therapy of this serious illness. 
1.1.2 Chemotherapy use in advanced pancreas cancer  
Chemotherapy for metastatic pancreas cancer has modest, at best, impact on PFS and OS. The 
“best” regimens for use as initial treatment of metastatic disease, FOLFIRINOX or 
gemcitabine + nab paclitaxel have respectively PFS’s of 6.4 and 5.5 mos. and OS’s of 11.1 
and 8.5 mos. (Conroy et al 2011, Von Hoff et al 2013). Toxicity particularly on the platinum 
based regimen was substantial (80% had hematologic toxicity, 45% ≥grade 3; 70% had 
peripheral neurotoxicity, 9% ≥grade 3) and led to dose reductions and treatment 
discontinuations. It is of note that median number of FOLFIRINOX cycles given was 10 (ie. 
~5 months of treatment) but the median PFS was 6.4 months suggesting some discontinuation 
prior to the planned 12 cycles and evidence of progression. Nevertheless platinum based 
regimens are widely used as first line therapy of metastatic pancreas cancer.  
1.1.3 PARP inhibition as a target for BRCA mutation positive cancer 
Investigators should be familiar with the current Olaparib (AZD2281) Investigator Brochure 
(IB). 
Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5’diphosphoribose [poly (ADP 
ribose)] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an 
oral therapy, both as a monotherapy (including maintenance) and for combination with 
chemotherapy and other anti-cancer agents. 
PARP inhibition is a novel approach to targeting tumours with deficiencies in DNA repair 
mechanisms.  PARP enzymes are essential for repairing DNA single strand breaks (SSBs).  
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Inhibiting PARPs leads to the persistence of SSBs, which are then converted to DNA double 
strand breaks (DSBs) during the process of DNA replication.  During the process of cell 
division, DSBs can be efficiently repaired in normal cells by homologous recombination 
repair.  Tumours with homologous recombination deficiencies (HRD), such as ovarian cancers 
in patients with gBRCA1/2 mutations, cannot accurately repair the DNA damage, which may 
become lethal to cells as it accumulates.  In such tumour types, Olaparib may offer a 
potentially efficacious and less toxic cancer treatment compared with currently available 
chemotherapy regimens.  
gBRCA1 and gBRCA2 defective tumours are intrinsically sensitive to PARP inhibitors, both in 
tumour models in vivo (Rottenberg et al 2008, Hay et al 2009) and in the clinic (Fitzsimmons 
D et al 1999, Fong et al 2009, Fowble et al 2001). The mechanism of action for Olaparib 
results from the trapping of inactive PARP onto the single-strand breaks preventing their 
repair (Helleday 2011, Murai et al 2012).  Persistence of SSBs during DNA replication results 
in their conversion into the more serious DNA DSBs that would normally be repaired by 
homologous repair.  Olaparib has been shown to inhibit selected tumour cell lines in vitro and 
in xenograft and primary explant models as well as in genetic BRCA knockout models, either 
as a stand-alone treatment or in combination with established chemotherapies. 
1.1.4 Pre-clinical experience 
The pre-clinical experience is fully described in the current version of the Olaparib IB. 
1.1.5 Toxicology and safety pharmacology summary 
Olaparib has been tested in a standard range of safety pharmacology studies eg, dog 
cardiovascular and respiratory function tests, and the rat Irwin test.  There were no noticeable 
effects on the cardiovascular or respiratory parameters in the anaesthetised dog or any 
behavioural, autonomic or motor effects in the rat at the doses studied. 
Rodent and dog toxicology studies have indicated that the primary target organ of toxicity is 
the bone marrow with recovery seen following withdrawal of Olaparib.  Ex vivo studies have 
confirmed that Olaparib is cytotoxic to human bone marrow cells. 
Olaparib was not mutagenic in the Ames test but was clastogenic in the Chinese hamster 
ovary (CHO) chromosome aberration test in vitro.  When dosed orally, Olaparib also induced 
micronuclei in the bone marrow of rats.  This profile is consistent with the potential for 
genotoxicity in man.  
Reproductive toxicology data indicate that Olaparib can have adverse effects on embryofoetal 
survival and development at dose levels that do not induce significant maternal toxicity.  
Further information can be found in the current version of the Olaparib IB. 
1.1.6 Clinical experience with Olaparib 
Below is an outline of the monotherapy Olaparib studies conducted in pancreas cancer 
patients. 
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1.1.6.1 Olaparib monotherapy studies in pancreas cancer patients 
Study D0810C00042 
Study 42 was a single arm phase II study of Olaparib (capsules) 400mg po bid in patients with 
germline BRCAm malignancies across multiple tumour types. Twenty three patients with 
germline BRCAm-associated advanced pancreas cancer after therapy with gemcitabine were 
treated with Olaparib capsules 400mg po bid. All patients had seen a prior gemcitabine 
regimen and over half a prior platinum containing regimen. The ORR was 22%, DCR 57%, 
PFS 4.6 mos. and OS 9.8 mos. (Kaufman B et al 2013) This level of activity compares 
favourably with that reported for other therapies reported in advanced previously treated 
pancreas cancer (Rahma et al 2013). A retrospective analysis of the patient data from study 42 
suggested greatest benefit from Olaparib in those (15) patients whose tumours had not 
progressed on a prior platinum treatment (ORR 33%, DCR 66%, PFS 6.4 mos., OS 13.1 
mos.). 
1.2 Research hypothesis 
Single agent Olaparib tablet 300 mg bid has superior efficacy and acceptable tolerability 
profile as compared with placebo in patients with deleterious or suspected deleterious 
germline mutation in BRCA1 and/or BRCA2 and metastatic pancreas cancer who have 
achieved disease control(absence of objective progression) after receiving a minimum of 16 
weeks of first line platinum based chemotherapy.  The efficacy in this study will be assessed 
by the primary analysis of PFS defined as the time from randomisation until the date of 
objective radiological disease progression according to modified RECIST1.1 criteria, or death 
(by any cause in the absence of disease progression) regardless of whether the patient 
withdraws from randomised therapy or receives another anti-cancer therapy prior to disease 
progression. To reduce bias, primary analysis of PFS will be based on blinded, independent 
central review of RECIST scans. Secondary endpoints include overall survival, DCR at 16 
weeks, ORR (in patients with baseline evaluable disease), PFS2, safety assessments and 
patient-reported symptoms, functioning and health related quality of life. 
1.3 Rationale for study design, doses and control group 
Mutations in gBRCA1 and gBRCA2 are a very rare but definable molecular subgroup of 
pancreas cancer which may be found in some identifiable populations with a prevalence as 
high as 15%. Cells that lack gBRCA1/2 function, such as cancer cells from patients with 
germline mutations in these genes, are deficient in their ability to repair double-strand DNA 
breaks through homologous recombination (Roy et al 2012). This deficiency is presumed to 
underlie the observation that gBRCA1/2-deficient cells are sensitive to interventions that 
promote double strand DNA breaks or cross-links, such as ionizing radiation and platinum-
based chemotherapeutic agents. Platinum based regimens are increasingly being used early in 
the treatment of advanced gBRCA-mutated breast and pancreas cancer, in addition to their 
established use in ovarian cancer. It is also presumed to underlie the observation that 
gBRCA1/2-deficient cells are sensitive to treatment with inhibitors of poly-(ADP-ribose)-
polymerases (PARP inhibitors) (Bryant et al 2005) which are presumed to force repair of 
single-strand breaks towards the homologous repair pathway rather than the pathways that 
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usually address single-strand breaks.  Phase I and proof-of-concept phase II studies have 
shown that PARP inhibitors have significant activity with limited toxicity when used as single 
agents in the treatment of gBRCA1/2 mutation-associated breast and ovarian cancer (Tutt A et 
al 2010; Audeh et al 2010) and pancreas cancer (Kaufman B et al 2013). The present trial is an 
important step in defining the role of Olaparib as a PARP inhibitor in patients with deleterious 
germline BRCA1/2 mutations and metastatic pancreas cancer and the strategy of switch 
maintenance to prolong disease control after beneficial effect of a platinum regimen as has 
been suggested for gBRCA-mutated ovarian cancer (Kim et al 2014, Ledermann et al 2013).  
The study will assess the efficacy of Olaparib relative to placebo as maintenance therapy after 
documentation of disease control(absence of progression) on an initial platinum based 
regimen for metastatic gBRCA pancreas cancer. The preliminary analysis of study 42 suggests 
selecting patients with tumours which are not known to be platinum resistant would increase 
the likelihood of benefit. Because of data to suggest that “sporadic” pancreas cancers may 
have tumour tissue BRCA mutations (Goggins M. et al 1996),  an exploratory analysis of 
tumour tissue will be done to assess the prevalence and feasibility of assaying tumour tissue 
for BRCA mutations and/or other markers of HRD.  In the future it may be possible to extend 
the use of PARPi to patients with tumours having non-BRCA deficiencies in dsDNA 
repair.  Olaparib has shown activity in ATM negative gastric cancer (Bang et al 2013) and 
there is suggestion of a similar sub-population in pancreas cancer (Kim et al 
2014).  Furthermore, independent groups have also identifed genomic signatures in pancreas 
cancer predicted to be associated with sensitivity to PARP inhibitors (Alexandrov et al 2013; 
Cowley et al 2013).  In order to further understand candidate methods for identifying these 
patients in future clinical trials we are asking all patients to donate a tumour sample at 
screening.  In order to understand the prevalence and relationship of these markers to BRCA 
status it is important that we are able to test samples from patients with and without gBRCA 
mutations. 
If the trial is successful it will give patients a relatively non-toxic oral therapeutic which will 
delay progression after stopping first line platinum based chemotherapy. 
1.3.1 Rationale for using Myriad Genetics 
The FDA has indicated that the gBRCA1 and gBRCA2 mutation assay will need to be 
approved as a companion diagnostic in the US. 
Myriad Genetics has been chosen as a partner in developing a companion diagnostic for 
gBRCA1 and gBRCA2 testing because it has extensive experience of gBRCA1 and gBRCA2 
mutation detection.  Myriad keeps a comprehensive database on gBRCA1 and gBRCA2 gene 
mutations and their clinical relevance.  Furthermore, Myriad has an established laboratory 
infrastructure, which supports high volume testing with turnaround times that can meet the 
needs of a clinical trial. 
1.4 Benefit/risk and ethical assessment  
As of 2 October 2013, an estimated 2103 patients with ovarian, breast, gastric, pancreas, and a 
variety of other solid tumours are estimated to have received treatment with Olaparib across 
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the dose range 10 mg qd to 600 mg bid in AstraZeneca-sponsored, investigator-sponsored, and 
collaborative group studies.  Olaparib has been given as either monotherapy (18 studies, an 
estimated 1214 patients) or in combination with other chemotherapy/anticancer agents 
(25 studies, an estimated 889 patients).  Many of these combinations studies are ongoing.  The 
majority of patients to date have received the capsule formulation of Olaparib (an estimated 
1635 patients).  Approximately 468 patients have received the tablet formulation to 
date.  Approximately 304 patients have received comparator or placebo across the Olaparib 
development programme. 
An analysis of monotherapy data across 12 AstraZeneca sponsored monotherapy studies in 
975 patients who have been given Olaparib capsule estimated that 16.1% (157/975) of patients 
had been exposed to Olaparib capsule for ≥12 months at the time of database closure for the 
12 studies.  Furthermore, 41/ 975 patients received treatment for >24 months (longest duration 
was 44 months).  From the available data to date, there is no evidence of any unexpected 
toxicity following long-term Olaparib (capsule) monotherapy exposure.  
Olaparib as monotherapy at doses up to 400 mg bid capsule is generally well tolerated, with 
most common AEs including nausea, fatigue, vomiting, anaemia mainly mild-to-moderate 
(CTCAE Grade ≤ 2) in severity.  In addition, in a small number of patients MDS/AML or 
pneumonitis have been observed and identified as important risks.  
1.4.1 Important potential risks 
1.4.1.1 Myelodysplastic syndrome/acute myeloid leukaemia 
There have been 16 reports of myelodysplastic syndrome (MDS) and/or acute myeloid 
leukaemia (AML) in patients treated with Olaparib as of 02 Oct 2013; 11 cases in Olaparib 
monotherapy trials and 5 cases in Olaparib combination studies with carboplatin and 
paclitaxel (n=4) or cediranib (n=1).  A total of 2103 patients are estimated to have received 
Olaparib, giving a cumulative incidence of 0.76% for MDS/AML, similar to the cumulative 
incidence reported from control arms of Olaparib randomised studies 0.7% (2/304 patients).  
All 16 patients had primary ovarian or peritoneal cancer and 12 of them were gBRCA1/2 
positive (3 cases gBRCA status unknown; 1 case negative).  It has been hypothesised that a 
deficiency in the expression of BRCA genes may leave patients more vulnerable to the adverse 
effects of chemotherapy, and therefore, at an increased risk of MDS/AML as a result of cancer 
treatment (Cole and Strair 2010).  Most patients had been treated with extensive previous 
chemotherapy ranging from 6 to 95 cycles over periods of 3.5 months to 15 years, including 
platinum agents, topoisomerase II inhibitors, alkylating agents and taxanes.  The median time 
from diagnosis of cancer to onset of MDS was 5.3 yrs (range 2.9 -12.7).  The median time 
from start of Olaparib treatment to onset of MDS was 0.9 years (0.1 to 4.8 years).  The 
reported events of MDS/AML occurred post discontinuation of Olaparib treatment in 8 of the 
16 patients following a median of 0.1 years post treatment discontinuation (range: 0.1 to 1 
years).  Half of the patients (n=8) had received Olaparib for ≤ 12 months (5 patients had ≤ 6 
months exposure) and the other 8 cases occurred following longer than 12 month Olaparib 
exposure (3 patients following 12-18 months exposure and 5 patients following >2 years 
exposure to Olaparib).  
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Since bone marrow is known to be a target organ for Olaparib toxicity, a risk of MDS/AML 
with long-term exposure to Olaparib cannot be excluded, but there is insufficient data at 
present to evaluate the strength, if any, of this relationship. Moreover, while non-clinical data 
suggest bone marrow progenitor cell populations are reduced temporarily following Olaparib 
treatment, there is no evidence to date linking Olaparib treatment to the generation of 
abnormal bone marrow precursors.  Furthermore, all patients who developed MDS/AML had 
extensive prior chemotherapy and while it is not possible to exclude the contribution of 
Olaparib, it is also considered that there were other potential contributing factors in all cases.  
Preclinical data also suggest potential benefit with PARP inhibitors in MDS/AML and clinical 
trials are now underway to assess this effect (Gaymes et al 2008). 
To ensure robust safety monitoring, patients in this clinical trial will have weekly safety 
assessments during the first cycle and then safety assessments every 3 weeks during the rest of 
the treatment period. Clinical guideline of managing bone marrow toxicity and use of G-CSF 
is implemented as the safety management plan. 
1.4.1.2 Pneumonitis 
As of 2nd of Oct 2013, 10 patients out of a total of 2103 patients estimated to have received 
Olaparib have reported pneumonitis, giving a cumulative incidence of 0.5% for pneumonitis.  
Pneumonitis was also reported for 2 patients (0.7%) of 304 patients that received placebo or 
comparator in the Olaparib trial programme (1 patient on placebo in Study 19 and 1 patient on 
paclitaxel in Study 39).  The patients were treated with Olaparib for breast cancer (n=2), 
ovarian cancer (n=2), non-small cell lung cancer (n=2), small cell lung cancer (n=1), pancreas 
cancer (n=1), gastric cancer (n=1) and thymic cancer (n=1).  Five of the 10 patients had a 
history of tobacco smoking.  The majority of patients had received prior radiotherapy and/or 
chemotherapy.  The majority of patients had relevant medical histories including pneumonitis, 
interstitial lung fibrosis, dyspnoea, haemoptysis, chest infection, allergic asthma, pleural 
effusion, and pleural metastases.   
Investigation of any new or worsening pulmonary symptoms has been implemented as a 
safety management plan (section 6.7.2). 
1.4.1.3 New Primary Malignancies  
Overall, the number of reports of new primary malignancies is low, with 21 events (in 19 
patients) being reported in 02 Oct 2103 Olaparib treated patients (0.9%) and one event 
(bladder cancer) reported in the placebo arm of the double-blind Study 19.  In randomised 
controlled studies, 5 events of new primary malignancies have been reported in four Olaparib 
treated patients and one event in a placebo treated patient: 
In the double blind maintenance Study 19, two events of new primary malignancies have been 
reported in Olaparib treated patients and one event in a placebo treated patient.  In the open 
label gBRCA ovarian monotherapy dose-finding Study 12, three events were reported in two 
Olaparib treated patients.  
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1 
Date 31 March 2014 
31(121) 
Of the 21 reported events in Olaparib treated patients, in ten the events were non-melanoma 
skin cancers.  There was one report of malignant melanoma.  The other 10 events of new 
primary malignancies were breast cancer (n=2), breast cancer in situ, gastric cancer, lung 
neoplasm (plus event of recurrence of the lung carcinoma), plasma cell myeloma, colon 
cancer, malignant muscle neoplasm (lesion present pre-Olaparib treatment) and one fatal 
event of T-lymphoblastic lymphoma/leukaemia.  
Of the 19 Olaparib treated patients subsequently diagnosed with a new primary malignancy, 
the majority were reported whilst receiving Olaparib treatment (16 patients).  In 3 patients the 
event was reported after Olaparib discontinuation  
 The duration of Olaparib treatment for the 19 patients was: 
• <6 months for 3 patients 
• 6 to 12 months for 6 patients 
• 12 to 18 months for 2 patients 
• 18 to 24 months for 2 patients 
• >2 years for 6 patients. 
The type of new primary cancers reported were generally in line with secondary cancers 
observed in ovarian and breast cancer populations reported in the literature (Bergfeldt et al 
1995, Fitzsimmons D et al 1999, Fong et al 2009, Fowble et al 2001, Wesolowski et al 2007), 
or were cancers such as skin cancer, known to be the most common cancer in the general 
population and associated with high cure rates. 
Ovarian cancer patients have been reported to have an increased risk of developing second 
primary malignancies.  Patients with gBRCA mutations are at risk of developing other primary 
cancers notably breast cancer (Ginsburg et al 2010) reported higher rates of skin cancers in 
patients with gBRCA1 (1.6%) and gBRCA2 (3.0%) mutations. 
There were other contributing factors/potential alternative explanations for the development of 
the new primary malignancy in all 19 Olaparib treated patients.  All patients had previously 
received various chemotherapy agents including multiple cycles of DNA damaging platinum 
containing chemotherapies, taxanes, anthracyclines and other alkylating and DNA damaging 
agents.  Four patients were reported to have had prior radiotherapy. Seven of the 19 patients 
had previous medical histories of cancer (ovarian, cervix, breast, peritoneal) and 3 patients 
with skin cancers had either had previous basal cell carcinoma reported or had skin lesions 
evident prior to study treatment) prior to the cancer under investigation in the Olaparib 
studies. 
There is insufficient evidence for an association between Olaparib treatment and the 
development of new primary malignancies in the clinical trial programme to date. 
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1.4.2 Potential benefit 
Phase II clinical studies have investigated the effect of Olaparib either as monotherapy or in 
combination with other chemotherapy agents in cancer patients.  In patients carrying germline 
BRCA mutations, monotherapy studies in patients with heavily pre-treated breast cancer have 
reported an objective response rate (ORR) of up to 41%.  In ovarian cancer patients, the 
pivotal phase II study D0810C00019 (“Study 19”), a double-blind, randomised study assessed 
the efficacy of Olaparib 400 mg bid capsules as a maintenance treatment following platinum-
based chemotherapy in patients with platinum sensitive relapsed high grade serous ovarian 
cancer.  The progression-free survival (PFS) following Olaparib maintenance therapy was 
significantly longer compared with the placebo group (HR 0.35; 95% CI: 0.25, 0.49; 
p<0.00001) in the overall population.  In the subgroup of patients with BRCA mutant ovarian 
cancer, the effect was even greater with a PFS HR of 0.18 (95% CI: 0.11, 0.31; p<0.00001; 
median 11.2 versus 4.3 months).  An interim analysis of OS was performed at 58% maturity.  
In the overall population, the analysis demonstrated a non-statistically significant numerical 
advantage for Olaparib-treated patients (OS HR 0.88; 95% CI 0.64-1.21; p=0.43808) and 
there was again a greater effect in the gBRCA-mutated subgroup:  the OS HR was 0.74 (95% 
CI 0.46 to 1.19; p=0.20813) with a numerical advantage in median overall survival observed 
with Olaparib (median 34.9 months versus 31.9 months with placebo).  Among the 62 
placebo-treated patients with gBRCA mutations, 14 switched to a PARP inhibitor post 
progression. In study D0810C00042 (“Study 42’), a single arm phase II study of Olaparib 
(capsules) 400mg po bid in patients with germline BRCAm malignancies across multiple 
tumour types, 23 patients with advanced gBRCAm associated pancreas cancer, all previously 
treated with gemcitabine were enrolled.  There were 1 CR and 4 PR’s (ORR 22%) with a 
disease control rate of 57%, a PFS of 4.6 months and an OS of 9.8 mos. Patients who had not 
progressed on a platinum containing regimen were most likely to benefit. The results of Study 
19 in ovarian cancer and Study 42 in pancreas cancer are the clinical basis for this 
investigation. 
In this randomised double blinded study, patients who have disease control after a minimum 
of 16 weeks of platinum based therapy will, on the investigational arm receive monotherapy 
Olaparib 300 mg tablet bid (or control placebo) until disease progression or development of 
unacceptable toxicity.  There is no intent to cap duration on Olaparib for these patients.   
Based on the available data on efficacy and safety, we anticipate that in the metastatic disease 
setting, Olaparib will have a positive benefit risk profile for the treatment of the very small 
well-defined population of advanced pancreas cancer patients with gBRCA mutations. 
 
1.5 Study Design  
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Figure 1 Study Flow Chart 
 
 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
34(121) 
This is a phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess 
the efficacy of Olaparib maintenance monotherapy in metastatic pancreatic cancer patients 
with gBRCA mutations [documented mutation in gBRCA1 or gBRCA2] that is predicted to be 
deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of 
function) and whose tumours have not progressed on at least 16 weeks of first line platinum 
based chemotherapy. 
Approximately 145 patients will be randomised using an Interactive Voice Response System / 
Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the 
treatments as specified below: 
• Olaparib tablets p.o. 300 mg twice daily  
• Matching placebo tablets p.o. twice daily  
Eligible patients will be those patients with pancreas cancer previously treated for metastatic 
disease gBRCA mutated, who have not progressed following completion of at least 16 weeks 
(can be more) of first line platinum-based chemotherapy.   
All patients must have a known deleterious or suspected deleterious germline BRCA mutation 
to be randomised; this may have been determined prior to enrolment into the study or may be 
assessed as part of the enrolment procedure for the study (via centrally provided Myriad 
Integrated BRACAnalysis test) 
Patients must have completed a minimum of 16 weeks of first line platinum-based therapy 
(eg, oxaliplatin, carboplatin or cisplatin) given continuously before randomisation to the study 
and should in the opinion of the investigator have had at least disease control. There must be 
absence of progression by imaging done within 4 weeks of randomisation. Patients whose 
platinum based therapy was discontinued as a result of toxicities specifically related to their 
platinum containing regimen are eligible if they received at least 16 weeks of platinum 
therapy and have continuously received the other chemotherapy drug(s) in their regimen (for 
example FOLFIRI for FOLFIRINOX etc.) and fulfil all other eligibility requirements 
(including non-progression at the time of enrolment).   
Patients known to have germline BRCA mutation/s prior to randomisation can enter the study 
based on this result provided they meet all other eligibility criteria.  The type of BRCA1/2 
mutation must be reported in the eCRF.  In addition the patients must consent to give 2 blood 
samples, the primary purpose of the first sample is for undertaking a confirmatory Myriad 
gBRCA test post randomisation and a second sample is required for assessment of current and 
future BRCA mutation assays. The patients will also submit the diagnostic pathology 
specimens (block or slides) if available for the exploratory portion of the study.  
Patients with unknown BRCA status must consent to give 2 blood samples for germline BRCA 
testing by Myriad (and all local ethical procedures for such genetic testing).  One sample will 
be used to test for BRCA mutations using the current commercial Myriad BRCA analysis test 
prior to study entry (Myriad Integrated BRACAnalysis).  The second blood sample from all 
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tested patients (including those who do not have a BRCA mutation) is required for assessment 
of current and future BRCA mutation assays.  When the result from the Myriad test indicates 
the patient does have a deleterious or suspected deleterious germline BRCA mutation and the 
patient meets all other eligibility criteria, the patient can be randomised into the study.  The 
patients will also submit the diagnostic pathology specimens (block or slides) if available.  
Residual blood (or its derivatives) from both samples may be used to evaluate future gBRCA 
companion diagnostic tests and for additional exploratory work, to elucidate the mechanism of 
response, understand the mode of action of study treatment, improve the understanding of 
pancreas cancer and disease recurrence (including gBRCA mutation status and it role in 
response). 
The 2 blood samples from patients with both known and unknown BRCA mutation status are 
needed in order to ensure sufficient information is collected in the study to enable the pre-
market approval of the Myriad germline BRCA test as a companion diagnostic for Olaparib in 
the USA.  In addition residual material may be used for the assessment of other current and 
future BRCA mutation diagnostic assays and/or assays that predict sensitivity to Olaparib. 
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is 
the day of the last infusion) and treatment started as soon as possible but no less than 4 and no 
more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, 
all previous chemotherapy treatment should be discontinued.  
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of 
treatment (Days 8, 15, 22 and 29).  Patients will then attend clinic visits every 4 weeks whilst 
on study treatment.  
Patients should continue to receive study treatment until objective radiological disease 
progression as per RECIST as assessed by the investigator and as long as in the investigator’s 
opinion they are benefiting from treatment and they do not meet any other discontinuation 
criteria as outlined in Section 3.9. 
Once a patient has discontinued study treatment, clinic visits will be reduced to every 8 weeks.  
Following discontinuation of study treatment, further treatment will be at the discretion of the 
investigator however it is anticipated (but not required) that patients will be retreated with 
their platinum based regimen.  Details of any further systemic anti-cancer treatment will be 
collected until death, loss to follow-up or withdrawal of consent.  In addition to their regular 8 
weekly contact, patients will be contacted in the 7 days following a specified date (data cut off 
date) to capture survival status at that point for each survival analysis.  Assessments will be 
performed as described in Table 1. 
Patients will have tumour assessments according to RECIST at baseline and every 8 weeks 
(±1week) up to 40 weeks and then every 12 weeks (±1 week) relative to date of randomisation 
until objective radiological disease progression according to modified RECIST criteria. All 
CT/MRI scans will be sent to an AstraZeneca appointed Clinical Research Organisation 
(CRO) for blinded independent central review. All treatment decisions will be based on site 
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assessment of scans. After the final primary progression free survival (PFS) analysis, central 
review of scans will no longer be required and investigators will be advised when to stop 
sending copies of the scans to the CRO conducting the central review.  Ongoing collection of 
site review tumour assessment is required and must be recorded in the electronic case report 
form (eCRF). 
RECIST will be modified to assess patients with clinical CR at entry who will be assessed as 
having no evidence of disease (NED) until they have progressed based on the appearance of 
new lesions. 
Any patient who discontinues study treatment for reasons other than objective radiological 
progression should continue, to undergo scheduled objective tumour assessments according to 
the study plan (see Table 1) in order to assess objective radiological progression of disease. 
Failure to do so may result in bias to the study results. 
Once a patient has progressed the patient will be followed for second progression (PFS2) 
every 8 weeks and then survival until the final analysis.  Patients will be contacted in the week 
following last patient last visit for each analysis of survival.  
The primary analysis of the study will occur when approximately 89 progression events have 
occurred, although an interim analysis for superiority will be done when 50% of the planned 
PFS events have occurred (see statistical Section 8).  The primary analysis will be based on a 
blinded independent central review (BICR) of disease progression by modified RECIST; 
however, a sensitivity analysis will be performed using the investigator-recorded assessment.  
All efficacy variables including overall survival will be analysed at the time of the primary 
analysis (providing sufficient events are available to make the analyses meaningful). 
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2. STUDY OBJECTIVES 
2.1 Primary objective 
Primary Objective: Outcome Measure: 
• To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo by progression free survival 
(PFS) 
• Progression Free Survival (PFS) by BICR 
using modified RECIST 1.1 
2.2 Secondary objectives 
Secondary Objective: Outcome Measure : 
• To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo 
• Overall Survival (observed and predicted 
using observed PFS and OS data) 
•  Time from randomisation to second 
progression (PFS2) 
• Time from randomisation to first subsequent 
therapy or death (TFST) 
• Time from randomisation to second 
subsequent therapy or death (TSST). 
• Time from randomisation to study treatment 
discontinuation or death (TDT) 
• Objective Response Rate by BICR using 
modified RECIST 1.1 criteria for evaluable 
patients 
• Disease Control Rate at 16 weeks by BICR 
using modified RECIST 1.1 criteria 
• To assess the effect of Olaparib on the 
Health-related Quality of Life 
(HRQoL) as measured by EORTC 
QLQ-C30 global QoL scale. 
• Adjusted mean change from baseline in 
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2.3 Safety objectives 
Safety Objective: Outcome Measure: 
• To assess the safety and tolerability of 
Olaparib maintenance monotherapy 
• Adverse event (AE), physical examination, 
vital signs including blood pressure (BP), 
pulse, electrocardiogram (ECG) and 
laboratory findings including clinical 
chemistry and haematology 
2.4 Exploratory objectives   
Exploratory Objective: Outcome Measure: 
• To assess the effect of Olaparib on 
functioning as measured by the EORTC 
QLQ-C30 functioning domains (physical, 
role, cognitive, emotional and social). 
• To assess the effect of Olaparib on 
pancreas cancer symptoms as measured 
by the EORTC QLQ-PAN26 items and 
scales. 
• To assess clinically relevant symptoms as 
measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, 
weight loss (or difficulty gaining 
weight/loss of appetite), jaundice 
• To assess change in performance status as 
measured by the ECOG Performance 
Status scale 
• Adjusted mean change from baseline on 
EORTC-QLQ-C30 functioning domains 
(physical, role, cognitive, emotional, 
social), on EORTC-QLQ-C30 + PAN26 
symptom scales and items (pain, fatigue, 
nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice and on 
performance status measured by the 
ECOG Performance Status scale 
• To investigate the health economic 
impact of treatment and the disease on 
hospital related resource use and health 
state utility 
• Number, type and reason of 
hospitalisations and hospital attendances, 
procedures undertaken and hospital 
length of stay.  
• Health state utility derived from the 
HRQL instrument, the EuroQoL EQ5D 
• To explore methods of estimating overall 
survival (OS) adjusting for the impact of 
the control arm receiving subsequent 
Polyadenosine 5’diphosphoribose [poly 
• Overall survival adjusted for impact of 
subsequent PARP inhibitors (or other 
potentially active investigational agents 
(if appropriate, to support reimbursement 
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(ADP ribose)] polymerise (PARP) 
inhibitors or imbalances between the 
treatment arms for other potentially 
active agents.  
appraisals) 
• To determine the frequency of and 
describe the nature of BRCA mutation/s 
in tumour samples and to compare this 
with germline BRCA mutation status. 
• BRCA1 and/or BRCA2 mutation status 
in tumour 
• To identify tumour tissue based 
biomarkers (including but not limited to 
somatic BRCA1/2 mutations, BRCA 
methylation and/or other HRD 
biomarkers) that could be used to guide 
future patient segmentation approaches 
for development 
• Future exploratory research into factors 
that may influence development of cancer 
and/or response to treatment (where 
response is defined broadly to include 
efficacy, tolerability or safety) may be 
performed on the collected and stored 
archival tumour samples (if available), 
blood samples at day 1 and on disease 
progression or on residual tissue material 
collected as part of the study. 
• Potential tissue biomarkers identified 
The exploratory analyses may not be reported in the clinical study report (CSR).  If not, they 
will be reported separately. 
3. PATIENT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL  
Each patient should meet all of the inclusion criteria and none of the exclusion criteria for this 
study prior to randomisation.  Under no circumstances can there be exceptions to this rule. 
3.1 Inclusion criteria 
For inclusion in the study patients should fulfil the following criteria: 
1. *Provision of informed consent prior to any study specific procedures  
2. *Patients must be male or female ≥18 years of age 
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3. *Histologically or cytologically confirmed pancreas adenocarcinoma receiving 
initial chemotherapy for metastatic disease and without evidence of disease 
progression on treatment 
4. Patients with measurable disease and/or non-measurable or no evidence of disease 
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in 
this study. RECIST 1.1 has been modified to allow the assessment of progression 
due to new lesions in patients with no evidence of disease at baseline.. 
5. Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or 
suspected deleterious (known or predicted to be detrimental/lead to loss of function) 
(See Section 1.5) 
6. Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or 
oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 
weeks of continuous platinum treatment and have no evidence of progression based 
on investigator’s opinion.  Patients who have received at least 16 weeks of a 
platinum regimen but had the platinum discontinued for toxicity but continued on 
the remaining drugs of their regimen are also eligible if they have no evidence of 
disease progression within 4 weeks of their last dose of chemotherapy. 
7. Patients who have received platinum as potentially curative treatment for a prior 
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer 
are eligible provided at least 12 months have elapsed between the last dose of 
platinum-based treatment and initiation of the platinum-based chemotherapy for 
metastatic pancreas cancer. 
8. Patients must have normal organ and bone marrow function measured within 4 
weeks prior to administration of study treatment as defined below: 
− Haemoglobin ≥  9.0 g/dL with no blood transfusions (packed red blood cells 
and platelet transfusions) in the past 28 days 
− Absolute neutrophil count (ANC) ≥ 1.5 x 109/L 
− White blood cells (WBC) >3 x 109/L 
− No features suggestive of MDS/AML on peripheral blood smear 
− Platelet count ≥ 100 x 109/L 
− Total bilirubin ≤ 1.5 x institutional upper limit of normal  
− AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value 
unless liver metastases are present in which case they must be ≤ 5x ULN 
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− Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) 
9. *ECOG performance status 0-1 at date signing of informed consent 
10. *Postmenopausal or evidence of non-childbearing status for women of childbearing 
potential: negative urine or serum pregnancy test. Postmenopausal is defined as: 
− Amenorrheic for 1 year or more following cessation of exogenous hormonal 
treatments 
− Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in 
the post menopausal range for women under 50 
− Radiation-induced oophorectomy with last menses >1 year ago 
− Chemotherapy-induced menopause with >1 year interval since last menses 
− Surgical sterilisation (bilateral oophorectomy or hysterectomy) 
11. *Patient is willing and able to comply with the protocol for the duration of the study 
including undergoing treatment and scheduled visits and examinations 
12. Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary tumour 
or a metastatic site if available or 3 unstained cytology slides if available. 
 
3.2 Exclusion Criteria  
Patients should not enter the study if any of the following exclusion criteria are fulfilled: 
1. *Involvement in the planning and/or conduct of the study (applies to AstraZeneca 
staff and/or staff at the study site). 
2. gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, 
“Variants of uncertain clinical significance” or “Variant of unknown significance” 
or “Variant, favour polymorphism” or “benign polymorphism” etc.). 
3. Progression of tumour between start of first line platinum based chemotherapy for 
metastatic pancreas cancer and randomisation. 
4. Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle 
1 Day 1 is not permitted. Palliative radiotherapy must have been completed 14 or 
more days before Cycle 1 Day 1. The patient can receive a stable dose of 
bisphosphonates or denosumab for bone metastases, before and during the study as 
long as these were started at least 2 weeks prior to study treatment. 
5. *Previous randomisation in the present study. 
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6. Exposure to an investigational product within 30 days or 5 half lives (whichever is 
longer) prior to randomisation 
7. *Any previous treatment with a PARP inhibitor, including Olaparib. 
8. *Patients with second primary cancer, EXCEPTIONS: adequately treated non-
melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal 
Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid 
tumours including lymphomas (without bone marrow involvement) curatively 
treated with no evidence of disease for ≥ 5 years prior to study entry. 
9. Resting ECG with QTc > 470 msec detected on 2 or more time points within a 24 
hour period or family history of long QT syndrome.  If ECG demonstrates QTc 
>470 msec, patient will be eligible only if repeat ECG demonstrates QTc ≤470 
msec. 
10. Concomitant use of known potent CYP3A4/5 inhibitors such as ketoconazole, 
itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and 
nelfinavir.  For further detail refer to Appendix H. 
11. Persistent toxicities (≥CTCAE grade 2) caused by previous cancer therapy, 
excluding alopecia and CTCAE grade 3 peripheral neuropathy. 
12. *Patients with myelodysplastic syndrome/acute myeloid leukaemia. 
13. Major surgery within 2 weeks of starting study treatment: patients must have 
recovered from any effects of any major surgery. 
14. *Immunocompromised patients, eg, patients who are known to be serologically 
positive for human immunodeficiency virus (HIV). 
15. *Clinically significant uncontrolled medical conditions are not permitted (eg active 
infection requiring IV antibiotics, symptomatic congestive heart failure, unstable 
angina pectoris, recent (3 months) myocardial infarction, extensive bilateral 
interstitial lung disease, psychiatric illness that would limit ability to comply with 
study procedures, and any other medical condition that, in the opinion of the 
investigator, places the patient at unacceptable risk of toxicity. NB: Diabetes which 
is controlled by medication does not exclude participation in the study 
16. *Patients with a history of treated CNS metastases are eligible, provided they meet 
all of the following criteria: Disease outside the CNS is present. No evidence of 
interim progression between the completion of CNS-directed therapy and the 
screening radiographic study. No history of intracranial haemorrhage or spinal cord 
haemorrhage. Minimum of 2 weeks between completion of radiotherapy and cycle 
1 Day 1 and recovery from significant (Grade ≥3) acute toxicity with no ongoing 
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requirement for ≥ 10mg of prednisone per day or an equivalent dose of other 
corticosteroid. 
17. *Patients unable to swallow orally administered medication and patients with 
gastrointestinal disorders likely to interfere with absorption of the study medication. 
18. *Pregnant or breast feeding women. 
19. *Previous allogeneic bone marrow transplant. 
20. *Patients with a known hypersensitivity to Olaparib or any of the excipients of the 
product. 
21. *Whole blood transfusions in the last 120 days prior to enrolment to the study 
which may interfere with gBRCA testing (packed red blood cells and platelet 
transfusions are acceptable, for timing refer to inclusion criteria no.8) 
Procedures for withdrawal of incorrectly enrolled patients see Section 3.4. 
3.3 Patient enrolment and randomisation 
Investigator(s) should keep a record, the patient screening log, of patients who entered pre-
study screening. 
The Principal Investigator will: 
1. Obtain signed informed consent from the potential patient before any study specific 
procedures are performed. 
2. Assign potential patients a unique enrolment number, beginning with ‘E#’.  (This 
number will be obtained through Interactive Voice/Web Response System 
[IVRS/IWRS]). 
3. Determine patient eligibility. See Sections 3.1 and 3.2 
4. Obtain the randomisation code (patient number) through IVRS/IWRS. 
As patients are screened for the study, they must be allocated an enrolment code (E-code). The 
E-code is a 7-digit number made up of the centre number and the patient number within that 
particular centre (eg, the first patient screened at centre number 0001 would be assigned the E-
code E0001001, the second patient screened would be E0001002 and so on). This number is 
the patient unique identifier and is used to identify the patient on the eCRFs. If a patient 
withdraws from participation in the study, then his/her enrolment/randomisation code cannot 
be reused. 
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3.4 Procedures for handling incorrectly enrolled or randomised 
patients 
Patients who fail to meet the inclusion/exclusion criteria should not, under any 
circumstances, be randomised or receive study medication.  There can be no exceptions to this 
rule. 
Where patients that do not meet the selection criteria are randomised in error or incorrectly 
started on treatment, or where patients subsequently fail to meet the study criteria post 
initiation, a discussion should occur between the AstraZeneca Study Team Physician and the 
investigator regarding whether to continue or discontinue the patient from treatment. Once a 
decision is made, Investigators need to ensure they comply with all applicable requirements 
for human patient protection and ethical review. 
The AstraZeneca Study Team Physician is to ensure all such decisions are appropriately 
documented. In situations where an agreement cannot be reached, the patient should have their 
study treatment stopped and be withdrawn from the study 
3.5 Methods for assigning treatment groups 
Patient eligibility will be established before treatment randomisation. Once the eligibility of a 
patient has been confirmed, the Investigator (or nominated assistant) should contact the 
IVRS/IWRS Centralised Randomisation Centre for allocation of randomised study treatment. 
The actual treatment given to individual patients will be determined by a randomisation 
scheme that has been loaded into the (IVRS/IWRS) database. The randomisation scheme will 
be produced by a computer software program called GRand (AZ Global Randomisation 
system) that incorporates a standard procedure for generating random numbers.  
A blocked randomisation will be generated and all centres will use the same list in order to 
minimise any imbalance in the number of patients assigned to each treatment group.  
Patients will be identified to the Centralised Randomisation Centre using patient Ecode and 
month/ year of birth. 
Randomisation codes will be assigned strictly sequentially as patients become eligible for 
randomisation. 
Eligible patients will be randomised in a 3:2 ratio (Olaparib:placebo) as specified below: 
• Olaparib tablets p.o. 300 mg twice daily 
• Placebo tablets p.o. twice daily  
It is recommended that patients commence study treatment as soon as possible after 
randomisation, and ideally within 3 days. 
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The IVRS/IWRS Centralised Randomisation Centre will inform the Investigator of the Kit ID 
number to be allocated to the patient at the randomisation visit. The Investigator will call/log 
in to the IVRS/IWRS for each subsequent dispensing visit for assignment of a new Kit ID 
number (s). 
The Kit ID number dispensed at each visit will correspond to the treatment to which the 
patient was originally randomised. 
3.6 Methods for ensuring blinding 
Olaparib and placebo treatment will be blinded. 
The study medication will be labelled using a unique Kit ID number, which is linked to the 
randomisation scheme. The active and placebo tablets will be identical and presented in the 
same packaging to ensure blinding of the study medication. 
3.7 Methods for unblinding  
3.7.1 Methods for ensuring blinding 
Olaparib and placebo treatment will be blinded. 
The study medication will be labelled using a unique Kit ID number, which is linked to the 
randomisation scheme. The active and placebo tablets will be identical and presented in the 
same packaging to ensure blinding of the study medication. 
3.7.2 Methods for unblinding the study 
Individual treatment codes, indicating the treatment randomisation for each randomised 
patient, will be available to the investigator(s) or pharmacists from the IVRS/IWRS. Routines 
for this will be described in the IVRS/IWRS user manual that will be provided to each centre. 
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment randomisation. The 
investigator documents and reports the action to AstraZeneca, without revealing the treatment 
given to patient to the AstraZeneca staff. 
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally related to an investigational product and that potentially require 
expedited reporting to regulatory authorities. Treatment codes will not be broken for the 
planned analyses of data until all decisions on the evaluability of the data from each individual 
patient have been made and documented. 
Except for medical reasons, patients, investigators and study monitors in the field will have no 
access to the individual treatment code until final analysis. 
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Patients of child bearing potential and their partners, who are sexually active, must agree to 
the use of two highly effective forms of contraception, while they are receiving study 
treatment and for 3 months after last dose of study drug.  For details please refer to Appendix 
E Acceptable Birth Control Method. 
3.8.2 Olaparib and CYP3A4/5 
Patients should avoid concomitant use of drugs, herbal supplements and/or ingestion of foods 
known to modulate CYP3A4/5 enzyme activity (see Section 7.7.2) starting 5 days before they 
are randomised until 30 days after the last dose of study medication. 
3.9 Discontinuation of investigational product 
Patients may discontinue study treatment in the following situations: 
• Patient decision.  The patient is at any time free to discontinue treatment, without 
prejudice to further treatment 
• Objective radiological disease progression 
• Adverse Event 
• Severe non-compliance to study protocol  
• Death 
3.9.1 Procedures for discontinuation of a patient from investigational product  
A patient that decides to discontinue study treatment will always be asked about the reason(s) 
and the presence of any adverse events.  If possible, they will be seen and assessed by an 
investigator(s).  Adverse events will be followed up (See Sections 6.3 and 6.4); questionnaires 
and all study drugs should be returned by the patient. 
If a patient is withdrawn from study, see Section 3.10. 
Any patient discontinuing study treatment should be seen at 30 days post discontinuation for 
the evaluations outlined in the study schedule.  The patient’s tumour status should be assessed 
clinically and, if appropriate, disease progression should be confirmed by radiological 
assessment.  After discontinuation of study treatment, the principal investigator/sub-
investigator will perform the best possible observation(s), test(s) and evaluation(s) as well as 
give appropriate medication and all possible measures for the safety of the patient.  In 
addition, they will record on the eCRF the date of discontinuation, the reasons, manifestation 
and treatment at the time of discontinuation.  Patients will be required to attend the treatment 
discontinuation visit.  The patient should return all study medication. 
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After discontinuation of the study treatment at any point in the study, all ongoing AEs or 
SAEs must be followed until resolution unless, in the investigator’s opinion the condition is 
unlikely to resolve due to the patients underlying disease, or the patient is lost to follow up 
(see Sections 6.3 and 6.4).  All new AEs and SAEs occurring during the 30 calendar days after 
the last dose of study medication must be reported (if SAEs, they must be reported to 
AstraZeneca within 24 hours as described in Section 6.4) and followed to resolution as above.  
Patients should be seen at least 30 days after discontinuing study treatment to collect and / or 
complete AE information.  Any untoward event occurring subsequent to the 30-day follow-up 
AE reporting period that the investigator assesses as possibly related to the study treatment 
should also be reported as an AE. 
Patients who discontinue treatment prior to disease progression should continue to have 
RECIST assessments as per the study schedule. All patients must be followed for objective 
progression (as per RECIST 1.1) and survival, up to the final analysis. 
3.10 Criteria for withdrawal  
Patients are at any time free to withdraw from study (study treatment and assessments), 
without prejudice to further treatment (withdrawal of consent).  Such patients will always be 
asked about the reason(s) and the presence of any adverse events.  If possible, they will be 
seen and assessed by an investigator.  Adverse events will be followed up (See Sections 6.3 
and 6.4); questionnaires (eg, for patient reported outcomes) and all study drugs should be 
returned by the patient. 
Withdrawn patients will not be replaced.  
Reasons for withdrawal from the study: 
• Voluntary withdrawal by the patient who is at any time free to discontinue their 
participation in the study, without prejudice to further treatment* 
• Incorrectly enrolled patients ie, the patient does not meet the required 
inclusion/exclusion criteria for the study 
• Patient lost to follow-up 
• Death 
*If a patient decides at any point in the trial that they do not wish to continue with the full 
study schedule of assessments but are still willing to provide important study information (eg 
disease recurrence information and/or survival status information) then the patient should 
continue in the study and information should continue to be collected on the clinical database.  
However if a patient does not wish to have any further data collected, only then should they be 
considered as withdrawing consent from the study.  To minimise the number of cases of early 
withdrawal the investigator should discuss the options with the patient in case they would still 
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be willing to undergo reduced assessments and/or reduced data collection, in which case they 
would remain in the study. 
*If a patient withdraws consent, they will be specifically asked if they are withdrawing 
consent to: 
− to further participation in the study including any further follow up (eg, survival calls) 
− withdrawal of consent to the use of their study generated data 
− withdrawal to the use of any samples (see Section 5.6.6) 
Data obtained prior to withdrawal of consent will be maintained in the clinical database and 
used in the study reporting. 
The status of ongoing, withdrawn (from the study) and ‘lost to follow up’ patients at the time 
of an overall survival analysis should be obtained by the site personnel by checking the 
patients notes, hospital records, contacting the patients general practitioner and checking 
publicly available death registries.  In the event that the patient has actively withdrawn 
consent to collection of further data the vital status of the patient can be obtained by site 
personnel from publicly available resources where it is possible to do so under applicable 
local laws. 
3.10.1 Screen failures  
Screening failures are patients who do not fulfil the eligibility criteria for the study, and 
therefore must not be randomised.  These patients should have the reason for study withdrawal 
recorded as ‘Incorrect Enrolment’ (ie, patient does not meet the required inclusion/exclusion 
criteria).  This reason for study withdrawal is only valid for screen failures (not randomised 
patients). 
3.10.2 Withdrawal of the informed consent 
Patients are free to withdraw from the study at any time (investigational product and 
assessments), without prejudice to further treatment. 
A patient who withdraws consent will always be asked about the reason(s) and the presence of 
any adverse events (AE).  The Investigator will follow up AEs outside of the clinical study. 
The patient will return electronic PRO (ePRO) devices.   
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused. Withdrawn patients will not be replaced.  
3.11 Discontinuation of the study 
The study may be stopped if, in the judgment of AstraZeneca, trial patients are placed at 
undue risk because of clinically significant findings that: 
• meet individual stopping criteria  or are otherwise considered significant  
• are assessed as causally related to study drug,  
• are not considered to be consistent with continuation of the study 
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Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded in the CRF. All reasons for discontinuation of 
treatment must be documented. 
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the patients’ interests 
4. STUDY PLAN AND TIMING OF PROCEDURES  
A study initiation visit must be conducted at the centre prior to the commencement of any 
study activities requiring informed consent. A schedule for the tests and evaluations to be 
conducted in this study is contained in this section and in Table 1.
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Informed consent  X X          
Randomisation f   X f         
Demographics X X          
Medical and surgical history, 
including blood transfusions a 
 X          
Prior cancer therapies 
including radiotherapy 
 X          
Inclusion/exclusion criteria X (all * 
criteria) b 
X          
Blood samples for gBRCA 
status c 
X   X d         
Archival paraffin embedded 
tumour tissue or cytology 
sample e 
X X          
Concomitant medications   X X X X X X X X X  
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
ECOG performance status   X     X X X X  
Vital signs   X g X  g    X X X X  
Physical examination h   X     X X X X  
ECG i  X As clinically indicated    
Tumour assessment 
(modified RECIST 1.1) j 








Every 8 weeks (± 1 week) until week 40 
then every 12 weeks (±1 week), relative to 
the date of randomisation j 
















 X X  l    X X X  X  
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Coagulation m  X As clinically indicated    
Urinalysis n  X As clinically indicated    
Pregnancy test  o X X X         
Biomarker blood sample p   X     X (only at 
progression) 
   
EORTC QLQ-C30 q  X     X X X X  
EORTC QLQ-PAN26 q  X  X X X X X X X  
Euro QoL EQ5D   X X    X X X X  
Hospital Resource Use   X X X X X X X X  





X X X X X X X X X  
Study drug dispensing s   X    X X     
Study drug return        X X X X  
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Subsequent cancer treatment t          X  X 
Second progression 
assessment u 
          X u 
Survival status v           X v 
 
 
a Include history of blood transfusion within previous 120 days from start of study treatment and the reasons eg bleeding or myelosuppression. 
b These screening assessments do not need capturing on the eCRF, but they must be recorded in the patient’s notes. 
c Patients must have a known deleterious or suspected deleterious BRCA mutation to be randomised to the study; this can be either a local lab result or a 
Myriad test result. Patients for whom their gBRCA status is already known, should be consented to the study within 28 days prior to day 1 of study 
treatment.  Any patient who consents to study related Myriad gBRCA status testing, must also have a blood sample taken at the same time for the 
purpose of developing and validating a future diagnostic test(s) for gBRCA mutations. 
d Samples to be taken on Day 1 only for patients with known gBRCA mutation who have not completed PART 1 Screening. The screening gBRCA test 
and method performed at site must be recorded in the eCRF. 
e Collection of an archival tumour sample is requested, if available, for all patients. These samples will be collected from the site pathologist during the 
screening Part 1 for patients with unknown gBRCA status and screening Part 2 for patients with known local gBRCA test. 
f Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and treatment started as soon 
as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous 
chemotherapy treatment should be discontinued. 
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g Vital signs performed on day 1 before every cycle. If vital signs assessed within 7 days before starting study treatment, it does not need to be repeated on 
Day 1 of study treatment unless investigator believes that it is likely to have changed significantly.  
h Physical examination should be performed according to the schedule. After the baseline assessment it is not necessary to record the details on the eCRF, 
any clinically significant changes not unequivocally related to disease progression, should be reported as adverse events. 
i ECG assessments to be completed within 7 days before starting treatment if patient is eligible following completion of all other PART 2 assessments. 
After screening, ECGs will only be required if clinically indicated. 
j Baseline RECIST assessments will be performed using CT scans of the chest, abdomen and pelvis (or MRI where CT is contraindicated) and should be 
performed no more than 28 days before start of study treatment and as close as possible to randomisation. A randomisation must be within 6 weeks of 
last chemotherapy. Treatment should be started as soon as possible but no less than 4 weeks and no more than 8 weeks after their last dose of 
chemotherapy. RECIST follow-up assessments will be performed every 8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) 
irrespective of treatment decisions. Follow-up assessment will include CT assessments of chest, abdomen and pelvis (or MRI where CT is 
contraindicated) for all patients. Any other sites at which new disease is suspected should also be appropriately imaged. Patients must be followed until 
disease progression assessed using modified RECIST 1.1 criteria.  If an unscheduled assessment was performed and the patient has not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits. Prior to primary analysis for PFS, all scans will be submitted for 
independent review. If progression is not confirmed at central review an additional RECIST assessment will be requested at the next scheduled visit. 
k For patients who discontinue study treatment prior to disease progression, RECIST assessments will continue until objective disease progression (every 
8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) relative to date of randomisation, until objective disease progression as defined 
by modified RECIST 1.1.). 
l Haematology and clinical chemistry should be performed at screening and day 1 of every cycle.  Safety blood samples do not need to be repeated on Day 
1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study treatment, unless the 
investigator believes that it is likely to have changed significantly.    
m Coagulation test should be performed at screening and if clinically indicated.  
n Urinalysis should be performed at screening. After screening, urinalysis will only be required if clinically indicated.  
o In the event of suspected pregnancy during the study, the test should be repeated and, if positive, the patient discontinued from study treatment 
immediately. 
p Mandatory blood samples for biomarker analysis to be taken prior to dosing on Cycle 1 Day 1 and at disease progression. 
q Questionnaires to be completed prior to randomisation once eligibility has been confirmed and then until objective radiological disease progression, at 
discontinuation of study treatment visit and then 30 days post last dose.  Questionnaires should be completed prior to dosing on all administrations. 
 r Adverse events must be captured from time of consent. However, in Screening PART 1 of the study only SAEs related to study procedures will be 
collected. 
s Continuous Olaparib 300mg/ placebo twice daily dosing. Sufficient study treatment should be dispensed for at least each treatment period plus overage, 
however additional treatment can be dispensed to patients to last longer in accordance with local practice.  
t All anti-cancer treatments (including, but not limited to, chemotherapy and targeted agents), and the Investigator’s opinion of response to them, plus the 
date of progression post discontinuation of study treatment, need to be recorded.  
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u Second disease progression (PFS2) assessment will be performed by the Investigator and defined according to local standard clinical practice and may 
involve any of; objective radiological or symptomatic progression or death.  Subsequent therapy will be collected for these patients from the time of 
treatment discontinuation. 
v The status of ongoing, withdrawn (from the study) and ‘lost to follow-up’ patients at the time of an OS analysis should be obtained by the site  personnel 
by checking the patients notes, hospital records, contacting the patient’s general practitioner and checking publicly available death registries.  In the 
event that the patient has actively withdrawn consent to the processing of their personal data the vital status of the patient can be obtained by site 
personnel from publicly available resources where it is possible to do so under applicable local laws (see Section3.10). In addition to their regular 8 
weekly contact, patients will be contacted in the 7 days following a specified date (data cut off date) for each survival analysis. 
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4.1 Enrolment/screening period 
Procedures will be performed according to the Study Plan.  
At screening, consenting patients are assessed to ensure that they meet eligibility criteria. 
Patients who do not meet these criteria must not be enrolled in the study. 
The following assessments and procedures should be performed during screening Part 1 and 
Part 2 as per Table 1. 
For details of the schedule and nature of assessments see below: 
• Month/ year of birth, sex, race and ethnicity  
• Medical and surgical history including previous cancer and radiotherapy and history of 
blood transfusions in previous 120 days  
• Previous chemotherapy 
− If patient received a prior platinum drug, in what setting (adjuvant or advanced) 
and reason for discontinuation (progression on therapy, discontinuation of 
therapy for reason other than progression, completion of planned program 
without progression,) 
• Current and concomitant medications including previous cancer therapies  
• ECOG Performance Status 
• Vital signs (blood pressure and pulse; body temperature), body weight, height 
• Haematology /Clinical chemistry/Urinalysis  
• Coagulation test 
− activated partial thromboblastin time {APTT}will be performed at baseline and 
if clinically indicated 
− international normalised ratio {INR} will be performed at baseline and if 
clinically indicated unless the patient is receiving warfarin. Patients taking 
warfarin may participate in this study; however, it is recommended that 
prothrombin time (INRand APTT) be monitored carefully at least once per 
week for the first month, then monthly if the INR is stable 
• Physical examination 
• CT (or MRI if CT is contraindicated) of chest, abdomen and pelvis 
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• ECG (within 7 days prior to the start of the study treatment) 
• Menopausal status; serum or urine pregnancy test for women of childbearing potential.  
The pregnancy test should be prior to performing the gBRCA blood test during 
screening part 1, within 28 days prior to the start of study treatment and confirmed on 
day 1 prior to dosing 
• For patients with unknown gBRCA status: gBRCA1/2 mutation status. 2 blood 
samples: One blood sample to test for gBRCA mutations using the current commercial 
Myriad BRACAnalysis test, and the second blood sample for a bridging study to 
validate the companion diagnostic test for Olaparib and/or assessment of current or 
future BRCA mutation assays 
• Patient Reported Quality of life questionnaire: EORTC QLQ-C30 and QLQ-PAN26 
should be completed prior to randomisation once eligibility is confirmed 
• Adverse events must be captured from time of consent.  However, in Screening Part 1 
of the study only SAEs related to study procedures will be collected.  In Screening Part 
2 all AEs/SAEs will be collected 
• Archival paraffin embedded tumour tissue sample or cytology sample requested, if 
available 
The Principal Investigator/Sub-Investigator should adhere to the study plan, procedures and 
perform tests/observations in accordance with the protocol. 
4.2 Treatment period 
The visit schedule is based on 28-day cycles.  
Patients will attend the clinic weekly on days 1 (1st day of treatment), 8, 15, 22, 29 following 
the commencement of study treatment and then every 4 weeks (day 1 of every cycle) until 
discontinuation of treatment. The following assessments will be performed at time points 
specified in the study schedule (see Table 1): 
• Vital signs: Day 1 of every cycle. Body weight is only required at day 1 of 1st day of 
study treatment, if it has not been assessed within 7 days of randomisation.  Any other 
time as clinically indicated 
• ECOG Performance Status: Day 1 of every cycle and until objective radiological 
disease progression, at discontinuation of study treatment visit and then 30 days post 
last dose  
• Haematology and clinical chemistry: Day 1 of every cycle. Safety blood samples do 
not need to be repeated on Day 1 of study treatment if there have been separate 
assessments within 7 days before starting study treatment and which must have been 3 
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weeks after last dose of chemotherapy based therapy, unless the investigator believes 
that it is likely to have changed significantly. 
 
• Physical examination: Day 1 before every cycle but assessments post Day 1 are not 
required to be captured on an eCRF, however any significant changes from baseline 
must be reported as an AE. 
• CT of chest, abdomen and pelvis (or MRI if CT is contraindicated) performed until 
objective disease progression. RECIST assessments to be scheduled every 8 weeks (±1 
week) from randomisation for the first 40 weeks and then every 12 weeks (±1 week). 
If progression is not confirmed by BICR an additional scan will be requested at the 
next scheduled visit. CT/MRI of chest, abdomen and pelvis to be performed until 
objective disease progression.  
• ECG at baseline and any time if clinically indicated  
• Urinalysis at baseline and any time if clinically indicated 
• Serum or urine pregnancy test for women of childbearing potential (prior to treatment 
on day 1 of 1st day of study treatment).  If the test is positive then a confirmatory test 
should be performed 
• For patients with known gBRCA status: gBRCA1/2 mutation status. 2 blood samples: 
One blood sample to test for gBRCA mutations using the current commercial Myriad 
BRACAnalysis  test, and the second blood sample for a bridging study to validate the 
companion diagnostic test for Olaparib and/or assessment of current or future BRCA 
mutation assays 
• AE and concomitant medications (including any blood transfusions) at every visit 
• Patient Reported Quality of life questionnaire: EORTC QLQ-C30 at baseline (prior to 
randomisation once eligibility is confirmed), every 4 weeks until objective radiological 
disease progression, at discontinuation of study treatment visit and then 30 days post 
last dose.   
• Patient Reported Quality of life questionnaire: QLQ-PAN26 at baseline (prior to 
randomisation once eligibility is confirmed), week 1, week 2, week 3 and every 4 
weeks until objective radiological disease progression, at discontinuation of study 
treatment visit and then 30 days post last dose.  
• Health economic data in terms of utility (EuroQoL EQ5D) at baseline and every 4 
weeks until objective radiological disease progression, at discontinuation of study 
treatment visit and then 30 days post last dose.  
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• Health economic data in terms of hospital resource use at each visit during treatment 
then until objective radiological disease progression, at discontinuation of study 
treatment visit and then 30 days post last dose.  
• Mandatory blood sample for biomarker analysis at cycle 1 day 1 (pre-dose) and 
disease progression (Section 5.4.1) 
Once patients have discontinued study treatment, other treatment options will be at the 
discretion of the investigator. 
4.3 Follow-up period 
4.3.1 Treatment discontinuation visit due to objective radiological disease 
progression 
Patients should be discontinued from study treatment if they have objective radiological 
disease progression according to modified RECIST 1.1 criteria (see Appendix F).  
Following radiological disease progression patients will be followed for PFS2 and OS. 
4.3.2 Treatment discontinuation visit due to any other discontinuation criteria 
Patients should be discontinued from study treatment if any discontinuation criteria are 
fulfilled (see Section 3.9).  The assessments to be carried out at the visit are detailed in the 
study schedule (Table 1). 
Patients who have discontinued from treatment but do not have radiological disease 
progression will continue to be followed for PFS by modified RECIST 1.1 assessments every 
8 weeks (+/-1 week) from date of randomisation during the first 40 weeks and then every 12 
weeks (+/-1 week) thereafter.  
4.3.3 Patients who have objective radiological disease progression but continue on 
study treatment 
Patients should be discontinued from study treatment if they have objective radiological 
disease progression according to RECIST (see Appendix F), however, patients may be 
allowed to continue study treatment if the investigator believes, and AZ Study Physician 
concurs, that the patient could continue to receive benefit, the patient is not experiencing 
serious toxicity, and there is no available better alternative treatment that could benefit the 
patient. These patients will continue study procedures as per Table 1 and will be followed for 
OS. Safety assessment can occur with the same frequency as the visits unless more frequent 
testing is clinically indicated. 
4.3.4 Follow-up 30 day after last dose of study treatment (follow-up visit) 
A follow-up visit should be conducted 30 days after the last dose of study treatment.  Any 
serious and/or non-serious AEs ongoing at the time of the Discontinuation Visit or which have 
occurred during the defined 30-day follow-up period must be followed-up (in accordance with 
Section 6.3).  Appropriate safety evaluations should be repeated and/or additional tests 
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performed at any time when clinically indicated, or at the discretion of the investigator, until 
resolution, unless, in the investigator’s opinion, the condition is unlikely to resolve due to the 
patient’s underlying disease.  If the patient is lost to follow-up, then this should be noted in the 
eCRF.  The assessments to be carried out at the 30 day follow up visit are detailed in the study 
schedule (Table 1). 
4.3.5 Survival 
Assessments for survival should be made every 8 weeks following objective radiological 
disease progression.  Survival information may be obtained via telephone contact with the 
patient, patient’s family or by contact with the patient’s current physician.  Survival data will 
be collected up to the time of the final overall survival (OS) analysis.  In addition, patients 
should be contacted in the week following the data cut-off for the primary PFS and final 
survival analyses to provide complete survival data. 
Patients will be followed up as per Table 1 to the point of the final analysis.  At this point 
investigators will be notified that no further data collection for the study is required.  
Monitoring and recording of SAEs will continue as per Section 6.4. 
The status of patients at the time of an overall survival analysis should be obtained by the site 
personnel by checking the patient’s notes, hospital records, contacting the patients general 
practitioner and checking publicly available death registries. In the event that the patient has 
actively withdrawn consent to the processing of their personal data the vital status of the 
patient can be obtained by site personnel from publicly available resources where it is possible 
to do so under applicable local laws (see Section 3.10). 
4.3.6 Second Progression 
Following objective progression, copies of the patient’s radiological scans are no longer 
required to be sent for blinded independent central review. Patients will be assessed every 8 
weeks for a second progression (using the patients’ status at first progression as the reference 
for assessment of second progression). A patient’s progression status is defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF. 
4.3.7 Subsequent Treatment 
Following objective progression on study as per modified RECIST 1.1, copies of the patient’s 
radiological scans are no longer required to be sent for blinded independent central review, 
provided that the central read confirms progression. If progression is not confirmed, one 
additional scan will be required at the next scheduled visit. Following objective progression 
patients will be assessed every 8 weeks for survival (see Section 4.3.5) but also for nature of 
subsequent treatment, response to subsequent treatment and investigator assessment of time to 
progression on the subsequent treatment. While other than the PFS2, response and time to 
progression on later therapies is not a specific endpoint of the trial, the information garnered 
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will help determine if there is an optimal sequencing of treatments for gBRCA-associated 
pancreas cancer and for planning of future clinical studies. 
The data cut-off date for the final statistical analysis for the primary objective of the study will 
be established when approximately 89 confirmed progression events are expected to have 
occurred. 
Patients on study treatment at the time of the data cut-off will continue to receive study 
treatment until they meet any discontinuation criteria as per Section 3.9.  
Patients on study treatment will be followed for core safety assessments (haematology, 
clinical chemistry, AEs/SAEs, concomitant medications and study treatment dosing details) 
Once the primary PFS analysis has been performed the collection of RECIST data for 
independent central review will cease. Patients who have not had an objective disease 
progression at the time of the data cut off for the primary analysis should continue to have 
RECIST assessments until first objective disease progression is determined by the 
investigator. RECIST assessments should be performed every 12 weeks (± 1week) from the 
last assessment prior to the data cut off date.  Patients will also be followed for information on 
vital status to obtain the data needed for the OS analysis and information on subsequent 
treatment.   
4.4 Patient management post final analysis 
The data cut-off date for the final statistical analysis of the study will be established when 
~106 confirmed OS events (~75 % maturity for OS analysis) are expected to have occurred. 
At this time point, the clinical study database will close to new data.  Patients who are 
receiving treatment can either choose to discontinue from the study or where the investigator 
believes patients are gaining clinical benefit; patients may continue to receive study treatment.  
All patients will receive follow up care in accordance with standard local clinical practice. 
AstraZeneca will continue to supply Olaparib after completion of this study until either 
Olaparib is licensed in that country, or it is determined that the benefit to risk profile does not 
support continued development of Olaparib, or the national health authority has deemed the 
drug not approvable.  In all these scenarios, AstraZeneca will work with investigators on the 
proper transition of patients to alternative therapies if possible. 
SAEs will continue to be reported to AstraZeneca Patient Safety Department, for any patients 
who continue on Olaparib until 30 days after study treatment is discontinued, in accordance 
with Section 6.4.  Additionally as stated any SAE or non-serious adverse event, that is 
ongoing at the end of the study, must be followed up to resolution unless the event is 
considered by the investigator to be unlikely to resolve, or the patient is lost to follow-up.  If 
an investigator learns of any SAEs, including death, at any time after a patient has completed 
the study, and he/she considers there is a reasonable possibility that the event is causally 
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related to the investigational product, the investigator should notify AstraZeneca, Patient 
Safety. 
Drug accountability should continue to be performed until the patient stops study treatment 
completely 
5. STUDY ASSESSMENTS   
The Rave Web Based Data Capture (WBDC) system will be used for data collection and 
query handling. The investigator will ensure that data are recorded on the electronic Case 
Report Forms as specified in the study protocol and in accordance with the instructions 
provided. 
The investigator ensures the accuracy, completeness and timeliness of the data recorded and 
of the provision of answers to data queries according to the Clinical Study Agreement. The 
investigator will sign the completed electronic Case Report Forms. A copy of the completed 
electronic Case Report Forms will be archived at the study site. 
5.1 Efficacy assessments 
5.1.1 CT and MRI scans Tumour assessments (Modified RECIST 1.1) 
Following the baseline assessment, subsequent tumour assessments according to modified 
RECIST 1.1 should be performed every 8 weeks (±1 week) for the first 40 weeks and then 
every 12 weeks (± 1 week) thereafter, relative to the date of randomisation, up to objective 
disease progression by RECIST. Patients who are determined to have progressed according to 
modified RECIST 1.1 criteria by the Investigator will have scans centrally reviewed for 
confirmation of objective disease progression. If disease progression is not confirmed at 
central review an additional RECIST assessment will be requested preferably at the next 
scheduled RECIST visit (8 weeks from last scan).   
For those patients with no evidence of disease at baseline, following a clinical complete 
response to chemotherapy, progression is defined by the detection of new lesions on follow up 
radiological assessments (modified RECIST 1.1). 
 
The imaging modalities used for RECIST assessment will be CT (MRI where CT is 
contraindicated) scans of the chest, abdomen and pelvis with other regions as clinically 
indicated for the assessment of disease.  Any other sites at which new disease is suspected 
should also be appropriately imaged.  The methods of assessment of tumour burden used at 
baseline must be used at each subsequent follow-up assessment. 
Radiological examinations performed in the conduct of this study should be retained at site as 
source data. 
Any missed copies of the scans are to be sent to an AstraZeneca appointed CRO for blinded 
independent central review. 
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All treatment decisions will be based on site assessment of scans.  After the primary PFS 
analysis, central review of scans will no longer be required and investigators will be advised 
when to stop sending copies of the scans to the CRO conducting the central review.   
It is important to follow the assessment schedule as closely as possible. If scans are performed 
outside of scheduled visit ± 1 week window interval and the patient has not progressed, every 
attempt should be made to perform the subsequent scans at their scheduled time points.  
Patients will be evaluated until objective radiological disease progression by modified 
RECIST 1.1 as per the study schedule (see Table 1), and then followed for second progression 
and survival, regardless of whether study treatment is discontinued or delayed and/or protocol 
violations, unless they withdraw consent. 
5.1.2 Tumour Evaluation 
Modified RECIST 1.1 criteria will be used to assess patient response to treatment by 
determining progression free survival (PFS) times.  (The modified RECIST 1.1 guidelines for 
measurable, non-measurable, target and non-target lesions and the objective tumour response 
criteria (complete response, partial response, stable disease, no evidence of disease or 
progression of disease) are presented in Appendix F.)  
The methods of assessment of tumour burden used at baseline - CT or MRI scans of chest, 
abdomen and pelvis, with other regions as clinically indicated for the assessment of disease 
must be used at each subsequent follow-up assessment, see Section 4.3.  
Following the baseline assessment, efficacy for all patients will be assessed by objective 
tumour assessments every 8 weeks (±1 week) up to 40 weeks then every 12 weeks (±1 week) 
relative to date of randomisation, according to the planned study schedule Table 1until 
objective radiological disease progression as defined by modified RECIST. If a patient 
discontinues treatment (and/or receives a subsequent cancer therapy) prior to progression then 
the patient should still continue to be followed until objective radiological disease progression 
as defined by modified RECIST 1.1. 
Categorization of objective tumour response assessment will be based on the modified 
RECIST criteria of response: complete response (CR), partial response (PR), stable disease 
(SD), progression of disease (PD), no evidence of disease (NED) and not evaluable (NE).  
Target lesion (TL) progression will be calculated in comparison to when the tumour burden 
was at a minimum (ie, smallest sum of diameters previously recorded on study).  In the 
absence of a best response of progression, tumour response (CR, PR, SD) will be calculated in 
comparison to the baseline tumour measurements obtained before randomisation. 
For patients with non-measurable disease only at baseline, categorization of objective tumour 
response assessment will be based on the RECIST criteria of response: CR (complete 
response), PD (progression of disease) and Non CR/Non PD. Patients with no disease at 
baseline will be assessed according to modified RECIST 1.1 criteria for new lesions with 
responses of No Evidence of Disease (NED) or progression of disease. 
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If the investigator is in doubt as to whether disease progression has occurred on study therapy, 
particularly with response to NTL (non-target lesion) or the appearance of a new lesion, it is 
advisable to continue treatment until the next scheduled assessment or sooner if clinically 
indicated and reassess the patient’s status.  If repeat scans confirm disease progression, then 
the date of the initial scan should be declared as the date of disease progression.  
To achieve ‘unequivocal progression’ on the basis of non-target disease, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD 
or PR in target disease, the overall tumour burden has increased sufficiently to merit 
discontinuation of therapy.  A modest increase in the size of one or more non-target lesions is 
usually not sufficient to qualify for unequivocal progression status. 
Following progression, patients should continue to be followed up for survival every 8 weeks 
as outlined in the study plan. It is important to follow the assessment schedule as closely as 
possible. Please refer to the study plan in Section 1.5 and CT/MRI scans in section 5.1.1. 
5.1.3 Central reading of scans 
An independent review of all scans used in the assessment of tumours according to modified 
RECIST will be conducted for data collected up to the data cut off for the primary analysis of 
PFS.  All imaging assessments including unscheduled visit scans will be collected on an 
ongoing basis and sent to an AstraZeneca appointed Contract Research Organisation (CRO) 
for central analysis. Results of this independent review will not be communicated to 
investigators (with the exception of confirmation of progression assessments), and the 
management of patients will be based solely upon the results of the RECIST assessment 
conducted by the investigator. 
The primary analysis for this study will be based on the blinded independent central review 
(BICR) of the radiological scans. 
5.2 Safety assessments 
5.2.1 Laboratory safety assessments 
Blood and urine samples for determination of clinical chemistry, haematology, coagulation, 
and urinalysis will be taken at the times indicated in the Study Schedule (see Table 1). 
These tests will be performed by the hospital’s local laboratory.  Additional analyses may be 
performed if clinically indicated.  
Any clinically significant abnormal laboratory values should be repeated as clinically 
indicated and recorded on the eCRF. 
The following laboratory variables will be measured: 
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Table 2 Laboratory Safety Variables 
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma) 
B-Haemoglobin  S-Sodium 
B-Red blood cells [RBC] S-Potassium 
B-Platelets S-Magnesium (baseline only and if clinically 
indicated) 
B-Mean cell volume [MCV] S-Calcium  
B-Mean cell haemoglobin concentration [MCHC]  S-Creatinine 
B-Mean cell haemoglobin [MCH] S-Total bilirubin 
B-White blood cells [WBC]  S-Gamma glutamyltransferase [GGT]  
B-Absolute differential white cell count 
− (neutrophils, lymphocytes, monocytes, 
eosinophils and basophils) and absolute 
neutrophil count or segmented neutrophil 
count and Band forms should be performed 
at each visit and when clinically indicated. 
If absolute differentials not available please 
provide % differentials. 
S-Aalkaline phosphatase [ALP] 
S-Aspartate transaminase [AST] 
S- alanine transaminase [ALT] 
S-Urea or blood urea nitrogen [BUN] 
S-Total protein 
S-Albumin 
S-Lactate dehydrogenase (LDH) 
  
Urine Tests  






Urinalysis (Microscopic analysis, baseline only and 
if clinically indicated) 
 
 
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities.  The laboratory results should be signed and dated and retained at 
centre as source data for laboratory variables.  For information on how AEs based on 
laboratory tests should be recorded and reported, see Section 5.2. 
NB. In case a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN please refer 
to Appendix D ‘Actions required in cases of combined increase of Aminotransferase and Total 
Bilirubin – Hy’s Law’, for further instructions. 
For blood volume see Section 5.6.1. 
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5.2.2 Physical examination 
For timing of individual measurement refer to study schedule (Table 1). 
A physical examination will be performed and include an assessment of the following: general 
appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, 
nose and throat), lymph nodes, thyroid, abdomen, musculo-skeletal (including spine and 
extremities) and neurological systems. 
5.2.3 ECOG 
ECOG Performance Status is a widely used, 5-level, clinician reported outcome of the 
patient’s performance status. Below is a description of the clinician’s grading system for the 
ECOG Performance Status (see also Appendix G). This measure will be applied according to 
the study schedule (see Table 1). 
Table 3 ECOG Performance Status a 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair 
5 Dead 
a As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982. 
  
5.2.4 ECG 
5.2.4.1 Resting 12-lead ECG 
ECGs are required during screening within 7 days prior to starting study treatment and when 
clinically indicated afterwards.  
Twelve-lead ECGs will be obtained after the patient has been rested in a supine position for at 
least 5 minutes in each case.  The investigator or designated physician will review the paper 
copies of each of the timed 12-lead ECGs on each of the study days when they are collected.  
ECGs will be recorded at 25 mm/sec.  All ECGs should be assessed by the investigator as to 
whether they are clinically significantly abnormal / not clinically significantly abnormal.  If 
there is a clinically significant abnormal finding, the investigator will record it as an AE on the 
eCRF.  The original ECG traces must be stored in the patient medical record as source data. 
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5.2.5 Vital signs 
Height will be assessed at screening only. 
Weight will be assessed at screening and as clinically indicated at any other time.  
5.2.5.1 Pulse and blood pressure 
Blood pressure and pulse rate will be measured preferably using a semi automatic BP 
recording device with an appropriate cuff size. 
5.2.5.2 Body temperature 
Body temperature will be measured in degrees Celsius using an automated thermometer. 
5.2.6 Other safety assessments 
Blood and urine samples for determination of clinical chemistry, haematology, coagulation, 
and urinalysis will be taken at the times indicated in the Study Schedule (see Table 1). 
These tests will be performed by the hospital’s local laboratory.  Additional analyses may be 
performed if clinically indicated.  
Any clinically significant abnormal laboratory values should be repeated as clinically 
indicated and recorded on the eCRF. 
5.2.6.1 Serum or urine pregnancy test 
Pregnancy tests on blood or urine samples will be performed for pre-menopausal women of 
childbearing potential as per the study schedule.  Tests will be performed by the hospital’s 
local laboratory.  If results are positive the patient is ineligible/must be discontinued from the 
study.  In the event of a suspected pregnancy during the study, the test should be repeated. 
Any changes in vital signs should be recorded as an AE, if applicable. 
5.2.7 Bone marrow or blood cytogenetic samples  
Bone marrow or blood cytogenetic samples may be collected as clinically indicated for 
patients with prolonged haematological toxicities as defined in Section 6.7.1.  
Bone marrow analysis should include an aspirate for cellular morphology, cytogenetic 
analysis and flow cytometry, and a core biopsy for bone marrow cellularity.  If it is not 
possible to conduct cytogenetic analysis or flow cytometry on the bone marrow aspirate, then 
attempts should be made to carry out the tests on a blood sample.  Full reports must be 
provided by the investigator for documentation on the Patient Safety database. 
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5.3 Other assessments 
5.3.1 Patient reported outcomes 
5.3.1.1 EORTC QLQ-C30 and QLQ-PAN26 
In this study patient reported disease related symptoms and health related quality of life will 
be evaluated using the validated EORTC QLQ-C30 and the PAN26 questionnaire.  The 
EORTC QLQ-C30 was developed to assess HRQOL and functioning, and is the most 
commonly used cancer-specific tool in oncology.  It has undergone extensive testing and 
validation as well as detailed cross cultural linguistic validation and has been used in pancreas 
cancer and gastric cancer trials (Fitzsimmons D et al 1999).  The PAN26 was developed 
specifically for patients with pancreas cancer and has been found to be reliable and valid in 
this population as well as in pancreatitis patients. 
The EORTC QLQ-C30 comprises 30 questions designed for all cancer types.  Questions can 
be grouped into the following scales: 
• 5 multi-item functional scales (physical, role, emotional, cognitive and social)  
• 3 multi-item symptom scales (fatigue, pain, nausea vomiting) 
• A 2-item global QoL scale 
• 5 single items assessing the following common cancer symptoms: 
− dyspnoea,  
− loss of appetite,  
− insomnia,  
− constipation,  
− diarrhoea 
• 1 item on the financial impact of the disease. 
The pancreas cancer module (PAN26) is intended for patients at all disease stages undergoing 
surgical resection, palliative surgical intervention, endoscopic palliation or palliative 
chemotherapy. The module comprises 26 questions assessing pain, dietary changes, jaundice, 
altered bowel habit, emotional problems related to pancreas cancer, and other symptoms 
(cachexia, indigestion, flatulence, dry mouth, taste changes). 
All the EORTC scales range from 0 to 100 (through transformation of scores).  A high scale 
score represents a higher response level.  Thus a high score for a functional scale represents a 
high / healthy level of functioning, while a high score for a symptom scale / item represents a 
high level of symptomatology / problems. 
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5.3.1.2 Administration of PRO questionnaires 
The EORTC QLQ-C30 and QLQ-PAN26 will be administered according to the study 
schedule (see Table 1).  
Questionnaires will be completed using a pencil and paper method of data collection. Each 
centre must allocate the responsibility for the administration (and training on ePRO device if 
used) of the questionnaires to a specific individual (eg, a research nurse, study coordinator) 
and if possible assign a back-up person to cover if that individual is absent.  The AZ Study 
Delivery Team (or delegate) will provide relevant training in administration of the 
questionnaires.  The significance and relevance of the data need to be explained carefully to 
participating patients so that they are motivated to comply with data collection. The site staff 
enters the information directly into the WBDC electronic database system. 
The instructions for completion of the PRO questionnaires are as follows: 
• The EORTC QLQ-C30 and QLQ-PAN26 must be completed prior to any other study 
procedures (following informed consent) and before discussion of disease progress to 
avoid biasing the patient’s responses to the questions.  Patients must complete the 
EORTC QLQ-C30 before completing the QLQ-PAN26. They must be completed in 
private by the patient. 
• The patient should be given sufficient time to complete at their own speed. 
• The patient should not receive help from relatives, friends or clinic staff to answer the 
questionnaire.  However, if the patient is unable to read the questionnaire (eg, is blind 
or illiterate) the questionnaire may be read out by trained clinic staff and responses 
recorded. 
• On completion of the questionnaire it should be handed back to the person responsible 
for questionnaires who should check for completeness. 
5.4 Biomarkers 
Tumour and blood samples will be collected for the biomarker work as detailed in the 
laboratory manual 
For blood volume see Section 5.6.1. 
5.4.1 Biomarker samples 
The biomarker samples will be collected as described in Table 4. 
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Table 4  Samples for Biomarker Research 
Sample Type Visits 
Whole blood sample for prospective 
germline BRCA testing at central laboratory 
for patients with unknown gBRCA status and 
for confirmation of gBRCA status for those 
with previous results 
Screening Part 1 for patients with unknown 
gBRCA status 
Day 1 for patients with known local gBRCA 
test 
Whole blood sample for assessment of 
current and future gBRCA mutation assay(s) 
Screening Part 1 for patients with unknown 
gBRCA status 
Day 1 for patients with known local gBRCA 
test 
Archival tumour sample (paraffin or 
cytology) – Requested, if available 
Screening Part 1 for patients with unknown 
gBRCA status 
Screening Part 2 for patients with known local 
gBRCA test 
Blood samples for biomarker analysis  Cycle 1 Day 1 and disease progression  
 
The samples and data from this research will be coded and not labelled with any personal 
details.  Each sample will be identified with the study and patient enrolment number.  In this 
way biomarker data may be correlated with clinical data, samples destroyed in the event of 
withdrawal of consent and regulatory audit enabled.  However, only the investigator will be 
able to link the biomarker sample to the individual patient.  The coded samples may be made 
available to groups or organisations working with AstraZeneca on this research or as part of 
the development of the drug and companion diagnostic.  However, the samples and any results 
will remain the responsibility of AstraZeneca at all times.  AstraZeneca will not give samples, 
sample derivatives or data derived from the samples to any other parties except as required by 
law.  
Biomarker data may be generated in real time during the study or retrospectively and will 
have unknown clinical significance.  AstraZeneca will not provide biomarker results to 
patients, their family members, any insurance company, an employer, clinical study 
investigator, general physician or any other third party unless required to do so by law.  The 
patient’s samples will not be used for any other purpose other than those described in the 
protocol. 
The exception to the above is the gBRCA status result from the Myriad assessment for patients 
with previously unknown local gBRCA status.  This result will be provided to the investigator 
and will be collected as part of the patient’s demography and medical history details. 
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5.4.2 Collection of blood sample for Myriad germline BRCA1 and BRCA2 testing 
All patients must have a known deleterious or suspected deleterious gBRCA mutation to be 
randomised; this may have been determined prior to study entry or may be assessed as part of 
the enrolment procedure for the study (via Myriad). 
5.4.2.1 Guidance for gBRCA testing of patients with known gBRCA status. 
For patients that can be randomised to the study on the basis of a pre-existing known gBRCA 
mutation test result, a blood sample for a confirmatory gBRCA mutation test by Myriad must 
be taken once the patient has consented to the study.  Should the result from the Myriad test 
indicate the patient does not have a deleterious or suspected deleterious gBRCA mutation; the 
patient can continue in the study and can continue to receive their allocated study treatment if 
deemed appropriate by the investigator.   
Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response). 
5.4.2.2 Guidance for gBRCA testing of patients with unknown gBRCA status. 
Patients that do not know their gBRCA status, but meet all other eligibility criteria must have a 
Myriad test prior to randomisation in to the study.  A blood sample for the Myriad BRCA test 
can be taken once all local ethical procedures for such testing have been completed.  If the 
result shows that the patient has a deleterious/suspected deleterious gBRCA mutation, the 
patient can then be randomised to the study.  In order to limit the time that the patient is not 
receiving study treatment after their last dose of chemotherapy, it may be necessary for the 
patient to have a Myriad BRCA test whilst still on chemotherapy.  
Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response). 
5.4.2.3 Collection of blood sample for assessment of current and future gBRCA 
mutation assay(s) 
All patients will be required to provide a mandatory 9 ml blood sample that will be stored for 
subsequent assessment of current and future gBRCA mutation assay(s). 
Samples may be required to support subsequent analysis as part of a bridging study between 
the Myriad BRCA test to be used in this study and the “to be marketed” diagnostic test which 
is currently under development. Samples are required to be collected from all patients 
including those shown not to have a deleterious or suspected deleterious gBRCA1 or gBRCA2 
mutation. 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
72(121) 
Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response). 
 
5.4.3 Exploratory Biomarker Research on Archival Tumour Samples (Paraffin 
block or tissue cytology slides) (Requested, if available) 
These samples will be collected from the site pathologist during the screening Part 1 for 
patients with unknown gBRCA status and screening Part 2 for patients with known local 
gBRCA test.  An adequately sized (minimum of 2 mm x 2 mm) historical tumour tissue 
paraffin block from a core biopsy from the primary tumour or a metastatic site is most 
desirable.  This sample will have been collected anytime since the time of original diagnosis 
but prior to study entry.  Alternatively, 10-20 pre-cut sections mounted on glass slides 
prepared from the block can be provided. If the only diagnostic test was cytologic, a paraffin 
block or three unstained slides of tumour tissue should be submitted if available. 
Collection of an archival tumour sample is requested if available for all patients for the 
assessment of tissue BRCA mutation status. Surplus tissue may be used for additional 
exploratory work, to elucidate the mechanism of response, understand the mode of action of 
study treatment, and improve the understanding of disease progression (including tumour 
BRCA mutation status and its role in response). 
Please refer to Investigator Laboratory Manual for further details of archival tissue collection, 
shipping and storage. 
5.4.4 Exploratory Blood samples for biomarker analysis (Mandatory) 
All consenting patients will be required to provide a blood sample at randomisation and 
disease progression for exploratory biomarker research. 
Patients will be required to provide: 
• 1x 6ml blood sample for preparation of serum at cycle 1 day 1 and disease 
progression. 
• 1x 6ml blood sample for preparation of plasma at cycle 1 day 1 and disease 
progression.  
Please refer to Investigator Laboratory Manual for further details of biomarker blood sample 
collection, shipping and storage.  
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5.5 Health economics 
Hospital related resource use and health state utility 
For the purposes of economic evaluation it is necessary to capture utility data and healthcare 
resource use related to the treatment and the underlying disease. Within the clinical trial utility 
data will be captured using the EuroQoL EQ5D instrument.  The following hospital resource 
use data will be collected using the Hospital Attendance (HOSPAD) module: 
 
1) Number of hospitalisations and attendances 
2) Primary symptom/reason associated with hospitalisation or attendance 
3) Length of stay, including time in intensive care. 
 
Additional information, including medications and procedures undertaken will be derived 
from data captured under existing modules, for example, concomitant medications and 
concomitant procedures. 
5.6 Biological sampling procedures  
5.6.1 Volume of blood 
The volume of blood that will be drawn from each patient will vary, dependent upon the 
length of time that the patient remains in the trial.  The total volume of blood to be drawn 
from each patient in the study, assuming they complete screening, 6 cycles of treatment, a 
treatment discontinuation visit and the 30-day follow-up visit, is 255mL. 
Safety laboratory assessments will be performed locally at each centre’s laboratory by means 
of their established methods.  The number of samples/blood volumes is therefore patient to 
site-specific change.  Extra blood samples may also be collected if, for example, additional 
samples are required for repeat safety assessments. 
The total volume of blood that will be drawn from each patient in this study is as follows: 
Table 5  Volume of blood to be drawn from each patient 






Safety Clinical chemistry 5 21 105 
 Haematology 5 21 105 
 Coagulation 3 1 3 
Whole blood sample for Myriad BRCA test 
(retrospective/prospective) 
Whole blood sample for assessment of 










Serum Pregnancy test (site may use urine 
instead) 
Site dependent Site may use 
urine instead 
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Serum sample for exploratory biomarkers, 
cycle 1 day 1 (mandatory) 
6 1 6 
Plasma sample for exploratory biomarkers, 
cycle 1 day 1 (mandatory) 
6 1 6 
Serum sample for exploratory biomarkers, 
disease progression (mandatory) 
6 1 6 
Plasma sample for exploratory biomarkers, 
disease progression (mandatory) 
6 1 6 
Total   255 
5.6.2 Handling, storage and destruction of biological samples 
The samples will be used up or disposed of after analyses or retained for further use as 
described here. 
Biological samples for future research will be retained at AstraZeneca or a CRO, on behalf of 
AstraZeneca for a maximum of 15 years following the Last Patient’s Last Visit in the study.  
The results from future analysis will not be reported in the Clinical Study Report but 
separately in a Scientific Report. 
5.6.3 Handling, storage and destruction of biological samples 
The samples will be used up or disposed of after analyses or retained for further use as 
described here. 
Biological samples for future research will be retained at AstraZeneca or a CRO, on behalf of 
AstraZeneca for a maximum of 15 years following the Last Patient’s Last Visit in the study.  
The results from future analysis will not be reported in the Clinical Study Report but 
separately in a Scientific Report. 
5.6.4 Labelling and shipment of biohazard samples 
The Principal Investigator ensures that samples are labelled and shipped in accordance with 
the Laboratory Manual and the Biological Substance, Category B Regulations (materials 
containing or suspected to contain infectious substances that do not meet Category A criteria),  
Any samples identified as Infectious Category A materials are not shipped and no further 
samples will be taken from the patient unless agreed with AstraZeneca and appropriate 
labelling, shipment and containment provisions are approved. 
5.6.5 Chain of custody of biological samples 
A full chain of custody is maintained for all samples throughout their lifecycle. 
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The Principal Investigator at each centre keeps full traceability of collected biological samples 
from the patients while in storage at the centre until shipment or disposal (where appropriate) 
and keeps documentation of receipt of arrival. 
The sample receiver keeps full traceability of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps documentation of receipt of arrival. 
AstraZeneca keeps oversight of the entire life cycle through internal procedures, monitoring of 
study sites and auditing of external laboratory providers. 
Samples retained for further use are registered in the AstraZeneca biobank system during the 
entire life cycle. 
If required, AstraZeneca will ensure that remaining biological samples are returned to the site, 
according to local regulations or at the end of the retention period, whichever is the sooner. 
5.6.6 Withdrawal of informed consent for donated biological samples 
If a patient withdraws consent to the use of donated biological samples, the samples will be 
disposed of/destroyed, and the action documented.  If samples are already analysed, 
AstraZeneca is not obliged to destroy the results of this research. 
gBRCA sample: As collection of the biological samples is an integral part of the study, then 
the patient is withdrawn from further study participation. 
Archival tumour sample: If consent to use the sample is withdrawn this will not impact 
eligibility to study. The patient may continue in the study if the patient is already randomised. 
Blood samples for biomarker analysis: Although mandatory, the patient may continue in the 
study if the patient is already randomised. 
 
The Principal Investigator: 
• Ensures patients’ withdrawal of informed consent to the use of donated samples is 
notified immediately to AstraZeneca 
• Ensures that biological samples from that patient, if stored at the study site, are 
immediately identified, disposed of /destroyed, and the action documented 
• Ensures the laboratory (ies) holding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed/destroyed, the action documented 
and the signed document returned to the study site 
• Ensures that the patient and AstraZeneca are informed about the sample disposal. 
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AstraZeneca ensures the central laboratory (ies) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroyed and the action 
documented and returned to the study site. 
6. SAFETY REPORTING AND MEDICAL MANAGEMENT 
The Principal Investigator is responsible for ensuring that all staff involved in the study are 
familiar with the content of this section. 
6.1 Definition of adverse events 
An adverse event is the development of an undesirable medical condition or the deterioration 
of a pre-existing medical condition following or during exposure to a pharmaceutical product, 
whether or not considered causally related to the product.  An undesirable medical condition 
can be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver) or the 
abnormal results of an investigation (eg, laboratory findings, electrocardiogram).  In clinical 
studies, an AE can include an undesirable medical condition occurring at any time, including 
run-in or washout periods, even if no study treatment has been administered. 
The term AE is used to include both serious and non-serious AEs. 
6.2 Definitions of serious adverse event 
A serious adverse event is an AE occurring during any study phase (ie, run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria: 
− Results in death 
− Is immediately life-threatening 
− Requires in-patient hospitalisation or prolongation of existing hospitalisation  
− Results in persistent or significant disability/incapacity or substantial disruption 
of the ability to conduct normal life functions 
− Is a congenital abnormality or birth defect 
− Is an important medical event that may jeopardise the patient or may require 
medical intervention to prevent one of the outcomes listed above. 
For further guidance on the definition of a SAE, see Appendix B to the Clinical Study 
Protocol. 
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6.3 Recording of adverse events 
6.3.1 Time period for collection of adverse events 
Adverse Events will be collected from time of signature of informed consent throughout the 
treatment period up to and including the 30-day follow-up period.  All ongoing and any new 
AEs/SAEs identified during the 30 calendar days follow up period, after the last dose of study 
medication must be followed to resolution. After any interim analysis, any ongoing AEs/SAEs 
need to be unlocked and followed for resolution. 
 SAEs will be recorded from the time of informed consent. 
6.3.2 Follow-up of unresolved adverse events 
Any SAEs or non-serious adverse event that is ongoing at the time of the 30-day 
follow up, must be followed up to resolution unless the event is considered by the 
investigator to be unlikely to resolve, or the patient is lost to follow up. 
AstraZeneca retains the right to request additional information for any patient 
with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary. 
6.3.3 Variables  
The following variables will be collect for each AE; 
− AE (verbatim) 
− The date when the AE started and stopped 
− Whether the AE is serious or not 
− Investigator causality rating against the Investigational Product (yes or no) 
− Action taken with regard to investigational product 
− Outcome. 
In addition, the following variables will be collected for SAEs: 
− Date AE met criteria for serious AE 
− Date Investigator became aware of serious AE 
− AE is serious due to 
− Date of hospitalisation 
− Date of discharge 
− Probable cause of death 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
78(121) 
− Date of death 
− Autopsy performed 
− Causality assessment in relation to Study procedure(s) 
− Causality assessment in relation to Other medication 
− Description of AE. 
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Section 6.2. 
Severity of AE 
For each episode on an adverse event, all changes to the CTCAE grade attained as well as the 
highest attained CTC grade should be reported. 
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE. On the other hand, a stroke 
that results in only a limited degree of disability may be considered a mild stroke but would be 
a SAE. 
The grading scales found in the National Cancer Institute (NCI) CTCAE version 4.0 will be 
utilised for all events with an assigned CTCAE grading.  For those events without assigned 
CTCAE grades the recommendation is that the CTCAE criteria that convert mild, moderate 
and severe events into CTCAE grades should be used. 
A copy of the CTCAE version can be downloaded from the NCI website. 
6.3.4 Causality collection 
The Investigator will assess causal relationship between Investigational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by the investigational product?’ 
For SAEs causal relationship will also be assessed for other medication and study procedures.  
Note that for SAEs that could be associated with any study procedure the causal relationship is 
implied as ‘yes’. 
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A guide to the interpretation of the causality question is found in Appendix B to the Clinical 
Study Protocol. 
6.3.5 Adverse events based on signs and symptoms 
All AEs spontaneously reported by the patient or reported in response to the open question 
from the study personnel: ‘Have you had any health problems since the previous visit/you 
were last asked?’, or revealed by observation will be collected and recorded in the CRF.  
When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a 
list of signs and symptoms.  However, if a diagnosis is known and there are other signs or 
symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom 
will be recorded separately. 
6.3.6 Adverse events based on examinations and tests 
The reporting of laboratory/vital signs/ECG abnormality as AE should be avoided unless one 
of the following is met: 
− Any criterion for an SAE is fulfilled 
− Causes study treatment discontinuation 
− Causes study treatment interruption 
− Causes study treatment dose reduction 
− The investigator believes that the abnormality should be reported as an AE 
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign 
will be considered as additional information.  Wherever possible the reporting investigator 
uses the clinical, rather than the laboratory term (eg, anaemia versus low haemoglobin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-
mandated parameters should be reported as AE(s). 
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE. 
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE. 
NB. Cases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN may 
need to be reported as SAEs, please refer to Appendix D ‘Actions required in cases of 
combined increase of Aminotransferase and Total Bilirubin – Hy’s Law’, for further 
instructions. 
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6.3.7 Hy’s Law 
Cases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN may need 
to be reported as SAEs. Please refer to Appendix D for further instruction in cases of 
combined increase of aminotransferase and total bilirubin. 
6.3.8 Disease progression 
Disease progression can be considered as a worsening of a patient’s condition attributable to 
the disease for which the investigational product is being studied.  The development of local 
regional recurrence or distant metastasis to the primary cancer under study should be 
considered as disease progression and not an AE.  Events, which are unequivocally due to 
disease progression, should not be reported as an AE during the study. 
New cancers 
The development of a new primary cancer (including skin cancer) should be regarded as an 
AE and will generally meet at least one of the serious criteria (see Section 6.2).  New primary 
cancers are those that are not the primary reason for the administration of the study treatment 
and have developed after the inclusion of the patient into the study.  They do not include 
metastases of the original cancer.  Symptoms of metastasis or the metastasis itself should not 
be reported as an AE/SAE, as they are considered to be disease progression. 
Lack of efficacy 
When there is deterioration in the cancer, for which the study treatment(s) is being used, there 
may be uncertainty as to whether this is lack of efficacy or an AE.  In such cases, unless the 
Sponsor or the reporting physician considers that the study treatment contributed to the 
deterioration of the condition, or local regulations state to the contrary, the deterioration 
should be considered to be a lack of efficacy and not an AE. 
Deaths 
All deaths that occur during the study, or within the protocol-defined 30-day post-study 
follow-up period after the administration of the last dose of study treatment, must be reported 
as follows: 
• Death clearly the result of disease progression should be reported to the study monitor 
at the next monitoring visit and should be documented in the DEATH eCRF but 
should not be reported as an SAE 
• Where death is not due (or not clearly due) to progression of the disease under study, 
the AE causing the death must be reported to the study monitor as a SAE within 24 
hours (see Section 6.4 for further details).  The report should contain a comment 
regarding the co-involvement of progression of disease, if appropriate, and should 
assign main and contributory causes of death.  This information can be captured in the 
‘death eCRF’. 
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Deaths with an unknown cause should always be reported as a SAE.  A post mortem maybe 
helpful in the assessment of the cause of death, and if performed a copy of the post-mortem 
results should be forwarded to AstraZeneca within the usual timeframes. 
6.4 Reporting of serious adverse events 
All SAEs have to be reported, whether or not considered causally related to the investigational 
product, or to the study procedure(s). All SAEs will be recorded in the CRF. 
If any SAE occurs in the course of the study, then investigators or other site personnel inform 
appropriate AstraZeneca representatives immediately, or no later than 24 hours of when he 
or she becomes aware of it. 
The designated AstraZeneca representative works with the investigator to ensure that all the 
necessary information is provided to the AstraZeneca Patient Safety data entry site within one 
calendar day of initial receipt for fatal and life threatening events and within five calendar 
days of initial receipt for all other SAEs. 
For fatal or life-threatening adverse events where important or relevant information is missing, 
active follow-up is undertaken immediately.  Investigators or other site personnel inform 
AstraZeneca representatives of any follow-up information on a previously reported SAE 
immediately, or no later than 24 hours of when he or she becomes aware of it. 
Once the Investigators or other site personnel indicate an AE is serious in the WBDC system, 
an automated email alert is sent to the designated AstraZeneca representative. 
If the WBDC system is not available, then the Investigator or other study site personnel 
reports a SAE to the appropriate AstraZeneca representative by telephone. 
The AstraZeneca representative will advise the Investigator/study site personnel how to 
proceed 
6.5 Overdose 
There is currently no specific treatment in the event of overdose of Olaparib and possible 
symptoms of overdose are not established.   
Adverse reactions associated with overdose should be treated symptomatically and should be 
managed appropriately.  
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant 
AE modules in the CRF and on the Overdose CRF module. 
An overdose without associated symptoms is only reported on the Overdose CRF module. 
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If an overdose on an AstraZeneca study drug occurs in the course of the study, then 
Investigators or other site personnel inform appropriate AstraZeneca representatives 
immediately, or no later than 24 hours of when he or she becomes aware of it. 
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site. 
For overdoses associated with SAE, standard reporting timelines apply (see Section 6.4).  For 
other overdoses, reporting should be done within 30 days. 
6.6 Pregnancy 
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca. 
6.6.1 Maternal exposure 
Women of childbearing potential are not allowed to be included in this study.  Should a 
pregnancy still occur, the investigational product should be discontinued immediately and the 
pregnancy reported to AstraZeneca 
If a patient becomes pregnant during the course of the study investigational product should be 
discontinued immediately. 
Pregnancy itself is not regarded as an adverse event unless there is a suspicion that the 
investigational product under study may have interfered with the effectiveness of a 
contraceptive medication.  Congenital abnormalities/birth defects and spontaneous 
miscarriages should be reported and handled as SAEs.  Elective abortions without 
complications should not be handled as AEs.  The outcome of all pregnancies (spontaneous 
miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnormality) 
should be followed up and documented even if the patient was discontinued from the study. 
If any pregnancy occurs, then the Investigator or other site personnel informs the appropriate 
AstraZeneca representatives within 1day ie, immediately but no later than 24 hours of when 
he or she becomes aware of it. 
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 5 
calendar days for SAEs (see Section 6.4) and within 30 days for all other pregnancies. 
The same timelines apply when outcome information is available. 
6.6.2 Paternal exposure  
Male patients should refrain from fathering a child or donating sperm during the study and for 
3 months following the last dose.  Pregnancy of the patient’s partners is not considered to be 
an adverse event.  However, the outcome of all pregnancies (spontaneous miscarriage, elective 
termination, ectopic pregnancy, normal birth or congenital abnormality) should if possible be 
followed up and documented. 
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The outcome of any conception occurring from the date of the first dose until 3 months after 
the last dose should be followed up and documented. 
To capture information about a pregnancy from the partner of a male patient, the male 
patient’s partner consent must be obtained to collect information related to the pregnancy and 
outcome; the male patient should not be asked to provide this information. A consent form 
specific to this situation must be used. 
6.7 Management of toxicity of Olaparib 
Any toxicity observed during the course of the study could be managed by interruption of the 
dose of study treatment or dose reductions.  Study treatment can be dose reduced to 250 mg 
bid as a first step and to 200 mg bid as a second step. 
6.7.1 Management of haematological toxicity Olaparib  
Table 6  Management of Haematological Toxicity Olaparib 
Toxicity Study treatment dose adjustment 
CTCAEa gr 1-2 Dose interruption as judged by the investigator; appropriate supportive 
treatment and causality investigation 
Repeat CTCAE gr 1-2 Dose interruption until recovery to CTCAE gr 1 and dose reduction to 250 
mg bid as first step and 200 mg bid as second step 
CTCAE gr 3-4 Dose interruption until recovered to CTCAE gr 1 for max of 4 weeks and 
dose reduction to 200 mg bid 
Repeat CTCAE gr 3-4 Discontinue study treatment 
a CTCAE Version 4 
6.7.1.1 Management of anaemia 
Adverse events of anaemia CTCAE grade 1 or 2 (Hb > 8 g/dl) should be investigated and 
managed as deemed appropriate by the investigator with or without interruption of study drug 
or change in dose, taking into account previous history of anaemia.  Common treatable causes 
of anaemia (eg, iron, vitamin B12 or folate deficiencies and hypothyroidism) should be 
investigated and appropriately managed.  In some cases management of anaemia may require 
blood transfusions.  However, if a patient develops anaemia CTCAE grade 3 (Hb < 8g/dl) or 
worse, study treatment should be interrupted for up to maximum of 4 weeks.   Study treatment 
can be restarted at the same dose if Hb has recovered to > 9 g/dl.  Any subsequently required 
anaemia related interruptions, considered likely to be dose related, or coexistent with newly 
developed neutropenia, and or thrombocytopenia, will require study treatment dose reductions 
to 250 mg bid as a first step and to 200 mg bid as a second step.  
If a patient has been treated for anaemia with multiple blood transfusions without study 
treatment interruptions and becomes blood transfusion dependant as judged by investigator, 
study treatment should be interrupted for up to a maximum of 4 weeks to allow for bone 
marrow recovery.  Study treatment should be restarted at a reduced dose. 
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6.7.1.2 Management of neutropenia and leukopenia 
Adverse event of neutropenia and leukopenia should be managed as deemed appropriate by 
the investigator with close follow up and interruption of study drug if CTC grade 3 or worse 
neutropenia occurs.  Primary prophylaxis with Granulocyte colony-stimulating factor (G-CSF) 
is not recommended, however, if a patient develops febrile neutropenia, study treatment 
should be stopped and appropriate management including G-CSF should be given according 
to local hospital guidelines.  Please note that G-CSF should not be used within at least 24 h (7 
days for pegylated G-CSF) of the last dose of study treatment unless absolutely necessary.  
Study treatment can be restarted at the same dose if an adverse event of neutropenia or 
leucopenia have been recovered up to CTCAE grade 1 (ANC ≥ 1.5 x 109/L).   
Any subsequent interruptions will require study treatment dose reductions to 250 mg bid as a 
first step and to 200 mg bid as a second step.  
6.7.1.3 Management of thrombocytopenia 
An adverse event of thrombocytopenia should be managed as deemed appropriate by the 
investigator.  If a patient develops thrombocytopenia CTCAE grade 3 or worse study 
treatment should be interrupted for a maximum of 4 weeks.  In some cases management of 
thrombocytopenia may require platelet transfusions.  Platelet transfusions should be done 
according to local hospital guidelines. 
Management of prolonged haematological toxicities while on study treatment. 
If a patient develops prolonged haematological toxicity such as: 
• ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse anaemia 
and/or development of blood transfusion dependence 
• ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse 
neutropenia (ANC < 1 x 109/L) 
• ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse 
thrombocytopenia (Platelets < 50 x 109/L) 
Weekly differential blood counts including reticulocytes and peripheral blood smear should be 
performed.  If any blood parameters remain clinically abnormal after 4 weeks of dose 
interruption, the patient should be referred to haematologist for further investigations.  Bone 
marrow analysis and/or blood cytogenetic analysis should be considered at this stage 
according to standard haematological practice.  
Development of a confirmed myelodysplastic syndrome or other clonal blood disorder should 
be reported as an SAE and full reports must be provided by the investigator to AstraZeneca 
Patient Safety.  Olaparib treatment should be discontinued if patient’s diagnosis of MDS 
and/or AML is confirmed. 
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6.7.2 Management of non-haematological toxicity Olaparib 
6.7.2.1 Management of new or worsening pulmonary symptoms  
If new or worsening pulmonary symptoms (eg, dyspnoea) or radiological abnormality occurs, 
an interruption in study treatment dosing is recommended and a diagnostic workup (including 
a high resolution CT scan) should be performed, to exclude pneumonitis.  Following 
investigation, if no evidence of abnormality is observed on CT imaging and symptoms 
resolve, then study treatment can be restarted, if deemed appropriate by the investigator.  If 
significant pulmonary abnormalities are identified, these need to be discussed with the 
AstraZeneca Study Physician.  
6.7.2.2 Management of nausea and vomiting 
Events of nausea and vomiting are known to be associated with Olaparib treatment. In Study 
D0810C00019 nausea was reported in 71% of the Olaparib treated patients and 36% in the 
placebo treated patients and vomiting was reported in 34% of the Olaparib treated patients and 
14% in the placebo treated patients. They are generally mild to moderate (CTCAE Grade 1 or 
2) severity, intermittent and manageable on continued treatment. The first onset generally 
occurs in the first month of treatment for nausea and within the first 6 months of treatment for 
vomiting. For nausea, the incidence generally plateaus at around 9 months, and for vomiting at 
around 6 to 7 months. 
No routine prophylactic anti-emetic treatment is required at the start of study treatment, 
however, patients should receive appropriate anti-emetic treatment at the first onset of nausea 
or vomiting and as required thereafter, in accordance with local treatment practice guidelines. 
As per international guidance on antiemetic use in cancer patients (ESMO, NCCN), generally 
a single agent antiemetic should be considered eg dopamine receptor antagonist, 
antihistamines, dexamethasone. 
6.7.2.3 Interruptions for intercurrent non-toxicity related events 
Study treatment dose interruption for conditions other than toxicity resolution should be kept 
as short as possible.  If a patient cannot restart study treatment within 4 weeks for resolution 
of intercurrent conditions not related to disease progression or toxicity, the case should be 
discussed with AZ study physician. 
All dose reductions and interruptions (including any missed doses), and the reasons for the 
reductions/interruptions are to be recorded in the eCRF. 
Study treatment should be stopped at least 3 days prior to planned surgery.  After surgery 
study treatment can be restarted when the wound has healed.  No stoppage of study treatment 
is required for any biopsy procedure. 
Study treatment should be discontinued for a minimum of 3 days before a patient undergoes 
radiation treatment.  Study treatment should be restarted within 4 weeks as long as any bone 
marrow toxicity has recovered. 
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Because the AEs related to Olaparib may include asthenia, fatigue and dizziness, patients 
should be advised to use caution while driving or using machinery if these symptoms occur.  
6.7.3 Management of toxicity on placebo 
Adverse events on placebo will be handled in the same manner as those arising on Olaparib 
(see sections 6.7) 
6.8 Study governance and oversight 
6.8.1 Data Monitoring Committee 
This study will use an external independent data monitoring committee (IDMC) to perform 
interim reviews of accumulating study safety data and the interim analyses for superiority and 
futility based on PFS.  This committee will be composed of therapeutic area experts and 
statisticians, who are not employed by AZ, and do not have any major conflict of interest.  
Following the review the IDMC will recommend whether the study should continue 
unchanged, be terminated, or be modified in any way.  Once the IDMC has reached a 
recommendation, a report will be provided to AstraZeneca.  The report will only include the 
recommendation and any potential protocol amendments and will not contain any unblinding 
information. 
A separate IDMC charter will be developed which will contain details of the IDMC members 
and clearly define the responsibilities of the IDMC. 
7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS 
7.1 Identity of investigational product(s) 
AstraZeneca’s Pharmaceutical Development, R&D Supply Chain will supply Olaparib and 
matching placebo to the Investigator as film-coated tablets as shown below. 
Investigational product Dosage form and strength 
Olapariba Tablet –100mg and 150 mg  
Placebo to match Olaparib Tablet to match each strength of Olaparib 
a Descriptive information for Olaparib can be found in the Investigator’s Brochure 
7.2 Dose and treatment regimens 
Study treatment is available as a green film-coated tablet containing 150 mg or 100 mg of 
Olaparib or matching placebo. 
For all centres, Olaparib and matching placebo will be packed in high-density polyethylene 
(HDPE) bottles with child-resistant closures.  The randomised study treatment will be 
dispensed to patients.  Each dosing container will contain sufficient medication for at least 
each treatment period plus overage.  The planned dose of 300 mg bid will be made up of two 
(2) x 150 mg tablets bid with 100 mg tablets used to manage dose reductions.  Tablets should 
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be taken at the same times each morning and evening of each day, approximately 12 hours 
apart with approximately 240 mL of water.  The Olaparib tablets should be swallowed whole 
and not chewed, crushed, dissolved or divided.  Olaparib tablets can be taken with a light 
meal/snack (eg, two pieces of toast or a couple of biscuits).Multiple bottles of Olaparib or 
matching placebo maybe required for dispensing in order to make up the desired dose.  
No cross over to Olaparib will be provided in this study.  
If vomiting occurs shortly after the Olaparib tablets are swallowed, the dose should only be 
replaced if all of the intact tablets can be seen and counted.  Should any patient enrolled on the 
study miss a scheduled dose for whatever reason (eg, as a result of forgetting to take the 
tablets or vomiting), the patient will be allowed to take the scheduled dose up to a maximum 
of 2 hours after that scheduled dose time.  If greater than 2 hours after the scheduled dose 
time, the missed dose is not to be taken and the patient should take their allotted dose at the 
next scheduled time. 
Once patients have been discontinued from study treatment, other treatment options will be at 
the discretion of the investigator. 
7.3 Labelling 
Labels for Olaparib will be prepared in accordance with Good Manufacturing Practice (GMP) 
and local regulatory guidelines.  The labels will fulfil GMP Annex 13 requirements for 
labelling.  Label text will be translated into local language.  
Specific dosing instructions will not be included on the label; the site must complete the 
“Patient Dispensing Card” with the details of the dosing instructions at the time of dispensing.   
The patient emergency contact details will not be on the label, unless it is a country-specific 
regulatory requirement, but can be found in the informed consent and the ‘Patient Dispensing 
Card’.  For emergency purposes the patient must be in possession of the emergency contact 
details at all times. 
7.4 Storage 
All study drugs should be kept in a secure place under appropriate storage conditions and may 
only dispensed by investigator or pharmacist qualified designee. The investigational product 
label on the Olaparib bottle and the IB specifies the appropriate storage conditions.  
7.5 Compliance 
The administration of all study drugs (including Olaparib and placebo) should be recorded in 
the appropriate sections of the eCRF. 
Patients should be given clear instructions on how and when to take their Olaparib.  Patients 
will self-administer Olaparib.  Study site staff will make tablet counts at regular intervals 
during treatment.  Compliance will be assessed by the tablet count and the information will be 
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recorded in the appropriate section of the eCRF.  After the tablet count has been performed, 
the remaining tablets will not be returned to the patient, but will be retained by the 
investigative site until reconciliation is completed by the study monitor.  All patients must 
return their bottle(s) of Olaparib at the appropriate scheduled visit, when a new bottle will be 
dispensed.  Patients will be instructed to notify study site personnel of missed doses.  Dates of 
missed or held doses will be recorded by the site staff on the eCRF. 
Patients must return all containers and any remaining tablets at the end of the study. 
7.6 Accountability 
The study treatment provided for this study will be used only as directed in the study protocol. 
The study personnel will account for all study drugs dispensed to and returned from the 
patient. 
Study site personnel, will account for all study drugs received at the site, unused study drugs 
and for appropriate destruction.  Certificates of delivery, destruction and return should be 
signed.  Any discrepancies must be accounted for on the appropriate forms. 
7.7 Concomitant and other treatments  
Any medications (with the detailed exceptions) which are considered necessary for the 
patient's welfare, and which it is believed will not interfere with the study medication, may be 
given at the discretion of the investigator, providing the medications, the doses, dates and 
reasons for administration are recorded. 
In addition, any unplanned diagnostic, therapeutic or surgical procedure performed during the 
study period must be recorded.  This includes any blood transfusions. 
The reasons for the use, doses and dates of treatment should be recorded in the patient’s 
medical records and appropriate sections of the eCRF. 
All medications (prescriptions or over the counter medications) continued at the start of study 
or started during the study or until 30 days from the end of the last protocol treatment and 
different from the study medication must be documented. 
7.7.1 Medications that may NOT be administered 
No other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy (Hormone 
replacement therapy (HRT) is acceptable), radiotherapy, biological therapy or other novel 
agent) is to be permitted while the patient is receiving study medication. 
Live virus and bacterial vaccines should not be administered whilst the patient is receiving 
study medication and during the 30 day follow up period.  An increased risk of infection by 
the administration of live virus and bacterial vaccines has been observed with conventional 
chemotherapy drugs and the effects with Olaparib are unknown. 
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7.7.2 CYP3A4/5 restrictions  
The use of any natural/herbal products or other “folk remedies” should be discouraged but use 
of these products, as well as use of all vitamins, nutritional supplements and all other 
concomitant medications must be recorded. 
Olaparib is an investigational drug for which no data on in vivo interactions are currently 
available.  Based on in vitro data and clinical exposure data, Olaparib is considered unlikely to 
cause clinically significant drug interactions through inhibition or induction of cytochrome 
P450 enzyme activity.  In vitro data have, however, also shown that the principal enzyme 
responsible for the formation of the 3 main metabolites of Olaparib is CYP3A4/5 and 
consequently, to ensure patient safety, the following potent inhibitors of CYP3A4/5 must not 
be used during this study for any patient receiving Olaparib. 
While this is not an exhaustive list, it covers the known potent inhibitors, which have most 
often previously been reported to be associated with clinically significant drug interactions: 
• ketoconazole, itraconazole, ritonavir, idnavir, saquinavir, telithromycin, clarithromycin 
and nelfinavir  
For patients taking any of the above, the required wash-out periods prior to starting Olaparib 
is one week. 
In addition, to avoid potential reductions in exposure due to drug interactions, the following 
CYP inducers should be avoided: 
• Phenytoin, rifampicin, rifapentin, rifabutin, carbamazepine, phenobarbitone, 
nevirapine, modafinil and St John’s Wort (Hypericum perforatum)  
For patients taking any of the above, the required wash-out periods prior to starting Olaparib 
are phenobarbitone 5 weeks, and for any of the others, 3 weeks. 
After randomisation if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary for the patient’s safety and welfare, the investigator must contact the 
AstraZeneca Study Physician.  A decision to allow the patient to continue in the study will be 
made on a case-by-case basis. 
7.7.3 Other concomitant treatment 
Other medication other than that described above, which is considered necessary for the 
patient’s safety and well being, may be given at the discretion of the Investigator and recorded 
in the appropriate sections of the Case Report Form. 
7.7.4 Anti-emetics/ Anti-diarrhoeals 
Should a patient develop nausea, vomiting and/or diarrhoea, then these symptoms should be 
reported as AEs (see section 6.3) and appropriate treatment of the event given. 
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7.7.5 Anticoagulant Therapy 
Patients who are taking warfarin may participate in this trial; however, it is recommended that 
prothrombin time (INR and APTT) be monitored carefully at least once per week for the first 
month, then monthly if the INR is stable.  Subcutaneous heparin is permitted. 
7.7.6 Administration of other anti-cancer agents 
Patients must not receive any other concurrent anti-cancer therapy, including investigational 
agents, while on study treatment. 
Treatment with bisphosphonates or RANKL inhibitor for the prevention of skeletal related 
events in patients with bone metastasis is permitted and must be started at least 5 days prior to 
randomisation. 
7.7.7 Subsequent therapies for cancer  
Details of first and subsequent therapies for cancer after discontinuation of treatment, will be 
collected.  Response to subsequent therapies and PFS on those therapies will also be collected. 
The choice of subsequent systemic anticancer treatment will be entirely at the discretion of the 
investigator although it is expected that many/most patients upon progression on study will be 
treated with a platinum based regimen 
8. STATISTICAL ANALYSIS AND SAMPLE SIZE 
DETERMINATION BY PAREXEL 
8.1 Statistical considerations 
• All personnel involved with the analysis of the study will remain blinded until database 
lock and protocol violators identified. 
• Analyses will be performed by AstraZeneca or its representatives.  
• A comprehensive statistical analysis plan (SAP) will be prepared and finalised before first 
patient in (FPI). 
8.2 Definitions of analysis sets 
Table 7 gives a summary of outcome variables and analysis populations 
8.2.1 Full analysis set 
Intention to treat (ITT): The primary statistical analysis of the efficacy of Olaparib will 
include all randomised patients and will compare the treatment groups on the basis of 
randomised treatment, regardless of the treatment actually received.  Patients who were 
randomised but did not subsequently go on to receive study treatment are included in the Full 
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Analysis Set (FAS). Therefore, all efficacy and health-related QoL data will be summarised 
and analysed using the FAS on an intention-to-treat (ITT) basis.  
In addition, key sensitivity analyses of efficacy endpoints will be performed in the subgroup 
of patients in the FAS that have a gBRCA mutation confirmed by the Myriad test. 
8.2.2 Safety analysis set 
All patients who received at least one dose of randomised investigational product, Olaparib or 
placebo, will be included in the safety analysis set.  Throughout the safety results sections, 
erroneously treated Olaparib patients (those randomised to Olaparib but actually given 
placebo at any time) will be accounted for in the Olaparib treatment group.  Erroneously 
treated placebo patients (those randomised to placebo but actually received at least one dose 
of Olaparib) will be accounted for in the Olaparib treatment group. 
8.2.3 PRO analysis set 
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data. 
Table 7 Summary of Outcome Variables and Analysis Populations 
Outcome Variable Populations 
Efficacy Data  
- Primary: PFS FAS (ITT), Myriad confirmed BRCAm subgroup  
- Secondary endpoints to be analysed: OS, PFS2, 
time to first subsequent therapy (TFST), time to 
second subsequent therapy (TSST), time to 
treatment discontinuation (TDT), time to 
deterioration and improvement rate of Global 
QoL and PAN-26 pain scale 
- Secondary endpoints to be summarised: 
objective response rate, disease control rate 
FAS (ITT), Myriad confirmed BRCAm subgroup 
 
 
FAS (ITT), Myriad confirmed BRCAm subgroup 
Demography FAS (ITT) 
Safety Data  
- Exposure Safety 
- Adverse Events Safety 
- Lab measurements Safety 
- Vital Signs Safety 
8.3 Calculation or derivation of efficacy variable(s) 
At each visit patients will be assigned a RECIST visit response of CR, PR, SD, PD, NE, NED 
depending on the status of their disease compared to baseline and previous assessments, based 
on the BICR review. This will be repeated using the Investigator assessed RECIST data. 
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8.3.1 Primary endpoint (PFS) 
PFS is defined as the time from randomisation until the date of objective radiological disease 
progression according to modified RECIST 1.1 or death (by any cause in the absence of 
disease progression) regardless of whether the patient withdraws from randomised therapy or 
receives another anticancer therapy prior to disease progression.  Patients who have not 
progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment from their last evaluable RECIST assessment.  However, if the patient progresses 
or dies after two or more missed visits, the patient will be censored at the time of the latest 
evaluable RECIST assessment. If the patient has no evaluable visits or does not have a 
baseline assessment they will be censored at day 1 unless they die within two tumour 
assessment visits of randomisation (17 weeks allowing for visit window). 
The PFS time will always be derived based on scan/assessment dates not visit dates. 
RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates. The following rules will be applied: 
a) Date of progression will be determined based on the earliest of the RECIST 
assessment/scan dates of the component that triggered the progression 
b) When censoring a patient for PFS the patient will be censored at the latest of the 
RECIST assessment/scan dates contributing to a particular overall visit assessment 
Overall visit assessments will be determined for each assessment (scheduled or unscheduled) 
and will contribute to the derivation of PFS. 
Objective progression is defined as at least a 20% increase in the sum of the diameters of the 
target lesions (compared to previous minimum sum) and an absolute increase of > 5 mm, or an 
overall non-target lesion assessment of progression or a new lesion.  
The primary analysis will be based on the blinded independent central review (BICR) of the 
radiological scans. A charter for the BICR will be developed in advance of the start of the 
study. A sensitivity analysis based on the programmatically derived PFS based on 
Investigator-recorded assessments will be carried out. 
As a supportive summary to PFS, time to start of first subsequent chemotherapy or death will 
be assessed (see section 8.8.3).  Time to first subsequent chemotherapy or death is defined as 
the time from the date of randomisation to the earlier of first subsequent chemotherapy start 
date, or death date.  Any patient not known to have had a further subsequent therapy or death 
will be censored at the last known time to have not received subsequent chemotherapy. 
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8.3.2 Secondary endpoints  
8.3.2.1 Overall Survival 
Overall survival is defined as the time from the date of randomisation until death due to any 
cause.  Any patient not known to have died at the time of analysis will be censored based on 
the last recorded date on which the patient was known to be alive. 
Note: Survival calls will be made in the week following the date of Data Cut Off (DCO) date 
for the analysis, and if patients are confirmed to be alive or if the death date is post the DCO 
date these patients will be censored at the date of DCO. 
8.3.2.2 Best overall RECIST response (BoR) 
Best overall RECIST response (BoR) is calculated based on the overall visit responses from 
each RECIST assessment, described in Appendix F. It is the best response a patient has had 
during their time in the study up until RECIST progression or the last evaluable assessment in 
the absence of RECIST progression.  
Categorisation of best overall response will be based on the RECIST criteria (Appendix F) 
using the following response categories: complete response (CR), partial response (PR), stable 
disease (SD), No Evidence of Disease (NED; applies only to those patients entering the study 
with no disease at baseline), progressive disease (PD) and not evaluable (NE). 
Best overall response will be determined programmatically based on the RECIST criteria 
using BICR data. 
For patients whose progression event is death, BoR will be calculated based on data up until 
the last evaluable RECIST assessment prior to death. 
For patients who die with no evaluable RECIST assessments, if the death occurred ≤ 17 weeks 
(ie 16 weeks ±1 week) after randomisation then BoR will be assigned to the progression (PD) 
category. For patients who die with no evaluable RECIST assessments, if the death occurred 
> 17 weeks (ie 16 weeks ±1week) after randomisation then BoR will be assigned to the 
nonevaluable (NE) category. 
Progression events that have been censored due to them being more than two missed visits 
after the last evaluable assessment will not contribute to the BoR derivation. 
A patient will be classified as a responder if the RECIST criteria for a CR or PR are satisfied 
at any time up to and including the defined analysis cut-off point. For each treatment group, 
the objective response rate (ORR) is the number of CR and PR divided by the number of 
patients in the group in the FAS with measurable disease at baseline. Only patients with PR 
and measurable disease at enrolment can achieve an objective response of CR or PR, other 
permissible categories of BoR are NE, PD. 
The disease control rate (DCR) is defined as the percentage of patients who have at least one 
confirmed visit response of CR or PR or have demonstrated SD or NED for at least 15 weeks 
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(ie 16 weeks ±1 week) prior to any evidence of progression. In the case of SD and NED, 
follow up assessments must have met the SD or NED criteria for a minimum interval of 15 
weeks following randomisation. 
8.3.2.3 Time from randomisation to second progression (PFS2) 
Time from randomisation to second progression (PFS2) is defined as the time from the date of 
randomisation to the earliest of the progression event subsequent to that used for the primary 
variable PFS or death.  
The date of second progression will be recorded by the Investigator and defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
progression or death.  RECIST measurements will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF.  Second progression status 
will be reviewed every 8 weeks following the progression event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progression has not been observed should be censored at the last time known to be alive and 
without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death). 
8.3.2.4 Time to first subsequent therapy or death (TFST) 
Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as 
the time from randomisation to the earlier of first subsequent therapy start date followingstudy 
treatment discontinuation, or death. Subsequent therapies will be reviewed to assesswhich 
represent clinically important treatments intended to control ovarian cancer. Any patient not 
known to have died at the time of the analysis and not known to have had a further 
intervention of this type will be censored at the last known time to have not received 
subsequent therapy, ie the last follow-up visit where this was confirmed. 
8.3.2.5 Time to second subsequent therapy or death (TSST) 
Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined 
as the time from randomisation to the earlier of the second subsequent therapy start date 
following study treatment discontinuation, or death. Any patient not known to have died at the 
time of the analysis and not known to have had a further intervention of this type will be 
censored at the last known time to have not received second subsequent therapy, ie the last 
follow-up visit where this was confirmed. 
8.3.2.6 Time to study treatment discontinuation or death (TDT) 
Time to study treatment discontinuation or death (TDT) will be assessed. TDT is defined as 
the time from randomisation to the earlier of the date of study treatment discontinuation or 
death. Any patient not known to have died at the time of analysis and not known to have 
discontinued study treatment will be censored based on the last recorded date on which the 
patient was known to be alive.  
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Note: Survival calls will be made in the week following the date of DCO for the analysis, and 
if patients are confirmed to be alive or if the death date is post the DCO date these patients 
will be censored at the date of DCO. 
8.3.2.7 Disease Control Rate (DCR) 
The disease control rate (DCR) is defined as the percentage of patients who have at least one 
confirmed visit response of CR or PR or have demonstrated SD for at least 16 weeks (ie 17 
weeks ±1 week) prior to any evidence of progression. In the case of SD, follow up 
assessments must have met the SD criteria for a minimum interval of 16 weeks following 
randomisation. 
8.4 Calculation or derivation of safety variable(s) 
Safety and tolerability will be assessed in terms of AEs, deaths, laboratory data, vital signs 
and ECG.  These will be collected for all patients.  Appropriate summaries of these data will 
be presented. 
8.4.1 Other significant adverse events (OAE) 
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs and DAEs.  Based on the expert’s judgement, 
significant adverse events of particular clinical importance may, after consultation with the 
Global Patient Safety Physician, be considered OAEs and reported as such in the Clinical 
Study Report.  A similar review of laboratory/vital signs/ECG data will be performed for 
identification of OAEs. 
Examples of these are marked haematological and other laboratory abnormalities, and certain 
events that lead to intervention (other than those already classified as serious), dose reduction 
or significant additional treatment. 
8.5 Calculation or derivation of patient reported outcome variables 
All items/questionnaires will be scored according to published scoring guidelines or the 
developer’s guidelines, if published guidelines are not available. 
EORTC-QLQC30 and QLQ-PAN26 
The EORTC QLQ-C30 will be scored according to the EORTC scoring manual (Fayers et al 
1999).  Each scale will be transformed to a 100-point scale as per the manual.   
Mean change from baseline in health related quality of life (HRQoL) will be assessed using 
the EORTC QLQ-C30 global QoL scale which includes two items from the QLQ-C30: “How 
would you rate your overall health during the past week?” (Item 29) and “How would you rate 
your overall quality of life during the past week?” (Item 30) 
The analysis population for PRO data will be the subset of the ITT population; patients must 
have a baseline score to be included in the analysis of PRO data. 
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The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life (two items: “How would you rate your 
overall health during the past week?” (Item 29) and “How would you rate your overall quality 
of life during the past week?” (Item 30)) and PAN-26 pancreatic pain (items 31, 33, 34, 35) 
scales . Time to global QoL and pancreatic pain scale worsening will be analysed using the 
same methodology and model as described for the primary analysis of PFS. However 
sensitivity analyses will not be performed (with the exception of attrition bias). 
Global QoL and PAN-26 pain scale improvement rate will be analysed using a logistic 
regression model and using the same covariates as used in the PFS analyses. If the overall 
response rate is < 5%, no analysis will be performed.  (Note that if the response rate in only 
one of the treatment groups is < 5% but ≥ 5% in the other treatment group then the analysis 
will still be performed.)  If the expected response rate is low (< 20%) a Fisher’s exact test will 
be considered and mid p-values used. The results of the analysis will be presented in terms of 
an odds ratio together with its associated profile likelihood CIs and p-values (based on twice 
the change in log-likelihood resulting from the addition of a treatment factor to the model). 
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group. 
HRQoL Visit responses 
A change of at least 10 points in the global QoL score will be considered as a clinically 
relevant or a minimally important difference (Osoba D et al 1998). 
For each subscale, if less than 50% of the subscale items are missing, then the subscale score 
will be divided by the number of non-missing items and multiplied by the total number of 
items on the subscales (Fayers et al 1999).  If at least 50% of the items are missing, then that 
subscale will be treated as missing.  Missing single items are treated as missing.  The reason 
for any missing questionnaire will be identified and recorded.  If there is evidence that the 
missing data are systematic, missing values will be handled to ensure that any possible bias is 
minimised. 
Scores for the QLQ-C30 will be derived using the developer instructions. Raw scores are 
calculated using the formula: 
RawScore = RS (I1+ I2+...+ In ) n 
A linear transformation to 0 – 100 is then applied to obtain a score (S) 
Function Scale:  
 
Symptoms Scales/items: 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
97(121) 
{(RS-1)/range}x100 
Global Health Status/Quality of Life: 
{(RS-1)/range}x100 
Range is the difference between the maximum possible value of RS and the minimum possible 
value. The QLQ-C30 has been designed so that all items in any scale take the same range of 
values. Therefore, the range of RS equals the range of the item values. Most items are scored 1 
to 4, giving range = 3. The exceptions are the items contributing to the global health status / 
QoL, which are 7-point questions with range = 6, and the initial yes/no items. 
The QLQ-PAN26 follows the same scoring criteria as the QLQ-C30. The QLQ-PAN26 
contains 26 items which comprise 7 multi-item scales (pancreas pain (4 items), eating related 
items (2 items), hepatic items (2 items), altered bowel habit (2 items), body image (2 items), 
health care satisfaction (2 items), sexuality (2 items)), and 10 single item scales (swollen 
abdomen, taste changes, indigestion, flatulence, weight loss, loss of muscle strength, dry 
mouth, burden of treatment, fear of future health, and ability to plan future.  
Within the specific module the items can be grouped into new domains rather than reporting 
specific items. When using this approach it is important that the correct scoring algorithm is 
followed.  
Higher scores represent more symptoms, except for health care satisfaction scale and sexuality 
scale where higher scores represent greater satisfaction and sexuality. For change scores, a 
score of +5 is considered deterioration (except for the two scales mentioned above) and a 
score of -5 is considered as improvement. 
Within the specific module the items can be grouped into new domains rather than reporting 
specific items. When using this approach it is important that the correct scoring algorithm is 
followed.  
1. Calculate the raw score for each scale 
raw score = RS = (I1+I2+…+In)/n 
 
2. Apply the following linear transformation for the sexuality scale:  
 
For all other scales (including the single items), apply this linear transformation: 
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Where range is 3 in each case. 
8.6 Calculation or derivation of pharmacogenetic variables 
To be defined in an exploratory analysis plan. 
8.7 Calculation or derivation of health economic variables 
Responses to the EuroQoL EQ5D questionnaire will be converted into utility scores using UK 
EQ5D valuation set. Alternative valuation sets may be used in scenario analyses.  Descriptive 
statistics, graphs and listings will be reported for health state utility by visits as well as change 
in these scores from baseline.  To support future economic evaluations of Olaparib, additional 
appropriate analyses may be undertaken, for example, mean health state utility pre and post 
treatment, and pre and post progression. 
Descriptive statistics relating to the frequency healthcare resource use items, including 
hospital episodes, type of contact (hospitalisation, outpatient, day case), reason, length of stay 
by ward type (including ICU) and procedures undertaken will be derived from the resource 
use information.  
The evaluable population will comprise all randomised patients and will compare the 
treatment groups on the basis of randomised treatment, regardless of the treatment actually 
received. 
8.8 Methods for statistical analyses 
A single interim PFS analysis for futility and superiority will be performed when 50% of the 
final number of progressions has been reached (approximately 45 PFS events).  The interim 
analysis will be performed by an Independent Data Monitoring Committee (IDMC) and full 
details will be provided in the IDMC charter.  A final PFS analysis will be performed when 
approximately 89 progression events have occurred (~60% maturity).  No further analyses of 
PFS are planned beyond this point unless requested by health authorities. 
Timing of the statistical analyses are given in Table 8. 
Table 8 Timing of statistical analyses 
Timing of analyses Outcome Variable 
 Efficacy Data 
Interim PFS analyses (~ 45 PFS events) 
 
Final PFS (~ 89 PFS events)  
 
- PFS  
- PFS, PFS2, TDT, TFST, TSST, OS, time to 
deterioration of Global QoL and PAN-26 pain scale  
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Timing of analyses Outcome Variable 
 Efficacy Data 
Final OS analyses (~ 106 OS events) - PFS2, TFST, TSST, OS, time to deterioration of 
Global QoL and PAN-26 pain scale 
 
** Only if superiority is met for PFS at the PFS interim analyses, will analyses of the following 
endpoints be performed: PFS2, TDT, TFST, TSST, OS, time to deterioration of Global QoL and PAN-
26 pain scale. 
The treatment comparison is Olaparib 300 mg bid vs. placebo to Olaparib 300 mg bid. 
Results of all statistical analysis will be presented using a 95% confidence interval and 2-sided 
p-value.  
The following table details which endpoints are to be subject to formal statistical analysis, 
together with pre-planned sensitivity analyses making clear which analysis is regarded as 
primary for that endpoint 
Table 9  Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses 
Endpoints Analysed Notes 
Primary analysis: log-rank test using BICR data 
Key sensitivity analysisa: log rank test using 
BICR data in randomised patients confirmed as 
gBRCA mutation positive by central Myriad test 
(if subset of FAS)  
Additional sensitivity analyses: 
1) Evaluation time bias analysis; log-rank test 
using BICR data 
2) Attrition bias analysis (using alternative 
censoring rules); log-rank test using BICR data 
3) Ascertainment bias analysis; log-rank test 
using investigator data 
4) Deviation bias analysis (if meaningful to do); 
log-rank test using BICR data 
PFS (Time from randomisation to first 
progression or death) 
 
Primary analysis: log-rank test  Overall Survival (Time from randomisation to 
death due to any cause) Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA 
mutation positive by central Myriad test (if subset 
of FAS) 
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Endpoints Analysed Notes 
 Supportive analysis: KM plot of time to censoring 
for OS 
Primary analysis: log-rank test  Second Progression Free Survival (PFS2) 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA 
mutation positive by central Myriad test (if subset 
of FAS) 
Primary analysis: Stratified log rank test of time 
from randomisation to treatment discontinuation  
Time to treatment discontinuation (TDT) 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA 
mutation positive by central Myriad test (if subset 
of FAS) 
Primary analysis: Stratified log rank test of time 
from randomisation to first subsequent therapy or 
death  
Time to first subsequent therapy (TFST) 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA 
mutation positive by central Myriad test (if subset 
of FAS) 
Primary analysis: Stratified log rank test of time 
from randomisation to second subsequent therapy 
or death  
Time to second subsequent therapy (TSST) 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA 
mutation positive by central Myriad test (if subset 
of FAS) 
Time to deterioration in global QoL (as measured 
by the global QOL score from the EORTC-QLQ-
C30 questionnaire) 
Primary analysis: Stratified log rank test of time 
from randomisation to deterioration in global 
QOL  
a See Section 8.8.3 for further details 
8.8.1 Multiplicity strategy for primary and key secondary endpoints 
In order to describe the nature of the benefits of Olaparib maintenance treatment, PFS, PFS2 
and OS will be tested at a 1-sided significance level of 2.5%. 
However, in order to strongly control the type I error at 2.5% 1-sided, a multiple testing 
procedure will also be employed across the primary endpoint and secondary endpoints 
intended for key label claims (ie OS).  
A hierarchical testing strategy will be employed where PFS is tested first using the full test 
mass (full test mass = alpha 5% 2 sided) and the key secondary endpoint of OS will then be 
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tested using a multiple testing procedure with a recycling strategy (ie, the MTP will recycle 
the test mass to the endpoint not yet rejected in the hierarchy outlined in Figure 2). 
Figure 2 Multiple Testing Procedures 
 
At the interim analyses for PFS, 1% of alpha will be spent; statistical significance will be 
declared at the interim analysis if the 1-sided p<0.005.  If the null hypothesis for PFS is not 
rejected at the interim analyses time point then PFS will be tested again when approximately 
89 PFS events have occurred. The final significance level will be determined accounting for 
the actual correlation between the interim and final PFS analyses. To ensure that the type I 
error will be controlled at 2.5% 1-sided level, if the interim occurs at exactly 50% of events 
and the number of PFS events at the final analysis is as expected then the 1-sided significance 
level to be applied for the final analysis would be 2.26%. (Stone 2010). If PFS is significant at 
either the interim or final analyses, the full test mass (alpha) will be carried forward to OS.   
OS will only be tested if the null hypothesis (of no difference) is rejected for PFS.  Two 
interim analyses for OS will be performed; the first at the time of the interim PFS analysis 
(approximately 45 PFS events) and the second at the time of the final PFS analysis 
(approximately 89 PFS events).  A final analysis of OS will be performed when approximate 
106 death events have occurred.  Statistical significance for OS will be declared the first at 
interim analyses for OS if the null hypothesis for PFS is rejected and the observed p-value for 
OS is p<0.005. If the null hypothesis for OS is not rejected at this time, then statistical 
significance for OS will be declared at the next interim analyses (final analysis of PFS) if the 
null hypothesis for PFS has been rejected and the observed 1-sided p-value for OS is < 
0.01499.  The final significance level will be determined accounting for the actual correlation 
between the interim and final OS analyses.  To ensure that the type I error will be controlled at 
the 2.5% 1-sided level, if the interim analyses occur at exactly 30% and 57% of events 
respectively and the number of OS events at the final analysis is approximately 106 then the 
1-sided significance level to be applied for the final analysis would be 1.53% 
All planned analyses will be performed, regardless of the outcome of the MTP.  
8.8.2 Analysis of the primary variable (s) 
A single interim PFS analysis for superiority will be performed when 50% of the final number 
of progressions has been reached (approximately 45 PFS events) based on the BICR.  A final 
PFS analysis will be performed when approximately 89 progression events have occurred 
(~60% maturity) based on the BICR.  No further analyses of PFS are planned beyond this 
point unless requested by Health Authorities. 
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PFS will be analysed using a log rank test.  The hazard ratio (HR) and confidence interval will 
be estimated from the U and V statistics obtained directly from the LIFETEST model (and 
using the Breslow approach for handling ties). 
The HR and its confidence interval will be estimated from the log-rank as follows (Berry et al 
1999 and Sellke et al 1983) 
 HR = exp(U/V) 
95% CI for HR = (exp{U/V – 1.96/ √V}, exp{U/V + 1.96/ √V}) 
Where U ∑ −=
i
ii ed )( 11 is the log-rank test statistic (with id1 and ie1 the observed and expected 
events in group 1) and √V the standard deviation of the log-rank test statistic as produced in 
the LIFETEST output.   
The HR (Olaparib vs. placebo) together with its corresponding 95% confidence interval (CI) 
and p-value will be presented (a HR less than 1 will favour Olaparib).   
A Kaplan-Meier (KM) plot of PFS will be presented by treatment group. Summaries of the 
number and percentage of patients experiencing a PFS event, and the type of event (RECIST 
or death) will be provided along with median PFS for each treatment arm. 
The assumption of proportionality will be assessed. Note that in the presence of non-
proportionality, the HR will be interpreted as an average HR over the observed extent of 
follow-up.  Proportionality will be tested firstly by producing plots of complementary log-log 
(event times) versus log (time) and, if these raise concerns, a time dependent covariate would 
be fitted to assess the extent to which this represents random variation.  
The primary analysis will be based on the programmatically derived PFS based on BICR 
overall visit assessments (ie Individual tumour measurements will not be used) and using all 
scans regardless of whether they were scheduled or not.  
The estimated PFS rates at 6 months and 12 months will be summarised (using the KM curve) 
and presented by treatment group. 
The number of patients prematurely censored will be summarised by treatment arm together 
with baseline prognostic factors of the prematurely censored patients.  A patient is defined as 
prematurely censored if they had not progressed and the latest scan prior to DCO was more 
than one scheduled tumour assessment interval (+ 2 weeks) prior to the DCO date. 
As patients will be randomised, imbalances in demographic factors between the treatment 
groups are not anticipated.  However if any imbalances should occur, the HR and associated 
confidence interval calculated from a Cox Proportional Hazards model containing treatment 
and these additional demographic variables, may be reported.   
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
103(121) 
Subgroup analyses will be conducted comparing PFS between treatments. The purpose of the 
subgroup analyses is to assess the consistency of treatment effect across potential or expected 
prognostic factors.  If there are too few events available for a meaningful analysis of a 
particular subgroup (it is not considered appropriate to present analyses where there are less 
than 20 events in a subgroup), the relationship between that subgroup and PFS will not be 
formally analysed.  In this case, only descriptive summaries will be provided 
The following subgroups of the full analysis set will be analysed for PFS: 
• Type of chemotherapy (doublets vs triplets) 
• Time on first line treatment till randomisation (≤6 months vs  >6 months) 
• Best response on first line treatment (SD vs PR/CR) 
• Measurable versus non measurable disease /no evidence of disease at baseline 
• BRCA mutation type, eg BRCA1, BRCA2 or BRCA1/2 (both)  
• Age at randomisation (>=65 vs. <65)  
• Race 
• Sex 
Other baseline variables may also be assessed if there is clinical justification.  
For each subgroup, the HRs (Olaparib: placebo) and associated CIs will be calculated from a 
Cox proportional hazards model (ties = Efron) that contains the treatment term, factor and 
treatment-by-factor interaction term.  The treatment effect HRs for each treatment comparison 
along with their confidence intervals will be obtained for each level of the subgroup from this 
single model.  The HRs and 95% CIs will be presented on a forest plot including the HR and 
95% CI from the overall population (using the primary analysis).   
No adjustment to the significance level for testing of subgroups will be made since all these 
subgroup analyses will be considered exploratory and may only be supportive of the primary 
analysis of PFS. 
A further analysis of PFS (using Investigator assessed RECIST) may be performed at the time 
of the OS analyses, if requested by Health authorities. 
8.8.3 Sensitivity analysis for the primary endpoint 
As a sensitivity analysis to the primary endpoint of PFS, the primary analysis will be repeated 
excluding any patients who did not have a gBRCA mutation status confirmed by the Myriad 
test.  The same methodology and model will be used as for the primary analysis of PFS and 
the HR and associated 95% CI will be reported. 
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Sensitivity analyses will be performed to assess the possible presence of time-assessment bias 
(ie, differential assessment times between treatment groups). 
Summary statistics for the number of weeks between the time of progression and the last 
evaluable RECIST assessment prior to progression will be presented for each treatment group. 
8.8.3.1 Evaluation-Time bias 
Sensitivity analyses will be performed to assess possible evaluation-time bias that may be 
introduced if scans are not performed at the protocol-scheduled time points. The midpoint 
between the time of progression and the previous evaluable RECIST assessment will be 
analysed using a stratified log rank test, as described for the primary analysis of PFS.  This 
approach has been shown to be robust to even highly asymmetric assessment schedules (Sun 
and Chen 2010). This approach will use the BICR RECIST assessments. 
8.8.3.2 Attrition bias 
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of patients who progressed or died in the 
absence of progression immediately following two, or more, non-evaluable tumour 
assessments will be included. In addition, patients who take subsequent therapy prior to 
progression or death will be censored at their last evaluable assessment prior to taking the 
subsequent therapy.  
Additionally a Kaplan-Meier plot of the time to censoring where the censoring indicator of the 
primary PFS analysis is reversed will be presented. 
8.8.3.3 Ascertainment bias 
A log-rank test will be repeated using the programmatically derived RECIST using 
Investigator assessed PFS.  The HR and 95% Confidence Interval will be presented.   
If there is an important discrepancy between the primary analysis using BICR assessments and 
this sensitivity analysis using Investigator assessments, then the proportion of patients with 
site but no central confirmation of progression will be summarised.  The approach of imputing 
an event at the next visit in the central review analysis may help inform the most likely HR 
value, but only if an important discrepancy exists.   
Disagreements between investigator and central reviews of RECIST progression will be 
presented for each treatment group.  The summary will include the early discrepancy rate 
which is the frequency of central review declared progressions before the Investigator review 
as a proportion of all central review progressions and the late discrepancy rate which is the 
frequency of central review declared progressions after the Investigator review as a proportion 
of all discrepancies. 
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8.8.3.4 Deviation bias (if meaningful to do) 
As a sensitivity analysis to the primary endpoint of PFS, an analysis excluding patients with 
deviations that may affect the efficacy of the trial therapy will be performed if > 10% of 
patients: 
• did not have the intended disease or indication or 
• did not receive any randomised therapy 
A log-rank test will be repeated using the BICR RECIST data, using the same ties as 
described for the primary analysis of PFS. The HR and 95% CI will be presented. 
8.8.4 Analysis of the secondary variable(s) 
8.8.4.1 Analysis of OS endpoint 
OS data will be analysed at the time of the interim (if PFS null hypothesis rejected) and final 
analyses of PFS and will use the same methodology and model (provided there are sufficient 
events available for a meaningful analysis [> 20 deaths], if not descriptive summaries will be 
provided).  A further analysis of OS will be performed when approximately 106 deaths have 
occurred. 
The sensitivity analysis outlined in Section 8.8.3 will not be repeated for OS with the 
exception of a Kaplan-Meier plot of the time to censoring where the censoring indicator of the 
primary OS is reversed. 
To assist in quantifying the PFS effect, at the time of the PFS analysis, a predicted treatment 
effect for OS at the final analysis will be derived using a weighted sum of the observed OS 
data and the predicted OS value using PFS data (Chen and Sun 2011). The estimate of the 
treatment effect for OS at the final analysis is defined as  where  is the 
observed treatment effect for OS at the time of the PFS analysis and   is the estimated 
treatment effect for OS based on the observed treatment effect for PFS, where represents the 
estimated slope relating PFS to OS from historical trials. The weightings (w) are based on the 
inverse of the variance (ie those with more uncertainty are given less weight). The variance is 
dependent on the correlation between the two endpoints. Details of the methodology will be 
provided in the statistical analysis plan (SAP). 
8.8.4.2 Analysis of PFS2 endpoint 
The analyses of PFS2 will use the same methodology and model as the primary analysis of 
PFS.  No multiplicity adjustment will be applied as this is viewed as a supportive endpoint. 
The date of second progression will be recorded by the Investigator and defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
progression or death.  RECIST measurements will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF.  Second progression status 
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will be reviewed every 8 weeks following the progression event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progression has not been observed should be censored at the last time known to be alive and 
without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death)  
As a key sensitivity, the analysis of PFS2 will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of PFS2 in this subset of patients will be 
presented by treatment group. 
A KM plot of the time to censoring where the censoring indicator of the primary PFS2 is 
reversed will be produced. 
Time from second progression to previous assessment will be summarised by treatment arm. 
8.8.4.3 Analysis of TDT endpoint 
Time to study treatment discontinuation or death (TDT) will be analysed using the same 
methodology and model as the primary analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.  No 
multiplicity adjustment will be applied as this is viewed as a supportive endpoint. 
As a key sensitivity, the analyses of TDT will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of TDT in this subset of patients will be 
presented by treatment group. 
8.8.4.4 Analysis of TFST endpoint 
Time to first subsequent therapy or death (TFST) will be analysed using the same 
methodology and model as the primary analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.  In 
addition, the time between progression and starting subsequent therapy will be assessed.   
As a key sensitivity, the analyses of TFST will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of TFST in this subset of patients will be 
presented by treatment group. 
8.8.4.5 Analysis of TSST endpoint 
Time to first second subsequent therapy or death (TSST) will be analysed analysed using the 
same methodology and model as the primary analysis of PFS.  The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.   
Summary tables of first and second subsequent therapies by treatment arm will be provided, as 
well as response to first subsequent therapy by treatment arm. 
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As a key sensitivity, the analyses of TSST will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of TSST in this subset of patients will be 
presented by treatment group. 
8.8.4.6 Analysis of PRO endpoints 
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data. 
The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales.  
Time to global QoL and pancreatic pain scale deterioration will be analysed using the same 
methodology and model as described for the primary analysis of PFS. However sensitivity 
analyses will not be performed (with the exception of attrition bias). 
Global QoL and PAN-26 pain scale improvement rate will be analysed using a logistic 
regression model.  If the overall response rate is < 5%, no analysis will be performed (note 
that if the response rate in only one of the treatment groups is < 5% but ≥ 5% in the other 
treatment group then the analysis will still be performed).  If the overall expected response 
rate is low (< 20%) a Fisher’s exact test will be considered and mid p-values used. The results 
of the analysis will be presented in terms of an odds ratio together with its associated profile 
likelihood CIs and p-values (based on twice the change in log-likelihood resulting from the 
addition of a treatment factor to the model). 
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group. 
Supportive analyses (of time to deterioration and improvement rates) will be performed for the 
individual QLQC30 domains (physical, role, cognitive, emotional, social).  Treatment 
estimates and 95% CI for each domain will be presented on forest plots (one for Time to 
deterioration and one for improvement rate).  P-values will not be calculated for these 
supportive analyses. These additional sub-scales are considered exploratory to support the 
primary QLQC30 global QoL and will be used to assess whether any observed differences in 
the global measure are driven by particular domains of functioning, symptoms or group of 
symptoms. 
Descriptive statistics and graphs will be reported for the Global QoL item and the pancreatic 
pain scale by visits as well as change in these scores from baseline.  Summary tables of 
QLQC30 best change rates will be provided (improvement, worsening, no change). 
As supportive analyses, change from baseline in global QoL and pancreatic pain scale scores 
will be analysed using a mixed model for repeated measures (MMRM) analysis of all of the 
post-baseline scores for each visit. The study discontinuation visit and the safety follow-up 
visit will be excluded from this analysis. Restricted maximum likelihood (REML) estimation 
will be used. The model will include treatment, pooled centre, visit and treatment by visit 
interaction as explanatory variables and the baseline score as a covariate. Treatment, visit and 
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treatment by visit interaction will be fixed effects in the model; centre will be a random effect. 
The treatment by visit interaction will remain in the model regardless of significance. 
An unstructured covariance matrix will be used to model the within-subject error and the 
Kenward-Roger approximation will be used to estimate the degrees of freedom.  
If the fit of the unstructured covariance structure fails to converge, the following covariance 
structures will be tried in order until convergence is reached: toeplitz with heterogeneity, 
autoregressive with heterogeneity, toeplitz, and autoregressive. If there are still issues with the 
fit of the model or estimation of the treatment effects, CENTRE will be treated as a fixed 
effect. 
The adjusted mean estimates and corresponding 95% confidence intervals will be presented 
by visit for each treatment group. 
No formal testing will be done on the global QoL and pancreatic pain scale data.  Data will be 
descriptive and plots will be used to visualise the adjusted mean global QoL score across time 
for each treatment arm. 
Compliance 
Overall compliance will be defined as the number of patients who provided both a baseline 
and at least one post baseline assessment for which there were sufficient data recorded for the 
visit to be evaluable for the global QoL score, divided by the number of patients randomised.  
Compliance over time is calculated separately for each visit, including baseline, as the number 
of patients providing an evaluable assessment for the global QoL score at that visit divided by 
the number of patients expected to have provided an assessment. 
QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will be 
summarised for each treatment group. 
8.8.4.7 Summary of Best overall RECIST Response (BoR) and ORR 
For each treatment arm, best overall response (BoR) will be summarised by n (%) for each 
category (CR, PR, SD, NED, PD, NE).  No formal statistical analyses are planned.   
The objective response rate (ORR) will be summarised (ie, number of patients (%)) by 
treatment group in patients in the FAS (ITT population) with measurable disease at baseline.  
Any patients who experienced CR or PR which was first observed whilst receiving subsequent 
therapy after discontinuation of Olaparib/placebo will be identified. The denominator for the 
response rate will be measurable disease as defined by the BICR data 
ORR and BOR will be presented based on the BICR data and also summarised in a similar 
way using the investigator recorded data. 
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8.8.4.8 Summary of DCR   
The disease control rate (DCR) will be summarised (ie, number of patients (%)) by treatment 
group in patients in the FAS (ITT population). 
DCR will be presented based on the BICR data and also the investigator recorded data. 
8.8.5 Exploratory analysis   
8.8.5.1 Exploratory analysis of PRO endpoints (PAN-26 symptom scales and items) 
Exploratory analyses, examining improvement rates and time to worsening, will be performed 
for the individual PAN-26 symptom scales and items (with a particular focus on fatigue, 
nausea, weight loss (difficulty gaining weight/loss of appetite), jaundice), and presented on 
forest plots (showing treatment estimates and 95% CI for each domain).  P-values will not be 
calculated for these exploratory analyses. 
Descriptive statistics and graphs will be reported for the symptom scales and items 
(specifically fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite and 
jaundice). Summary tables of PAN26 best change rates will be provided (improvement, 
worsening, no change). 
Change from baseline in QLQC30 functioning domain scores and PAN-26 scales and items 
may be analysed using the same MMRM model described in Section 8.8.4.6 for Global QoL 
score and the pancreatic pain score. 
Descriptive summaries for individual symptom items within the PAN-26 will also be 
provided. 
8.8.5.2 Analysis of Healthcare Resource Use 
A health economic analysis of resource use will be estimated, including descriptive statistics 
relating frequency of hospitalisations and hospital admission, type of attendance, length of 
stay and procedures undertaken, and the primary symptom/reason for the attendance.  
Descriptive statistics, graphs and listings will be reported for health state utility by visits as 
well as change in these scores from baseline.  To support future economic evaluations of 
Olaparib, additional appropriate analyses may be undertaken, for example, mean health state 
utility pre and post treatment, and pre and post progression. 
The evaluable population will comprise all randomised patients and will compare the 
treatment groups on the basis of randomised treatment, regardless of the treatment actually 
received. 
8.8.5.3 Analysis of ECOG Performance status 
Shift tables will be provided showing best and then worst on treatment change in performance 
status vs baseline, by treatment. 
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Change from baseline in levels of ECOG performance status at each post randomisation time 
point will be reported descriptively (n, %) by treatment group, as well as the proportion of 
patients with ECOG status of 0 at baseline (ie cannot improve).     
8.8.6 Impact of Switching to PARP inhibitors (or other potentially active 
investigational agents) on Overall Survival Analyses 
Exploratory analyses of OS adjusting for impact of subsequent PARP inhibitor trial or 
treatment may be performed if a sufficient proportion of patients receive the therapies of 
interest.  Methods such as Rank Preserving Structural Failure Time (RPSFT) (Robins et al 
1991), Inverse Probability of Censoring Weighting (IPCW) (Robins 1993) and other methods 
in development will be explored.  The decision to adjust and final choice of methods will be 
based on a blinded review of the data and the plausibility of the underlying assumptions.  
Baseline and time-dependent characteristics will be explored, and summaries of baseline 
characteristics will be summarised for patients receiving physician’s choice of chemotherapy, 
splitting between those that have and haven’t received a PARP inhibitor at the time of the 
analyses.  Further detail will be provided in the SAP and Payer Analysis Plan. These analyses 
are intended to support reimbursement appraisals. 
8.8.7 Exploratory translational science endpoints 
Full statistical methods for exploratory endpoints will be defined in a separate translation 
science analysis plan. 
8.8.8 Biomarkers 
Biomarker data will be summarised descriptively using tables and plots.  If the data is 
available at the time of developing the CSR then the biomarker data will be included in the 
CSR.  Otherwise the biomarker data will be reported in a separate addendum to the CSR (if 
applicable).  Further details on the data summaries and plots for the biomarker data for the 
CSR will be provided in the SAP. 
BRCA status will be summarised for all patients based on the central myriad test result.  This 
will highlight any patients with a negative BRCA result from the central test. 
8.9 Sample Size Determination 
The primary endpoint of the study is PFS.   Approximately 145 patients will be randomised 
(3:2 ratio of Olaparib:placebo) and the primary PFS analysis will occur once approximately 89 
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
superiority will be performed when 50% of the final number of progressions has been reached 
(approximately 45 PFS events) based on BICR. 
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.26% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median OS for placebo.  At the interim 
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analyses, 0.5% of alpha (1-sided) will be spent, and controlling the type I error across the two 
time points, 89 PFS events will be required at the final analyses.   
Statistical significance will be declared at the interim analysis if the 1-sided p<0.005.  
Assuming 45 PFS events at the interim, a HR ≤ 0.46 would equate to a 1-sided p<0.005.  If 
the null hypothesis for PFS is not rejected at the interim analyses time point then PFS will be 
tested again when approximately 89 PFS events have occurred.  The final significance level 
will be determined accounting for the actual correlation between the interim and final PFS 
analyses. To ensure that the type I error will be controlled at 2.5% 1-sided level, if the interim 
occurs at exactly 50% of events and the number of PFS events at the final analysis is as 
expected then the 1-sided significance level to be applied for the final analysis would be 
2.26%. (Stone 2010).  Assuming 89 PFS events, a HR ≤ 0.65 would equate to a 1-sided p-
value <0.0226. 
Patients are to be followed for the final analysis of OS (when approximately 106 death events 
have occurred).  With 106 OS events the study has 80% power to show a statistically 
significant difference in OS at the 1-sided 2.5% level if the assumed true treatment effect is a 
HR 0.57; this translates to an approximate 6 month improvement in median OS over an 
assumed 8 month median OS on placebo, assuming OS is exponentially distributed. 
Assuming that the study accrual period will be approximately 15 months, 89 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study.  It is estimated that 45 PFS events will occur approximately 13 to 14 
months after first patient in.  It is estimated that 106 death events will occur approximately 31 
months after first patient in. 
8.9.1 Interim analysis 
A single interim PFS analysis for superiority and futility will be performed when 50% of the 
final number of progressions has been reached (approximately 45 PFS events) based on BICR.  
The interim analysis will be performed by an Independent Data Management Committee 
(IDMC) and full details will be provided in the IDMC charter.   
Section 8.8.1 details the spending function used to account for multiplicity introduced by 
including interim analyses for superiority. 
Interim analyses of OS will be performed at the time of the interim analyses of PFS (~89 PFS 
events),and again at the final analyses at the final analyses of PFS (~89 events), and when 
approximately 106 OS events have occurred. 
If the interim PFS results indicate superiority, then analyses of all other endpoints would be 
performed and the results of these analyses will form the basis for submissions for regulatory 
approval. Patients would continue to be followed for PFS and survival until ~89 PFS events 
had occurred, and then followed for survival until 106 patients had died. 
The futility analyses on PFS will be used to guide decisions on stopping the study for futility 
or continuing the study.  Details will be documented in the IDMC charter. 
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9. STUDY AND DATA MANAGEMENT BY PAREXEL 
9.1 Training of study site personnel 
Before the first patient is entered into the study, an AstraZeneca representative will review and 
discuss the requirements of the Clinical Study Protocol and related documents with the 
investigational staff and also train them in any study specific procedures and the WBDC 
system(s) utilised. 
The Principal Investigator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved. 
The Principal Investigator will maintain a record of all individuals involved in the study 
(medical, nursing and other staff). 
9.2 Monitoring of the study 
During the study, an AstraZeneca representative will have regular contacts with the study site, 
including visits to: 
− Provide information and support to the Investigator(s) 
− Confirm that facilities remain acceptable 
− Confirm that the investigational team is adhering to the protocol, that data are 
being accurately and timely recorded in the CRFs, that biological samples are 
handled in accordance with the Laboratory Manual and that study drug 
accountability checks are being performed 
− Perform source data verification (a comparison of the data in the CRFs with the 
patient’s medical records at the hospital or practice, and other records relevant 
to the study) including verification of informed consent of participating 
patients. This will require direct access to all original records for each patient 
(eg, clinic charts) 
− Ensure withdrawal of informed consent to the use of the patient’s biological 
samples is reported and biological samples are identified and disposed 
of/destroyed accordingly, and the action is documented, and reported to the 
patient. 
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct. 
9.2.1 Source data 
Refer to the Clinical Study Agreement for location of source data.  
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9.2.2 Study agreements 
The Principal Investigator at each/the centre should comply with all the terms, conditions, and 
obligations of the Clinical Study Agreement, or equivalent, for this study.  In the event of any 
inconsistency between this Clinical Study Protocol and the Clinical Study Agreement, the 
terms of Clinical Study Protocol shall prevail with respect to the conduct of the study and the 
treatment of patients and in all other respects, not relating to study conduct or treatment of 
patients, the terms of the Clinical Study Agreement shall prevail. 
Agreements between AstraZeneca and the Principal Investigator should be in place before any 
study-related procedures can take place, or patients are enrolled. 
9.2.3 Archiving of study documents 
The Investigator follows the principles outlined in the Clinical Study Agreement (CSA).  
9.3 Study timetable and end of study 
The end of the study is defined as ‘the last visit of the last patient undergoing the study’. 
The study is expected to start in Q2 2014 and to end by Q2 2017 
The study may be terminated at individual centres if the study procedures are not being 
performed according to GCP, or if recruitment is slow.  AstraZeneca may also terminate the 
entire study prematurely if concerns for safety arise within this study or in any other study 
with Olaparib. 
9.4 Data management by PAREXEL 
Data management will be performed by PAREXEL. . 
The data collected through third party sources will be obtained and reconciled against study 
data. 
Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version the Medical Dictionary for Regulatory Activities (MedDRA).  Medications 
will be classified according to the AstraZeneca Drug Dictionary.  All coding will be 
performed by the Medical Coding Team at the AstraZeneca Data Management Centre. 
Data queries will be raised for inconsistent, impossible or missing data.  All entries to the 
study database will be available in an audit trail. 
The data will be validated as defined in the Data Management Plan. Quality control 
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly. 
When all data have been coded, validated, and locked, clean file will be declared.  Any 
treatment revealing data may thereafter be added and the final database will be locked. 
Clinical Study Protocol 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition1 
Date 31 March 2014 
114(121) 
Data associated with biological samples will be transferred from laboratories internal or 
external to AstraZeneca.  Data from external providers (eg central laboratories) will be 
validated as appropriate to ensure it is consistent with the clinical data and included in the 
final database.  In the case of biomarker (tumour tissue or blood for exploratory analyses) 
data, the results of any analyses will not be recorded in the database, but information relating 
to the processing of the sample, including the original date of biopsy (historical tumour tissue 
sample and the actual date the sample(s) were collected) will be recorded in the eCRF and 
database. 
Exploratory genotype data generated in this study will be stored in the AstraZeneca 
genotyping LIMS database, or other appropriate secure system within AstraZeneca and/or 
third party contracted to work with AstraZeneca to analyse samples.  The results from this 
exploratory genetic research will not be reported in the CSR. 
Some or all of the clinical datasets from the main study may be merged with the genetic data 
in a suitable secure environment separate from the clinical database. 
Site staff will enter PRO booklet data into Medidata Rave exactly as reported by the patient. 
10. ETHICAL AND REGULATORY REQUIREMENTS 
10.1 Ethical conduct of the study 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological 
Samples. 
10.2 Patient data protection 
The Informed Consent Form will incorporate (or, in some cases, be accompanied by a 
separate document incorporating) wording that complies with relevant data protection and 
privacy legislation. 
AstraZeneca will not provide individual genotype results to patients, any insurance company, 
any employer, their family members, general physician or any other third party, unless 
required to do so by law. 
The exception to the above is the result of the Myriad BRCA test. This will be made available 
to the Investigator and patient. 
Extra precautions are taken to preserve confidentiality and prevent genetic data being linked to 
the identity of the patient. In exceptional circumstances, however, certain individuals might 
see both the genetic data and the personal identifiers of a patient. For example, in the case of a 
medical emergency, an AstraZeneca Physician or an investigator might know a patient’s 
identity and also have access to his or her genetic data. Also Regulatory authorities may 
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require access to the relevant files, though the patient’s medical information and the genetic 
files would remain physically separate. 
10.3 Ethics and regulatory review 
An Institutional Review Board (IRB)/Ethics Committee should approve the final study 
protocol, including the final version of the Informed Consent Form and any other written 
information and/or materials to be provided to the patients.  The investigator will ensure the 
distribution of these documents to the applicable Ethics Committee, and to the study site staff. 
The opinion of the Ethics Committee should be given in writing. The investigator should 
submit the written approval to AstraZeneca before enrolment of any patient into the study.  
The Ethics Committee should approve all advertising used to recruit patients for the study. 
AstraZeneca should approve any modifications to the Informed Consent Form that are needed 
to meet local requirements. 
If required by local regulations, the protocol should be re-approved by the Ethics Committee 
annually. 
Before enrolment of any patient into the study, the final study protocol, including the final 
version of the Informed Consent Form is approved by the national regulatory authority or a 
notification to the national regulatory authority is done, according to local regulations. 
AstraZeneca will handle the distribution of any of these documents to the national regulatory 
authorities. 
AstraZeneca will provide Regulatory Authorities, Ethics Committees and Principal 
Investigators with safety updates/reports according to local requirements, including SUSARs 
(Suspected Unexpected Serious Adverse Reactions), where relevant. 
Each Principal Investigator is responsible for providing the Ethics Committees/IRB with 
reports of any serious and unexpected adverse drug reactions from any other study conducted 
with the investigational product.  AstraZeneca will provide this information to the Principal 
Investigator so that he/she can meet these reporting requirements. 
10.4 Informed consent 
The Principal Investigator(s) at each centre will: 
• Ensure each patient is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study 
• Ensure each patient is notified that they are free to discontinue from the study at any 
time 
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• Ensure that each patient is given the opportunity to ask questions and allowed time to 
consider the information provided 
• Ensure each patient provides signed and dated informed consent before conducting any 
procedure specifically for the study 
• Ensure the original, signed Informed Consent Form(s) is/are stored in the 
Investigator’s Study File 
• Ensure a copy of the signed Informed Consent Form is given to the patient 
• Ensure that any incentives for patients who participate in the study as well as any 
provisions for patients harmed as a consequence of study participation are described in 
the informed consent form that is approved by an Ethics Committee. 
10.5 Changes to the protocol and informed consent form 
Study procedures will not be changed without the mutual agreement of the International co-
ordinating Investigator, National Co-ordinating Investigator, and the Principal Investigator 
and AstraZeneca. 
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study Protocol). 
The amendment is to be approved by the relevant Ethics Committee and if applicable, also the 
national regulatory authority approval, before implementation.  Local requirements are to be 
followed for revised protocols. 
AstraZeneca will distribute any subsequent amendments and new versions of the protocol to 
each Principal Investigator(s). For distribution to Ethics Committee see Section 10.3. 
If a protocol amendment requires a change to a centre’s Informed Consent Form, AstraZeneca 
and the centre’s Ethics Committee are to approve the revised Informed Consent Form before 
the revised form is used.  
If local regulations require, any administrative change will be communicated to or approved 
by each Ethics Committee. 
10.6 Audits and inspections 
Authorised representatives of AstraZeneca, a regulatory authority, or an Ethics Committee 
may perform audits or inspections at the centre, including source data verification.  The 
purpose of an audit or inspection is to systematically and independently examine all study-
related activities and documents, to determine whether these activities were conducted, and 
data were recorded, analysed, and accurately reported according to the protocol, Good Clinical 
Practice (GCP), guidelines of the International Conference on Harmonisation (ICH), and any 
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applicable regulatory requirements.  The investigator will contact AstraZeneca immediately if 
contacted by a regulatory agency about an inspection at the centre. 
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FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE) 
Life threatening 
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure). 
Hospitalisation 
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study. 
Important medical event or medical intervention 
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize the subject or may require 
medical intervention to prevent one or more outcomes listed in the definition of serious.  
These should usually be considered as serious. 
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used. 
Examples of such events are: 
• Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment 
• Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring 
treatment with N-acetylcysteine 
• Intensive treatment in an emergency room or at home for allergic bronchospasm 
• Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsions that do not result in hospitalisation 
• Development of drug dependency or drug abuse. 
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A GUIDE TO INTERPRETING THE CAUSALITY QUESTION 
The following factors should be considered when deciding if there is a “reasonable 
possibility” that an AE may have been caused by the drug. 
• Time Course.  Exposure to suspect drug.  Has the subject actually received the 
suspect drug?  Did the AE occur in a reasonable temporal relationship to the 
administration of the suspect drug? 
• Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? OR could the AE be anticipated from its pharmacological 
properties? 
• Dechallenge experience.  Did the AE resolve or improve on stopping or reducing 
the dose of the suspect drug? 
• No alternative cause.  The AE cannot be reasonably explained by another aetiology 
such as the underlying disease, other drugs, other host or environmental factors. 
• Rechallenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally recommend or support 
a rechallenge. 
• Laboratory tests.  A specific laboratory investigation (if performed) has confirmed 
the relationship? 
A “reasonable possibility” could be considered to exist for an AE where one or more of these 
factors exist. 
In contrast, there would not be a “reasonable possibility” of causality if none of the above 
criteria apply or where there is evidence of exposure and a reasonable time course but any 
dechallenge (if performed) is negative or ambiguous or there is another more likely cause of 
the AE. 
In difficult cases, other factors could be considered such as: 
• Is this a recognised feature of overdose of the drug? 
• Is there a known mechanism? 
Ambiguous cases should be considered as being a “reasonable possibility” of a causal 
relationship unless further evidence becomes available to refute this.  Causal relationship in 
cases where the disease under study has deteriorated due to lack of effect should be classified 
as no reasonable possibility. 
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LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES 
International Airline Transportation Association (IATA) classifies biohazardous agents into 3 
categories (http://www.iata.org/whatwedo/cargo/dgr/Pages/infectious_substances.aspx). 
For transport purposes the classification of infectious substances according to risk groups was 
removed from the Dangerous Goods Regulations (DGR) in the 46th edition (2005).  Infectious 
substances are now classified either as Category A, Category B or Exempt.  There is no direct 
relationship between Risk Groups and categories A and B. 
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are eg, Ebola, Lassa fever virus: 
• are to be packed and shipped in accordance with IATA Instruction 602. 
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the following UN 
number and proper shipping name: 
• UN 3373 – Biological Substance, Category B 
• are to be packed in accordance with UN3373 and IATA 650 
Exempt - all other materials with minimal risk of containing pathogens 
• Clinical trial samples will fall into Category B or exempt under IATA regulations 
• Clinical trial samples will routinely be packed and transported at ambient 
temperature in IATA 650 compliant packaging 
(http://www.iata.org/whatwedo/cargo/dgr/Pages/infectious_substances.aspx) 
• Biological samples transported in dry ice require additional dangerous goods 
specification for the dry-ice content 
• IATA compliant courier and packaging materials should be used for packing and 
transportation and packing should be done by an IATA certified person, as 
applicable 
• Samples routinely transported by road or rail are subject to local regulations which 
require that they are also packed and transported in a safe and appropriate way to 
contain any risk of infection or contamination by using approved couriers and 
packaging / containment materials at all times.  The IATA 650 biological sample 
containment standards are encouraged wherever possible when road or rail transport 
is used. 
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Appendix D 
Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilirubin - Hy’s Law 
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1. INTRODUCTION 
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for determining whether a patient meets 
potential Hy’s Law (PHL) criteria at any point during the study. 
The Investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria 
are met.  Hy’s Law criteria are met if there is no alternative explanation for the elevations in 
liver biochemistry other than Drug Induced Liver Injury (DILI) caused by the Investigational 
Product (IP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safety reporting processes. 
2. DEFINITIONS 
Potential Hy’s Law (PHL) 
A Potential Hy’s Law (PHL) case is defined as a study subject with an increase in serum 
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Normal (ULN) together with Total Bilirubin (TBL) ≥ 2xULN irrespective of serum Alkaline 
Phosphatase (ALP), at any point during the study following the start of study medication. 
Hy’s Law (HL) 
A Hy’s Law (HL) case is defined as a study subject with an increase in serum AST or ALT 
≥ 3x ULN together with TBL ≥ 2xULN, where no other reason can be found to explain the 
combination of increases, eg, elevated serum ALP indicating cholestasis, viral hepatitis, 
another drug. 
For PHL and HL to be met the elevation in transaminases must precede or be coincident with 
(ie, on the same day) the elevation in TBL, but there is no specified timeframe within which 
the elevations in transaminases and TBL must occur. 
3. IDENTIFICATION OF POTENTIAL HY’S LAW CASES 
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any patient who meets any of the following identification criteria in 
isolation or in combination: 
• ALT ≥ 3xULN 
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• AST ≥ 3xULN 
• TBL ≥ 2xULN 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will: 
• Determine whether the patient meets PHL criteria (see Section 2 of this Appendix 
for definition) by reviewing laboratory reports from all previous visits 
• Promptly enter the laboratory data into the laboratory CRF. 
4. FOLLOW-UP 
4.1 Potential Hy’s Law Criteria not met 
If the patient does not meet PHL criteria the Investigator will: 
• Perform follow-up on subsequent laboratory results according to the guidance 
provided in the Clinical Study Protocol. 
4.2 Potential Hy’s Law Criteria met 
If the patient does meet PHL criteria the Investigator will: 
• Determine whether PHL criteria were met at any study visit prior to starting study 
treatment in the presence of liver metastases (See Section 6) 
• Notify the AstraZeneca representative who will then inform the central Study Team. 
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patient’s follow-up and the continuous review of data.  Subsequent to 
this contact the Investigator will: 
• Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated  
• Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician 
• Complete the 3 Liver CRF Modules as information becomes available 
• If at any time (in consultation with the Study Physician) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures. 
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5. REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW 
CASES 
The instructions in this section should be followed for all cases where PHL criteria were met. 
No later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the IP.  
The AstraZeneca Medical Science Director and Global Safety Physician will also be involved 
in this review together with other subject matter experts as appropriate. 
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below. 
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE: 
• If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF 
• If the alternative explanation is an AE/SAE, record the AE/SAE in the CRF 
accordingly and follow the AZ standard processes. 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IP: 
• Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes.  
− The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply 
− As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned. 
If there is an unavoidable delay of over 3 weeks in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation until such time as an informed decision can be made: 
• Report an SAE (report term ‘Potential Hy’s Law’) applying serious criteria and 
causality assessment as per above 
• Continue follow-up and review according to agreed plan.  Once the necessary 
supplementary information is obtained, repeat the review and assessment to 
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determine whether HL criteria are met.  Update the SAE report according to the 
outcome of the review. 
6. ACTIONS REQUIRED WHEN POTENTIAL HY’S LAW 
CRITERIA ARE MET BEFORE AND AFTER STARTING 
STUDY TREATMENT 
This section is applicable to patients who meet PHL criteria on study treatment having 
previously met PHL criteria at a study visit prior to starting study treatment.  
At the first on study treatment occurrence of PHL criteria being met (including the 30-day 
follow-up period) the Investigator will: 
• Determine if there has been a significant change in the patients’ condition# 
compared with the last visit where PHL criteria were met# 
− If there is no significant change no action is required 
− If there is a significant change, notify the AstraZeneca representative, who will 
inform the central Study Team, then follow the subsequent process described is 
Section 4.2 of this Appendix. 
# A ‘significant’ change in the patient’s condition refers to a subsequent clinically relevant 
change in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in 
isolation or in combination, or a clinically relevant change in associated symptoms such as 
fatigue, vomiting, rash, right upper quadrant pain, jaundice, eosinophilia.  The determination 
of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty. 
7. ACTIONS REQUIRED FOR REPEAT EPISODES OF 
POTENTIAL HY’S LAW 
This section is applicable when a patient meets PHL criteria on study treatment (including the 
30-day follow-up period) and has already met PHL criteria at a previous on study treatment 
visit. 
The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence. 
The investigator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the following question: 
• Was the alternative cause for the previous occurrence of PHL criteria being met 
chronic or progressing malignant disease or did the patient meet PHL criteria prior 
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to starting study treatment and at their first on study treatment visit as described in 
Section 6? 
If No: follow the process described in Section 4.2 of this Appendix 
If Yes: 
Determine if there has been a significant change in the patient’s condition# compared with 
when PHL criteria were previously met: 
• If there is no significant change no action is required 
• If there is a significant change follow the process described in Section 4.2 of this 
Appendix. 
# A ‘significant’ change in the patient’s condition refers to a subsequent clinically relevant 
change in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in 
isolation or in combination, or a clinically relevant change in associated symptoms, such as 
fatigue, vomiting, rash, right upper quadrant pain, jaundice, eosinophilia.  The determination 
of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty. 
8. REFERENCES 
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1. ACCEPTABLE BIRTH CONTROL METHODS 
Olaparib is regarded as a compound with medium/high foetal risk. 
Patients of childbearing potential and their partners, who are sexually active, must agree to the 
use of two highly effective forms of contraception in combination while they are receiving 
study treatment and for 3 months after last dose of study drug. 
Acceptable Non-hormonal birth control methods include 
• Total/True abstinence: when the subject refrains from any form of sexual 
intercourse and this is in line with their usual and/or preferred lifestyle; this must 
continue for the total duration of the study treatment and for 3 months after the last 
dose of study drug.  [Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods), and withdrawal are not acceptable methods of 
contraception] 
• Vasectomised sexual partner plus male condom. With participant assurance that 
partner received post-vasectomy confirmation of azoospermia 
• Tubal occlusion plus male condom 
• IUD plus male condom. Provided coils are copper-banded 
Acceptable hormonal methods   
• Etonogestrel implants (eg, Implanon, Norplan) + male condom 
• Normal and low dose combined oral pills + male condom 
• Norelgestromin / EE transdermal system + male condom 
• Intravaginal device + male condom (eg, EE and etonogestrel) 
• Cerazette (desogestrel) + male condom. Cerazette is currently the only highly 
efficacious progesterone based pill 
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1. INTRODUCTION 
This appendix details the implementation of modified RECIST (Response Evaluation Criteria 
in Solid Tumours) 1.1 guidelines (Eisenhauer et al 2009) for the study D081FC00001 with 
regards to investigator assessment of tumour burden including protocol-specific requirements 
for this study. 
2. DEFINITION OF MEASURABLE, NON-MEASURABLE, 
TARGET AND NON-TARGET LESIONS 
Patients with measurable disease and/or non measurable  disease or no evidence of disease 
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study. 
RECIST 1.1 has been modified to allow the assessment of progression due to new lesions in 
patients with no evidence of disease at base-line. 
Measurable lesions  
A lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10 mm in 
the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm with CT or 
MRI and which is suitable for accurate repeated measurements. 
Non-measurable lesions 
• All other lesions, including small lesions (longest diameter < 10 mm or pathological 
lymph nodes with ≥ 10 mm to < 15 mm short axis at baseline.  Nodes with < 10 mm 
short axis are considered non-pathological and should not be recorded as non-target 
lesions (NTLs) 
• Truly non-measurable lesions include the following: bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, abdominal masses/abdominal 
organomegaly identified by physical examination that are not measurable by CT or 
MRI 
• Previously irradiated lesions. Localised post-radiation changes which affect lesion 
size, may occur.  Therefore, lesions that have been previously irradiated will not be 
considered measurable and must be selected as NTLs at baseline and followed up as 
part of the NTL assessment 
• Skin lesions assessed by clinical examination  
• Brain metastasis 
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Special cases 
• Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue 
components, can be considered measurable if the soft tissue component meets the 
definition of measurability. Blastic lesions are considered non-measurable. 
• Cystic metastases can be considered measurable lesions if they meet the criteria for 
measurability from a radiological point of view, but if non-cystic lesions are present 
in the same patient; these non-cystic lesions should be selected as target lesions 
(TLs). 
Target lesions 
A maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), representative 
of all lesions involved suitable for accurate repeated measurement, should be identified as TLs 
at baseline. 
Non-target lesions 
All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline. 
3. METHODS OF MEASUREMENT 
The same method of assessment and the same technique should be used to characterise 
each identified and reported lesion at baseline and during follow-up. 
The methods to be used for RECIST assessment are summarised in Table 1 and those 
excluded for tumour assessments in this study are discussed below, with the rationale 
provided. 
Table 1 Summary of Methods of Assessment 





X-ray, Chest x-ray 
Clinical examination  
CT (preferred) 
MRI 





3.1 CT and MRI  
CT and MRI are generally considered to be the best currently available and reproducible 
methods to measure TLs selected for response assessment and to assess NTLs and 
identification of new lesions. 
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In study D081FC00001 it is recommended that CT examinations of the chest, abdomen and 
pelvis will be used to assess tumour burden at baseline and follow-up visits.  CT examination 
with intravenous contrast media administration is the preferred method.  MRI should be used 
where CT is not feasible or it is medically contra-indicated.  For assessment of brain lesions 
MRI is the preferred method. 
3.2 Clinical examination  
In study D081FC00001 clinical examination will not be used for assessment of TL. Clinically 
detected lesions can be selected as target lesions if they are assessed by CT or MRI scans. 
Clinical examination can be used to assess NTL and to identify the presence of new lesions. 
3.3 X-rays 
3.3.1 Chest X-ray 
Chest X-rays will not be used for assessment of TLs as they will be assessed by CT or MRI 
examination.  Chest X-rays can, however, be used to assess NTLs and to identify the presence 
of new lesions. 
3.3.2 Plain X-ray  
In study D081FC00001 plain X-rays may be used as a method of assessment for bone NTLs 
and to identify the presence of new bone lesions.  
3.4 Ultrasound  
Ultrasound examination will not be used for assessment of TLs and NTLs as it is not a 
reproducible method, does not provide an accurate assessment of tumour size and it is 
subjective and operator dependent. Ultrasound examination can, however, be used to identify 
the presence of new lesions.  If new clinical symptoms occur and an ultrasound is performed 
then new lesions should be confirmed by CT or MRI examination. 
3.5 Endoscopy and laparoscopy  
Endoscopy and laparoscopy will not be used for tumour assessments as they are not validated 
in the context of tumour measurements. 
3.6 Tumour markers  
Tumour markers will not be used for tumour response assessments per RECIST 1.1. 
3.7 Cytology and histology  
Histology will not be used as part of the tumour response assessment per RECIST 1.1.  
Cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment is required when the measurable tumour has met criteria for response or 
stable disease.  In such circumstances, the cytology is necessary to differentiate between 
response / stable disease (an effusion may be a side effect of the treatment) and progressive 
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disease (if the neoplastic origin of the fluid is confirmed).  Where cytology findings are not 
available, any effusion that significantly worsens (from trace to large) or the appearance of a 
clinically significant effusion (requiring change in drug therapy) during the study treatment 
will be considered to be progression of NTLs or disease progression due to new lesions. 
3.8 Isotopic bone scan  
Bone lesions identified on an isotopic bone scan at baseline and confirmed by CT, MRI or X-
ray at baseline should be recorded as NTLs and followed by the same method as per baseline 
assessment.   
In the D081FC00001 study isotopic bone scans may be used as a method of assessment to 
identify the presence of new bone lesions at follow-up visits.  New lesions will be recorded 
where a positive hot-spot that was not present on the baseline bone scan assessment is 
identified on a bone scan performed at any time during the study.  The Investigator should 
consider the positive hot-spot to be a significant new site of malignant disease and represent 
true disease progression in order to record the new lesion.  Confirmation by CT, MRI and X-
ray is recommended where bone scan findings are equivocal. 
3.9 FDG-PET scan  
In the D081FC00001 study FDG-PET (fluorodeoxyglucose positron emission tomography) 
scans may be used as a method for identifying new lesions, according with the following 
algorithm: New lesions will be recorded where there is positive FDG uptake (defined as when 
an uptake greater than twice that of the surrounding tissue is observed) not present on baseline 
FDG-PET scan or in a location corresponding to a new lesion on CT/MRI at the same follow-
up visit.  If there is no baseline FDG-PET scan available, and no evidence of new lesions on 
CT/MRI scans then follow-up CT/MRI assessments should be continued, scheduled as per 
protocol or clinical indicated, in order to confirm new lesions. 
4. TUMOUR RESPONSE EVALUATION  
4.1 Schedule of evaluation 
Baseline tumour assessments should encompass all areas of known predilection for metastases 
in the disease under evaluation and should additionally investigate areas that may be involved 
based on signs and symptoms of individual patients and should be performed no more than 28 
days before the start of study treatment.  Follow-up assessments should be performed every 8 
weeks (±1 week) for 40 weeks and then every 12 weeks ± 1 week relative to date of 
randomisation, until objective disease progression as defined by modified RECIST 1.1.  See 
Table 1: Study Schedule from Study Protocol for further information. Any other sites at which 
new disease is suspected should also be adequately imaged at follow-up. 
If an unscheduled assessment was performed and the patient has not progressed, every attempt 
should be made to perform the subsequent assessments at their scheduled visits. This schedule 
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is to be followed in order to minimise any unintentional bias caused by some patients being 
assessed at a different frequency than other patients. 
All patients will continue to be assessed for radiological tumour assessments according to the 
study schedule, until objective radiological disease progression, irrespective of reasons for 
discontinuation of treatment. 
4.2 Target lesions  
4.2.1 Documentation of target lesions 
A maximum of 5 measurable lesions, with a maximum of 2 lesions per organ (including 
lymph nodes), representative of all lesions involved, should be identified as TLs at baseline.  
Target lesions should be selected on the basis of their size (longest diameter for non-nodal 
lesions or short axis for nodal lesions) but in addition should be those that lend themselves to 
reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion 
does not lend itself to reproducible measurement in which circumstance the next largest lesion, 
which can be measured reproducibly, should be selected. 
The site and location of each TL should be documented as well as the longest diameter for 
non-nodal lesions (or short axis for lymph nodes).  All measurements should be recorded in 
millimetres.  At baseline, the sum of the diameters for all TLs will be calculated and reported 
as the baseline sum of diameters.  At follow-up visits the sum of diameters for all TLs will be 
calculated and reported as the follow-up sum of diameters. 
Special cases: 
• For TLs measurable in 2 or 3 dimensions, always report the longest diameter.  For 
pathological lymph nodes measurable in 2 or 3 dimensions, always report the short 
axis.  
• If the CT/MRI slice thickness used is > 5mm, the minimum size of measurable 
disease at baseline should be twice the slice thickness of the baseline scan. 
• If a lesion has completely disappeared, the longest diameter should be recorded as 0 
mm. 
• If a TL splits into two or more parts, then record the sum of the diameters of those 
parts. 
• If two or more TLs merge then the sum of the diameters of the combined lesion 
should be recorded for one of the lesions and 0 mm recorded for the other lesion(s). 
• If a TL is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned.  If an accurate measure can be given, this 
should be recorded, even if it is below 5 mm. 
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• If a TL cannot be measured accurately due to it being too large, provide an estimate 
of the size of the lesion. 
• When a TL has had any intervention eg, radiotherapy, embolisation, surgery etc, 
during the study, the size of the TL should still be provided where possible. 
4.2.2 Evaluation of target lesions 
Table 2 provides the definitions of the criteria used to determine objective tumour visit 
response for TLs. 
Table 2 Overall Visit Response for Target Lesions 
Complete Response (CR) Disappearance of all TLs since baseline. Any pathological lymph 
nodes selected as TLs must have a reduction in short axis to < 10 
mm. 
Partial Response (PR) At least a 30% decrease in the sum of diameters of TLs, taking as 
reference the baseline sum of diameters. 
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD 
Progressive Disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as 
reference the smallest sum on study (this includes the baseline 
sum if that is the smallest on study).  In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5mm. 
Not Evaluable (NE) Only relevant if any of the TLs were not assessed or not evaluable 
or had a lesion intervention at this visit. 
Note: If the sum of diameters meets the progressive disease 
criteria, progressive disease overrides not evaluable (NE) as a TL 
response 
4.3 Non-Target lesions  
4.3.1 Evaluation of non-target lesions 
All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline.  Measurements are not required for these lesions but their status should be followed 
at subsequent visits.  At each visit, an overall assessment of the NTL response should be 
recorded by the investigator.  This section provides the definitions of the criteria used to 
determine and record overall response for NTLs at the investigational site at each visit. 
Table 3 Overall Visit Response for Non-Target Lesions  
Complete Response (CR) Disappearance of all NTLs since baseline.  All lymph nodes must 
be non-pathological in size (< 10 mm short axis). 
Non-CR/Non PD Persistence of one or more NTLs. 
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Progressive Disease (PD) Unequivocal progression of existing NTLs.  Unequivocal 
progression may be due to an important progression in one lesion 
only or in several lesions.  In all cases the progression MUST 
clinically significant for the physician to consider changing or 
stopping therapy 
Not Evaluable (NE) Only relevant when one or some of the NTLs were not assessed 
and in the investigator’s opinion they are not able to provide an 
evaluable overall NTL assessment at this visit. 
Note: For patients without TLs at baseline, this is relevant if any 
of the NTLs were not assessed at this visit and the progression 
criteria have not been met. 
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficiently to merit discontinuation of therapy.  A 
modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status. 
4.4 New Lesions 
Details of any new lesions will also be recorded with the date of assessment.  The presence of 
one or more new lesions is assessed as progression. 
A lesion identified at a follow up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. 
The finding of a new lesion should be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumour. 
If a new lesion is equivocal, for example because of its small size, the treatment and tumour 
assessments should be continued until the new lesion has been confirmed.  If repeat scans 
confirm there is a new lesion, then the progression date should be declared using the date of 
the initial scan. 
4.5 Symptomatic deterioration 
Symptomatic deterioration is not a descriptor of an objective response: it is a reason for 
stopping study therapy. 
Patients with ‘symptomatic deterioration’ requiring discontinuation of treatment without 
objective evidence of disease progression at that time should continue to undergo tumour 
assessments where possible until objective disease progression is observed. 
4.6 Evaluation of Overall Visit Response and Best Overall Response  
The overall visit response will be derived using the algorithm shown in Table 4 
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Table 4 Overall Visit Response 
Target lesions Non-Target lesions New Lesions Overall response 
CR CR No CR 
CR NA No CR 
NA CR No CR 
CR Non-CR/Non PD No PR 
CR NE No PR 
PR Non PD or NE No PR 
SD  Non PD or NE No SD 
NA Non CR/Non PD No SD (Non CR/non PD) 
NE Non-PD or NE No NE 
NA NE No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
NA NA No NED 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease 
IR = incomplete response, NE = not evaluable, NED = no evidence of disease, NA = not applicable (relevant 
when no TLs/NTLs at baseline) 
5. CENTRAL REVIEW  
All CT/MRI scans will be sent to an AstraZeneca appointed Clinical Research Organisation 
(CRO) for blinded independent central review. After the final Progression Free Survival (PFS) 
analysis, central review of scans will no longer be required.  Patients should continue to 
receive study treatment until objective radiological disease progression as per modified 
RECIST 1.1 as assessed by the investigator, and as long as in the investigator’s opinion they 
are benefiting from treatment and they do not meet any other discontinuation criteria.  The 
CRO appointed by AstraZeneca to perform the independent central review for this study will 
provide specification for radiological imaging protocols in standard acquisition guidelines 
documentation. 
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1. ECOG PERFORMANCE STATUS 
1.1 Example of Performance Status (ECOG SCALE) 
 
DESCRIPTION ECOG GRADE 
Fully active, able to carry on all pre-disease performance without 
restriction. 0 
Restricted in physically strenuous activity, but ambulatory and able 
to carry out work of a light or sedentary nature, ie light housework, 
office work. 
1 
Ambulatory and capable of self-care, but unable to carry out any 
work activities. Up and about more than 50% of waking hours. 2 
Capable of only limited self care, confined to bed or chair more than 
50% of waking hours. 3 
Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair. 4 
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GUIDANCE REGARDING POTENTIAL INTERACTIONS WITH 
CONCOMITANT MEDICATIONS 
NB. While this is not an exhaustive list, it covers the known potent inhibitors and inducers, 
which have most often previously been reported to be associated with clinically significant 
drug interactions.  Please contact the Medical Monitor or AstraZeneca physician if further 
clarification is required. 
1. POTENT INHIBITORS OF CYP3A4/5 
In vitro data has shown that the principal enzyme responsible for the formation of the 3 main 
metabolites of olaparib is CYP3A4/5 and consequently, to ensure patient safety, the following 
inhibitors of CYP3A4/5 must not be used during this study. 
Table 1 Competitive inhibitors of CYP3A4/5 









Table 2 Time dependent inhibitors of CYP3A4/5 




2. INDUCERS OF CYP 
In addition, to avoid potential reductions in exposure due to drug interactions, the following 
CYP3 inducers should be avoided: 
Table 3 Inducers of CYP 
Drug Minimum washout period prior to starting olaparib 
Carbamazepine 3 Weeks 
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Table 3 Inducers of CYP 







St John’s Wort (Hypericum perforatum) 
 
Phenobarbitone 5 Weeks 
 
After randomisation if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary for the patient’s safety and welfare, the investigator must contact the 
AstraZeneca Study Physician. A decision to allow the patient to continue in the study will be 
made on a case-by-case basis. 
3. NATURAL / HERBAL PRODUCTS 
The use of any natural/herbal products or other “folk remedies” should be discouraged but use 
of these products, as well as use of all vitamins, nutritional supplements and all other 
concomitant medications must be recorded in the appropriate eCRF. 
4. INTERACTIONS WITH P450 
Olaparib is an investigational drug for which no data on in vivo interactions is currently 
available.  Based on in vitro data and clinical exposure data, olaparib is considered unlikely to 
cause clinically significant drug interactions through inhibition or induction of cytochrome 
P450 enzyme activity. 
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Appendix I 
Patient Reported Outcomes EORTC QLQ-C30, QLQ-PAN26, EQ-5D-5L 
 
ENGLISH 
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
Please fill in your initials: bbbb
Your birthdate (Day, Month, Year): cececdde
Today's date (Day, Month, Year):  31 cececdde
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
5. Do you need help with eating, dressing, washing 
 yourself or using the toilet? 1 2 3 4 
During the past week: Not at A Quite Very 
  All Little a Bit Much 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
 Please go on to the next page
ENGLISH 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
29. How would you rate your overall health during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 
30. How would you rate your overall quality of life during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 


UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
2
Under each heading, please tick the ONE box that best describes your health TODAY
MOBILITY
I have no problems in walking about 
I have slight problems in walking about 
I have moderate problems in walking about 
I have severe problems in walking about 
I am unable to walk about 
SELF-CARE
I have no problems washing or dressing myself 
I have slight problems washing or dressing myself 
I have moderate problems washing or dressing myself 
I have severe problems washing or dressing myself 
I am unable to wash or dress myself 
USUAL ACTIVITIES (e.g. work, study, housework, 
family or leisure activities)
I have no problems doing my usual activities 
I have slight problems doing my usual activities 
I have moderate problems doing my usual activities 
I have severe problems doing my usual activities 
I am unable to do my usual activities 
PAIN / DISCOMFORT
I have no pain or discomfort 
I have slight pain or discomfort 
I have moderate pain or discomfort 
I have severe pain or discomfort 
I have extreme pain or discomfort 
ANXIETY / DEPRESSION
I am not anxious or depressed 
I am slightly anxious or depressed 
I am moderately anxious or depressed 
I am severely anxious or depressed 
I am extremely anxious or depressed 
UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
3
 We would like to know how good or bad your health is 
TODAY.
 This scale is numbered from 0 to 100.
 100 means the best health you can imagine.
0 means the worst health you can imagine.
 Mark an X on the scale to indicate how your health is TODAY.
 Now, please write the number you marked on the scale in the 
box below. 
                    






















The best health     
you can imagine
The worst health   
you can imagine
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PROTOCOL SYNOPSIS
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre 
Study of Maintenance Olaparib Monotherapy in Patients with gBRCA
Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed 
on First Line Platinum Based Chemotherapy
Study centre(s) and number of patients planned: Approximately 80 centres worldwide will 
be initiated to randomise approximately 145 patients with germline BRCA1/2 mutations and 
metastatic adenocarcinoma of the pancreas (hereafter referred to as pancreas cancer).  
Additional countries and centres may be added dependent on recruitment rates.
Study period Phase of development
Estimated date of first patient enrolled Q2 2014 III
Estimated date of last patient completed Q2 2017
Besides the main study, an exploratory study looking at the feasibility of assaying for and 
determining the prevalence of tumour tissue biomarkers (including but not limited to somatic 
BRCA1/2 mutations, methylation and/or other HRD biomarkers) will be done on tissue 
samples submitted by patients screened for gBRCA. The information from this exploratory 
analysis may potentially guide future pancreas cancer Olaparib studies.
Objectives
Primary Objective: Outcome Measure:
 To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo by progression free survival 
(PFS)
 Progression Free Survival (PFS) by BICR 
using modified RECIST 1.1
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Secondary Objective: Outcome Measure:
 To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo
 Overall Survival (observed and predicted 
using observed PFS and OS data)
 Time from randomisation to second 
progression (PFS2)
 Time from randomisation to first subsequent 
therapy or death (TFST)
 Time from randomisation to second 
subsequent therapy or death (TSST).
 Time from randomisation to study treatment 
discontinuation or death (TDT)
 Objective Response Rate by BICR using 
modified RECIST 1.1 criteria for evaluable 
patients
 Disease Control Rate at 16 weeks by BICR 
using modified RECIST 1.1 criteria
 To assess the effect of Olaparib on the 
Health-related Quality of Life 
(HRQoL) as measured by EORTC 
QLQ-C30 global QoL scale.
 Adjusted mean change from baseline in 
global QoL score from the EORTC-QLQ-
C30 questionnaire
Safety Objective: Outcome Measure:
 To assess the safety and tolerability of 
Olaparib maintenance monotherapy
 Adverse event (AE), physical examination, 
vital signs including blood pressure (BP), 
pulse, electrocardiogram (ECG) and 
laboratory findings including clinical 
chemistry and haematology
Exploratory Objective: Outcome Measure:
 To assess the effect of Olaparib on 
functioning as measured by the EORTC 
QLQ-C30 functioning domains (physical, 
 Adjusted mean change from baseline on 
EORTC-QLQ-C30 functioning domains 
(physical, role, cognitive, emotional, 
social), on EORTC-QLQ-C30 + PAN26 
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role, cognitive, emotional and social).
 To assess the effect of Olaparib on 
pancreas cancer symptoms as measured 
by the EORTC QLQ-PAN26 items and 
scales.
 To assess clinically relevant symptoms as 
measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, 
weight loss (or difficulty gaining 
weight/loss of appetite), jaundice
 To assess change in performance status as 
measured by the ECOG Performance 
Status scale
symptom scales and items (pain, fatigue, 
nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice and on 
performance status measured by the 
ECOG Performance Status scale
 To investigate the health economic 
impact of treatment and the disease on 
hospital related resource use and health 
state utility
 Number, type and reason of 
hospitalisations and hospital attendances, 
procedures undertaken and hospital 
length of stay. 
 Health state utility derived from the 
HRQL instrument, the EuroQoL EQ5D
 To explore methods of estimating overall 
survival (OS) adjusting for the impact of 
the control arm receiving subsequent 
Polyadenosine 5’diphosphoribose [poly 
(ADP ribose)] polymerise (PARP) 
inhibitors or imbalances between the 
treatment arms for other potentially 
active agents. 
 Overall survival adjusted for impact of 
subsequent PARP inhibitors (or other 
potentially active investigational agents 
(if appropriate, to support reimbursement 
appraisals)
 To determine the frequency of and 
describe the nature of BRCA mutation/s 
in tumour samples and to compare this 
with germline BRCA mutation status.
 BRCA1 and/or BRCA2 mutation status 
in tumour
 To identify tumour tissue based 
biomarkers (including but not limited to 
somatic BRCA1/2 mutations, BRCA 
methylation and/or other HRD 
biomarkers) that could be used to guide 
future patient segmentation approaches 
 Potential tissue biomarkers identified
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for development
 Future exploratory research into factors 
that may influence development of cancer 
and/or response to treatment (where 
response is defined broadly to include 
efficacy, tolerability or safety) may be 
performed on the collected and stored 
archival tumour samples (if available), 
blood samples at day 1 and on disease 
progression or on residual tissue material 
collected as part of the study.
The exploratory analyses may not be reported in the clinical study report (CSR).  If not, they 
will be reported separately.
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Study Flow Chart 
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Target Patient population
All patients randomised in the study will be selected based on the following 2 principles: 
 Genetic selection:  Documented germline mutation in BRCA1 or BRCA2 that is 
predicted to be deleterious or suspected deleterious (known or predicted to be 
detrimental/lead to loss of function).  Patients with gBRCA1 and/or gBRCA2 mutations 
that are considered to be non detrimental (eg, “Variants of uncertain clinical 
significance” or “Variant of unknown significance” or “Variant, favor polymorphism” 
or “benign polymorphism,” etc) will not be eligible for the study.
 Treatment setting: All eligible patients must have metastatic gBRCAm pancreas 
cancer, must have received a minimum of 16 weeks of platinum based treatment and 
must have no evidence of progression based on investigator’s opinion. Study treatment 
will be started after randomisation as soon as possible but no less than 4 and no more 
than 8 weeks after last dose of first line chemotherapy. Tumour response during study 
treatment will be assessed using modified RECIST 1.1.  Baseline assessments will be 
performed using CT or MRI scans of the chest, abdomen and pelvis and should be 
performed no more than 28 days prior to start of study treatment, and as close as 
possible to randomisation. Follow-up assessments should be performed every 8 weeks 
(±1 week) for 40 weeks and then every 12 weeks ± 1 week relative to date of 
randomisation, until objective disease progression as defined by modified RECIST 1.1.
An exploratory study looking at the feasibility of assaying for and determining the prevalence 
of tumour tissue biomarkers (including but not limited to somatic BRCA1/2 mutations, 
methylation and/or other HRD biomarkers) will be done on tissue samples submitted by 
patients screened for gBRCA. The information from this exploratory analysis may potentially 
guide future pancreas cancer Olaparib studies.
After confirmation of eligibility, patients will be randomised (using an IVRS) in a 3:2 ratio 
(Olaparib:placebo) to the treatments as specified below:
 Olaparib tablets po. 300 mg twice daily
 Placebo tablets twice daily
Investigational product, dosage and mode of administration
Olaparib is available as a green film-coated tablet containing 150 mg or 100 mg of Olaparib.  
Patients will be administered study treatment orally at a dose of 300 mg twice daily (bid). The 
planned dose of 300 mg bid will be made up of two x 150 mg tablets bid with 100 mg tablets 
used to manage dose reductions. 
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Comparator, dosage and mode of administration
Placebo will be available as green film-coated tablets matching the Olaparib tablets. These 
should be taken as per instructions for Olaparib tablets.
Duration of treatment
Patients should continue to receive study treatment until objective radiological disease 
progression per modified RECIST 1.1 as assessed by the investigator or unacceptable toxicity 
and they do not meet any other discontinuation criteria.  Patients who are determined to have 
progressed according to modified RECIST 1.1 criteria by the Investigator will have scans 
centrally reviewed for confirmation of objective disease progression. If disease progression is 
not confirmed at central review one additional RECIST assessment will be requested 
preferably at the next scheduled RECIST visit. Once patients have been discontinued from 
study treatment, other treatment options will be at the discretion of the investigator. Patients 
and investigators will not be routinely unblinded to study treatment prior to the final OS 
analysis. It is expected that many if not most patients will be restarted on a platinum based 
regimen at progression on study therapy. Whatever the regimen, they will be assessed for 
PFS2 and followed for survival.  
Statistical methods
Approximately 145 patients will be randomised (3:2 ratio of Olaparib:placebo) and the 
primary PFS analysis will occur once approximately 87 PFS events (confirmed via a central 
review) have occurred.   A single interim PFS analysis for futility will be performed when 
50% of the final number of progression events needed for the primary PFS analysis has been 
reached (approximately 44 PFS events).  The interim analysis will be performed by an 
Independent Data Management Committee (IDMC) and full details will be provided in the 
IDMC charter.  
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.5% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median PFS for placebo. 
Assuming that the study accrual period will be approximately 15 months, 87 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 44 PFS events will occur approximately 13 to 14 
months after the first patient enters the trial.
Patients are to be followed for the final analysis of OS (when approximately 106 death events 
have occurred).  With 106 OS events the study has 80% power to show a statistically 
significant difference in OS at the 2.5% level (1-sided) if the assumed true treatment effect is a 
HR 0.57; this translates to an approximate 6 month improvement in median OS over an 
assumed 8 month median OS on placebo, assuming OS is exponentially distributed.
The primary statistical analysis of the efficacy of Olaparib will include all randomised patients 
(Full Analysis Set; FAS) and will compare the treatment groups on the basis of randomised 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib  
Study Code D081FC00001
Edition Number 2
Date 28 February 2015
9(120)
treatment, regardless of the treatment actually received. In addition, key sensitivity analyses of 
efficacy endpoints will be performed in the subgroup of patients in the FAS that have a 
gBRCA mutation confirmed by the Myriad test. When assessing safety and tolerability, 
summaries will be produced based on the Safety Analysis Set.  This will include all patients 
who receive at least one dose of randomised treatment (Olaparib or placebo).  The safety data 
will be summarised descriptively and will not be formally analysed.
PFS will be analysed using a log rank test.  The HR together with its 95% confidence 
interval (CI) and p-value will be presented (a HR less than 1 will favour Olaparib).  The 
primary analysis will be based on a blinded independent central review (BICR) of disease 
progression by modified RECIST 1.1; however, a sensitivity analysis will be performed using
the investigator-recorded assessment.
Subgroup analyses will be conducted to assess consistency of treatment effect across potential 
prognostic factors (see Section 8.8.2 for all predefined subgroups).  An analysis will not be 
performed if there are too few events available for a meaningful analysis of a particular 
subgroup (ie, if there are less than 20 events in a subgroup).
OS analyses will be performed at the same time as the primary analysis of PFS and will use 
the same methodology and model as PFS.  A final analysis of OS will be performed when 
approximately 106 death events have occurred and a multiplicity adjustment will be made to 
account for the different analyses. At the time of the PFS analysis, a predicted treatment effect 
for OS at the final analysis will be derived using a weighted sum of the observed OS data and 
the predicted OS value using PFS data.
Exploratory analyses of OS which attempt to adjust for any potential confounding impact of 
subsequent use of PARP inhibitors on the control arm may be performed if an appropriate 
proportion of patient’s on the control arm receive such treatments and sufficient information is 
collected on subsequent therapy use.
PFS2 analyses will be performed at the same time as the primary analysis of PFS, and at the 
time of the final analysis of OS.  PFS2 will be analysed using the same methodology and 
model as PFS.
In order to describe the nature of the benefits of Olaparib maintenance treatment, PFS, PFS2 
and OS will be tested at a 1-sided significance level of 2.5%. However, in order to strongly 
control the type I error, a multiple testing procedure will also be employed where PFS is tested 
first using the full test mass and OS will be tested if the null hypothesis for PFS is rejected.
Secondary analyses of time to treatment discontinuation, time to first subsequent therapy or 
death, and time to second subsequent therapy or death will be provided, using the same 
methodology as specified for the primary analyses of PFS; however no multiplicity 
adjustment will be applied as these are viewed as supportive endpoints.
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Objective tumour response rates and disease control rates (based on central review) will be 
summarised for the two treatment arms.  In addition, the investigator reported response rates 
will also be summarised. 
Patient Reported Outcomes
The impact of olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC QLQ-C30 global quality of life (QoL) and QLQ-PAN26 pancreatic 
pain scales. Adjusted mean change from baseline in global QoL score will be analysed 
using a mixed model for repeated measures (MMRM) analysis of all of the post-baseline 
scores for each visit and will be presented by treatment group.  As a supportive analysis, 
global QoL improvement rate will be analysed using a logistic regression model.
An exploratory analysis will examine adjusted mean change from baseline on EORTC 
QLQ-C30 functioning domains (physical, role, cognitive, emotional, social) and on 
EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (including pancreatic pain, 
fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite), jaundice).
EORTC QLQ-C30 and QLQ-PAN26 compliance (overall compliance and by visit 
compliance) will be summarised for each treatment group.
Health Economics
An exploratory health economic analysis of resource use will be estimated, including 
descriptive statistics relating frequency of hospitalisations and hospital admission, type of 
attendance, length of stay and procedures undertaken, and the primary symptom/reason for the 
attendance. For utility, descriptive statistics, graphs and listings will be reported for health 
state utility by visit as well as change in these scores from baseline. To support future 
economic evaluations of Olaparib, additional appropriate analyses may be undertaken, for 
example, mean health state utility pre and post treatment and pre and post progression.
Biomarkers
The most important biomarker research will be done on non-randomised and 
randomised patients. Screened patients will submit tumour samples for tBRCA/BRCA
methylation/ HRD analyses. A combination of evaluability, prevalence and sensitivity for 
known gBRCA will be used to determine the feasibility of investigating Olaparib in future 
studies.
Appropriate summaries of exploratory outcome variables and data listings will be produced 
and compared across the two treatment arms. Graphical methods will be widely used in 
exploring the characteristics and relationships of outcome variables.
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LIST OF ABBREVIATIONS AND DEFINITION OF TERMS




AE Adverse event (see definition in Section 6.1)
ALP Alkaline phophatase
ALT Alanine aminotransferase
AML Acute myeloid leukaemia
ANC Absolute neutrophil count
APTT Activated partial thromboblastin time
AST Aspartate aminotransferase
AUC Area under the plasma concentration-time curve
Baseline Refers to the most recent assessment of any variable prior to dosing with 
study treatment
BICR Blinded Independent Central Review
bid Bis in die (twice daily)
BoR Best Overall RECIST Response
BP Blood pressure
gBRCA germline Breast Cancer susceptibility gene
BRCA mutation or 
BRCAm
Breast Cancer susceptibility gene mutation (see gBRCA mutation or 
gBRCAm)
BUN Blood urea nitrogen
CHO Chinese hamster ovary
CI Confidence Interval 
CR Complete Response
CRF Case Report Form (electronic/paper)
CRO Clinical Research Organisation
CSA Clinical Study Agreement
CSR Clinical Study Report
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Event
DAE Discontinuation of Investigational Product due to Adverse Event
DCIS ductal carcinoma in situ
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DCO Data Cut Off
DCR Disease control rate
DNA Deoxyribonucleic acid 
DSB Double strand break
ECG Electrocardiogram
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
E-code Enrolment code (allocated by IVRS/IWRS)
ECOG Eastern Cooperative Oncology Group: A performance status using scales 
and criteria to assess how a patient’s disease is progressing
eCRF Electronic Case Report form
EORTC QLQ-C30 The EORTC QLQ-C30 is a questionnaire developed to assess the quality of 
life of cancer patients
EORTC QLQ-PAN26 The EORTC QLQ-PAN26 module comprises 26 questions assessing pain, 
dietary changes, jaundice, altered bowel habit, emotional problems related 
to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, 
dry mouth, taste changes)
EQ-5D-5L/ EQ-5D EuroQoL five dimensions, five level (EQ-5D-5L) health state utility index
FAS Full Analysis Set
FDA Food and Drug Administration
FFPE Formalin Fixed Paraffin Embedded
FSH Follicle stimulating hormone
gBRCA mutation or 
gBRCAm
The term "gBRCA mutation" is used to refer to a germline BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 
recommendations for standards for interpretation and reporting of sequence 
variants 
gBRCA wt gBRCA wildtype (patients without evidence of BRCA1 or BRCA2
deleterious or suspected deleterious mutations)
GCP Good Clinical Practice
G-CSF Granulocyte colony-stimulating factor
GGT Gamma glutamyl transferase
GMP Good Manufacturing Practice
GRand AZ Global Randomisation system
Hb Haemoglobin 
HDPE High-density polyethylene
HIV Human Immunodeficiency Virus
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HR Hazard Ratio
HRD Homologous recombination repair deficiencies
HRQoL Health-related Quality of Life
IATA International Air Transport Association 
IB Investigator’s brochure




If a study is conducted in several countries the International Co-ordinating 
Investigator is the Investigator co-ordinating the investigators and/or 
activities internationally. 
IDMC   Independent Data Monitoring Committee
INR International Normalised Ratio
IPCW Inverse Probability of Censoring Weighting
IRB Institutional Review Board
IVRS Interactive Voice Response System




LIMS Laboratory Information Management System
m Metre
MCH Mean cell haemoglobin
MCHC Mean cell haemoglobin concentration
MCV Mean cell volume
MDS Myelodysplastic syndrome
mg Milli-gram
MRI Magnetic resonance imaging
nab nanoparticle albumen bound
NCI National Cancer Institute
NE Not evaluable
NTL Non-target lesions
OAE Other Significant Adverse Event (see definition in Section 8.4.1)
ORR Objective response rates
OS Overall survival
PARP Polyadenosine 5’diphosphoribose [poly (ADP ribose)] polymerisation
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PD Progressive disease
PFS Progression Free Survival
p.o. Per os (by mouth, orally)
PR Partial response
QoL Quality of Life
RECIST Response Evaluation Criteria In Solid Tumours.  This study will use 
modified RECIST version 1.1
RPSFT Rank Preserving Structural Failure Time
SAE Serious adverse event (see definition in Section 6.2
SAP Statistical Analysis Plan
SD Stable disease
SSB Single strand break
SUSARs Suspected Unexpected Serious Adverse Reactions
Study treatment Olaparib or control arm chemotherapy
tBRCA mutation or 
tBRCAm
The term "tBRCA mutation" is used to refer to a somatic tumour BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 




WBC White blood cells
WBDC Web Based Data Capture
wt Wildtype (patients without evidence of BRCA1 or BRCA2 deleterious or 
suspected deleterious mutations)
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1. INTRODUCTION
1.1 Background and rationale for conducting this study
1.1.1 Pancreas cancer and its treatment 
Pancreas cancer is a life-threatening disease and is the fourth leading cause of cancer death in 
the West.  In 2013, it is estimated that there were 45,220 newly diagnosed pancreas cancer 
cases in the US, and approximately 38,460 people deaths from pancreas cancer (American 
Cancer Society 2013).  Worldwide, it was estimated that 266,000 people died of pancreas 
cancer in 2008 (.
Fitzsimmons D et al 1999
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life 
(QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the 
QLQ-C30 in patients with pancreatic cancer. Eur. J. Cancer 35: 939-941, 1999.
Fong et al 2009
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of 
poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 
2009;361(2):123-34.
Fowble et al 2001 
Fowble B, Hanlon A, Freedman G, Nocolaou N, Anderson P. Second cancers after 
conservative surgery and radiation for stages I-II breast cancer : identifying a subset of women 
at increased risk. Int J Radiat Oncol, Biol, Phys. 2001; 51 (3);679-690.
Gaymes et al 2008
Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC, Farzaneh F, and Mufti GJ. 
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic 
cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 
Haematologica 2009; 94:638-646. doi:10.3324/haematol.2008.00193
Ginsburg et al 2010
Ginsburg et al BRCA1 and BRCA2 families and the risk of skin cancer Springer 
Science+Business Media B.V. 2010
Goggins M. et al 1996
Germline M et al BRCA2 gene mutations in patients with apparently sporadic pancreatic 
carcinomas. Cancer Res. 1996 Dec 1;56(23):5360-4
Hay et al 2009
Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) 
polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary 
tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 
2009;69(9):3850-5.
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Hahn et al 2003
Hahn et al BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 
2003 Feb 5;95(3):214-21.
Helleday 2011
Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing 
up the misunderstandings. Molecular Oncology 2011; 5: 387-393.
Jemal A et al 2011).
The poor prognosis of pancreas cancer (~90% of patients who are diagnosed will die of the 
disease) is a function of late presentation of the disease when inoperable/ locally advanced or 
metastatic. Furthermore treatment of metastatic pancreas cancer even with the most “active” 
regimens such as FOLFIRINOX (Conroy et al 2011) or gemcitabine + nab paclitaxel (Von 
Hoff et al 2013) is associated with median survivals of less than one year, and for single agent 
treatments at best only 6 months. Unfortunately the toxicity of the most active combination 
chemotherapy regimens limits the duration of exposure to patients even if benefiting from the 
treatment. The neurotoxicity of both FOLFIRINOX and gemcitabine + nab paclitaxel in the 
former case generally leads to discontinuation of some or all of the drugs at or before 6 
months of treatment and in the later case dose attenuation.  The FOLFIRINOX study 
recommended no more than a total of 6 months of chemotherapy for patients who had a 
response (Conroy et al 2011).Furthermore there are few if any established second line 
regimens available (American Cancer Society 2013) and benefit if any, is at most a few 
months of survival (Rahma et al 2013). Despite the development of more “active” regimens 
for first treatment of metastatic pancreatic cancer in the last decade, their limited absolute 
benefit and significant toxicity strongly suggest that improving the results of initial therapy of 
metastatic pancreas cancer constitutes an unmet medical need. Furthermore to date there has 
been no marker, clinical or molecular that would predict for increased likelihood of benefit 
from systemic therapies for pancreas cancer. 
Although carriers of deleterious germline mutations of the BRCA1 and particularly 
gene are known to have an increased risk of developing pancreas cancer (The Breast 
Linkage Consortium 1999, Goggins M. et al 1996), the prevalence of  gBRCAm in the 
unselected cases of pancreas cancer is unclear but likely less than 5 % In a tissue based 
7% of patients with resected pancreas cancer or human xenografts had “germline” 
in their tumour (Goggins M. et al 1996) but this cohort may not represent the typical 
unselected cases and the prevalence is likely somewhat lower.  There are specific 
however, where the association is much stronger. In Ashkenazi Jewish patients with 
cancer, the prevalence of gBRCAm is 6-10% in unselected patients (Fayers et al 2001
Fayers et al. EORTC QLQ-C30 Scoring Manual (Third Edition). Belgium: EORTC Quality of 
Life Group, 2001.
Ferrone CR et al 2009, Ozcelik et al 1997) and 15% in patients with a family history of 
the disease (Sadler ZK. 2012). In pancreas cancer patients with a family history of the 
disease, reported prevalence of carrying a germline BRCA2 mutation may be as high as 
17-19% (Murphy KM et al 2002, Hahn et al 2003).Given the small size of the gBRCAm 
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subpopulation in pancreas cancer, information comparing the natural history of this 
group with the overall pancreas cancer population is minimal. One study of the natural 
history of Ashkenazi Jews with pancreas cancer treated with surgery (most of whom 
eventually died of the disease) could find no difference in survival between those who 
had germline BRCAm (n=8) vs. those who did not (n=137). The study however did not 
extend beyond 2004 and did not include patients treated with more modern 
chemotherapies (Fayers et al 2001
Fayers et al. EORTC QLQ-C30 Scoring Manual (Third Edition). Belgium: EORTC Quality of 
Life Group, 2001.
Ferrone CR et al 2009). In a large study of the natural history of BRCAm associated pancreas 
cancer, the median all–stage overall survival (OS) for 58 patients was 14 months (95% CI 10-
23 months). Median OS for patients with stage 1-2 disease has not been reached at 60 months. 
Median OS for stage 3-4 was 12 months (95% CI 6-15). Superior OS was observed for 
patients with stage III and IV disease treated with platinum versus those treated with non-
platinum chemotherapies (22 vs 9 months; p=0.039 (Golan et al unpublished data). There are 
no approved treatments for patients with germline BRCA1/2 mutations and these patients are 
treated with regimens used for standard advanced pancreas (Lowery M et al 2011).
Recent data suggest there may also be a number of pancreas cancer patients’ tumours with 
ATM defects or a gBRCA-like or HRD phenotype (Cowley et al 2013). The development of a 
test to identify such tumours may broaden the patient population which could benefit from 
PARP inhibitors. Obtaining tumour tissue to look for the prevalence these other potential 
markers of drug sensitivity is another unmet need in advancing therapy of this serious illness.
1.1.2 Chemotherapy use in advanced pancreas cancer 
Chemotherapy for metastatic pancreas cancer has modest, at best, impact on PFS and OS. The 
“best” regimens for use as initial treatment of metastatic disease, FOLFIRINOX or 
gemcitabine + nab paclitaxel have respectively PFS’s of 6.4 and 5.5 mos. and OS’s of 11.1 
and 8.5 mos. (Conroy et al 2011, Von Hoff et al 2013). Toxicity particularly on the platinum 
based regimen was substantial (80% had hematologic toxicity, 45% ≥grade 3; 70% had 
peripheral neurotoxicity, 9% ≥grade 3) and led to dose reductions and treatment 
discontinuations. It is of note that median number of FOLFIRINOX cycles given was 10 (ie. 
~5 months of treatment) but the median PFS was 6.4 months suggesting some discontinuation 
prior to the planned 12 cycles and evidence of progression. Nevertheless platinum based 
regimens are widely used as first line therapy of metastatic pancreas cancer. 
1.1.3 PARP inhibition as a target for BRCA mutation positive cancer
Investigators should be familiar with the current Olaparib (AZD2281) Investigator Brochure 
(IB).
Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5’diphosphoribose [poly (ADP 
ribose)] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an 
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oral therapy, both as a monotherapy (including maintenance) and for combination with 
chemotherapy and other anti-cancer agents.
PARP inhibition is a novel approach to targeting tumours with deficiencies in DNA repair 
mechanisms.  PARP enzymes are essential for repairing DNA single strand breaks (SSBs).  
Inhibiting PARPs leads to the persistence of SSBs, which are then converted to DNA double 
strand breaks (DSBs) during the process of DNA replication.  During the process of cell 
division, DSBs can be efficiently repaired in normal cells by homologous recombination 
repair.  Tumours with homologous recombination deficiencies (HRD), such as ovarian cancers 
in patients with gBRCA1/2 mutations, cannot accurately repair the DNA damage, which may 
become lethal to cells as it accumulates.  In such tumour types, Olaparib may offer a 
potentially efficacious and less toxic cancer treatment compared with currently available 
chemotherapy regimens. 
gBRCA1 and gBRCA2 defective tumours are intrinsically sensitive to PARP inhibitors, both in 
tumour models in vivo Rottenberg et al 2008, Hay et al 2009) and in the clinic (.
Fitzsimmons D et al 1999, Fong et al 2009, Fowble et al 2001). The mechanism of action for 
Olaparib results from the trapping of inactive PARP onto the single-strand breaks preventing 
their repair (Helleday 2011, Murai et al 2012).  Persistence of SSBs during DNA replication 
results in their conversion into the more serious DNA DSBs that would normally be repaired 
by homologous repair.  Olaparib has been shown to inhibit selected tumour cell lines in vitro 
and in xenograft and primary explant models as well as in genetic BRCA knockout models, 
either as a stand-alone treatment or in combination with established chemotherapies.
1.1.4 Pre-clinical experience
The pre-clinical experience is fully described in the current version of the Olaparib IB.
1.1.5 Toxicology and safety pharmacology summary
Olaparib has been tested in a standard range of safety pharmacology studies eg, dog 
cardiovascular and respiratory function tests, and the rat Irwin test.  There were no noticeable 
effects on the cardiovascular or respiratory parameters in the anaesthetised dog or any 
behavioural, autonomic or motor effects in the rat at the doses studied.
Rodent and dog toxicology studies have indicated that the primary target organ of toxicity is 
the bone marrow with recovery seen following withdrawal of Olaparib.  Ex vivo studies have 
confirmed that Olaparib is cytotoxic to human bone marrow cells.
Olaparib was not mutagenic in the Ames test but was clastogenic in the Chinese hamster 
ovary (CHO) chromosome aberration test in vitro.  When dosed orally, Olaparib also induced 
micronuclei in the bone marrow of rats.  This profile is consistent with the potential for
genotoxicity in man. 
Reproductive toxicology data indicate that Olaparib can have adverse effects on embryofoetal 
survival and development at dose levels that do not induce significant maternal toxicity. 
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Further information can be found in the current version of the Olaparib IB.
1.1.6 Clinical experience with Olaparib
Below is an outline of the monotherapy Olaparib studies conducted in pancreas cancer 
patients.
1.1.6.1 Olaparib monotherapy studies in pancreas cancer patients
Study D0810C00042
Study 42 was a single arm phase II study of Olaparib (capsules) 400mg po bid in patients with 
germline BRCAm malignancies across multiple tumour types. Twenty three patients with 
germline BRCAm-associated advanced pancreas cancer after therapy with gemcitabine were 
treated with Olaparib capsules 400mg po bid. All patients had seen a prior gemcitabine 
regimen and over half a prior platinum containing regimen. The ORR was 22%, DCR 57%, 
PFS 4.6 mos. and OS 9.8 mos (Kaufman B et al 2013). This level of activity compares 
favourably with that reported for other therapies reported in advanced previously treated 
pancreas cancer (Rahma et al 2013). A retrospective analysis of the patient data from study 42 
suggested greatest benefit from Olaparib in those (15) patients whose tumours had not 
progressed on a prior platinum treatment (ORR 33%, DCR 66%, PFS 6.4 mos., OS 13.1 
mos.).
1.2 Research hypothesis
Single agent Olaparib tablet 300 mg bid has superior efficacy and acceptable tolerability 
profile as compared with placebo in patients with deleterious or suspected deleterious 
germline mutation in BRCA1 and/or BRCA2 and metastatic pancreas cancer who have 
achieved disease control(absence of objective progression) after receiving a minimum of 16 
weeks of first line platinum based chemotherapy.  The efficacy in this study will be assessed 
by the primary analysis of PFS defined as the time from randomisation until the date of 
objective radiological disease progression according to modified RECIST1.1 criteria, or death 
(by any cause in the absence of disease progression) regardless of whether the patient 
withdraws from randomised therapy or receives another anti-cancer therapy prior to disease 
progression. To reduce bias, primary analysis of PFS will be based on blinded, independent 
central review of RECIST scans. Secondary endpoints include overall survival, DCR at 16 
weeks, ORR (in patients with baseline evaluable disease), PFS2, safety assessments and 
patient-reported symptoms, functioning and health related quality of life.
1.3 Rationale for study design, doses and control group
Mutations in gBRCA1 and gBRCA2 are a very rare but definable molecular subgroup of 
pancreas cancer which may be found in some identifiable populations with a prevalence as 
high as 15%. Cells that lack gBRCA1/2 function, such as cancer cells from patients with 
germline mutations in these genes, are deficient in their ability to repair double-strand DNA 
breaks through homologous recombination (Roy et al 2012). This deficiency is presumed to 
underlie the observation that gBRCA1/2-deficient cells are sensitive to interventions that 
promote double strand DNA breaks or cross-links, such as ionizing radiation and platinum-
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based chemotherapeutic agents. Platinum based regimens are increasingly being used early in 
the treatment of advanced gBRCA-mutated breast and pancreas cancer, in addition to their 
established use in ovarian cancer. It is also presumed to underlie the observation that
gBRCA1/2-deficient cells are sensitive to treatment with inhibitors of poly-(ADP-ribose)-
polymerases (PARP inhibitors) (Bryant et al 2005) which are presumed to force repair of 
single-strand breaks towards the homologous repair pathway rather than the pathways that 
usually address single-strand breaks.  Phase I and proof-of-concept phase II studies have 
shown that PARP inhibitors have significant activity with limited toxicity when used as single 
agents in the treatment of gBRCA1/2 mutation-associated breast and ovarian cancer (Tutt A et 
al 2010; Audeh et al 2010) and pancreas cancer (Kaufman B et al 2013). The present trial is an 
important step in defining the role of Olaparib as a PARP inhibitor in patients with deleterious 
germline BRCA1/2 mutations and metastatic pancreas cancer and the strategy of switch 
maintenance to prolong disease control after beneficial effect of a platinum regimen as has 
been suggested for gBRCA-mutated ovarian cancer (Kim et al 2014, Ledermann et al 2013).  
The study will assess the efficacy of Olaparib relative to placebo as maintenance therapy after 
documentation of disease control(absence of progression) on an initial platinum based 
regimen for metastatic gBRCA pancreas cancer. The preliminary analysis of study 42 suggests 
selecting patients with tumours which are not known to be platinum resistant would increase 
the likelihood of benefit. Because of data to suggest that “sporadic” pancreas cancers may 
have tumour tissue BRCA mutations (Goggins M. et al 1996), an exploratory analysis of 
tumour tissue will be done to assess the prevalence and feasibility of assaying tumour tissue 
for BRCA mutations and/or other markers of HRD.  In the future it may be possible to extend 
the use of PARPi to patients with tumours having non-BRCA deficiencies in dsDNA 
repair. Olaparib has shown activity in ATM negative gastric cancer (Bang et al 2013) and 
there is suggestion of a similar sub-population in pancreas cancer (Kim et al 
2014). Furthermore, independent groups have also identifed genomic signatures in pancreas 
cancer predicted to be associated with sensitivity to PARP inhibitors (Alexandrov et al 2013; 
Cowley et al 2013). In order to further understand candidate methods for identifying these 
patients in future clinical trials we are asking all patients to donate a tumour sample at 
screening. In order to understand the prevalence and relationship of these markers to BRCA
status it is important that we are able to test samples from patients with and without gBRCA
mutations.
If the trial is successful it will give patients a relatively non-toxic oral therapeutic which will 
delay progression after stopping first line platinum based chemotherapy.
1.3.1 Rationale for using Myriad Genetics
The FDA has indicated that the gBRCA1 and gBRCA2 mutation assay will need to be 
approved as a companion diagnostic in the US.
Myriad Genetics has been chosen as a partner in developing a companion diagnostic for 
gBRCA1 and gBRCA2 testing because it has extensive experience of gBRCA1 and gBRCA2
mutation detection.  Myriad keeps a comprehensive database on gBRCA1 and gBRCA2 gene 
mutations and their clinical relevance.  Furthermore, Myriad has an established laboratory 
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infrastructure, which supports high volume testing with turnaround times that can meet the 
needs of a clinical trial.
1.4 Benefit/risk and ethical assessment 
As of 2 October 2013, an estimated 2103 patients with ovarian, breast, gastric, pancreas, and a 
variety of other solid tumours are estimated to have received treatment with Olaparib across 
the dose range 10 mg qd to 600 mg bid in AstraZeneca-sponsored, investigator-sponsored, and 
collaborative group studies. Olaparib has been given as either monotherapy (18 studies, an 
estimated 1214 patients) or in combination with other chemotherapy/anticancer agents 
(25 studies, an estimated 889 patients). Many of these combinations studies are ongoing. The 
majority of patients to date have received the capsule formulation of Olaparib (an estimated 
1635 patients). Approximately 468 patients have received the tablet formulation to 
date. Approximately 304 patients have received comparator or placebo across the Olaparib 
development programme.
An analysis of monotherapy data across 12 AstraZeneca sponsored monotherapy studies in 
975 patients who have been given Olaparib capsule estimated that 16.1% (157/975) of patients 
had been exposed to Olaparib capsule for ≥12 months at the time of database closure for the 
12 studies.  Furthermore, 41/ 975 patients received treatment for >24 months (longest duration 
was 44 months).  From the available data to date, there is no evidence of any unexpected 
toxicity following long-term Olaparib (capsule) monotherapy exposure. 
Additionally statistical analysis of the pooled QT/QTc data from 2 studies in a total of 
109 patients for the primary multiple dose analysis and 119 patients for the supportive 
single dose analysis showed that following multiple dosing of olaparib (300 mg bd), the 
upper confidence limit of the 2-sided 90% confidence interval (CI) around the mean 
treatment effect for QT Fridericia Correction Formula (QTcF) was <10 ms at all time 
points. Furthermore, the supportive analysis showed that following a single dose of 
olaparib, of either 100mg or 300mg the upper confidence limit of the 2-sided 90%CI 
around the mean treatment effect for QTcF was also <10 ms at all time points.
In conclusion, there was no indication of a clinically relevant effect of olaparib on 
cardiac repolarisation (as determined by prolongation of QTcF) following multiple 
dosing (300 mg bd) or following single dosing.
As a further supporting analysis, concentration-effect modelling of the pooled QT/QTc 
data from the same patients was conducted. Predictions, from the concentration-effect 
relationship obtained of the likely magnitude of effect of olaparib on ΔQTcF, showed 
that at the range of plasma concentrations achieved following the 300 mg bd tablet dose, 
olaparib would not be expected to cause prolongation of QTc interval of a magnitude 
that would be of clinical concern or which would cross the threshold for regulatory 
concern as described in ICH E14.
Olaparib as monotherapy at doses up to 400 mg bid capsule is generally well tolerated, with 
most common AEs including nausea, fatigue, vomiting, anaemia mainly mild-to-moderate 
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(CTCAE Grade ≤ 2) in severity.  In addition, in a small number of patients MDS/AML or 
pneumonitis have been observed and identified as important risks. 
1.4.1 Important potential risks
1.4.1.1 Myelodysplastic syndrome/acute myeloid leukaemia
There have been 16 reports of myelodysplastic syndrome (MDS) and/or acute myeloid 
leukaemia (AML) in patients treated with Olaparib as of 02 Oct 2013; 11 cases in Olaparib 
monotherapy trials and 5 cases in Olaparib combination studies with carboplatin and 
paclitaxel (n=4) or cediranib (n=1).  A total of 2103 patients are estimated to have received 
Olaparib, giving a cumulative incidence of 0.76% for MDS/AML, similar to the cumulative 
incidence reported from control arms of Olaparib randomised studies 0.7% (2/304 patients).  
All 16 patients had primary ovarian or peritoneal cancer and 12 of them were gBRCA1/2
positive (3 cases gBRCA status unknown; 1 case negative).  It has been hypothesised that a 
deficiency in the expression of BRCA genes may leave patients more vulnerable to the adverse 
effects of chemotherapy, and therefore, at an increased risk of MDS/AML as a result of cancer 
treatment (Cole and Strair 2010).  Most patients had been treated with extensive previous 
chemotherapy ranging from 6 to 95 cycles over periods of 3.5 months to 15 years, including 
platinum agents, topoisomerase II inhibitors, alkylating agents and taxanes.  The median time 
from diagnosis of cancer to onset of MDS was 5.3 yrs (range 2.9 -12.7).  The median time 
from start of Olaparib treatment to onset of MDS was 0.9 years (0.1 to 4.8 years).  The 
reported events of MDS/AML occurred post discontinuation of Olaparib treatment in 8 of the 
16 patients following a median of 0.1 years post treatment discontinuation (range: 0.1 to 1 
years).  Half of the patients (n=8) had received Olaparib for ≤ 12 months (5 patients had ≤ 6 
months exposure) and the other 8 cases occurred following longer than 12 month Olaparib 
exposure (3 patients following 12-18 months exposure and 5 patients following >2 years 
exposure to Olaparib). 
Since bone marrow is known to be a target organ for Olaparib toxicity, a risk of MDS/AML 
with long-term exposure to Olaparib cannot be excluded, but there is insufficient data at 
present to evaluate the strength, if any, of this relationship. Moreover, while non-clinical data 
suggest bone marrow progenitor cell populations are reduced temporarily following Olaparib 
treatment, there is no evidence to date linking Olaparib treatment to the generation of 
abnormal bone marrow precursors.  Furthermore, all patients who developed MDS/AML had 
extensive prior chemotherapy and while it is not possible to exclude the contribution of 
Olaparib, it is also considered that there were other potential contributing factors in all cases.  
Preclinical data also suggest potential benefit with PARP inhibitors in MDS/AML and clinical 
trials are now underway to assess this effect (Gaymes et al 2008).
To ensure robust safety monitoring, patients in this clinical trial will have weekly safety 
assessments during the first cycle and then safety assessments every 4 weeks during the rest of 
the treatment period. Clinical guideline of managing bone marrow toxicity and use of G-CSF 
is implemented as the safety management plan.
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of Oct 2013, 10 patients out of a total of 2103 patients estimated to have received 
Olaparib have reported pneumonitis, giving a cumulative incidence of 0.5% for pneumonitis.  
Pneumonitis was also reported for 2 patients (0.7%) of 304 patients that received placebo or 
comparator in the Olaparib trial programme (1 patient on placebo in Study 19 and 1 patient on 
paclitaxel in Study 39).  The patients were treated with Olaparib for breast cancer (n=2), 
ovarian cancer (n=2), non-small cell lung cancer (n=2), small cell lung cancer (n=1), pancreas 
cancer (n=1), gastric cancer (n=1) and thymic cancer (n=1).  Five of the 10 patients had a 
history of tobacco smoking.  The majority of patients had received prior radiotherapy and/or 
chemotherapy.  The majority of patients had relevant medical histories including pneumonitis, 
interstitial lung fibrosis, dyspnoea, haemoptysis, chest infection, allergic asthma, pleural 
effusion, and pleural metastases.  
Investigation of any new or worsening pulmonary symptoms has been implemented as a 
safety management plan (section 6.7.2).
1.4.1.3 New Primary Malignancies 
Overall, the number of reports of new primary malignancies is low, with 21 events (in 19 
patients) being reported in 02 Oct 2103 Olaparib treated patients (0.9%) and one event 
(bladder cancer) reported in the placebo arm of the double-blind Study 19.  In randomised 
controlled studies, 5 events of new primary malignancies have been reported in four Olaparib 
treated patients and one event in a placebo treated patient:
In the double blind maintenance Study 19, two events of new primary malignancies have been 
reported in Olaparib treated patients and one event in a placebo treated patient. In the open 
label gBRCA ovarian monotherapy dose-finding Study 12, three events were reported in two 
Olaparib treated patients. 
Of the 21 reported events in Olaparib treated patients, in ten the events were non-melanoma 
skin cancers.  There was one report of malignant melanoma.  The other 10 events of new 
primary malignancies were breast cancer (n=2), breast cancer in situ, gastric cancer, lung 
neoplasm (plus event of recurrence of the lung carcinoma), plasma cell myeloma, colon 
cancer, malignant muscle neoplasm (lesion present pre-Olaparib treatment) and one fatal 
event of T-lymphoblastic lymphoma/leukaemia. 
Of the 19 Olaparib treated patients subsequently diagnosed with a new primary malignancy, 
the majority were reported whilst receiving Olaparib treatment (16 patients).  In 3 patients the 
event was reported after Olaparib discontinuation 
The duration of Olaparib treatment for the 19 patients was:
 <6 months for 3 patients
 6 to 12 months for 6 patients
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 12 to 18 months for 2 patients
 18 to 24 months for 2 patients
 >2 years for 6 patients.
The type of new primary cancers reported were generally in line with secondary cancers 
observed in ovarian and breast cancer populations reported in the literature (Bergfeldt et al 
1995, .
Fitzsimmons D et al 1999, Fong et al 2009, Fowble et al 2001, Wesolowski et al 2007), or 
were cancers such as skin cancer, known to be the most common cancer in the general 
population and associated with high cure rates.
Ovarian cancer patients have been reported to have an increased risk of developing second 
primary malignancies.  Patients with gBRCA mutations are at risk of developing other primary 
cancers notably breast cancer (Ginsburg et al 2010) reported higher rates of skin cancers in 
patients with gBRCA1 (1.6%) and gBRCA2 (3.0%) mutations.
There were other contributing factors/potential alternative explanations for the development of 
the new primary malignancy in all 19 Olaparib treated patients.  All patients had previously 
received various chemotherapy agents including multiple cycles of DNA damaging platinum 
containing chemotherapies, taxanes, anthracyclines and other alkylating and DNA damaging 
agents.  Four patients were reported to have had prior radiotherapy. Seven of the 19 patients 
had previous medical histories of cancer (ovarian, cervix, breast, peritoneal) and 3 patients 
with skin cancers had either had previous basal cell carcinoma reported or had skin lesions 
evident prior to study treatment) prior to the cancer under investigation in the Olaparib 
studies.
There is insufficient evidence for an association between Olaparib treatment and the 
development of new primary malignancies in the clinical trial programme to date.
1.4.2 Potential benefit
Phase II clinical studies have investigated the effect of Olaparib either as monotherapy or in 
combination with other chemotherapy agents in cancer patients.  In patients carrying germline 
BRCA mutations, monotherapy studies in patients with heavily pre-treated breast cancer have 
reported an objective response rate (ORR) of up to 41%.  In ovarian cancer patients, the 
pivotal phase II study D0810C00019 (“Study 19”), a double-blind, randomised study assessed 
the efficacy of Olaparib 400 mg bid capsules as a maintenance treatment following platinum-
based chemotherapy in patients with platinum sensitive relapsed high grade serous ovarian 
cancer.  The progression-free survival (PFS) following Olaparib maintenance therapy was 
significantly longer compared with the placebo group (HR 0.35; 95% CI: 0.25, 0.49; 
p<0.00001) in the overall population.  In the subgroup of patients with BRCA mutant ovarian 
cancer, the effect was even greater with a PFS HR of 0.18 (95% CI: 0.11, 0.31; p<0.00001; 
median 11.2 versus 4.3 months).  An interim analysis of OS was performed at 58% maturity. 
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In the overall population, the analysis demonstrated a non-statistically significant numerical 
advantage for Olaparib-treated patients (OS HR 0.88; 95% CI 0.64-1.21; p=0.43808) and 
there was again a greater effect in the gBRCA-mutated subgroup:  the OS HR was 0.74 (95% 
CI 0.46 to 1.19; p=0.20813) with a numerical advantage in median overall survival observed 
with Olaparib (median 34.9 months versus 31.9 months with placebo).  Among the 62 
placebo-treated patients with gBRCA mutations, 14 switched to a PARP inhibitor post 
progression. In study D0810C00042 (“Study 42’), a single arm phase II study of Olaparib 
(capsules) 400mg po bid in patients with germline BRCAm malignancies across multiple 
tumour types, 23 patients with advanced gBRCAm associated pancreas cancer, all previously 
treated with gemcitabine were enrolled.  There were 1 CR and 4 PR’s (ORR 22%) with a 
disease control rate of 57%, a PFS of 4.6 months and an OS of 9.8 mos. Patients who had not 
progressed on a platinum containing regimen were most likely to benefit. The results of Study 
19 in ovarian cancer and Study 42 in pancreas cancer are the clinical basis for this 
investigation.
In this randomised double blinded study, patients who have disease control after a minimum 
of 16 weeks of platinum based therapy will, on the investigational arm receive monotherapy 
Olaparib 300 mg tablet bid (or control placebo) until disease progression or development of 
unacceptable toxicity. There is no intent to cap duration on Olaparib for these patients.  
Based on the available data on efficacy and safety, we anticipate that in the metastatic disease 
setting, Olaparib will have a positive benefit risk profile for the treatment of the very small 
well-defined population of advanced pancreas cancer patients with gBRCA mutations.
1.5 Study Design 
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Figure 1 Study Flow Chart
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This is a phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess 
the efficacy of Olaparib maintenance monotherapy in metastatic pancreatic cancer patients 
with gBRCA mutations [documented mutation in gBRCA1 or gBRCA2 that is predicted to be 
deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of 
function) and whose tumours have not progressed on at least 16 weeks of first line platinum 
based chemotherapy.
Approximately 145 patients will be randomised using an Interactive Voice Response System / 
Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the 
treatments as specified below:
 Olaparib tablets p.o. 300 mg twice daily 
 Matching placebo tablets p.o. twice daily 
Eligible patients will be those patients with pancreas cancer previously treated for metastatic 
disease gBRCA mutated, who have not progressed following completion of at least 16 weeks 
(can be more) of first line platinum-based chemotherapy.  
All patients must have a known deleterious or suspected deleterious germline BRCA mutation 
to be randomised; this may have been determined prior to enrolment into the study or may be 
assessed as part of the enrolment procedure for the study (via centrally provided Myriad 
Integrated BRACAnalysis test)
Patients must have completed a minimum of 16 weeks of first line platinum-based therapy 
(eg, oxaliplatin, carboplatin or cisplatin) given continuously before randomisation to the study 
and should in the opinion of the investigator have had at least disease control. There must be 
absence of progression by imaging done within 4 weeks of randomisation. Patients whose 
platinum based therapy was discontinued as a result of toxicities specifically related to their 
platinum containing regimen are eligible if they received at least 16 weeks of platinum 
therapy and have continuously received the other chemotherapy drug(s) in their regimen (for 
example FOLFIRI for FOLFIRINOX etc.) and fulfil all other eligibility requirements 
(including non-progression at the time of enrolment).  
Patients known to have germline BRCA mutation/s prior to randomisation can enter the study 
based on this result provided they meet all other eligibility criteria.  The type of BRCA1/2
mutation must be reported in the eCRF.  In addition the patients must consent to give 2 blood 
samples, the primary purpose of the first sample is for undertaking a confirmatory Myriad 
gBRCA test post randomisation and a second sample is required for assessment of current and 
future BRCA mutation assays. The patients will also submit the diagnostic pathology 
specimens (block or slides) if available for the exploratory portion of the study.
Patients with unknown BRCA status must consent to give 2 blood samples for germline BRCA
testing by Myriad (and all local ethical procedures for such genetic testing).  One sample will 
be used to test for BRCA mutations using the current commercial Myriad BRCA analysis test 
prior to study entry (Myriad Integrated BRACAnalysis).  The second blood sample from all 
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tested patients (including those who do not have a BRCA mutation) is required for assessment 
of current and future BRCA mutation assays.  When the result from the Myriad test indicates 
the patient does have a deleterious or suspected deleterious germline BRCA mutation and the 
patient meets all other eligibility criteria, the patient can be randomised into the study. The 
patients will also submit the diagnostic pathology specimens (block or slides) if available. 
Residual blood (or its derivatives) from both samples may be used to evaluate future gBRCA
companion diagnostic tests and for additional exploratory work, to elucidate the mechanism of 
response, understand the mode of action of study treatment, improve the understanding of 
pancreas cancer and disease recurrence (including gBRCA mutation status and it role in 
response).
The 2 blood samples from patients with both known and unknown BRCA mutation status are 
needed in order to ensure sufficient information is collected in the study to enable the pre-
market approval of the Myriad germline BRCA test as a companion diagnostic for Olaparib in 
the USA.  In addition residual material may be used for the assessment of other current and 
future BRCA mutation diagnostic assays and/or assays that predict sensitivity to Olaparib.
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is 
the day of the last infusion) and treatment started as soon as possible but no less than 4 and no 
more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, 
all previous chemotherapy treatment should be discontinued. 
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of 
treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks whilst 
on study treatment. 
Patients should continue to receive study treatment until objective radiological disease 
progression as per RECIST as assessed by the investigator and as long as in the investigator’s 
opinion they are benefiting from treatment and they do not meet any other discontinuation 
criteria as outlined in Section 3.9.
Once a patient has discontinued study treatment, clinic visits will be reduced to every 8 weeks.  
Following discontinuation of study treatment, further treatment will be at the discretion of the 
investigator however it is anticipated (but not required) that patients will be retreated with 
their platinum based regimen.  Details of any further systemic anti-cancer treatment will be 
collected until death, loss to follow-up or withdrawal of consent.  In addition to their regular 8 
weekly contact, patients will be contacted in the 7 days following a specified date (data cut off 
date) to capture survival status at that point for each survival analysis.  Assessments will be 
performed as described in Table 1.
Patients will have tumour assessments according to RECIST at baseline and every 8 weeks 
(±1week) up to 40 weeks and then every 12 weeks (±1 week) relative to date of randomisation 
until objective radiological disease progression according to modified RECIST criteria. All 
CT/MRI scans will be sent to an AstraZeneca appointed Clinical Research Organisation 
(CRO) for blinded independent central review. All treatment decisions will be based on site 
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assessment of scans. After the final primary progression free survival (PFS) analysis, central 
review of scans will no longer be required and investigators will be advised when to stop 
sending copies of the scans to the CRO conducting the central review.  Ongoing collection of 
site review tumour assessment is required and must be recorded in the electronic case report 
form (eCRF).
RECIST will be modified to assess patients with clinical CR at entry who will be assessed as 
having no evidence of disease (NED) until they have progressed based on the appearance of 
new lesions.
Any patient who discontinues study treatment for reasons other than objective radiological 
progression should continue, to undergo scheduled objective tumour assessments according to 
the study plan (see Table 1) in order to assess objective radiological progression of disease. 
Failure to do so may result in bias to the study results.
Once a patient has progressed the patient will be followed for second progression (PFS2) 
every 8 weeks and then survival until the final analysis.  Patients will be contacted in the week 
following last patient last visit for each analysis of survival. 
The primary analysis of the study will occur when approximately 87 progression events have 
occurred, although an interim analysis for futility will be done when 50% of the planned PFS 
events have occurred (see statistical Section 8).  
The primary analysis will be based on a blinded independent central review (BICR) of disease 
progression by modified RECIST; however, a sensitivity analysis will be performed using the 
investigator-recorded assessment.  All efficacy variables including overall survival will be 
analysed at the time of the primary analysis (providing sufficient events are available to make 
the analyses meaningful).
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Primary Objective: Outcome Measure:
 To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo by progression free survival 
(PFS)
 Progression Free Survival (PFS) by BICR 
using modified RECIST 1.1
2.2 Secondary objectives
Secondary Objective: Outcome Measure :
 To determine the efficacy of Olaparib 
maintenance monotherapy compared to 
placebo
 Overall Survival (observed and predicted 
using observed PFS and OS data)
 Time from randomisation to second 
progression (PFS2)
 Time from randomisation to first subsequent 
therapy or death (TFST)
 Time from randomisation to second 
subsequent therapy or death (TSST).
 Time from randomisation to study treatment 
discontinuation or death (TDT)
 Objective Response Rate by BICR using 
modified RECIST 1.1 criteria for evaluable 
patients
 Disease Control Rate at 16 weeks by BICR 
using modified RECIST 1.1 criteria
 To assess the effect of Olaparib on the 
Health-related Quality of Life 
(HRQoL) as measured by EORTC 
QLQ-C30 global QoL scale.
 Adjusted mean change from baseline in 
global QoL score from the EORTC-QLQ-C30 
questionnaire
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2.3 Safety objectives
Safety Objective: Outcome Measure:
 To assess the safety and tolerability of 
Olaparib maintenance monotherapy
 Adverse event (AE), physical examination, 
vital signs including blood pressure (BP), 
pulse, electrocardiogram (ECG) and 
laboratory findings including clinical 
chemistry and haematology
2.4 Exploratory objectives  
Exploratory Objective: Outcome Measure:
 To assess the effect of Olaparib on 
functioning as measured by the EORTC 
QLQ-C30 functioning domains (physical, 
role, cognitive, emotional and social).
 To assess the effect of Olaparib on 
pancreas cancer symptoms as measured 
by the EORTC QLQ-PAN26 items and 
scales.
 To assess clinically relevant symptoms as 
measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, 
weight loss (or difficulty gaining 
weight/loss of appetite), jaundice
 To assess change in performance status as 
measured by the ECOG Performance 
Status scale
 Adjusted mean change from baseline on 
EORTC-QLQ-C30 functioning domains 
(physical, role, cognitive, emotional, 
social), on EORTC-QLQ-C30 + PAN26 
symptom scales and items (pain, fatigue, 
nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice and on 
performance status measured by the 
ECOG Performance Status scale
 To investigate the health economic 
impact of treatment and the disease on 
hospital related resource use and health 
state utility
 Number, type and reason of 
hospitalisations and hospital attendances, 
procedures undertaken and hospital 
length of stay. 
 Health state utility derived from the 
HRQL instrument, the EuroQoL EQ5D
 To explore methods of estimating overall 
survival (OS) adjusting for the impact of 
the control arm receiving subsequent 
Polyadenosine 5’diphosphoribose [poly 
 Overall survival adjusted for impact of 
subsequent PARP inhibitors (or other 
potentially active investigational agents 
(if appropriate, to support reimbursement 
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(ADP ribose)] polymerise (PARP) 
inhibitors or imbalances between the 
treatment arms for other potentially 
active agents. 
appraisals)
 To determine the frequency of and 
describe the nature of BRCA mutation/s 
in tumour samples and to compare this 
with germline BRCA mutation status.
 BRCA1 and/or BRCA2 mutation status 
in tumour
 To identify tumour tissue based 
biomarkers (including but not limited to 
somatic BRCA1/2 mutations, BRCA 
methylation and/or other HRD 
biomarkers) that could be used to guide 
future patient segmentation approaches 
for development
 Future exploratory research into factors 
that may influence development of cancer 
and/or response to treatment (where 
response is defined broadly to include 
efficacy, tolerability or safety) may be 
performed on the collected and stored 
archival tumour samples (if available), 
blood samples at day 1 and on disease 
progression or on residual tissue material 
collected as part of the study.
 Potential tissue biomarkers identified
The exploratory analyses may not be reported in the clinical study report (CSR).  If not, they 
will be reported separately.
3. PATIENT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL 
Each patient should meet all of the inclusion criteria and none of the exclusion criteria for this 
study prior to randomisation.  Under no circumstances can there be exceptions to this rule.
3.1 Inclusion criteria
For inclusion in the study patients should fulfil the following criteria:
1. *Provision of informed consent prior to any study specific procedures 
2. *Patients must be male or female ≥18 years of age
Revised Clinical Study Protocol_Global
Drug Substance Olaparib  
Study Code D081FC00001
Edition Number 2
Date 28 February 2015
40(120)
3. *Histologically or cytologically confirmed pancreas adenocarcinoma receiving 
initial chemotherapy for metastatic disease and without evidence of disease 
progression on treatment
4. Patients with measurable disease and/or non-measurable or no evidence of disease 
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in 
this study. RECIST 1.1 has been modified to allow the assessment of progression 
due to new lesions in patients with no evidence of disease at baseline..
5. Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or 
suspected deleterious (known or predicted to be detrimental/lead to loss of function) 
(See Section 1.5)
6. Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or 
oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 
weeks of continuous platinum treatment and have no evidence of progression based 
on investigator’s opinion.  Patients who have received at least 16 weeks of a 
platinum regimen but had the platinum discontinued for toxicity but continued on 
the remaining drugs of their regimen are also eligible if they have no evidence of 
disease progression within 4 weeks of their last dose of chemotherapy.
7. Patients who have received platinum as potentially curative treatment for a prior 
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer 
are eligible provided at least 12 months have elapsed between the last dose of 
platinum-based treatment and initiation of the platinum-based chemotherapy for 
metastatic pancreas cancer.
8. Patients must have normal organ and bone marrow function measured within 4 
weeks prior to administration of study treatment as defined below:
 Haemoglobin ≥  9.0 g/dL with no blood transfusions (packed red blood cells 
and platelet transfusions) in the past 28 days
 Absolute neutrophil count (ANC) ≥ 1.5 x 10
9
/L
 White blood cells (WBC) >3 x 10
9
/L
 No features suggestive of MDS/AML on peripheral blood smear
 Platelet count ≥ 100 x 10
9
/L
 Total bilirubin ≤ 1.5 x institutional upper limit of normal 
 AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value 
unless liver metastases are present in which case they must be ≤ 5x ULN
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 Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
9. *ECOG performance status 0-1 at date signing of informed consent
10. *Postmenopausal or evidence of non-childbearing status for women of childbearing 
potential: negative urine or serum pregnancy test. Postmenopausal is defined as:
 Amenorrheic for 1 year or more following cessation of exogenous hormonal 
treatments
 Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in 
the post menopausal range for women under 50
 Radiation-induced oophorectomy with last menses >1 year ago
 Chemotherapy-induced menopause with >1 year interval since last menses
 Surgical sterilisation (bilateral oophorectomy or hysterectomy)
11. *Patient is willing and able to comply with the protocol for the duration of the study 
including undergoing treatment and scheduled visits and examinations
12. Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary tumour 
or a metastatic site if available or 3 unstained cytology slides if available.
3.2 Exclusion Criteria 
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
1. *Involvement in the planning and/or conduct of the study (applies to AstraZeneca 
staff and/or staff at the study site).
2. gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, 
“Variants of uncertain clinical significance” or “Variant of unknown significance” 
or “Variant, favour polymorphism” or “benign polymorphism” etc.).
3. Progression of tumour between start of first line platinum based chemotherapy for 
metastatic pancreas cancer and randomisation.
4. Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle 
1 Day 1 is not permitted. Palliative radiotherapy must have been completed 14 or 
more days before Cycle 1 Day 1. The patient can receive a stable dose of 
bisphosphonates or denosumab for bone metastases, before and during the study as 
long as these were started at least 2 weeks prior to study treatment.
5. *Previous randomisation in the present study.
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6. Exposure to an investigational product within 30 days or 5 half lives (whichever is 
longer) prior to randomisation
7. *Any previous treatment with a PARP inhibitor, including Olaparib.
8. *Patients with second primary cancer, EXCEPTIONS: adequately treated non-
melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal 
Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid 
tumours including lymphomas (without bone marrow involvement) curatively 
treated with no evidence of disease for ≥ 5 years prior to study entry.
9. Resting ECG with QTC ≥ 450 msec detected on 2 or more time points within a 24 
hour period or family history of long QT syndrome. If ECG demonstrates QTC ≥
450 msec, patient will only be eligible if repeat ECG demonstrates QTC ≤ 450 
msec.
10. Concomitant use of known potent CYP3A4/5 inhibitors such as ketoconazole, 
itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and 
nelfinavir.  For further detail refer to Appendix H.
11. Persistent toxicities (≥CTCAE grade 2) caused by previous cancer therapy, 
excluding alopecia and CTCAE grade 3 peripheral neuropathy.
12. *Patients with myelodysplastic syndrome/acute myeloid leukaemia.
13. Major surgery within 2 weeks of starting study treatment: patients must have 
recovered from any effects of any major surgery.
14. *Immunocompromised patients, eg, patients who are known to be serologically 
positive for human immunodeficiency virus (HIV).
15. *Clinically significant uncontrolled medical conditions are not permitted (eg active 
infection requiring IV antibiotics, symptomatic congestive heart failure, unstable 
angina pectoris, recent (3 months) myocardial infarction, extensive bilateral 
interstitial lung disease, psychiatric illness that would limit ability to comply with 
study procedures, and any other medical condition that, in the opinion of the 
investigator, places the patient at unacceptable risk of toxicity. NB: Diabetes which 
is controlled by medication does not exclude participation in the study
16. *Patients with a history of treated CNS metastases are eligible, provided they meet 
all of the following criteria: Disease outside the CNS is present. No evidence of 
interim progression between the completion of CNS-directed therapy and the 
screening radiographic study. No history of intracranial haemorrhage or spinal cord 
haemorrhage. Minimum of 2 weeks between completion of radiotherapy and cycle 
1 Day 1 and recovery from significant (Grade ≥3) acute toxicity with no ongoing 
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requirement for ≥ 10mg of prednisone per day or an equivalent dose of other 
corticosteroid.
17. *Patients unable to swallow orally administered medication and patients with 
gastrointestinal disorders likely to interfere with absorption of the study medication.
18. *Pregnant or breast feeding women.
19. *Previous allogeneic bone marrow transplant.
20. *Patients with a known hypersensitivity to Olaparib or any of the excipients of the 
product.
21. *Whole blood transfusions in the last 120 days prior to enrolment to the study 
which may interfere with gBRCA testing (packed red blood cells and platelet 
transfusions are acceptable, for timing refer to inclusion criteria no.8)
Procedures for withdrawal of incorrectly enrolled patients see Section 3.4.
3.3 Patient enrolment and randomisation
Investigator(s) should keep a record, the patient screening log, of patients who entered pre-
study screening.
The Principal Investigator will:
1. Obtain signed informed consent from the potential patient before any study specific 
procedures are performed.
2. Assign potential patients a unique enrolment number, beginning with ‘E#’.  (This 
number will be obtained through Interactive Voice/Web Response System 
[IVRS/IWRS]).
3. Determine patient eligibility. See Sections 3.1 and 3.2
4. Obtain the randomisation code (patient number) through IVRS/IWRS.
As patients are screened for the study, they must be allocated an enrolment code (E-code). The 
E-code is a 7-digit number made up of the centre number and the patient number within that 
particular centre (eg, the first patient screened at centre number 0001 would be assigned the E-
code E0001001, the second patient screened would be E0001002 and so on). This number is 
the patient unique identifier and is used to identify the patient on the eCRFs. If a patient 
withdraws from participation in the study, then his/her enrolment/randomisation code cannot 
be reused.
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3.4 Procedures for handling incorrectly enrolled or randomised 
patients
Patients who fail to meet the inclusion/exclusion criteria should not, under any 
circumstances, be randomised or receive study medication.  There can be no exceptions to this 
rule.
Where patients that do not meet the selection criteria are randomised in error or incorrectly 
started on treatment, or where patients subsequently fail to meet the study criteria post 
initiation, a discussion should occur between the AstraZeneca Study Team Physician and the 
investigator regarding whether to continue or discontinue the patient from treatment. Once a 
decision is made, Investigators need to ensure they comply with all applicable requirements 
for human patient protection and ethical review.
The AstraZeneca Study Team Physician is to ensure all such decisions are appropriately 
documented. In situations where an agreement cannot be reached, the patient should have their 
study treatment stopped and be withdrawn from the study
3.5 Methods for assigning treatment groups
Patient eligibility will be established before treatment randomisation. Once the eligibility of a 
patient has been confirmed, the Investigator (or nominated assistant) should contact the 
IVRS/IWRS Centralised Randomisation Centre for allocation of randomised study treatment.
The actual treatment given to individual patients will be determined by a randomisation
scheme that has been loaded into the (IVRS/IWRS) database. The randomisation scheme will 
be produced by a computer software program called GRand (AZ Global Randomisation
system) that incorporates a standard procedure for generating random numbers.
A blocked randomisation will be generated and all centres will use the same list in order to 
minimise any imbalance in the number of patients assigned to each treatment group. 
Patients will be identified to the Centralised Randomisation Centre using patient Ecode and 
month/ year of birth.
Randomisation codes will be assigned strictly sequentially as patients become eligible for 
randomisation.
Eligible patients will be randomised in a 3:2 ratio (Olaparib:placebo) as specified below:
 Olaparib tablets p.o. 300 mg twice daily
 Placebo tablets p.o. twice daily 
It is recommended that patients commence study treatment as soon as possible after 
randomisation, and ideally within 3 days.
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The IVRS/IWRS Centralised Randomisation Centre will inform the Investigator of the Kit ID 
number to be allocated to the patient at the randomisation visit. The Investigator will call/log 
in to the IVRS/IWRS for each subsequent dispensing visit for assignment of a new Kit ID 
number (s).
The Kit ID number dispensed at each visit will correspond to the treatment to which the 
patient was originally randomised.
3.6 Methods for ensuring blinding
Olaparib and placebo treatment will be blinded.
The study medication will be labelled using a unique Kit ID number, which is linked to the 
randomisation scheme. The active and placebo tablets will be identical and presented in the 
same packaging to ensure blinding of the study medication.
3.7 Methods for unblinding 
3.7.1 Methods for ensuring blinding
Olaparib and placebo treatment will be blinded.
The study medication will be labelled using a unique Kit ID number, which is linked to the 
randomisation scheme. The active and placebo tablets will be identical and presented in the 
same packaging to ensure blinding of the study medication.
3.7.2 Methods for unblinding the study
Individual treatment codes, indicating the treatment randomisation for each randomised 
patient, will be available to the investigator(s) or pharmacists from the IVRS/IWRS. Routines 
for this will be described in the IVRS/IWRS user manual that will be provided to each centre.
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment randomisation. The 
investigator documents and reports the action to AstraZeneca, without revealing the treatment 
given to patient to the AstraZeneca staff.
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally related to an investigational product and that potentially require 
expedited reporting to regulatory authorities. Treatment codes will not be broken for the 
planned analyses of data until all decisions on the evaluability of the data from each individual 
patient have been made and documented.
Except for medical reasons, patients, investigators and study monitors in the field will have no 
access to the individual treatment code until final analysis.
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Patients of child bearing potential and their partners, who are sexually active, must agree to 
the use of two highly effective forms of contraception, while they are receiving study 
treatment and for 3 months after last dose of study drug.  For details please refer to Appendix 
E Acceptable Birth Control Method.
3.8.2 Olaparib and CYP3A4/5
Patients should avoid concomitant use of drugs, herbal supplements and/or ingestion of foods 
known to modulate CYP3A4/5 enzyme activity (see Section 7.7.2) starting 5 days before they 
are randomised until 30 days after the last dose of study medication.
3.9 Discontinuation of investigational product
Patients may discontinue study treatment in the following situations:
 Patient decision.  The patient is at any time free to discontinue treatment, without 
prejudice to further treatment
 Objective radiological disease progression
 Adverse Event
 Severe non-compliance to study protocol 
 Death
3.9.1 Procedures for discontinuation of a patient from investigational product 
A patient that decides to discontinue study treatment will always be asked about the reason(s) 
and the presence of any adverse events.  If possible, they will be seen and assessed by an 
investigator(s).  Adverse events will be followed up (See Sections 6.3 and 6.4); questionnaires
and all study drugs should be returned by the patient.
If a patient is withdrawn from study, see Section 3.10.
Any patient discontinuing study treatment should be seen at 30 days post discontinuation for 
the evaluations outlined in the study schedule.  The patient’s tumour status should be assessed 
clinically and, if appropriate, disease progression should be confirmed by radiological 
assessment.  After discontinuation of study treatment, the principal investigator/sub-
investigator will perform the best possible observation(s), test(s) and evaluation(s) as well as 
give appropriate medication and all possible measures for the safety of the patient.  In 
addition, they will record on the eCRF the date of discontinuation, the reasons, manifestation 
and treatment at the time of discontinuation.  Patients will be required to attend the treatment 
discontinuation visit.  The patient should return all study medication.
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After discontinuation of the study treatment at any point in the study, all ongoing AEs or 
SAEs must be followed until resolution unless, in the investigator’s opinion the condition is 
unlikely to resolve due to the patients underlying disease, or the patient is lost to follow up 
(see Sections 6.3 and 6.4).  All new AEs and SAEs occurring during the 30 calendar days after 
the last dose of study medication must be reported (if SAEs, they must be reported to 
AstraZeneca within 24 hours as described in Section 6.4) and followed to resolution as above.  
Patients should be seen at least 30 days after discontinuing study treatment to collect and / or 
complete AE information.  Any untoward event occurring subsequent to the 30-day follow-up 
AE reporting period that the investigator assesses as possibly related to the study treatment 
should also be reported as an AE.
Patients who discontinue treatment prior to disease progression should continue to have 
RECIST assessments as per the study schedule. All patients must be followed for objective 
progression (as per RECIST 1.1) and survival, up to the final analysis.
3.10 Criteria for withdrawal 
Patients are at any time free to withdraw from study (study treatment and assessments), 
without prejudice to further treatment (withdrawal of consent).  Such patients will always be 
asked about the reason(s) and the presence of any adverse events.  If possible, they will be 
seen and assessed by an investigator.  Adverse events will be followed up (See Sections 6.3
and 6.4); questionnaires (eg, for patient reported outcomes) and all study drugs should be 
returned by the patient.
Withdrawn patients will not be replaced. 
Reasons for withdrawal from the study:
 Voluntary withdrawal by the patient who is at any time free to discontinue their 
participation in the study, without prejudice to further treatment*
 Incorrectly enrolled patients ie, the patient does not meet the required 
inclusion/exclusion criteria for the study
 Patient lost to follow-up
 Death
*If a patient decides at any point in the trial that they do not wish to continue with the full 
study schedule of assessments but are still willing to provide important study information (eg 
disease recurrence information and/or survival status information) then the patient should 
continue in the study and information should continue to be collected on the clinical database.  
However if a patient does not wish to have any further data collected, only then should they be 
considered as withdrawing consent from the study.  To minimise the number of cases of early 
withdrawal the investigator should discuss the options with the patient in case they would still 
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be willing to undergo reduced assessments and/or reduced data collection, in which case they 
would remain in the study.
*If a patient withdraws consent, they will be specifically asked if they are withdrawing 
consent to:
 to further participation in the study including any further follow up (eg, 
survival calls)
 withdrawal of consent to the use of their study generated data
 withdrawal to the use of any samples (see Section 5.6.5)
Data obtained prior to withdrawal of consent will be maintained in the clinical database and 
used in the study reporting.
The status of ongoing, withdrawn (from the study) and ‘lost to follow up’ patients at the time 
of an overall survival analysis should be obtained by the site personnel by checking the 
patients notes, hospital records, contacting the patients general practitioner and checking 
publicly available death registries.  In the event that the patient has actively withdrawn 
consent to collection of further data the vital status of the patient can be obtained by site 
personnel from publicly available resources where it is possible to do so under applicable 
local laws.
3.10.1 Screen failures 
Screening failures are patients who do not fulfil the eligibility criteria for the study, and 
therefore must not be randomised.  These patients should have the reason for study 
withdrawal recorded as ‘Incorrect Enrolment’ (ie, patient does not meet the required 
inclusion/exclusion criteria).  This reason for study withdrawal is only valid for screen failures 
(not randomised patients).
3.10.2 Withdrawal of the informed consent
Patients are free to withdraw from the study at any time (investigational product and 
assessments), without prejudice to further treatment.
A patient who withdraws consent will always be asked about the reason(s) and the presence of 
any adverse events (AE).  The Investigator will follow up AEs outside of the clinical study. 
The patient will return electronic PRO (ePRO) devices.  
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused. Withdrawn patients will not be replaced. 
3.11 Discontinuation of the study
The study may be stopped if, in the judgment of AstraZeneca, trial patients are placed at 
undue risk because of clinically significant findings that:
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 meet individual stopping criteria or are otherwise considered significant 
 are assessed as causally related to study drug, 
 are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded in the CRF. All reasons for discontinuation of 
treatment must be documented.
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the patients’ interests
4. STUDY PLAN AND TIMING OF PROCEDURES 
A study initiation visit must be conducted at the centre prior to the commencement of any 
study activities requiring informed consent. A schedule for the tests and evaluations to be 
conducted in this study is contained in this section and in Table 1.
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d






Medical and surgical history, 
including blood transfusions 
a
X
Prior cancer therapies 
including radiotherapy
X









Archival paraffin embedded 




Concomitant medications X X X X X X X X X
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d
ECOG performance status X X X X X




X X X X
Physical examination 
h
X X X X X
ECG 
i
X As clinically indicated
Tumour assessment 











Every 8 weeks (± 1 week) until week 40 
then every 12 weeks (±1 week), relative to 
the date of randomisation 
j


















X X X X X X X
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d
Coagulation 
m
X As clinically indicated
Urinalysis 
n
X As clinically indicated
Pregnancy test  
o
X X X
Biomarker blood sample 
p




X X X X X
EORTC QLQ-PAN26 
q
X X X X X X X X
Euro QoL EQ5D X X X X X X








X X X X X X X X X
Study drug dispensing 
s
X X X 
Study drug return X X X X
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d












a Include history of blood transfusion within previous 120 days from start of study treatment and the reasons eg bleeding or myelosuppression.
b These screening assessments do not need capturing on the eCRF, but they must be recorded in the patient’s notes.
c Patients must have a known deleterious or suspected deleterious BRCA mutation to be randomised to the study; this can be either a local lab result or a 
Myriad test result. Patients for whom their gBRCA status is already known, should be consented to the study within 28 days prior to day 1 of study 
treatment.  Any patient who consents to study related Myriad gBRCA status testing, must also have a blood sample taken at the same time for the 
purpose of developing and validating a future diagnostic test(s) for gBRCA mutations.
d Samples to be taken on Day 1 only for patients with known gBRCA mutation who have not completed PART 1 Screening. The screening gBRCA test 
and method performed at site must be recorded in the eCRF.
e Collection of an archival tumour sample is requested, if available, for all patients. These samples will be collected from the site pathologist during the 
screening Part 1 for patients with unknown gBRCA status and screening Part 2 for patients with known local gBRCA test.
f Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and treatment started as soon 
as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous 
chemotherapy treatment should be discontinued.
g Vital signs performed on day 1 before every cycle. If vital signs assessed within 7 days before starting study treatment, it does not need to be repeated on 
Day 1 of study treatment unless investigator believes that it is likely to have changed significantly. 
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h Physical examination should be performed according to the schedule. After the baseline assessment it is not necessary to record the details on the eCRF, 
any clinically significant changes not unequivocally related to disease progression, should be reported as adverse events.
i ECG assessments to be completed within 14 days before starting treatment if patient is eligible following completion of all other PART 2 assessments. 
After screening, ECGs will only be required if clinically indicated.
j Baseline RECIST assessments will be performed using CT scans of the chest, abdomen and pelvis (or MRI where CT is contraindicated) and should be 
performed no more than 28 days before start of study treatment and as close as possible to randomisation. A randomisation must be within 6 weeks of 
last chemotherapy. Treatment should be started as soon as possible but no less than 4 weeks and no more than 8 weeks after their last dose of 
chemotherapy. RECIST follow-up assessments will be performed every 8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) 
irrespective of treatment decisions. Follow-up assessment will include CT assessments of chest, abdomen and pelvis (or MRI where CT is 
contraindicated) for all patients. Any other sites at which new disease is suspected should also be appropriately imaged. Patients must be followed until 
disease progression assessed using modified RECIST 1.1 criteria.  If an unscheduled assessment was performed and the patient has not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits. Prior to primary analysis for PFS, all scans will be submitted for 
independent review. If progression is not confirmed at central review an additional RECIST assessment will be requested at the next scheduled visit.
k For patients who discontinue study treatment prior to disease progression, RECIST assessments will continue until objective disease progression (every 
8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) relative to date of randomisation, until objective disease progression as defined 
by modified RECIST 1.1.).
l Haematology and clinical chemistry should be performed at screening, cycle 1 day 1, 8, 15, 22 and day 1 of every cycle.  Safety blood samples do not 
need to be repeated on Day 1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study 
treatment, unless the investigator believes that it is likely to have changed significantly.  
m Coagulation test should be performed at screening and if clinically indicated. 
n Urinalysis should be performed at screening. After screening, urinalysis will only be required if clinically indicated. 
o In the event of suspected pregnancy during the study, the test should be repeated and, if positive, the patient discontinued from study treatment 
immediately.
p Mandatory blood samples for biomarker analysis to be taken prior to dosing on Cycle 1 Day 1 and at disease progression.
q Questionnaires to be completed prior to randomisation once eligibility has been confirmed and then until objective radiological disease progression, at 
discontinuation of study treatment visit and then 30 days post last dose.  Questionnaires should be completed prior to dosing on all administrations.
r Adverse events must be captured from time of consent. Only SAE’s related to blood sampling for the Myriad gBRCA test will be collected at this 
visit.
s Continuous Olaparib 300mg/ placebo twice daily dosing. Sufficient study treatment should be dispensed for at least each treatment period plus overage, 
however additional treatment can be dispensed to patients to last longer in accordance with local practice. 
t All anti-cancer treatments (including, but not limited to, chemotherapy and targeted agents), and the Investigator’s opinion of response to them, plus the 
date of progression post discontinuation of study treatment, need to be recorded. 
u Second disease progression (PFS2) assessment will be performed by the Investigator and defined according to local standard clinical practice and may 
involve any of; objective radiological or symptomatic progression or death.  Subsequent therapy will be collected for these patients from the time of 
treatment discontinuation.
v The status of ongoing, withdrawn (from the study) and ‘lost to follow-up’ patients at the time of an OS analysis should be obtained by the site  personnel 
by checking the patients notes, hospital records, contacting the patient’s general practitioner and checking publicly available death registries.  In the 
event that the patient has actively withdrawn consent to the processing of their personal data the vital status of the patient can be obtained by site 
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personnel from publicly available resources where it is possible to do so under applicable local laws (see Section 3.10). In addition to their regular 8 
weekly contact, patients will be contacted in the 7 days following a specified date (data cut off date) for each survival analysis.
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4.1 Enrolment/screening period
Procedures will be performed according to the Study Plan. 
At screening, consenting patients are assessed to ensure that they meet eligibility criteria. 
Patients who do not meet these criteria must not be enrolled in the study.
The following assessments and procedures should be performed during screening Part 1 and 
Part 2 as per Table 1.
For details of the schedule and nature of assessments see below:
 Month/ year of birth, sex, race and ethnicity 
 Medical and surgical history including previous cancer and radiotherapy and history 
of blood transfusions in previous 120 days 
 Previous chemotherapy
 If patient received a prior platinum drug, in what setting (adjuvant or advanced) 
and reason for discontinuation (progression on therapy, discontinuation of 
therapy for reason other than progression, completion of planned program 
without progression,)
 Current and concomitant medications including previous cancer therapies 
 ECOG Performance Status
 Vital signs (blood pressure and pulse; body temperature), body weight, height
 Haematology /Clinical chemistry/Urinalysis 
 Coagulation test
 activated partial thromboblastin time {APTT}will be performed at baseline and 
if clinically indicated
 international normalised ratio {INR} will be performed at baseline and if 
clinically indicated unless the patient is receiving warfarin. Patients taking 
warfarin may participate in this study; however, it is recommended that 
prothrombin time (INRand APTT) be monitored carefully at least once per 
week for the first month, then monthly if the INR is stable
 Physical examination
 CT (or MRI if CT is contraindicated) of chest, abdomen and pelvis
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 ECG (within 14 days prior to the start of the study treatment)
 Menopausal status; serum or urine pregnancy test for women of childbearing 
potential.  The pregnancy test should be prior to performing the gBRCA blood test 
during screening part 1, within 28 days prior to the start of study treatment and 
confirmed on day 1 prior to dosing
 For patients with unknown gBRCA status: gBRCA1/2 mutation status. 2 blood 
samples: One blood sample to test for gBRCA mutations using the current 
commercial Myriad BRACAnalysis test, and the second blood sample for a bridging 
study to validate the companion diagnostic test for Olaparib and/or assessment of 
current or future BRCA mutation assays
 Patient Reported Quality of life questionnaire: EORTC QLQ-C30 and QLQ-PAN26 
should be completed prior to randomisation once eligibility is confirmed
 Adverse events must be captured from time of consent.  Only SAE’s related to 
blood sampling for the Myriad gBRCA test will be collected at this visit. In 
Screening Part 2 all AEs/SAEs will be collected
 Archival paraffin embedded tumour tissue sample or cytology sample requested, if 
available
The Principal Investigator/Sub-Investigator should adhere to the study plan, procedures and 
perform tests/observations in accordance with the protocol.
4.2 Treatment period
The visit schedule is based on 28-day cycles. 
Patients will attend the clinic weekly on days 1 (1st day of treatment), 8, 15, 22, 29 following 
the commencement of study treatment and then every 4 weeks (day 1 of every cycle) until 
discontinuation of treatment. The following assessments will be performed at time points 
specified in the study schedule (see Table 1):
 Vital signs: Day 1 of every cycle. Body weight is only required at day 1 of 1st day 
of study treatment, if it has not been assessed within 7 days of randomisation.  Any 
other time as clinically indicated
 ECOG Performance Status: Day 1 of every cycle and until objective radiological 
disease progression, at discontinuation of study treatment visit and then 30 days 
post last dose 
 Haematology and clinical chemistry: cycle 1 day 1, 8, 15, 22 and day 1 of every 
cycle. Safety blood samples do not need to be repeated on Day 1 of study treatment 
if there have been separate assessments within 7 days before starting study 
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treatment and which must have been 3 weeks after last dose of chemotherapy based 
therapy, unless the investigator believes that it is likely to have changed 
significantly.
 Physical examination: Day 1 before every cycle but assessments post Day 1 are not 
required to be captured on an eCRF, however any significant changes from baseline 
must be reported as an AE.
 CT of chest, abdomen and pelvis (or MRI if CT is contraindicated) performed until 
objective disease progression. RECIST assessments to be scheduled every 8 weeks 
(±1 week) from randomisation for the first 40 weeks and then every 12 weeks (±1 
week). If progression is not confirmed by BICR an additional scan will be requested 
at the next scheduled visit. CT/MRI of chest, abdomen and pelvis to be performed 
until objective disease progression. 
 ECG at baseline and any time if clinically indicated 
 Urinalysis at baseline and any time if clinically indicated
 Serum or urine pregnancy test for women of childbearing potential (prior to 
treatment on day 1 of 1st day of study treatment).  If the test is positive then a 
confirmatory test should be performed
 For patients with known gBRCA status: gBRCA1/2 mutation status. 2 blood 
samples: One blood sample to test for gBRCA mutations using the current 
commercial Myriad BRACAnalysis  test, and the second blood sample for a 
bridging study to validate the companion diagnostic test for Olaparib and/or 
assessment of current or future BRCA mutation assays
 AE and concomitant medications (including any blood transfusions) at every visit
 Patient Reported Quality of life questionnaire: EORTC QLQ-C30 at baseline (prior 
to randomisation once eligibility is confirmed), every 4 weeks until objective 
radiological disease progression, at discontinuation of study treatment visit and then 
30 days post last dose.  
 Patient Reported Quality of life questionnaire: QLQ-PAN26 at baseline (prior to 
randomisation once eligibility is confirmed), week 1, week 2, week 3 and every 4 
weeks until objective radiological disease progression, at discontinuation of study 
treatment visit and then 30 days post last dose. 
 Health economic data in terms of utility (EuroQoL EQ5D) at baseline and every 4 
weeks until objective radiological disease progression, at discontinuation of study 
treatment visit and then 30 days post last dose. 
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 Health economic data in terms of hospital resource use at each visit during 
treatment then until objective radiological disease progression, at discontinuation of 
study treatment visit and then 30 days post last dose. 
 Mandatory blood sample for biomarker analysis at cycle 1 day 1 (pre-dose) and 
disease progression (Section 5.4.1)
Once patients have discontinued study treatment, other treatment options will be at the 
discretion of the investigator.
4.3 Follow-up period
4.3.1 Treatment discontinuation visit due to objective radiological disease 
progression
Patients should be discontinued from study treatment if they have objective radiological 
disease progression according to modified RECIST 1.1 criteria (see Appendix F). 
Following radiological disease progression patients will be followed for PFS2 and OS.
4.3.2 Treatment discontinuation visit due to any other discontinuation criteria
 Patients should be discontinued from study treatment if any discontinuation criteria 
are fulfilled (see Section 3.9).  The assessments to be carried out at the visit are 
detailed in the study schedule (Table 1).
Patients who have discontinued from treatment but do not have radiological disease 
progression will continue to be followed for PFS by modified RECIST 1.1 assessments every 
8 weeks (+/-1 week) from date of randomisation during the first 40 weeks and then every 12 
weeks (+/-1 week) thereafter. 
4.3.3 Patients who have objective radiological disease progression but continue on 
study treatment
Patients should be discontinued from study treatment if they have objective radiological 
disease progression according to RECIST (see Appendix F), however, patients may be 
allowed to continue study treatment if the investigator believes, and AZ Study Physician 
concurs, that the patient could continue to receive benefit, the patient is not experiencing 
serious toxicity, and there is no available better alternative treatment that could benefit the 
patient. These patients will continue study procedures as per Table 1 and will be followed for 
OS. Safety assessment can occur with the same frequency as the visits unless more frequent 
testing is clinically indicated.
4.3.4 Follow-up 30 day after last dose of study treatment (follow-up visit)
A follow-up visit should be conducted 30 days after the last dose of study treatment.  Any 
serious and/or non-serious AEs ongoing at the time of the Discontinuation Visit or which have 
occurred during the defined 30-day follow-up period must be followed-up (in accordance with 
Section 6.3).  Appropriate safety evaluations should be repeated and/or additional tests 
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performed at any time when clinically indicated, or at the discretion of the investigator, until 
resolution, unless, in the investigator’s opinion, the condition is unlikely to resolve due to the 
patient’s underlying disease.  If the patient is lost to follow-up, then this should be noted in the 
eCRF.  The assessments to be carried out at the 30 day follow up visit are detailed in the study 
schedule (Table 1).
4.3.5 Survival
Assessments for survival should be made every 8 weeks following objective radiological 
disease progression.  Survival information may be obtained via telephone contact with the 
patient, patient’s family or by contact with the patient’s current physician.  Survival data will 
be collected up to the time of the final overall survival (OS) analysis.  In addition, patients 
should be contacted in the week following the data cut-off for the primary PFS and final 
survival analyses to provide complete survival data.
Patients will be followed up as per Table 1 to the point of the final analysis.  At this point 
investigators will be notified that no further data collection for the study is required.  
Monitoring and recording of SAEs will continue as per Section 6.4.
The status of patients at the time of an overall survival analysis should be obtained by the site 
personnel by checking the patient’s notes, hospital records, contacting the patients general 
practitioner and checking publicly available death registries. In the event that the patient has 
actively withdrawn consent to the processing of their personal data the vital status of the 
patient can be obtained by site personnel from publicly available resources where it is possible 
to do so under applicable local laws (see Section 3.10).
4.3.6 Second Progression
Following objective progression, copies of the patient’s radiological scans are no longer 
required to be sent for blinded independent central review. Patients will be assessed every 8 
weeks for a second progression (using the patients’ status at first progression as the reference 
for assessment of second progression). A patient’s progression status is defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF.
4.3.7 Subsequent Treatment
Following objective progression on study as per modified RECIST 1.1, copies of the patient’s 
radiological scans are no longer required to be sent for blinded independent central review, 
provided that the central read confirms progression. If progression is not confirmed, one 
additional scan will be required at the next scheduled visit. Following objective progression 
patients will be assessed every 8 weeks for survival (see Section 4.3.5) but also for nature of 
subsequent treatment, response to subsequent treatment and investigator assessment of time to 
progression on the subsequent treatment. While other than the PFS2, response and time to 
progression on later therapies is not a specific endpoint of the trial, the information garnered 
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will help determine if there is an optimal sequencing of treatments for gBRCA-associated 
pancreas cancer and for planning of future clinical studies.
The data cut-off date for the final statistical analysis for the primary objective of the study will 
be established when approximately 87 confirmed progression events are expected to have 
occurred.
Patients on study treatment at the time of the data cut-off will continue to receive study 
treatment until they meet any discontinuation criteria as per Section 3.9. 
Patients on study treatment will be followed for core safety assessments (haematology, 
clinical chemistry, AEs/SAEs, concomitant medications and study treatment dosing details)
Once the primary PFS analysis has been performed the collection of RECIST data for 
independent central review will cease. Patients who have not had an objective disease 
progression at the time of the data cut off for the primary analysis should continue to have 
RECIST assessments until first objective disease progression is determined by the 
investigator. RECIST assessments should be performed every 12 weeks (± 1week) from the 
last assessment prior to the data cut off date.  Patients will also be followed for information on 
vital status to obtain the data needed for the OS analysis and information on subsequent 
treatment.  
4.4 Patient management post final analysis
The data cut-off date for the final statistical analysis of the study will be established when 
~106 confirmed OS events (~75 % maturity for OS analysis) are expected to have occurred.
At this time point, the clinical study database will close to new data.  Patients who are 
receiving treatment can either choose to discontinue from the study or where the investigator 
believes patients are gaining clinical benefit; patients may continue to receive study treatment.  
All patients will receive follow up care in accordance with standard local clinical practice.
AstraZeneca will continue to supply Olaparib after completion of this study until either 
Olaparib is licensed in that country, or it is determined that the benefit to risk profile does not 
support continued development of Olaparib, or the national health authority has deemed the 
drug not approvable.  In all these scenarios, AstraZeneca will work with investigators on the 
proper transition of patients to alternative therapies if possible.
SAEs will continue to be reported to AstraZeneca Patient Safety Department, for any patients 
who continue on Olaparib until 30 days after study treatment is discontinued, in accordance 
with Section 6.4.  Additionally as stated any SAE or non-serious adverse event, that is 
ongoing at the end of the study, must be followed up to resolution unless the event is 
considered by the investigator to be unlikely to resolve, or the patient is lost to follow-up.  If 
an investigator learns of any SAEs, including death, at any time after a patient has completed 
the study, and he/she considers there is a reasonable possibility that the event is causally 
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related to the investigational product, the investigator should notify AstraZeneca, Patient 
Safety.
Drug accountability should continue to be performed until the patient stops study treatment 
completely
5. STUDY ASSESSMENTS  
The Rave Web Based Data Capture (WBDC) system will be used for data collection and
query handling. The investigator will ensure that data are recorded on the electronic Case
Report Forms as specified in the study protocol and in accordance with the instructions
provided.
The investigator ensures the accuracy, completeness and timeliness of the data recorded and
of the provision of answers to data queries according to the Clinical Study Agreement. The
investigator will sign the completed electronic Case Report Forms. A copy of the completed
electronic Case Report Forms will be archived at the study site.
5.1 Efficacy assessments
5.1.1 CT and MRI scans Tumour assessments (Modified RECIST 1.1)
Following the baseline assessment, subsequent tumour assessments according to modified 
RECIST 1.1 should be performed every 8 weeks (±1 week) for the first 40 weeks and then 
every 12 weeks (± 1 week) thereafter, relative to the date of randomisation, up to objective 
disease progression by RECIST. Patients who are determined to have progressed according to 
modified RECIST 1.1 criteria by the Investigator will have scans centrally reviewed for 
confirmation of objective disease progression. If disease progression is not confirmed at 
central review an additional RECIST assessment will be requested preferably at the next 
scheduled RECIST visit (8 weeks from last scan).  
For those patients with no evidence of disease at baseline, following a clinical complete 
response to chemotherapy, progression is defined by the detection of new lesions on follow up 
radiological assessments (modified RECIST 1.1).
The imaging modalities used for RECIST assessment will be CT (MRI where CT is 
contraindicated) scans of the chest, abdomen and pelvis with other regions as clinically 
indicated for the assessment of disease.  Any other sites at which new disease is suspected 
should also be appropriately imaged.  The methods of assessment of tumour burden used at 
baseline must be used at each subsequent follow-up assessment.
Radiological examinations performed in the conduct of this study should be retained at site as 
source data.
Any missed copies of the scans are to be sent to an AstraZeneca appointed CRO for blinded 
independent central review.
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All treatment decisions will be based on site assessment of scans.  After the primary PFS 
analysis, central review of scans will no longer be required and investigators will be advised 
when to stop sending copies of the scans to the CRO conducting the central review.  
It is important to follow the assessment schedule as closely as possible. If scans are performed 
outside of scheduled visit ± 1 week window interval and the patient has not progressed, every 
attempt should be made to perform the subsequent scans at their scheduled time points.  
Patients will be evaluated until objective radiological disease progression by modified 
RECIST 1.1 as per the study schedule (see Table 1), and then followed for second progression 
and survival, regardless of whether study treatment is discontinued or delayed and/or protocol 
violations, unless they withdraw consent.
5.1.2 Tumour Evaluation
Modified RECIST 1.1 criteria will be used to assess patient response to treatment by 
determining progression free survival (PFS) times.  (The modified RECIST 1.1 guidelines for 
measurable, non-measurable, target and non-target lesions and the objective tumour response 
criteria (complete response, partial response, stable disease, no evidence of disease or 
progression of disease) are presented in Appendix F.) 
The methods of assessment of tumour burden used at baseline - CT or MRI scans of chest, 
abdomen and pelvis, with other regions as clinically indicated for the assessment of disease 
must be used at each subsequent follow-up assessment, see Section 4.3. 
Following the baseline assessment, efficacy for all patients will be assessed by objective 
tumour assessments every 8 weeks (±1 week) up to 40 weeks then every 12 weeks (±1 week) 
relative to date of randomisation, according to the planned study schedule Table 1 until 
objective radiological disease progression as defined by modified RECIST. If a patient 
discontinues treatment (and/or receives a subsequent cancer therapy) prior to progression then 
the patient should still continue to be followed until objective radiological disease progression 
as defined by modified RECIST 1.1.
Categorization of objective tumour response assessment will be based on the modified 
RECIST criteria of response: complete response (CR), partial response (PR), stable disease 
(SD), progression of disease (PD), no evidence of disease (NED) and not evaluable (NE).  
Target lesion (TL) progression will be calculated in comparison to when the tumour burden 
was at a minimum (ie, smallest sum of diameters previously recorded on study).  In the 
absence of a best response of progression, tumour response (CR, PR, SD) will be calculated in 
comparison to the baseline tumour measurements obtained before randomisation.
For patients with non-measurable disease only at baseline, categorization of objective tumour 
response assessment will be based on the RECIST criteria of response: CR (complete 
response), PD (progression of disease) and Non CR/Non PD. Patients with no disease at 
baseline will be assessed according to modified RECIST 1.1 criteria for new lesions with 
responses of No Evidence of Disease (NED) or progression of disease.
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If the investigator is in doubt as to whether disease progression has occurred on study therapy, 
particularly with response to NTL (non-target lesion) or the appearance of a new lesion, it is 
advisable to continue treatment until the next scheduled assessment or sooner if clinically 
indicated and reassess the patient’s status.  If repeat scans confirm disease progression, then 
the date of the initial scan should be declared as the date of disease progression. 
To achieve ‘unequivocal progression’ on the basis of non-target disease, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD 
or PR in target disease, the overall tumour burden has increased sufficiently to merit 
discontinuation of therapy.  A modest increase in the size of one or more non-target lesions is 
usually not sufficient to qualify for unequivocal progression status.
Following progression, patients should continue to be followed up for survival every 8 weeks 
as outlined in the study plan. It is important to follow the assessment schedule as closely as 
possible. Please refer to the study plan in Section 1.5 and CT/MRI scans in section 5.1.1
5.1.3 Central reading of scans
An independent review of all scans used in the assessment of tumours according to modified 
RECIST will be conducted for data collected up to the data cut off for the primary analysis of 
PFS.  All imaging assessments including unscheduled visit scans will be collected on an 
ongoing basis and sent to an AstraZeneca appointed Contract Research Organisation (CRO) 
for central analysis. Results of this independent review will not be communicated to 
investigators (with the exception of confirmation of progression assessments), and the 
management of patients will be based solely upon the results of the RECIST assessment 
conducted by the investigator.
The primary analysis for this study will be based on the blinded independent central review 
(BICR) of the radiological scans.
5.2 Safety assessments
5.2.1 Laboratory safety assessments
Blood and urine samples for determination of clinical chemistry, haematology, coagulation, 
and urinalysis will be taken at the times indicated in the Study Schedule (see Table 1).
These tests will be performed by the hospital’s local laboratory.  Additional analyses may be 
performed if clinically indicated. 
Any clinically significant abnormal laboratory values should be repeated as clinically 
indicated and recorded on the eCRF.
The following laboratory variables will be measured:
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Table 2 Laboratory Safety Variables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Haemoglobin S-Sodium
B-Red blood cells [RBC] S-Potassium
B-Platelets S-Magnesium (baseline only and if clinically 
indicated)
B-Mean cell volume [MCV] S-Calcium 
B-Mean cell haemoglobin concentration [MCHC] S-Creatinine
B-Mean cell haemoglobin [MCH] S-Total bilirubin
B-White blood cells [WBC] S-Gamma glutamyltransferase [GGT] 
B-Absolute differential white cell count
 (neutrophils, lymphocytes, monocytes, 
eosinophils and basophils) and absolute 
neutrophil count or segmented neutrophil 
count and Band forms should be performed 
at each visit and when clinically indicated. 




S- alanine transaminase [ALT]










Urinalysis (Microscopic analysis, baseline only and 
if clinically indicated)
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities.  The laboratory results should be signed and dated and retained at 
centre as source data for laboratory variables.  For information on how AEs based on 
laboratory tests should be recorded and reported, see Section 5.2.
NB. In case a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN please refer 
to Appendix D ‘Actions required in cases of combined increase of Aminotransferase and Total 
Bilirubin – Hy’s Law’, for further instructions.
For blood volume see Section 5.6.1.
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5.2.2 Physical examination
For timing of individual measurement refer to study schedule (Table 1).
A physical examination will be performed and include an assessment of the following: general 
appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, 
nose and throat), lymph nodes, thyroid, abdomen, musculo-skeletal (including spine and 
extremities) and neurological systems.
5.2.3 ECOG
ECOG Performance Status is a widely used, 5-level, clinician reported outcome of the 
patient’s performance status. Below is a description of the clinician’s grading system for the 
ECOG Performance Status (see also Appendix G). This measure will be applied according to 
the study schedule (see Table 1).
Table 3 ECOG Performance Status 
a
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
a As published in Am. J. Clin. Oncol.:
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.
5.2.4 ECG
5.2.4.1 Resting 12-lead ECG
ECGs are required during screening within 14 days prior to starting study treatment and when 
clinically indicated afterwards. 
Twelve-lead ECGs will be obtained after the patient has been rested in a supine position for at 
least 5 minutes in each case.  The investigator or designated physician will review the paper 
copies of each of the timed 12-lead ECGs on each of the study days when they are collected. 
ECGs will be recorded at 25 mm/sec.  All ECGs should be assessed by the investigator as to 
whether they are clinically significantly abnormal / not clinically significantly abnormal.  If 
there is a clinically significant abnormal finding, the investigator will record it as an AE on the 
eCRF.  The original ECG traces must be stored in the patient medical record as source data.
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5.2.5 Vital signs
Height will be assessed at screening only.
Weight will be assessed at screening and as clinically indicated at any other time. 
5.2.5.1 Pulse and blood pressure
Blood pressure and pulse rate will be measured preferably using a semi automatic BP 
recording device with an appropriate cuff size.
5.2.5.2 Body temperature
Body temperature will be measured in degrees Celsius using an automated thermometer.
5.2.6 Other safety assessments
Blood and urine samples for determination of clinical chemistry, haematology, coagulation, 
and urinalysis will be taken at the times indicated in the Study Schedule (see Table 1).
These tests will be performed by the hospital’s local laboratory.  Additional analyses may be 
performed if clinically indicated. 
Any clinically significant abnormal laboratory values should be repeated as clinically 
indicated and recorded on the eCRF.
5.2.6.1 Serum or urine pregnancy test
Pregnancy tests on blood or urine samples will be performed for pre-menopausal women of 
childbearing potential as per the study schedule.  Tests will be performed by the hospital’s 
local laboratory.  If results are positive the patient is ineligible/must be discontinued from the 
study.  In the event of a suspected pregnancy during the study, the test should be repeated.
Any changes in vital signs should be recorded as an AE, if applicable.
5.2.7 Bone marrow or blood cytogenetic samples 
Bone marrow or blood cytogenetic samples may be collected as clinically indicated for 
patients with prolonged haematological toxicities as defined in Section 6.7.1
Bone marrow analysis should include an aspirate for cellular morphology, cytogenetic 
analysis and flow cytometry, and a core biopsy for bone marrow cellularity.  If it is not 
possible to conduct cytogenetic analysis or flow cytometry on the bone marrow aspirate, then 
attempts should be made to carry out the tests on a blood sample.  Full reports must be 
provided by the investigator for documentation on the Patient Safety database.
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5.3 Other assessments
5.3.1 Patient reported outcomes
5.3.1.1 EORTC QLQ-C30 and QLQ-PAN26
In this study patient reported disease related symptoms and health related quality of life will 
be evaluated using the validated EORTC QLQ-C30 and the PAN26 questionnaire.  The 
EORTC QLQ-C30 was developed to assess HRQOL and functioning, and is the most 
commonly used cancer-specific tool in oncology.  It has undergone extensive testing and 
validation as well as detailed cross cultural linguistic validation and has been used in pancreas 
cancer and gastric cancer trials (.
Fitzsimmons D et al 1999). The PAN26 was developed specifically for patients with pancreas 
cancer and has been found to be reliable and valid in this population as well as in pancreatitis 
patients.
The EORTC QLQ-C30 comprises 30 questions designed for all cancer types.  Questions can 
be grouped into the following scales:
 5 multi-item functional scales (physical, role, emotional, cognitive and social) 
 3 multi-item symptom scales (fatigue, pain, nausea vomiting)
 A 2-item global QoL scale
 5 single items assessing the following common cancer symptoms:
 dyspnoea, 




 1 item on the financial impact of the disease.
The pancreas cancer module (PAN26) is intended for patients at all disease stages undergoing 
surgical resection, palliative surgical intervention, endoscopic palliation or palliative 
chemotherapy. The module comprises 26 questions assessing pain, dietary changes, jaundice, 
altered bowel habit, emotional problems related to pancreas cancer, and other symptoms 
(cachexia, indigestion, flatulence, dry mouth, taste changes).
All the EORTC scales range from 0 to 100 (through transformation of scores).  A high scale 
score represents a higher response level.  Thus a high score for a functional scale represents a 
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high / healthy level of functioning, while a high score for a symptom scale / item represents a 
high level of symptomatology / problems.
5.3.1.2 Administration of PRO questionnaires
The EORTC QLQ-C30 and QLQ-PAN26 will be administered according to the study 
schedule (see Table 1). 
Questionnaires will be completed using a pencil and paper method of data collection. Each 
centre must allocate the responsibility for the administration (and training on ePRO device if 
used) of the questionnaires to a specific individual (eg, a research nurse, study coordinator) 
and if possible assign a back-up person to cover if that individual is absent.  The AZ Study 
Delivery Team (or delegate) will provide relevant training in administration of the 
questionnaires.  The significance and relevance of the data need to be explained carefully to 
participating patients so that they are motivated to comply with data collection. The site staff 
enters the information directly into the WBDC electronic database system.
The instructions for completion of the PRO questionnaires are as follows:
 The EORTC QLQ-C30 and QLQ-PAN26 must be completed prior to any other 
study procedures (following informed consent) and before discussion of disease 
progress to avoid biasing the patient’s responses to the questions.  Patients must 
complete the EORTC QLQ-C30 before completing the QLQ-PAN26. They must be 
completed in private by the patient.
 The patient should be given sufficient time to complete at their own speed.
 The patient should not receive help from relatives, friends or clinic staff to answer 
the questionnaire.  However, if the patient is unable to read the questionnaire (eg, is 
blind or illiterate) the questionnaire may be read out by trained clinic staff and 
responses recorded.
 On completion of the questionnaire it should be handed back to the person 
responsible for questionnaires who should check for completeness.
5.4 Biomarkers
Tumour and blood samples will be collected for the biomarker work as detailed in the 
laboratory manual
For blood volume see Section 5.6.1.
5.4.1 Biomarker samples
The biomarker samples will be collected as described in Table 4.
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Table 4 Samples for Biomarker Research
Sample Type Visits
Whole blood sample for prospective 
germline BRCA testing at central laboratory 
for patients with unknown gBRCA status and 
for confirmation of gBRCA status for those 
with previous results
Screening Part 1 for patients with unknown 
gBRCA status
Day 1 for patients with known local gBRCA
test
Whole blood sample for assessment of 
current and future gBRCA mutation assay(s)
Screening Part 1 for patients with unknown 
gBRCA status
Day 1 for patients with known local gBRCA
test
Archival tumour sample (paraffin or 
cytology) – Requested, if available
Screening Part 1 for patients with unknown 
gBRCA status
Screening Part 2 for patients with known local 
gBRCA test
Blood samples for biomarker analysis Cycle 1 Day 1 and disease progression 
The samples and data from this research will be coded and not labelled with any personal 
details.  Each sample will be identified with the study and patient enrolment number.  In this 
way biomarker data may be correlated with clinical data, samples destroyed in the event of 
withdrawal of consent and regulatory audit enabled.  However, only the investigator will be 
able to link the biomarker sample to the individual patient.  The coded samples may be made 
available to groups or organisations working with AstraZeneca on this research or as part of 
the development of the drug and companion diagnostic.  However, the samples and any results 
will remain the responsibility of AstraZeneca at all times.  AstraZeneca will not give samples, 
sample derivatives or data derived from the samples to any other parties except as required by 
law. 
Biomarker data may be generated in real time during the study or retrospectively and will 
have unknown clinical significance.  AstraZeneca will not provide biomarker results to 
patients, their family members, any insurance company, an employer, clinical study 
investigator, general physician or any other third party unless required to do so by law.  The 
patient’s samples will not be used for any other purpose other than those described in the 
protocol.
The exception to the above is the gBRCA status result from the Myriad assessment for patients 
with previously unknown local gBRCA status.  This result will be provided to the investigator 
and will be collected as part of the patient’s demography and medical history details.
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5.4.2 Collection of blood sample for Myriad germline BRCA1 and BRCA2 testing
All patients must have a known deleterious or suspected deleterious gBRCA mutation to be 
randomised; this may have been determined prior to study entry or may be assessed as part of 
the enrolment procedure for the study (via Myriad).
5.4.2.1 Guidance for gBRCA testing of patients with known gBRCA status.
For patients that can be randomised to the study on the basis of a pre-existing known gBRCA
mutation test result, a blood sample for a confirmatory gBRCA mutation test by Myriad must 
be taken once the patient has consented to the study.  Should the result from the Myriad test 
indicate the patient does not have a deleterious or suspected deleterious gBRCA mutation; the 
patient can continue in the study and can continue to receive their allocated study treatment if 
deemed appropriate by the investigator.  
Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response).
5.4.2.2 Guidance for gBRCA testing of patients with unknown gBRCA status.
Patients that do not know their gBRCA status, but meet all other eligibility criteria must have a 
Myriad test prior to randomisation in to the study.  A blood sample for the Myriad BRCA test 
can be taken once all local ethical procedures for such testing have been completed.  If the 
result shows that the patient has a deleterious/suspected deleterious gBRCA mutation, the 
patient can then be randomised to the study.  In order to limit the time that the patient is not 
receiving study treatment after their last dose of chemotherapy, it may be necessary for the 
patient to have a Myriad BRCA test whilst still on chemotherapy. 
Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response).
5.4.2.3 Collection of blood sample for assessment of current and future gBRCA
mutation assay(s)
All patients will be required to provide a mandatory 9 ml blood sample that will be stored for 
subsequent assessment of current and future gBRCA mutation assay(s).
Samples may be required to support subsequent analysis as part of a bridging study between 
the Myriad BRCA test to be used in this study and the “to be marketed” diagnostic test which 
is currently under development. Samples are required to be collected from all patients 
including those shown not to have a deleterious or suspected deleterious gBRCA1 or gBRCA2
mutation.
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Residual blood (or its derivatives) may be used to evaluate future gBRCA companion 
diagnostic tests and for additional exploratory work, to elucidate the mechanism of response, 
understand the mode of action of study treatment, and improve the understanding of pancreas 
cancer and disease recurrence (including gBRCA mutation status and its role in response).
5.4.3 Exploratory Biomarker Research on Archival Tumour Samples (Paraffin 
block or tissue cytology slides) (Requested, if available)
These samples will be collected from the site pathologist during the screening Part 1 for 
patients with unknown gBRCA status and screening Part 2 for patients with known local 
gBRCA test.  An adequately sized (minimum of 2 mm x 2 mm) historical tumour tissue 
paraffin block from a core biopsy from the primary tumour or a metastatic site is most 
desirable.  This sample will have been collected anytime since the time of original diagnosis 
but prior to study entry.  Alternatively, 10-20 pre-cut sections mounted on glass slides 
prepared from the block can be provided. If the only diagnostic test was cytologic, a paraffin 
block or three unstained slides of tumour tissue should be submitted if available.
Collection of an archival tumour sample is requested if available for all patients for the 
assessment of tissue BRCA mutation status. Surplus tissue may be used for additional 
exploratory work, to elucidate the mechanism of response, understand the mode of action of 
study treatment, and improve the understanding of disease progression (including tumour 
BRCA mutation status and its role in response).
Please refer to Investigator Laboratory Manual for further details of archival tissue collection, 
shipping and storage.
5.4.4 Exploratory Blood samples for biomarker analysis (Mandatory)
All consenting patients will be required to provide a blood sample at randomisation and 
disease progression for exploratory biomarker research.
Patients will be required to provide:
 1x 6ml blood sample for preparation of serum at cycle 1 day 1 and disease 
progression.
 1x 6ml blood sample for preparation of plasma at cycle 1 day 1 and disease 
progression. 
Please refer to Investigator Laboratory Manual for further details of biomarker blood sample 
collection, shipping and storage. 
5.5 Health economics
Hospital related resource use and health state utility
For the purposes of economic evaluation it is necessary to capture utility data and healthcare 
resource use related to the treatment and the underlying disease. Within the clinical trial utility 
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data will be captured using the EuroQoL EQ5D instrument.  The following hospital resource 
use data will be collected using the Hospital Attendance (HOSPAD) module:
1. Number of hospitalisations and attendances
2. Primary symptom/reason associated with hospitalisation or attendance
3. Length of stay, including time in intensive care.
Additional information, including medications and procedures undertaken will be derived 
from data captured under existing modules, for example, concomitant medications and 
concomitant procedures.
5.6 Biological sampling procedures 
5.6.1 Volume of blood
The volume of blood that will be drawn from each patient will vary, dependent upon the 
length of time that the patient remains in the trial.  The total volume of blood to be drawn 
from each patient in the study, assuming they complete screening, 6 cycles of treatment, a 
treatment discontinuation visit and the 30-day follow-up visit, is 255mL.
Safety laboratory assessments will be performed locally at each centre’s laboratory by means 
of their established methods.  The number of samples/blood volumes is therefore patient to 
site-specific change.  Extra blood samples may also be collected if, for example, additional 
samples are required for repeat safety assessments.
The total volume of blood that will be drawn from each patient in this study is as follows:
Table 5 Volume of blood to be drawn from each patient






Safety Clinical chemistry 5 21 105
Haematology 5 21 105
Coagulation 3 1 3
Whole blood sample for Myriad BRCA test 
(retrospective/prospective)
Whole blood sample for assessment of 







Serum Pregnancy test (site may use urine 
instead)
Site dependent Site may use 
urine instead
Serum sample for exploratory biomarkers, 
cycle 1 day 1 (mandatory)
6 1 6
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Plasma sample for exploratory biomarkers, 
cycle 1 day 1 (mandatory)
6 1 6
Serum sample for exploratory biomarkers, 
disease progression (mandatory)
6 1 6




5.6.2 Handling, storage and destruction of biological samples
The samples will be used up or disposed of after analyses or retained for further use as 
described here.
Biological samples for future research will be retained at AstraZeneca or a CRO, on behalf of 
AstraZeneca for a maximum of 15 years following the Last Patient’s Last Visit in the study.  
The results from future analysis will not be reported in the Clinical Study Report but 
separately in a Scientific Report.
5.6.3 Labelling and shipment of biohazard samples
The Principal Investigator ensures that samples are labelled and shipped in accordance with 
the Laboratory Manual and the Biological Substance, Category B Regulations (materials 
containing or suspected to contain infectious substances that do not meet Category A criteria), 
Any samples identified as Infectious Category A materials are not shipped and no further 
samples will be taken from the patient unless agreed with AstraZeneca and appropriate 
labelling, shipment and containment provisions are approved.
5.6.4 Chain of custody of biological samples
A full chain of custody is maintained for all samples throughout their lifecycle.
The Principal Investigator at each centre keeps full traceability of collected biological samples 
from the patients while in storage at the centre until shipment or disposal (where appropriate) 
and keeps documentation of receipt of arrival.
The sample receiver keeps full traceability of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps documentation of receipt of arrival.
AstraZeneca keeps oversight of the entire life cycle through internal procedures, monitoring of 
study sites and auditing of external laboratory providers.
Samples retained for further use are registered in the AstraZeneca biobank system during the 
entire life cycle.
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If required, AstraZeneca will ensure that remaining biological samples are returned to the site, 
according to local regulations or at the end of the retention period, whichever is the sooner.
5.6.5 Withdrawal of informed consent for donated biological samples
If a patient withdraws consent to the use of donated biological samples, the samples will be 
disposed of/destroyed, and the action documented.  If samples are already analysed,
AstraZeneca is not obliged to destroy the results of this research.
gBRCA sample: As collection of the biological samples is an integral part of the study, then 
the patient is withdrawn from further study participation.
Archival tumour sample: If consent to use the sample is withdrawn this will not impact 
eligibility to study. The patient may continue in the study if the patient is already randomised.
Blood samples for biomarker analysis: Although mandatory, the patient may continue in the 
study if the patient is already randomised.
The Principal Investigator:
 Ensures patients’ withdrawal of informed consent to the use of donated samples is 
notified immediately to AstraZeneca
 Ensures that biological samples from that patient, if stored at the study site, are 
immediately identified, disposed of /destroyed, and the action documented
 Ensures the laboratory (ies) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed/destroyed, the action 
documented and the signed document returned to the study site
 Ensures that the patient and AstraZeneca are informed about the sample disposal.
AstraZeneca ensures the central laboratory (ies) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroyed and the action 
documented and returned to the study site.
6. SAFETY REPORTING AND MEDICAL MANAGEMENT
The Principal Investigator is responsible for ensuring that all staff involved in the study are 
familiar with the content of this section.
6.1 Definition of adverse events
An adverse event is the development of an undesirable medical condition or the deterioration 
of a pre-existing medical condition following or during exposure to a pharmaceutical product, 
whether or not considered causally related to the product.  An undesirable medical condition 
can be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver) or the 
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abnormal results of an investigation (eg, laboratory findings, electrocardiogram).  In clinical 
studies, an AE can include an undesirable medical condition occurring at any time, including 
run-in or washout periods, even if no study treatment has been administered.
The term AE is used to include both serious and non-serious AEs.
6.2 Definitions of serious adverse event
A serious adverse event is an AE occurring during any study phase (ie, run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria:
 Results in death
 Is immediately life-threatening
 Requires in-patient hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability/incapacity or substantial disruption 
of the ability to conduct normal life functions
 Is a congenital abnormality or birth defect
 Is an important medical event that may jeopardise the patient or may require 
medical intervention to prevent one of the outcomes listed above.
For further guidance on the definition of a SAE, see Appendix B to the Clinical Study
Protocol.
6.3 Recording of adverse events
6.3.1 Time period for collection of adverse events
Adverse Events will be collected from time of signature of informed consent throughout the 
treatment period up to and including the 30-day follow-up period.  All ongoing and any new 
AEs/SAEs identified during the 30 calendar days follow up period, after the last dose of study 
medication must be followed to resolution. After any interim analysis, any ongoing AEs/SAEs 
need to be unlocked and followed for resolution.
SAEs will be recorded from the time of informed consent.
6.3.2 Follow-up of unresolved adverse events
Any SAEs or non-serious adverse event that is ongoing at the time of the 30-day 
follow up, must be followed up to resolution unless the event is considered by the 
investigator to be unlikely to resolve, or the patient is lost to follow up. 
AstraZeneca retains the right to request additional information for any patient 
with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.
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6.3.3 Variables 
The following variables will be collect for each AE;
 AE (verbatim)
 The date when the AE started and stopped
 Whether the AE is serious or not
 Investigator causality rating against the Investigational Product (yes or no)
 Action taken with regard to investigational product
 Outcome.
In addition, the following variables will be collected for SAEs:
 Date AE met criteria for serious AE
 Date Investigator became aware of serious AE
 AE is serious due to
 Date of hospitalisation
 Date of discharge
 Probable cause of death
 Date of death
 Autopsy performed
 Causality assessment in relation to Study procedure(s)
 Causality assessment in relation to Other medication
 Description of AE.
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Section 6.2.
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Severity of AE
For each episode on an adverse event, all changes to the CTCAE grade attained as well as the 
highest attained CTC grade should be reported.
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE. On the other hand, a stroke 
that results in only a limited degree of disability may be considered a mild stroke but would be 
a SAE.
The grading scales found in the National Cancer Institute (NCI) CTCAE version 4.0 will be 
utilised for all events with an assigned CTCAE grading.  For those events without assigned 
CTCAE grades the recommendation is that the CTCAE criteria that convert mild, moderate 
and severe events into CTCAE grades should be used.
A copy of the CTCAE version can be downloaded from the NCI website.
6.3.4 Causality collection
The Investigator will assess causal relationship between Investigational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by the investigational product?’
For SAEs causal relationship will also be assessed for other medication and study procedures.  
Note that for SAEs that could be associated with any study procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causality question is found in Appendix B to the Clinical 
Study Protocol.
6.3.5 Adverse events based on signs and symptoms
All AEs spontaneously reported by the patient or reported in response to the open question 
from the study personnel: ‘Have you had any health problems since the previous visit/you 
were last asked?’, or revealed by observation will be collected and recorded in the CRF.  
When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a 
list of signs and symptoms.  However, if a diagnosis is known and there are other signs or 
symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom 
will be recorded separately.
6.3.6 Adverse events based on examinations and tests
The reporting of laboratory/vital signs/ECG abnormality as AE should be avoided unless one 
of the following is met:
 Any criterion for an SAE is fulfilled
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 Causes study treatment discontinuation
 Causes study treatment interruption
 Causes study treatment dose reduction
 The investigator believes that the abnormality should be reported as an AE
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign 
will be considered as additional information.  Wherever possible the reporting investigator 
uses the clinical, rather than the laboratory term (eg, anaemia versus low haemoglobin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-
mandated parameters should be reported as AE(s).
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE.
NB. Cases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN may 
need to be reported as SAEs, please refer to Appendix D ‘Actions required in cases of 
combined increase of Aminotransferase and Total Bilirubin – Hy’s Law’, for further 
instructions.
6.3.7 Hy’s Law
Cases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥ 2xULN may need 
to be reported as SAEs. Please refer to Appendix D for further instruction in cases of 
combined increase of aminotransferase and total bilirubin.
6.3.8 Disease progression
Disease progression can be considered as a worsening of a patient’s condition attributable to 
the disease for which the investigational product is being studied.  The development of local 
regional recurrence or distant metastasis to the primary cancer under study should be 
considered as disease progression and not an AE.  Events, which are unequivocally due to 
disease progression, should not be reported as an AE during the study.
New cancers
The development of a new primary cancer (including skin cancer) should be regarded as an 
AE and will generally meet at least one of the serious criteria (see Section 6.2).  New primary 
cancers are those that are not the primary reason for the administration of the study treatment 
and have developed after the inclusion of the patient into the study.  They do not include 
metastases of the original cancer.  Symptoms of metastasis or the metastasis itself should not 
be reported as an AE/SAE, as they are considered to be disease progression.
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Lack of efficacy
When there is deterioration in the cancer, for which the study treatment(s) is being used, there 
may be uncertainty as to whether this is lack of efficacy or an AE.  In such cases, unless the 
Sponsor or the reporting physician considers that the study treatment contributed to the 
deterioration of the condition, or local regulations state to the contrary, the deterioration 
should be considered to be a lack of efficacy and not an AE.
Deaths
All deaths that occur during the study, or within the protocol-defined 30-day post-study 
follow-up period after the administration of the last dose of study treatment, must be reported 
as follows:
 Death clearly the result of disease progression should be reported to the study 
monitor at the next monitoring visit and should be documented in the DEATH 
eCRF but should not be reported as an SAE
 Where death is not due (or not clearly due) to progression of the disease under 
study, the AE causing the death must be reported to the study monitor as a SAE 
within 24 hours (see Section 6.4 for further details).  The report should contain a 
comment regarding the co-involvement of progression of disease, if appropriate, 
and should assign main and contributory causes of death.  This information can be 
captured in the ‘death eCRF’.
Deaths with an unknown cause should always be reported as a SAE.  A post mortem maybe 
helpful in the assessment of the cause of death, and if performed a copy of the post-mortem 
results should be forwarded to AstraZeneca within the usual timeframes.
6.4 Reporting of serious adverse events
All SAEs have to be reported, whether or not considered causally related to the investigational 
product, or to the study procedure(s). All SAEs will be recorded in the CRF.
If any SAE occurs in the course of the study, then investigators or other site personnel inform 
appropriate AstraZeneca representatives immediately, or no later than 24 hours of when he 
or she becomes aware of it.
The designated AstraZeneca representative works with the investigator to ensure that all the 
necessary information is provided to the AstraZeneca Patient Safety data entry site within one
calendar day of initial receipt for fatal and life threatening events and within five calendar
days of initial receipt for all other SAEs.
For fatal or life-threatening adverse events where important or relevant information is missing, 
active follow-up is undertaken immediately.  Investigators or other site personnel inform 
AstraZeneca representatives of any follow-up information on a previously reported SAE 
immediately, or no later than 24 hours of when he or she becomes aware of it.
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Once the Investigators or other site personnel indicate an AE is serious in the WBDC system, 
an automated email alert is sent to the designated AstraZeneca representative.
If the WBDC system is not available, then the Investigator or other study site personnel 
reports a SAE to the appropriate AstraZeneca representative by telephone.
The AstraZeneca representative will advise the Investigator/study site personnel how to 
proceed
6.5 Overdose
There is currently no specific treatment in the event of overdose of Olaparib and possible 
symptoms of overdose are not established.  
Adverse reactions associated with overdose should be treated symptomatically and should be 
managed appropriately. 
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant 
AE modules in the CRF and on the Overdose CRF module.
An overdose without associated symptoms is only reported on the Overdose CRF module.
If an overdose on an AstraZeneca study drug occurs in the course of the study, then 
Investigators or other site personnel inform appropriate AstraZeneca representatives 
immediately, or no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site.
For overdoses associated with SAE, standard reporting timelines apply (see Section 6.4).  For 
other overdoses, reporting should be done within 30 days.
6.6 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca.
6.6.1 Maternal exposure
Women of childbearing potential are not allowed to be included in this study.  Should a 
pregnancy still occur, the investigational product should be discontinued immediately and the 
pregnancy reported to AstraZeneca
If a patient becomes pregnant during the course of the study investigational product should be 
discontinued immediately.
Pregnancy itself is not regarded as an adverse event unless there is a suspicion that the 
investigational product under study may have interfered with the effectiveness of a 
contraceptive medication.  Congenital abnormalities/birth defects and spontaneous 
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miscarriages should be reported and handled as SAEs.  Elective abortions without 
complications should not be handled as AEs.  The outcome of all pregnancies (spontaneous 
miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnormality)
should be followed up and documented even if the patient was discontinued from the study.
If any pregnancy occurs, then the Investigator or other site personnel informs the appropriate 
AstraZeneca representatives within 1day ie, immediately but no later than 24 hours of when 
he or she becomes aware of it.
The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 5 
calendar days for SAEs (see Section 6.4) and within 30 days for all other pregnancies.
The same timelines apply when outcome information is available.
6.6.2 Paternal exposure 
Male patients should refrain from fathering a child or donating sperm during the study and for 
3 months following the last dose.  Pregnancy of the patient’s partners is not considered to be 
an adverse event.  However, the outcome of all pregnancies (spontaneous miscarriage, elective 
termination, ectopic pregnancy, normal birth or congenital abnormality) should if possible be 
followed up and documented.
The outcome of any conception occurring from the date of the first dose until 3 months after 
the last dose should be followed up and documented.
To capture information about a pregnancy from the partner of a male patient, the male 
patient’s partner consent must be obtained to collect information related to the pregnancy and 
outcome; the male patient should not be asked to provide this information. A consent form 
specific to this situation must be used.
6.7 Management of toxicity of Olaparib
Any toxicity observed during the course of the study could be managed by interruption of the 
dose of study treatment or dose reductions.  Study treatment can be dose reduced to 250 mg 
bid as a first step and to 200 mg bid as a second step.
6.7.1 Management of haematological toxicity Olaparib 
Table 6 Management of Haematological Toxicity Olaparib
Toxicity Study treatment dose adjustment
CTCAEa gr 1-2 Dose interruption as judged by the investigator; appropriate supportive 
treatment and causality investigation
Repeat CTCAE gr 1-2 Dose interruption until recovery to CTCAE gr 1 and dose reduction to 250 
mg bid as first step and 200 mg bid as second step
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Toxicity Study treatment dose adjustment
CTCAE gr 3-4 Dose interruption until recovered to CTCAE gr 1 for max of 4 weeks and 
dose reduction to 250 mg bid as first step and 200 mg bid as second 
step




6.7.1.1 Management of anaemia
Patients can enter the study with a haemoglobin value of > 9g/dl, this should be taken 
into account when considering the management of anaemia. Adverse events of anaemia 
CTCAE grade 1 or 2 (Hb > 8 g/dl) should be investigated and managed as deemed appropriate 
by the investigator with or without interruption of study drug or change in dose, taking into 
account previous history of anaemia.  Common treatable causes of anaemia (eg, iron, vitamin 
B12 or folate deficiencies and hypothyroidism) should be investigated and appropriately 
managed.  In some cases management of anaemia may require blood transfusions.  However, 
if a patient develops anaemia CTCAE grade 3 (Hb < 8g/dl) or worse, study treatment should 
be interrupted for up to maximum of 4 weeks.   Study treatment can be restarted at a reduced 
dose (see Table 4) if Hb has recovered to > 9 g/dl.  Any subsequently required anaemia 
related interruptions, considered likely to be dose related, or coexistent with newly developed 
neutropenia, and or thrombocytopenia, will require a further study treatment dose reduction 
to 200 mg bid. 
If a patient has been treated for anaemia with multiple blood transfusions without study 
treatment interruptions and becomes blood transfusion dependant as judged by investigator, 
study treatment should be interrupted for up to a maximum of 4 weeks to allow for bone 
marrow recovery.  Study treatment should be restarted at a reduced dose if bone marrow 
recovers.
6.7.1.2 Management of neutropenia and leukopenia
Adverse event of neutropenia and leukopenia should be managed as deemed appropriate by 
the investigator with close follow up and interruption of study drug if CTC grade 3 or worse 
neutropenia occurs.  Primary prophylaxis with Granulocyte colony-stimulating factor (G-CSF) 
is not recommended, however, if a patient develops febrile neutropenia, study treatment 
should be stopped and appropriate management including G-CSF should be given according 
to local hospital guidelines.  Please note that G-CSF should not be used within at least 24 h (7 
days for pegylated G-CSF) of the last dose of study treatment unless absolutely necessary. 
Study treatment can be restarted at the same dose if an adverse event of neutropenia or 
leucopenia have been recovered up to CTCAE grade 1 (ANC ≥ 1.5 x 10
9
/L).  
Any subsequent interruptions will require study treatment dose reductions to 250 mg bid as a 
first step and to 200 mg bid as a second step. 
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6.7.1.3 Management of thrombocytopenia
An adverse event of thrombocytopenia should be managed as deemed appropriate by the 
investigator.  If a patient develops thrombocytopenia CTCAE grade 3 or worse study 
treatment should be interrupted for a maximum of 4 weeks.  In some cases management of 
thrombocytopenia may require platelet transfusions.  Platelet transfusions should be done 
according to local hospital guidelines.
Management of prolonged haematological toxicities while on study treatment.
If a patient develops prolonged haematological toxicity such as:
 ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse anaemia 
and/or development of blood transfusion dependence
 ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse 
neutropenia (ANC < 1 x 10
9
/L)
 ≥2 week interruption/delay in study treatment due to CTC grade 3 or worse 
thrombocytopenia (Platelets < 50 x 10
9
/L)
Weekly differential blood counts including reticulocytes and peripheral blood smear should be 
performed.  If any blood parameters remain clinically abnormal after 4 weeks of dose 
interruption, the patient should be referred to haematologist for further investigations.  Bone 
marrow analysis and/or blood cytogenetic analysis should be considered at this stage 
according to standard haematological practice. 
Development of a confirmed myelodysplastic syndrome or other clonal blood disorder should 
be reported as an SAE and full reports must be provided by the investigator to AstraZeneca 
Patient Safety.  Olaparib treatment should be discontinued if patient’s diagnosis of MDS 
and/or AML is confirmed.
6.7.2 Management of non-haematological toxicity Olaparib
6.7.2.1 Management of new or worsening pulmonary symptoms 
If new or worsening pulmonary symptoms (eg, dyspnoea) or radiological abnormality occurs, 
an interruption in study treatment dosing is recommended and a diagnostic workup (including 
a high resolution CT scan) should be performed, to exclude pneumonitis.  Following 
investigation, if no evidence of abnormality is observed on CT imaging and symptoms 
resolve, then study treatment can be restarted, if deemed appropriate by the investigator.  If 
significant pulmonary abnormalities are identified, these need to be discussed with the 
AstraZeneca Study Physician. 
6.7.2.2 Management of nausea and vomiting
Events of nausea and vomiting are known to be associated with Olaparib treatment. In Study 
D0810C00019 nausea was reported in 71% of the Olaparib treated patients and 36% in the 
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placebo treated patients and vomiting was reported in 34% of the Olaparib treated patients and 
14% in the placebo treated patients. They are generally mild to moderate (CTCAE Grade 1 or 
2) severity, intermittent and manageable on continued treatment. The first onset generally 
occurs in the first month of treatment for nausea and within the first 6 months of treatment for 
vomiting. For nausea, the incidence generally plateaus at around 9 months, and for vomiting at 
around 6 to 7 months.
No routine prophylactic anti-emetic treatment is required at the start of study treatment, 
however, patients should receive appropriate anti-emetic treatment at the first onset of nausea 
or vomiting and as required thereafter, in accordance with local treatment practice guidelines. 
As per international guidance on antiemetic use in cancer patients (ESMO, NCCN), generally 
a single agent antiemetic should be considered eg dopamine receptor antagonist, 
antihistamines, dexamethasone.
6.7.2.3 Interruptions for intercurrent non-toxicity related events
Study treatment dose interruption for conditions other than toxicity resolution should be kept 
as short as possible.  If a patient cannot restart study treatment within 4 weeks for resolution 
of intercurrent conditions not related to disease progression or toxicity, the case should be 
discussed with AZ study physician.
All dose reductions and interruptions (including any missed doses), and the reasons for the 
reductions/interruptions are to be recorded in the eCRF.
Study treatment should be stopped at least 3 days prior to planned surgery.  After surgery 
study treatment can be restarted when the wound has healed.  No stoppage of study treatment 
is required for any biopsy procedure.
Study treatment should be discontinued for a minimum of 3 days before a patient undergoes 
radiation treatment.  Study treatment should be restarted within 4 weeks as long as any bone 
marrow toxicity has recovered.
Because the AEs related to Olaparib may include asthenia, fatigue and dizziness, patients 
should be advised to use caution while driving or using machinery if these symptoms occur. 
6.7.3 Management of toxicity on placebo
Adverse events on placebo will be handled in the same manner as those arising on Olaparib 
(see sections 6.7)
6.8 Study governance and oversight
6.8.1 Data Monitoring Committee
This study will use an external independent data monitoring committee (IDMC) to perform 
interim reviews of accumulating study safety data and the interim analyses for futility based 
on PFS.  
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This committee will be composed of therapeutic area experts and statisticians, who are not 
employed by AZ, and do not have any major conflict of interest.  Following the review the 
IDMC will recommend whether the study should continue unchanged, be terminated, or be 
modified in any way.  Once the IDMC has reached a recommendation, a report will be 
provided to AstraZeneca.  The report will only include the recommendation and any potential 
protocol amendments and will not contain any unblinding information.
A separate IDMC charter will be developed which will contain details of the IDMC members 
and clearly define the responsibilities of the IDMC.
7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS
7.1 Identity of investigational product(s)
AstraZeneca’s Pharmaceutical Development, R&D Supply Chain will supply Olaparib and 
matching placebo to the Investigator as film-coated tablets as shown below.
Investigational product Dosage form and strength
Olaparib
a
Tablet –100mg and 150 mg 
Placebo to match Olaparib Tablet to match each strength of Olaparib
a
Descriptive information for Olaparib can be found in the Investigator’s Brochure
7.2 Dose and treatment regimens
Study treatment is available as a green film-coated tablet containing 150 mg or 100 mg of 
Olaparib or matching placebo.
For all centres, Olaparib and matching placebo will be packed in high-density polyethylene 
(HDPE) bottles with child-resistant closures.  The randomised study treatment will be 
dispensed to patients.  Each dosing container will contain sufficient medication for at least 
each treatment period plus overage.  The planned dose of 300 mg bid will be made up of two 
(2) x 150 mg tablets bid with 100 mg tablets used to manage dose reductions.  Tablets should 
be taken at the same times each morning and evening of each day, approximately 12 hours 
apart with approximately 240 mL of water.  The Olaparib tablets should be swallowed whole 
and not chewed, crushed, dissolved or divided.  Olaparib tablets can be taken with a light 
meal/snack (eg, two pieces of toast or a couple of biscuits).Multiple bottles of Olaparib or 
matching placebo maybe required for dispensing in order to make up the desired dose. 
No cross over to Olaparib will be provided in this study. 
If vomiting occurs shortly after the Olaparib tablets are swallowed, the dose should only be 
replaced if all of the intact tablets can be seen and counted.  Should any patient enrolled on the 
study miss a scheduled dose for whatever reason (eg, as a result of forgetting to take the 
tablets or vomiting), the patient will be allowed to take the scheduled dose up to a maximum 
of 2 hours after that scheduled dose time.  If greater than 2 hours after the scheduled dose 
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time, the missed dose is not to be taken and the patient should take their allotted dose at the 
next scheduled time.
Once patients have been discontinued from study treatment, other treatment options will be at 
the discretion of the investigator.
7.3 Labelling
Labels for Olaparib will be prepared in accordance with Good Manufacturing Practice (GMP) 
and local regulatory guidelines.  The labels will fulfil GMP Annex 13 requirements for 
labelling. Label text will be translated into local language. 
Specific dosing instructions will not be included on the label; the site must complete the 
“Patient Dispensing Card” with the details of the dosing instructions at the time of dispensing.  
The patient emergency contact details will not be on the label, unless it is a country-specific 
regulatory requirement, but can be found in the informed consent and the ‘Patient Dispensing 
Card’.  For emergency purposes the patient must be in possession of the emergency contact 
details at all times.
7.4 Storage
All study drugs should be kept in a secure place under appropriate storage conditions and may 
only dispensed by investigator or pharmacist qualified designee. The investigational product 
label on the Olaparib bottle and the IB specifies the appropriate storage conditions. 
7.5 Compliance
The administration of all study drugs (including Olaparib and placebo) should be recorded in 
the appropriate sections of the eCRF.
Patients should be given clear instructions on how and when to take their Olaparib.  Patients 
will self-administer Olaparib.  Study site staff will make tablet counts at regular intervals 
during treatment.  Compliance will be assessed by the tablet count and the information will be 
recorded in the appropriate section of the eCRF.  After the tablet count has been performed, 
the remaining tablets will not be returned to the patient, but will be retained by the 
investigative site until reconciliation is completed by the study monitor.  All patients must 
return their bottle(s) of Olaparib at the appropriate scheduled visit, when a new bottle will be 
dispensed.  Patients will be instructed to notify study site personnel of missed doses.  Dates of 
missed or held doses will be recorded by the site staff on the eCRF.
Patients must return all containers and any remaining tablets at the end of the study.
7.6 Accountability
The study treatment provided for this study will be used only as directed in the study protocol.
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The study personnel will account for all study drugs dispensed to and returned from the 
patient.
Study site personnel, will account for all study drugs received at the site, unused study drugs 
and for appropriate destruction.  Certificates of delivery, destruction and return should be 
signed.  Any discrepancies must be accounted for on the appropriate forms.
7.7 Concomitant and other treatments 
Any medications (with the detailed exceptions) which are considered necessary for the 
patient's welfare, and which it is believed will not interfere with the study medication, may be 
given at the discretion of the investigator, providing the medications, the doses, dates and 
reasons for administration are recorded.
In addition, any unplanned diagnostic, therapeutic or surgical procedure performed during the 
study period must be recorded.  This includes any blood transfusions.
The reasons for the use, doses and dates of treatment should be recorded in the patient’s 
medical records and appropriate sections of the eCRF.
All medications (prescriptions or over the counter medications) continued at the start of study 
or started during the study or until 30 days from the end of the last protocol treatment and 
different from the study medication must be documented.
7.7.1 Medications that may NOT be administered
No other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy (Hormone 
replacement therapy (HRT) is acceptable), radiotherapy, biological therapy or other novel 
agent) is to be permitted while the patient is receiving study medication.
Live virus and bacterial vaccines should not be administered whilst the patient is receiving 
study medication and during the 30 days follow up period.  An increased risk of infection by 
the administration of live virus and bacterial vaccines has been observed with conventional 
chemotherapy drugs and the effects with Olaparib are unknown.
7.7.2 CYP3A4/5 restrictions 
The use of any natural/herbal products or other “folk remedies” should be discouraged but use 
of these products, as well as use of all vitamins, nutritional supplements and all other 
concomitant medications must be recorded.
Olaparib is an investigational drug for which no data on in vivo interactions are currently 
available.  Based on in vitro data and clinical exposure data, Olaparib is considered unlikely to 
cause clinically significant drug interactions through inhibition or induction of cytochrome 
P450 enzyme activity.  In vitro data have, however, also shown that the principal enzyme 
responsible for the formation of the 3 main metabolites of Olaparib is CYP3A4/5 and 
consequently, to ensure patient safety, the following potent inhibitors of CYP3A4/5 must not 
be used during this study for any patient receiving Olaparib.
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While this is not an exhaustive list, it covers the known potent inhibitors, which have most 
often previously been reported to be associated with clinically significant drug interactions:
 ketoconazole, itraconazole, ritonavir, idnavir, saquinavir, telithromycin, 
clarithromycin and nelfinavir 
For patients taking any of the above, the required wash-out periods prior to starting Olaparib 
is one week.
In addition, to avoid potential reductions in exposure due to drug interactions, the following 
CYP inducers should be avoided:
 Phenytoin, rifampicin, rifapentin, rifabutin, carbamazepine, phenobarbitone, 
nevirapine, modafinil and St John’s Wort (Hypericum perforatum) 
For patients taking any of the above, the required wash-out periods prior to starting Olaparib 
are phenobarbitone 5 weeks, and for any of the others, 3 weeks.
After randomisation if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary for the patient’s safety and welfare, the investigator must contact the 
AstraZeneca Study Physician.  A decision to allow the patient to continue in the study will be 
made on a case-by-case basis.
7.7.3 Other concomitant treatment
Other medication other than that described above, which is considered necessary for the 
patient’s safety and well being, may be given at the discretion of the Investigator and recorded 
in the appropriate sections of the Case Report Form.
7.7.4 Anti-emetics/ Anti-diarrhoeals
Should a patient develop nausea, vomiting and/or diarrhoea, then these symptoms should be 
reported as AEs (see section 6.3) and appropriate treatment of the event given.
7.7.5 Anticoagulant Therapy
Patients who are taking warfarin may participate in this trial; however, it is recommended that 
prothrombin time (INR and APTT) be monitored carefully at least once per week for the first 
month, then monthly if the INR is stable.  Subcutaneous heparin is permitted.
7.7.6 Administration of other anti-cancer agents
Patients must not receive any other concurrent anti-cancer therapy, including investigational 
agents, while on study treatment.
Treatment with bisphosphonates or RANKL inhibitor for the prevention of skeletal related 
events in patients with bone metastasis is permitted and must be started at least 5 days prior to 
randomisation.
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7.7.7 Subsequent therapies for cancer 
Details of first and subsequent therapies for cancer after discontinuation of treatment, will be 
collected.  Response to subsequent therapies and PFS on those therapies will also be collected.
The choice of subsequent systemic anticancer treatment will be entirely at the discretion of the 
investigator although it is expected that many/most patients upon progression on study will be 
treated with a platinum based regimen
8. STATISTICAL ANALYSIS AND SAMPLE SIZE 
DETERMINATION BY PAREXEL
8.1 Statistical considerations
 All personnel involved with the analysis of the study will remain blinded until 
database lock and protocol violators identified.
 Analyses will be performed by AstraZeneca or its representatives. 
 A comprehensive statistical analysis plan (SAP) will be prepared and finalised 
before first patient in (FPI).
8.2 Definitions of analysis sets
Table 7 gives a summary of outcome variables and analysis populations
8.2.1 Full analysis set
Intention to treat (ITT): The primary statistical analysis of the efficacy of Olaparib will 
include all randomised patients and will compare the treatment groups on the basis of 
randomised treatment, regardless of the treatment actually received.  Patients who were 
randomised but did not subsequently go on to receive study treatment are included in the Full 
Analysis Set (FAS). Therefore, all efficacy and health-related QoL data will be summarised 
and analysed using the FAS on an intention-to-treat (ITT) basis. 
In addition, key sensitivity analyses of efficacy endpoints will be performed in the subgroup 
of patients in the FAS that have a gBRCA mutation confirmed by the Myriad test.
8.2.2 Safety analysis set
All patients who received at least one dose of randomised investigational product, Olaparib or 
placebo, will be included in the safety analysis set.  Throughout the safety results sections, 
erroneously treated Olaparib patients (those randomised to Olaparib but actually given 
placebo at any time) will be accounted for in the Olaparib treatment group.  Erroneously 
treated placebo patients (those randomised to placebo but actually received at least one dose 
of Olaparib) will be accounted for in the Olaparib treatment group.
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8.2.3 PRO analysis set
The analysis population for PRO data will be the subset of the FAS (ITT) population who
have evaluable baseline EORTC QLQ-C30 and QLQ-PAN26 forms.
Table 7 Summary of Outcome Variables and Analysis Populations
Outcome Variable Populations
Efficacy Data
- Primary: PFS FAS (ITT), Myriad confirmed BRCAm subgroup 
- Secondary endpoints to be analysed:
OS, PFS2, time to first subsequent therapy 
(TFST), time to second subsequent therapy 
(TSST), time to treatment discontinuation (TDT)
FAS (ITT), Myriad confirmed BRCAm subgroup
-Adjusted mean change from baseline in 
EORTC QLQ-C30 global QoL score
PRO (subset of the FAS (ITT) who have 
evaluable baseline EORTC QLQ-C30 and 
QLQ-PAN26 forms) 
-Secondary endpoints to be summarised:
-Objective response rate FAS (ITT) (patients with measurable disease at 
baseline only), Myriad confirmed BRCAm
subgroup





- Adverse Events Safety
- Lab measurements Safety
- Vital Signs Safety
8.3 Calculation or derivation of efficacy variable(s)
At each visit patients will be assigned a RECIST visit response of CR, PR, SD, PD, NE, NED 
depending on the status of their disease compared to baseline and previous assessments, based 
on the BICR review. This will be repeated using the Investigator assessed RECIST data.
8.3.1 Primary endpoint (PFS)
PFS is defined as the time from randomisation until the date of objective radiological disease 
progression according to modified RECIST 1.1 or death (by any cause in the absence of 
disease progression) regardless of whether the patient withdraws from randomised therapy or 
receives another anticancer therapy prior to disease progression.  Patients who have not 
progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment from their last evaluable RECIST assessment.  However, if the patient progresses 
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or dies after two or more missed visits, the patient will be censored at the time of the latest 
evaluable RECIST assessment. If the patient has no evaluable visits or does not have a 
baseline assessment they will be censored at day 1 unless they die within two tumour 
assessment visits of randomisation (17 weeks allowing for visit window).
The PFS time will always be derived based on scan/assessment dates not visit dates.
RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates. The following rules will be applied:
a) Date of progression will be determined based on the earliest of the RECIST 
assessment/scan dates of the component that triggered the progression
b) When censoring a patient for PFS the patient will be censored at the latest of the 
RECIST assessment/scan dates contributing to a particular overall visit assessment
Overall visit assessments will be determined for each assessment (scheduled or unscheduled) 
and will contribute to the derivation of PFS.
Objective progression is defined as at least a 20% increase in the sum of the diameters of the 
target lesions (compared to previous minimum sum) and an absolute increase of > 5 mm, or an 
overall non-target lesion assessment of progression or a new lesion. 
The primary analysis will be based on the blinded independent central review (BICR) of the 
radiological scans. A charter for the BICR will be developed in advance of the start of the 
study. A sensitivity analysis based on the programmatically derived PFS based on 
Investigator-recorded assessments will be carried out.
8.3.2 Secondary endpoints 
8.3.2.1 Overall Survival
Overall survival is defined as the time from the date of randomisation until death due to any 
cause.  Any patient not known to have died at the time of analysis will be censored based on 
the last recorded date on which the patient was known to be alive.
Note: Survival calls will be made in the week following the date of Data Cut Off (DCO) date 
for the analysis, and if patients are confirmed to be alive or if the death date is post the DCO 
date these patients will be censored at the date of DCO.
8.3.2.2 Best overall RECIST response (BoR)
Best overall RECIST response (BoR) is calculated based on the overall visit responses from 
each RECIST assessment, described in Appendix F. It is the best response a patient has had 
after randomisation but prior to starting any subsequent cancer and prior to RECIST 
progression or the last evaluable assessment in the absence of RECIST progression.
Categorisation of best overall response will be based on the RECIST criteria (Appendix F) 
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using the following response categories: complete response (CR), partial response (PR), stable 
disease (SD), No Evidence of Disease (NED; applies only to those patients entering the study 
with no disease at baseline), progressive disease (PD) and not evaluable (NE).
Best overall response will be determined programmatically based on the RECIST criteria 
using BICR data.  In addition, this will also be reported using investigator-recorded 
assessment.
For patients whose progression event is death, BoR will be calculated based on data up until 
the last evaluable RECIST assessment prior to death.
For patients who die with no evaluable RECIST assessments, if the death occurred ≤ 17 weeks 
(ie 16 weeks ±1 week) after randomisation then BoR will be assigned to the progression (PD) 
category. For patients who die with no evaluable RECIST assessments, if the death occurred 
  17 weeks (ie 16 weeks ±1week) after randomisation then BoR will be assigned to the
nonevaluable (NE) category.
Progression events that have been censored due to them being more than two missed visits 
after the last evaluable assessment will not contribute to the BoR derivation.
A patient will be classified as a responder if the RECIST criteria for a CR or PR are satisfied 
at any time up to and including the defined analysis cut-off point. For each treatment group, 
the objective response rate (ORR) is the number of CR and PR divided by the number of 
patients in the group in the FAS with measurable disease at baseline. Only patients with PR 
and measurable disease at enrolment can achieve an objective response of CR or PR, other 
permissible categories of BoR are NE, PD.
The disease control rate (DCR) is defined as the percentage of patients who have at least one 
confirmed visit response of CR or PR or have demonstrated SD or NED for at least 15 weeks 
(ie 16 weeks ±1 week) prior to any evidence of progression. In the case of SD and NED, 
follow up assessments must have met the SD or NED criteria for a minimum interval of 15 
weeks following randomisation.
8.3.2.3 Time from randomisation to second progression (PFS2)
Time from randomisation to second progression (PFS2) is defined as the time from the date of 
randomisation to the earliest of the progression event subsequent to that used for the primary 
variable PFS or death. 
The date of second progression will be recorded by the Investigator and defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF. Second progression status 
will be reviewed every 8 weeks following the progression event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progression has not been observed should be censored at the last time known to be alive and 
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without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death).
8.3.2.4 Time to first subsequent therapy or death (TFST)
Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as 
the time from randomisation to the earlier of first subsequent cancer start date following study 
treatment discontinuation, or death. Any patient not known to have died at the time of the 
analysis and not known to have had a further intervention of this type will be censored at the 
last known time to have not received subsequent therapy, ie the last follow-up visit where this 
was confirmed.
8.3.2.5 Time to second subsequent therapy or death (TSST)
Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined 
as the time from randomisation to the earlier of the second subsequent cancer start date 
following study treatment discontinuation, or death. Any patient not known to have died at the 
time of the analysis and not known to have had a further intervention of this type will be 
censored at the last known time to have not received second subsequent therapy, ie the last 
follow-up visit where this was confirmed.
8.3.2.6 Time to study treatment discontinuation or death (TDT)
Time to study treatment discontinuation or death (TDT) will be assessed. TDT is defined as 
the time from randomisation to the earlier of the date of study treatment discontinuation or 
death. Any patient not known to have died at the time of analysis and not known to have 
discontinued study treatment will be censored based on the last recorded date on which the 
patient was known to be alive. 
Note: Survival calls will be made in the week following the date of DCO for the analysis, and 
if patients are confirmed to be alive or if the death date is post the DCO date these patients 
will be censored at the date of DCO.
8.3.2.7 Disease Control Rate (DCR)
The disease control rate (DCR) is defined as the percentage of patients who have at least one 
confirmed visit response of CR or PR or have demonstrated SD for at least 16 weeks (ie 17 
weeks ±1 week) prior to any evidence of progression. In the case of SD, follow up 
assessments must have met the SD criteria for a minimum interval of 16 weeks following 
randomisation.
8.4 Calculation or derivation of safety variable(s)
Safety and tolerability will be assessed in terms of AEs, deaths, laboratory data, vital signs 
and ECG.  These will be collected for all patients.  Appropriate summaries of these data will 
be presented.
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8.4.1 Other significant adverse events (OAE)
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs and DAEs.  Based on the expert’s judgement, 
significant adverse events of particular clinical importance may, after consultation with the 
Global Patient Safety Physician, be considered OAEs and reported as such in the Clinical 
Study Report.  A similar review of laboratory/vital signs/ECG data will be performed for 
identification of OAEs.
Examples of these are marked haematological and other laboratory abnormalities, and certain 
events that lead to intervention (other than those already classified as serious), dose reduction 
or significant additional treatment.
8.5 Calculation or derivation of patient reported outcome variables
All items/questionnaires will be scored according to published scoring guidelines or the 
developer’s guidelines, if published guidelines are not available.
EORTC QLQ-C30 and QLQ-PAN26
The EORTC QLQ-C30 will be scored according to the EORTC scoring manual (Fayers 
et al 2001).  Each scale will be transformed to a 100-point scale as per the manual.
HRQoL Visit responses
A change of at least 10 points in the global QoL score will be considered as a clinically 
relevant or a minimally important difference (Osoba D et al 1998).
For each subscale, if less than 50% of the subscale items are missing, then the subscale score 
will be divided by the number of non-missing items and multiplied by the total number of 
items on the subscales Fayers et al 1999).  If at least 50% of the items are missing, then that 
subscale will be treated as missing.  Missing single items are treated as missing.  The reason 
for any missing questionnaire will be identified and recorded.  If there is evidence that the 
missing data are systematic, missing values will be handled to ensure that any possible bias is 
minimised.
Scores for the QLQ-C30 will be derived using the developer instructions. Raw scores are 
calculated using the formula:
Raw Score = RS I1+ I2+...+ In n
A linear transformation to 0 – 100 is then applied to obtain a score (S)
Function Scale: 
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Global Health Status/Quality of Life:
{(RS-1)/range}x100
Range is the difference between the maximum possible value of RS and the minimum possible 
value. The QLQ-C30 has been designed so that all items in any scale take the same range of 
values. Therefore, the range of RS equals the range of the item values. Most items are scored 1 
to 4, giving range = 3. The exceptions are the items contributing to the global health status / 
QoL, which are 7-point questions with range = 6, and the initial yes/no items.
The QLQ-PAN26 follows the same scoring criteria as the QLQ-C30. The QLQ-PAN26 
contains 26 items which comprise 7 multi-item scales (pancreas pain (4 items), eating related 
items (2 items), hepatic items (2 items), altered bowel habit (2 items), body image (2 items), 
health care satisfaction (2 items), sexuality (2 items)), and 10 single item scales (swollen 
abdomen, taste changes, indigestion, flatulence, weight loss, loss of muscle strength, dry 
mouth, burden of treatment, fear of future health, and ability to plan future. 
Within the specific module the items can be grouped into new domains rather than reporting 
specific items. When using this approach it is important that the correct scoring algorithm is 
followed. 
Higher scores represent more symptoms, except for health care satisfaction scale and sexuality 
scale where higher scores represent greater satisfaction and sexuality.
The threshold for a clinically important deterioration is outlined below (Table 8):
Table 8 Visit Response in EORTC QLQ-C30 Global QoL Score
Score Change from baseline Visit response
EORTC QLQ-C30 global 
QoL score
≥ +10 Improved




Further detail will be provided in the SAP.
Best overall QoL response
A patient’s best overall QoL response will be derived as the best QoL response the 
patient achieved, based on evaluable QoL data collected from randomisation up to the 
earliest of starting any subsequent cancer therapy or death.  The criteria in Table 9 will 
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be used to assign a best QoL response for HRQoL based on the 2-item global QoL score.  
Improvement rate will be defined as the proportion of patients whose best overall QoL 
response was “Improved”.




Improved Two visit responses of “improved” a minimum of 21 days 
apart without an intervening visit response of “deterioration”
No Change Does not qualify for overall score response of “improved”.  
Two visit responses of either “no change” or “improved” and 
“no change” a minimum of 21 days apart without an 
intervening visit response of “deterioration”
Deterioration Does not qualify for overall score response of “improved”.  A 
visit response of “deterioration” without response of 
“improved” or “no change” within 21 days.
Other Does not qualify for one of the above.
Compliance
Summary measures of overall compliance and compliance over time will be derived for 
the EORTC QLQ-C30 and QLQ-PAN26 questionnaires.  These will be based upon:
 Received forms = number of EORTC QLQ-C30 / QLQ-PAN26 questionnaire 
forms received back plus the number not received back where the reason was 
‘Subject too affected by symptoms of disease under investigation’.
 Expected forms = number of patients still under QoL follow-up at the specified 
assessment time excluding patients in countries with no available translation.  
 Evaluable forms = subset of expected EORTC QLQ-C30 / QLQ-PAN26 
questionnaire forms with at least one subscale that can be determined; or 
where the reason questionnaire not completed is ticked as ‘Subject too affected 
by symptoms of disease under investigation’.
Thus the compliance rate for QLQ-C30 and for QLQ-PAN26 is defined as the number of 
patients with an evaluable baseline and at least one evaluable follow-up form (as defined 
above), divided by the number of patients expected to have completed at least a baseline 
EORTC QLQ-C30 / QLQ-PAN26 questionnaire form.  In addition, an overall 
compliance rate defined as number of patients with an evaluable baseline and at least 
one evaluable follow-up, divided by the number of patients expected to have completed 
at least a baseline for both, the EORTC QLQ-C30 AND QLQ-PAN26 questionnaire 
form, will be calculated.
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Compliance over time will be calculated separately for each visit, including baseline, as the 
number of patients with an evaluable baseline form and a form at the time point (as defined 
above), divided by number of patients still expected to complete forms at that visit.  Similarly, 
the evaluability rate over time will be calculated separately for each visit, including baseline, 
as the number of evaluable forms (per definition above), divided by the number of received 
forms.
Within the specific module the items can be grouped into new domains rather than reporting 
specific items. When using this approach it is important that the correct scoring algorithm is 
followed. 
1. Calculate the raw score for each scale
Raw score = RS = (I1+I2+…+In)/n
2. Apply the following linear transformation for the sexuality scale: 
For all other scales (including the single items), apply this linear transformation:
Where range is 3 in each case.
8.6 Calculation or derivation of pharmacogenetic variables
To be defined in an exploratory analysis plan.
8.7 Calculation or derivation of health economic variables
Responses to the EuroQoL EQ5D questionnaire will be converted into utility scores using UK 
EQ5D valuation set. Alternative valuation sets may be used in scenario analyses.  Descriptive 
statistics, graphs and listings will be reported for health state utility by visits as well as change 
in these scores from baseline. To support future economic evaluations of Olaparib, additional 
appropriate analyses may be undertaken, for example, mean health state utility pre and post 
treatment, and pre and post progression.
Descriptive statistics relating to the frequency healthcare resource use items, including 
hospital episodes, type of contact (hospitalisation, outpatient, day case), reason, length of stay 
by ward type (including ICU) and procedures undertaken will be derived from the resource 
use information. 
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The evaluable population will comprise all randomised patients and will compare the 
treatment groups on the basis of randomised treatment, regardless of the treatment actually 
received.
8.8 Methods for statistical analyses
A single interim PFS analysis for futility will be performed when 50% of the final number of 
progression events required for the primary PFS analysis has been reached (approximately 
44 PFS events).  The interim analysis will be performed by an Independent Data Monitoring 
Committee (IDMC) and full details will be provided in the IDMC charter.  A final PFS 
analysis will be performed when approximately 87 progression events have occurred (60%
maturity).  No further analyses of PFS are planned beyond this point unless requested by 
health authorities
Timing of the statistical analyses are given in Table 10
Table 10 Timing of statistical analyses
Timing of analyses Outcome Variable
Efficacy Data
Interim PFS analyses (~ 44 PFS events) - PFS 
Final PFS (~ 87 PFS events) - PFS, PFS2, TDT, TFST, TSST, OS, adjusted mean 
change from baseline in global QoL score
Final OS analyses (~ 106 OS events) - PFS2, TFST, TSST, OS, adjusted mean change from 
baseline in global QoL score
The treatment comparison is Olaparib 300 mg bid vs. placebo to Olaparib 300 mg bid.
Results of all statistical analysis will be presented using a 95% confidence interval and 2-sided 
p-value. 
The following table details which endpoints are to be subject to formal statistical analysis, 
together with pre-planned sensitivity analyses making clear which analysis is regarded as 
primary for that endpoint
Table 11 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses
Endpoints Analysed Notes
PFS (Time from randomisation to first 
progression or death)
Primary analysis: log-rank test using BICR data
Key sensitivity analysis
a
: log rank test using 
BICR data in randomised patients confirmed as 
gBRCA mutation positive by central Myriad test 
(if subset of FAS) 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib  
Study Code D081FC00001
Edition Number 2




1) Evaluation time bias analysis; log-rank test 
using BICR data
2) Attrition bias analysis (using alternative 
censoring rules); log-rank test using BICR data
3) Ascertainment bias analysis; log-rank test 
using investigator data
4) Deviation bias analysis (if meaningful to do); 
log-rank test using BICR data
Overall Survival (Time from randomisation to 
death due to any cause)
Primary analysis: log-rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Supportive analysis: KM plot of time to censoring 
for OS
Second Progression Free Survival (PFS2) Primary analysis: log-rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to treatment discontinuation (TDT) Primary analysis: log rank test of time from 
randomisation to treatment discontinuation 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to first subsequent therapy (TFST) Primary analysis: log rank test of time from 
randomisation to first subsequent therapy or death 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to second subsequent therapy (TSST) Primary analysis: log rank test of time from 
randomisation to second subsequent therapy or 
death 
Primary analysis: log rank test of time from 
randomisation to treatment discontinuation 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib  
Study Code D081FC00001
Edition Number 2
Date 28 February 2015
101(120)
Endpoints Analysed Notes
Adjusted mean change from baseline in global 
QoL score from the EORTC QLQ-C30 
questionnaire
Primary analysis: mixed model for repeated 
measures (MMRM) analysis of all of the post-
baseline scores for each visit
Supportive analysis: logistic regression on 
global QoL score improvement rate.
a
See Section 8.8.3 for further details
8.8.1 Multiplicity strategy for primary and key secondary endpoints
In order to describe the nature of the benefits of Olaparib maintenance treatment, PFS, PFS2 
and OS will be tested at a 1-sided significance level of 2.5%.
However, in order to strongly control the type I error at 2.5% 1-sided, a multiple testing 
procedure will also be employed across the primary endpoint and secondary endpoints 
intended for key label claims (ie OS). 
A hierarchical testing strategy will be employed where PFS is tested first using the full test 
mass (full test mass = alpha 5% 2 sided) and the key secondary endpoint of OS will then be 
tested using a multiple testing procedure with a recycling strategy (ie, the MTP will recycle 
the test mass to the endpoint not yet rejected in the hierarchy outlined in Figure 2).
Figure 2 Multiple Testing Procedures
OS will only be tested if the null hypothesis (of no difference) is rejected for PFS. One
interim analysis for OS will be performed at the time of the final PFS analysis (approximately 
87 PFS events).  A final analysis of OS will be performed when approximately 106 death 
events have occurred. The Lan and DeMets approach that approximates the O’Brien & 
Fleming spending function will be employed to preserve the overall 1-sided type I error 
rate of 2.5% (Lan and DeMets 1983).  If the interim analysis for OS occurs at exactly 
57% of the 106 OS events, statistical significance for OS will be declared if the null 
hypothesis for PFS is rejected and the observed p-value for OS is p<0.003, which equates to 
a HR ≤ 0.49.  The significance level at the final analysis will be determined based on the 
exact number of events at the time of the interim and final analyses.  If the interim 
analysis for OS occurs at exactly 57% of events and the number of OS events at the final 
analysis is approximately 106 then the 1-sided significance level to be applied for the final 
analysis will be 2.4%.  Statistical significance for OS will be declared if the observed p-
value for OS is p<0.024, which equates to a HR ≤ 0.68.
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All planned analyses will be performed, regardless of the outcome of the MTP. 
8.8.2 Analysis of the primary variable (s)
The primary PFS analysis will be performed when approximately 87 progression events have 
occurred (60% maturity) based on the BICR.  No further analyses of PFS are planned beyond 
this point unless requested by Health Authorities
PFS will be analysed using a log rank test.  The hazard ratio (HR) and confidence interval will 
be estimated from the U and V statistics obtained directly from the LIFETEST model (and 
using the Breslow approach for handling ties).
The HR and its confidence interval will be estimated from the log-rank as follows (Berry et al 
1999 and Sellke et al 1983)
HR = exp(U/V)
95% CI for HR = (exp{U/V – 1.96/ √V}, exp{U/V + 1.96/ √V})





is the log-rank test statistic (with id1 and ie1 the observed and expected 
events in group 1) and √V the standard deviation of the log-rank test statistic as produced in 
the LIFETEST output.  
The HR (Olaparib vs. placebo) together with its corresponding 95% confidence interval (CI) 
and p-value will be presented (a HR less than 1 will favour Olaparib).  
A Kaplan-Meier (KM) plot of PFS will be presented by treatment group. Summaries of the 
number and percentage of patients experiencing a PFS event, and the type of event (RECIST 
or death) will be provided along with median PFS for each treatment arm.
The assumption of proportionality will be assessed. Note that in the presence of non-
proportionality, the HR will be interpreted as an average HR over the observed extent of 
follow-up.  Proportionality will be tested firstly by producing plots of complementary log-log 
(event times) versus log (time) and, if these raise concerns, a time dependent covariate would 
be fitted to assess the extent to which this represents random variation. 
The primary analysis will be based on the programmatically derived PFS based on BICR 
overall visit assessments (ie Individual tumour measurements will not be used) and using all 
scans regardless of whether they were scheduled or not. 
The estimated PFS rates at 6 months and 12 months will be summarised (using the KM curve) 
and presented by treatment group.
The number of patients prematurely censored will be summarised by treatment arm together 
with baseline prognostic factors of the prematurely censored patients.  A patient is defined as 
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prematurely censored if they had not progressed and the latest scan prior to DCO was more 
than one scheduled tumour assessment interval (+ 2 weeks) prior to the DCO date.
Subgroup analyses will be conducted comparing PFS between treatments. The purpose of the 
subgroup analyses is to assess the consistency of treatment effect across potential or expected 
prognostic factors.  If there are too few events available for a meaningful analysis of a 
particular subgroup (it is not considered appropriate to present analyses where there are less 
than 20 events in a subgroup), the relationship between that subgroup and PFS will not be 
formally analysed.  In this case, only descriptive summaries will be provided
The following subgroups of the full analysis set will be analysed for PFS:
 Previous chemotherapy (FOLFIRINOX variants vs gemcitabine/cisplatin)
 Presence or absence of biliary stent
 Type of previous chemotherapy (doublets vs triplets)
 Time on first line treatment till randomisation (≤6 months vs  >6 months)
 Best response on first line treatment (SD vs PR/CR)
 Measurable versus non measurable disease /no evidence of disease at baseline
 BRCA mutation type, eg BRCA1, BRCA2 or BRCA1/2 (both) 
 Age at randomisation (>=65 vs. <65) 
 Race
 Sex
Other baseline variables may also be assessed if there is clinical justification. 
For each subgroup, the HRs (Olaparib: placebo) and associated CIs will be calculated from a 
Cox proportional hazards model (ties = Efron) that contains the treatment term, factor and 
treatment-by-factor interaction term.  The treatment effect HRs for each treatment comparison 
along with their confidence intervals will be obtained for each level of the subgroup from this 
single model.  The HRs and 95% CIs will be presented on a forest plot including the HR and 
95% CI from the overall population (using the primary analysis).  
No adjustment to the significance level for testing of subgroups will be made since all these 
subgroup analyses will be considered exploratory and may only be supportive of the primary 
analysis of PFS.
A further analysis of PFS (using Investigator assessed RECIST) may be performed at the time 
of the OS analyses, if requested by Health authorities.
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8.8.3 Sensitivity analysis for the primary endpoint
As a sensitivity analysis to the primary endpoint of PFS, the primary analysis will be repeated 
excluding any patients who did not have a gBRCA mutation status confirmed by the Myriad 
test.  The same methodology and model will be used as for the primary analysis of PFS and 
the HR and associated 95% CI will be reported.
Sensitivity analyses will be performed to assess the possible presence of time-assessment bias 
(ie, differential assessment times between treatment groups).
Summary statistics for the number of weeks between the time of progression and the last 
evaluable RECIST assessment prior to progression will be presented for each treatment group.
8.8.3.1 Evaluation-Time bias
Sensitivity analyses will be performed to assess possible evaluation-time bias that may be 
introduced if scans are not performed at the protocol-scheduled time points. The midpoint 
between the time of progression and the previous evaluable RECIST assessment will be 
analysed using a stratified log rank test, as described for the primary analysis of PFS.  This 
approach has been shown to be robust to even highly asymmetric assessment schedules (Sun 
and Chen 2010). This approach will use the BICR RECIST assessments.
8.8.3.2 Attrition bias
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of subjects who progressed or died in the 
absence of progression immediately following two, or more, non-evaluable tumour 
assessments will be included. In addition, subjects who take subsequent therapy prior to their 
last evaluable RECIST assessment or progression or death will be censored at their last 
evaluable assessment prior to taking the subsequent therapy.
Additionally a Kaplan-Meier plot of the time to censoring where the censoring indicator of the 
primary PFS analysis is reversed will be presented.
8.8.3.3 Ascertainment bias
A log-rank test will be repeated using the programmatically derived RECIST using 
Investigator assessed PFS.  The HR and 95% Confidence Interval will be presented.  
If there is an important discrepancy between the primary analysis using BICR assessments and 
this sensitivity analysis using Investigator assessments, then the proportion of patients with 
site but no central confirmation of progression will be summarised.  The approach of imputing 
an event at the next visit in the central review analysis may help inform the most likely HR 
value, but only if an important discrepancy exists.  
Disagreements between investigator and central reviews of RECIST progression will be 
presented for each treatment group.  The summary will include the early discrepancy rate 
which is the frequency of central review declared progressions before the Investigator review 
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as a proportion of all central review progressions and the late discrepancy rate which is the 
frequency of central review declared progressions after the Investigator review as a proportion 
of all discrepancies.
8.8.3.4 Deviation bias (if meaningful to do)
As a sensitivity analysis to the primary endpoint of PFS, an analysis excluding patients with 
deviations that may affect the efficacy of the trial therapy will be performed if > 10% of 
patients:
 did not have the intended disease or indication or
 did not receive any randomised therapy
A log-rank test will be repeated using the BICR RECIST data, using the same ties as 
described for the primary analysis of PFS. The HR and 95% CI will be presented.
8.8.4 Analysis of the secondary variable(s)
8.8.4.1 Analysis of OS endpoint
OS data will be analysed at the time of the final analyses of PFS and will use the same 
methodology and model (provided there are sufficient events available for a meaningful 
analysis [> 20 deaths], if not descriptive summaries will be provided).  A further analysis of 
OS will be performed when approximately 106 deaths have occurred.
The sensitivity analysis outlined in Section 8.8.3 will not be repeated for OS with the 
exception of a Kaplan-Meier plot of the time to censoring where the censoring indicator of the 
primary OS is reversed.
To assist in quantifying the PFS effect, at the time of the PFS analysis, a predicted treatment 
effect for OS at the final analysis will be derived using a weighted sum of the observed OS 
data and the predicted OS value using PFS data (Chen and Sun 2011). The estimate of the 
treatment effect for OS at the final analysis is defined as where is 
the observed treatment effect for OS at the time of the PFS analysis and is the 
estimated treatment effect for OS based on the observed treatment effect for PFS, where 
represents the estimated slope relating PFS to OS from historical trials. The weightings (w) 
are based on the inverse of the variance (ie those with more uncertainty are given less weight). 
The variance is dependent on the correlation between the two endpoints. Details of the 
methodology will be provided in the statistical analysis plan (SAP).
8.8.4.2 Analysis of PFS2 endpoint
The analyses of PFS2 will use the same methodology and model as the primary analysis of 
PFS.  No multiplicity adjustment will be applied as this is viewed as a supportive endpoint.
The date of second progression will be recorded by the Investigator and defined according to 
local standard clinical practice and may involve any of; objective radiological or symptomatic 
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progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF. Second progression status 
will be reviewed every 8 weeks following the progression event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progression has not been observed should be censored at the last time known to be alive and
without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death) 
As a key sensitivity, the analysis of PFS2 will be repeated in those patients whose gBRCAm
status is confirmed by the Myriad test. A KM plot of PFS2 in this subset of patients will be 
presented by treatment group.
A KM plot of the time to censoring where the censoring indicator of the primary PFS2 is 
reversed will be produced.
Time from second progression to previous assessment will be summarised by treatment arm.
8.8.4.3 Analysis of TDT endpoint
Time to study treatment discontinuation or death (TDT) will be analysed using the same 
methodology and model as the primary analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.  No 
multiplicity adjustment will be applied as this is viewed as a supportive endpoint.
As a key sensitivity, the analyses of TDT will be repeated in those patients whose gBRCAm
status is confirmed by the Myriad test. A KM plot of TDT in this subset of patients will be 
presented by treatment group.
8.8.4.4 Analysis of TFST endpoint
Time to first subsequent therapy or death (TFST) will be analysed using the same 
methodology and model as the primary analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.  In 
addition, the time between progression and starting subsequent therapy will be assessed.  
As a key sensitivity, the analyses of TFST will be repeated in those patients whose gBRCAm
status is confirmed by the Myriad test. A KM plot of TFST in this subset of patients will be 
presented by treatment group.
8.8.4.5 Analysis of TSST endpoint
Time to first second subsequent therapy or death (TSST) will be analysed analysed using the 
same methodology and model as the primary analysis of PFS.  The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by treatment arm.  
Summary tables of first and second subsequent therapies by treatment arm will be provided, as 
well as response to first subsequent therapy by treatment arm.
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As a key sensitivity, the analyses of TSST will be repeated in those patients whose gBRCAm
status is confirmed by the Myriad test. A KM plot of TSST in this subset of patients will be 
presented by treatment group.
8.8.4.6 Analysis of PRO endpoints
The analysis population for PRO data will be the PRO analysis set including patients with 
evaluable baseline EORTC QLQ-C30 and QLQ-PAN26 forms.
The impact of olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales. 
Adjusted mean change from baseline in global QoL score will be analysed using a mixed 
model for repeated measures (MMRM) analysis of all of the post-baseline scores for each 
visit and will be presented by treatment group.  The study discontinuation visit and the 
safety follow-up visit will be excluded from this analysis. Restricted maximum likelihood 
(REML) estimation will be used. The model will include treatment, visit and treatment 
by visit interaction as explanatory variables and the baseline QoL score as a covariate. 
Treatment, visit and treatment by visit interaction will be fixed effects in the model.  The 
treatment by visit interaction will remain in the model regardless of significance.
An unstructured covariance matrix will be used to model the within-subject error and 
the Kenward-Roger approximation will be used to estimate the degrees of freedom. 
If the fit of the unstructured covariance structure fails to converge, the following 
covariance structures will be tried in order until convergence is reached: toeplitz with 
heterogeneity, autoregressive with heterogeneity, toeplitz, and autoregressive. 
The adjusted mean change from baseline estimates and corresponding 95% CIs will be 
presented by visit for each treatment group and corresponding plots over time will be 
presented.
As a supportive analysis, EORTC QLQ-C30 global QoL score improvement rate will be 
analysed using a logistic regression model.  If the overall response rate is < 5%, no analysis 
will be performed (note that if the response rate in only one of the treatment groups is < 5% 
but ≥ 5% in the other treatment group then the analysis will still be performed). If the overall 
expected response rate is low (< 20%) a Fisher’s exact test will be considered and mid p-
values used. The results of the analysis will be presented in terms of an odds ratio together 
with its associated profile likelihood CIs and p-values (based on twice the change in log-
likelihood resulting from the addition of a treatment factor to the model).
EORTC QLQ-C30 compliance (overall compliance and by visit compliance) will be 
summarised for each treatment group.
Descriptive statistics and graphs will be reported for the global QoL score by visits as well as 
unadjusted change in these scores from baseline. Summary tables of EORTC QLQ-C30 
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best overall QoL response as defined in Table 9 will be provided (improvement, 
deterioration, no change).
An exploratory analysis will examine adjusted mean change from baseline on 
QLQ-PAN26 symptom scales/items (including pancreatic pain).  This is detailed in
Section 8.8.5.1.
8.8.4.7 Summary of Best overall RECIST Response (BoR) and ORR
For each treatment arm, best overall response (BoR) will be summarised by n (%) for each 
category (CR, PR, SD, NED, PD, NE).  No formal statistical analyses are planned.  
The objective response rate (ORR) will be summarised (ie, number of patients (%)) by 
treatment group in patients in the FAS (ITT population) with measurable disease at baseline.  
Any patients who experienced CR or PR which was first observed whilst receiving subsequent 
therapy after discontinuation of Olaparib/placebo will be identified. The denominator for the 
response rate will be measurable disease as defined by the BICR data
ORR and BOR will be presented based on the BICR data and also summarised in a similar 
way using the investigator recorded data.
8.8.4.8 Summary of DCR  
The disease control rate (DCR) will be summarised (ie, number of patients (%)) by treatment 
group in patients in the FAS (ITT population).
DCR will be presented based on the BICR data and also the investigator recorded data.
8.8.5 Exploratory analysis  
8.8.5.1 Exploratory analysis of PRO endpoints (QLQ-PAN-26 symptom scales and 
items)
Exploratory analyses examining adjusted mean change from baseline will be performed for 
EORTC QLQ-C30 functioning domains (physical, role, cognitive, emotional, social) and 
for the individual EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (with a 
particular focus on pancreatic pain, fatigue, nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice), using the same MMRM model described in Section 
8.8.4.6 for the global QoL score.
Descriptive statistics and graphs will be reported for the EORTC QLQ-C30 functioning 
domains and EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (specifically 
pancreatic pain, fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite) and 
jaundice).
EORTC QLQ- PAN26 compliance (overall compliance and by visit compliance) will be 
summarised for each treatment group.
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8.8.5.2 Analysis of Healthcare Resource Use
A health economic analysis of resource use will be estimated, including descriptive statistics 
relating frequency of hospitalisations and hospital admission, type of attendance, length of 
stay and procedures undertaken, and the primary symptom/reason for the attendance. 
Descriptive statistics, graphs and listings will be reported for health state utility by visits as 
well as change in these scores from baseline. To support future economic evaluations of 
Olaparib, additional appropriate analyses may be undertaken, for example, mean health state 
utility pre and post treatment, and pre and post progression.
The evaluable population will comprise all randomised patients and will compare the 
treatment groups on the basis of randomised treatment, regardless of the treatment actually 
received.
8.8.5.3 Analysis of ECOG Performance status
Shift tables will be provided showing best and then worst on treatment change in performance 
status vs baseline, by treatment.
Change from baseline in levels of ECOG performance status at each post randomisation time 
point will be reported descriptively (n, %) by treatment group, as well as the proportion of 
patients with ECOG status of 0 at baseline (ie cannot improve).    
8.8.6 Impact of Switching to PARP inhibitors (or other potentially active
investigational agents) on Overall Survival Analyses
Exploratory analyses of OS adjusting for impact of subsequent PARP inhibitor trial or 
treatment may be performed if a sufficient proportion of patients receive the therapies of 
interest.  Methods such as Rank Preserving Structural Failure Time (RPSFT) (Robins et al 
1991), Inverse Probability of Censoring Weighting (IPCW) (Robins 1993) and other methods 
in development will be explored.  The decision to adjust and final choice of methods will be 
based on a blinded review of the data and the plausibility of the underlying assumptions.  
Baseline and time-dependent characteristics will be explored, and summaries of baseline 
characteristics will be summarised for patients receiving physician’s choice of chemotherapy, 
splitting between those that have and haven’t received a PARP inhibitor at the time of the 
analyses.  Further detail will be provided in the SAP and Payer Analysis Plan. These analyses 
are intended to support reimbursement appraisals.
8.8.7 Exploratory translational science endpoints
Full statistical methods for exploratory endpoints will be defined in a separate translation 
science analysis plan.
8.8.8 Biomarkers
Biomarker data will be summarised descriptively using tables and plots.  If the data is 
available at the time of developing the CSR then the biomarker data will be included in the 
CSR.  Otherwise the biomarker data will be reported in a separate addendum to the CSR (if 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib  
Study Code D081FC00001
Edition Number 2
Date 28 February 2015
110(120)
applicable).  Further details on the data summaries and plots for the biomarker data for the 
CSR will be provided in the SAP.
BRCA status will be summarised for all patients based on the central myriad test result.  This 
will highlight any patients with a negative BRCA result from the central test.
8.9 Sample Size Determination
The primary endpoint of the study is PFS.   Approximately 145 patients will be randomised 
(3:2 ratio of Olaparib:placebo) and the primary PFS analysis will occur once approximately 87
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
futility will be performed when 50% of the final number of progression events required for 
the primary PFS analysis has been reached (approximately 44 PFS events) based on BICR.
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.5% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median OS for placebo. 87 PFS events 
will be required at the final analyses.  
Patients are to be followed for the final analysis of OS (when approximately 106 death events 
have occurred).  With 106 OS events the study has 80% power to show a statistically 
significant difference in OS at the 1-sided 2.5% level if the assumed true treatment effect is a 
HR 0.57; this translates to an approximate 6 month improvement in median OS over an 
assumed 8 month median OS on placebo, assuming OS is exponentially distributed.
Assuming that the study accrual period will be approximately 15 months, 87 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 44 PFS events will occur approximately 13 to 14 
months after first patient in.  It is estimated that 106 death events will occur approximately 31 
months after first patient in.
8.9.1 Interim analysis
A single interim PFS analysis for futility will be performed when 50% of the final number of
progression events required for the primary PFS analysis has been reached (approximately 
44 PFS events) based on BICR.  The interim analysis will be performed by an Independent 
Data Management Committee (IDMC) and full details will be provided in the IDMC charter.  
Safety data including death rates will also be reviewed at this time.
The futility assessment will be based on the probability of eventually showing statistical 
significance for the primary endpoint when the final number of PFS events (n=87) is 
reached (Lachin 2005).  The determination of this probability will be conditional on the 
observed data at the time of the interim analysis and on the assumed hazard ratio for the 
alternative hypothesis (PFS HR=0.54).  If the probability is less than 20%, the IDMC 
will consider the option of declaring futility.
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The exact figure used for the futility boundary will be calculated by AZ and sent to the 
IDMC at the time of the interim analysis, based on the number of events which have 
occurred at that time.  As an example, if exactly 50% of the PFS events required for the 
primary PFS analysis have occurred at the time of the interim analysis (44 events), then 
the HR that corresponds to 20% conditional power for the interim analysis will be 1.02.  
Therefore, if the observed HR for PFS at the interim is more than 1.02, the IDMC will 
consider the option of declaring futility.
An interim analysis of OS will be performed at the time of the primary analysis of PFS 
(approximately 87 events), and again when approximately 106 OS events have occurred.
The futility analyses on PFS will be used to guide decisions on stopping the study for futility 
or continuing the study.  Details will be documented in the IDMC charter.
9. STUDY AND DATA MANAGEMENT BY PAREXEL
9.1 Training of study site personnel
Before the first patient is entered into the study, an AstraZeneca representative will review and 
discuss the requirements of the Clinical Study Protocol and related documents with the 
investigational staff and also train them in any study specific procedures and the WBDC
system(s) utilised.
The Principal Investigator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved.
The Principal Investigator will maintain a record of all individuals involved in the study 
(medical, nursing and other staff).
9.2 Monitoring of the study
During the study, an AstraZeneca representative will have regular contacts with the study site, 
including visits to:
 Provide information and support to the Investigator(s)
 Confirm that facilities remain acceptable
 Confirm that the investigational team is adhering to the protocol, that data are 
being accurately and timely recorded in the CRFs, that biological samples are 
handled in accordance with the Laboratory Manual and that study drug 
accountability checks are being performed
 Perform source data verification (a comparison of the data in the CRFs with the 
patient’s medical records at the hospital or practice, and other records relevant 
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to the study) including verification of informed consent of participating 
patients. This will require direct access to all original records for each patient 
(eg, clinic charts)
 Ensure withdrawal of informed consent to the use of the patient’s biological 
samples is reported and biological samples are identified and disposed 
of/destroyed accordingly, and the action is documented, and reported to the 
patient.
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct.
9.2.1 Source data
Refer to the Clinical Study Agreement for location of source data. 
9.2.2 Study agreements
The Principal Investigator at each/the centre should comply with all the terms, conditions, and 
obligations of the Clinical Study Agreement, or equivalent, for this study.  In the event of any 
inconsistency between this Clinical Study Protocol and the Clinical Study Agreement, the 
terms of Clinical Study Protocol shall prevail with respect to the conduct of the study and the 
treatment of patients and in all other respects, not relating to study conduct or treatment of 
patients, the terms of the Clinical Study Agreement shall prevail.
Agreements between AstraZeneca and the Principal Investigator should be in place before any 
study-related procedures can take place, or patients are enrolled.
9.2.3 Archiving of study documents
The Investigator follows the principles outlined in the Clinical Study Agreement (CSA). 
9.3 Study timetable and end of study
The end of the study is defined as ‘the last visit of the last patient undergoing the study’.
The study is expected to start in Q2 2014 and to end by Q2 2017
The study may be terminated at individual centres if the study procedures are not being 
performed according to GCP, or if recruitment is slow.  AstraZeneca may also terminate the 
entire study prematurely if concerns for safety arise within this study or in any other study 
with Olaparib.
9.4 Data management by PAREXEL
Data management will be performed by PAREXEL. .
The data collected through third party sources will be obtained and reconciled against study 
data.
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Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version the Medical Dictionary for Regulatory Activities (MedDRA).  Medications 
will be classified according to the AstraZeneca Drug Dictionary.  All coding will be 
performed by the Medical Coding Team at the AstraZeneca Data Management Centre.
Data queries will be raised for inconsistent, impossible or missing data.  All entries to the 
study database will be available in an audit trail.
The data will be validated as defined in the Data Management Plan. Quality control 
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly.
When all data have been coded, validated, and locked, clean file will be declared.  Any 
treatment revealing data may thereafter be added and the final database will be locked.
Data associated with biological samples will be transferred from laboratories internal or 
external to AstraZeneca.  Data from external providers (eg central laboratories) will be 
validated as appropriate to ensure it is consistent with the clinical data and included in the 
final database.  In the case of biomarker (tumour tissue or blood for exploratory analyses) 
data, the results of any analyses will not be recorded in the database, but information relating 
to the processing of the sample, including the original date of biopsy (historical tumour tissue 
sample and the actual date the sample(s) were collected) will be recorded in the eCRF and 
database.
Exploratory genotype data generated in this study will be stored in the AstraZeneca 
genotyping LIMS database, or other appropriate secure system within AstraZeneca and/or 
third party contracted to work with AstraZeneca to analyse samples.  The results from this 
exploratory genetic research will not be reported in the CSR.
Some or all of the clinical datasets from the main study may be merged with the genetic data 
in a suitable secure environment separate from the clinical database.
Site staff will enter PRO booklet data into Medidata Rave exactly as reported by the patient.
10. ETHICAL AND REGULATORY REQUIREMENTS
10.1 Ethical conduct of the study
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological 
Samples.
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10.2 Patient data protection
The Informed Consent Form will incorporate (or, in some cases, be accompanied by a 
separate document incorporating) wording that complies with relevant data protection and 
privacy legislation.
AstraZeneca will not provide individual genotype results to patients, any insurance company, 
any employer, their family members, general physician or any other third party, unless 
required to do so by law.
The exception to the above is the result of the Myriad BRCA test. This will be made available 
to the Investigator and patient.
Extra precautions are taken to preserve confidentiality and prevent genetic data being linked to 
the identity of the patient. In exceptional circumstances, however, certain individuals might 
see both the genetic data and the personal identifiers of a patient. For example, in the case of a 
medical emergency, an AstraZeneca Physician or an investigator might know a patient’s 
identity and also have access to his or her genetic data. Also Regulatory authorities may 
require access to the relevant files, though the patient’s medical information and the genetic 
files would remain physically separate.
10.3 Ethics and regulatory review
An Institutional Review Board (IRB)/Ethics Committee should approve the final study 
protocol, including the final version of the Informed Consent Form and any other written 
information and/or materials to be provided to the patients.  The investigator will ensure the 
distribution of these documents to the applicable Ethics Committee, and to the study site staff.
The opinion of the Ethics Committee should be given in writing. The investigator should 
submit the written approval to AstraZeneca before enrolment of any patient into the study. 
The Ethics Committee should approve all advertising used to recruit patients for the study.
AstraZeneca should approve any modifications to the Informed Consent Form that are needed 
to meet local requirements.
If required by local regulations, the protocol should be re-approved by the Ethics Committee 
annually.
Before enrolment of any patient into the study, the final study protocol, including the final 
version of the Informed Consent Form is approved by the national regulatory authority or a 
notification to the national regulatory authority is done, according to local regulations.
AstraZeneca will handle the distribution of any of these documents to the national regulatory 
authorities.
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AstraZeneca will provide Regulatory Authorities, Ethics Committees and Principal 
Investigators with safety updates/reports according to local requirements, including SUSARs 
(Suspected Unexpected Serious Adverse Reactions), where relevant.
Each Principal Investigator is responsible for providing the Ethics Committees/IRB with 
reports of any serious and unexpected adverse drug reactions from any other study conducted 
with the investigational product.  AstraZeneca will provide this information to the Principal 
Investigator so that he/she can meet these reporting requirements.
10.4 Informed consent
The Principal Investigator(s) at each centre will:
 Ensure each patient is given full and adequate oral and written information about 
the nature, purpose, possible risk and benefit of the study
 Ensure each patient is notified that they are free to discontinue from the study at any 
time
 Ensure that each patient is given the opportunity to ask questions and allowed time 
to consider the information provided
 Ensure each patient provides signed and dated informed consent before conducting 
any procedure specifically for the study
 Ensure the original, signed Informed Consent Form(s) is/are stored in the 
Investigator’s Study File
 Ensure a copy of the signed Informed Consent Form is given to the patient
 Ensure that any incentives for patients who participate in the study as well as any 
provisions for patients harmed as a consequence of study participation are described 
in the informed consent form that is approved by an Ethics Committee.
10.5 Changes to the protocol and informed consent form
Study procedures will not be changed without the mutual agreement of the International co-
ordinating Investigator, National Co-ordinating Investigator, and the Principal Investigator 
and AstraZeneca.
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study Protocol).
The amendment is to be approved by the relevant Ethics Committee and if applicable, also the 
national regulatory authority approval, before implementation.  Local requirements are to be 
followed for revised protocols.
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AstraZeneca will distribute any subsequent amendments and new versions of the protocol to 
each Principal Investigator(s). For distribution to Ethics Committee see Section 10.3.
If a protocol amendment requires a change to a centre’s Informed Consent Form, AstraZeneca 
and the centre’s Ethics Committee are to approve the revised Informed Consent Form before 
the revised form is used. 
If local regulations require, any administrative change will be communicated to or approved 
by each Ethics Committee.
10.6 Audits and inspections
Authorised representatives of AstraZeneca, a regulatory authority, or an Ethics Committee 
may perform audits or inspections at the centre, including source data verification.  The 
purpose of an audit or inspection is to systematically and independently examine all study-
related activities and documents, to determine whether these activities were conducted, and 
data were recorded, analysed, and accurately reported according to the protocol, Good Clinical 
Practice (GCP), guidelines of the International Conference on Harmonisation (ICH), and any 
applicable regulatory requirements.  The investigator will contact AstraZeneca immediately if 
contacted by a regulatory agency about an inspection at the centre.
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FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE) 
Life threatening 
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure). 
Hospitalisation 
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study. 
Important medical event or medical intervention 
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize the subject or may require 
medical intervention to prevent one or more outcomes listed in the definition of serious.  
These should usually be considered as serious. 
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used. 
Examples of such events are: 
• Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment 
• Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring 
treatment with N-acetylcysteine 
• Intensive treatment in an emergency room or at home for allergic bronchospasm 
• Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsions that do not result in hospitalisation 
• Development of drug dependency or drug abuse. 
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A GUIDE TO INTERPRETING THE CAUSALITY QUESTION 
The following factors should be considered when deciding if there is a “reasonable 
possibility” that an AE may have been caused by the drug. 
• Time Course.  Exposure to suspect drug.  Has the subject actually received the 
suspect drug?  Did the AE occur in a reasonable temporal relationship to the 
administration of the suspect drug? 
• Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? OR could the AE be anticipated from its pharmacological 
properties? 
• Dechallenge experience.  Did the AE resolve or improve on stopping or reducing 
the dose of the suspect drug? 
• No alternative cause.  The AE cannot be reasonably explained by another aetiology 
such as the underlying disease, other drugs, other host or environmental factors. 
• Rechallenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally recommend or support 
a rechallenge. 
• Laboratory tests.  A specific laboratory investigation (if performed) has confirmed 
the relationship? 
A “reasonable possibility” could be considered to exist for an AE where one or more of these 
factors exist. 
In contrast, there would not be a “reasonable possibility” of causality if none of the above 
criteria apply or where there is evidence of exposure and a reasonable time course but any 
dechallenge (if performed) is negative or ambiguous or there is another more likely cause of 
the AE. 
In difficult cases, other factors could be considered such as: 
• Is this a recognised feature of overdose of the drug? 
• Is there a known mechanism? 
Ambiguous cases should be considered as being a “reasonable possibility” of a causal 
relationship unless further evidence becomes available to refute this.  Causal relationship in 
cases where the disease under study has deteriorated due to lack of effect should be classified 
as no reasonable possibility. 
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LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES 
International Airline Transportation Association (IATA) classifies biohazardous agents into 3 
categories (http://www.iata.org/whatwedo/cargo/dgr/Pages/infectious_substances.aspx). 
For transport purposes the classification of infectious substances according to risk groups was 
removed from the Dangerous Goods Regulations (DGR) in the 46th edition (2005).  Infectious 
substances are now classified either as Category A, Category B or Exempt.  There is no direct 
relationship between Risk Groups and categories A and B. 
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are eg, Ebola, Lassa fever virus: 
• are to be packed and shipped in accordance with IATA Instruction 602. 
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the following UN 
number and proper shipping name: 
• UN 3373 – Biological Substance, Category B 
• are to be packed in accordance with UN3373 and IATA 650 
Exempt - all other materials with minimal risk of containing pathogens 
• Clinical trial samples will fall into Category B or exempt under IATA regulations 
• Clinical trial samples will routinely be packed and transported at ambient 
temperature in IATA 650 compliant packaging 
(http://www.iata.org/whatwedo/cargo/dgr/Pages/infectious_substances.aspx) 
• Biological samples transported in dry ice require additional dangerous goods 
specification for the dry-ice content 
• IATA compliant courier and packaging materials should be used for packing and 
transportation and packing should be done by an IATA certified person, as 
applicable 
• Samples routinely transported by road or rail are subject to local regulations which 
require that they are also packed and transported in a safe and appropriate way to 
contain any risk of infection or contamination by using approved couriers and 
packaging / containment materials at all times.  The IATA 650 biological sample 
containment standards are encouraged wherever possible when road or rail transport 
is used. 
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1. INTRODUCTION 
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for determining whether a patient meets 
potential Hy’s Law (PHL) criteria at any point during the study. 
The Investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria 
are met.  Hy’s Law criteria are met if there is no alternative explanation for the elevations in 
liver biochemistry other than Drug Induced Liver Injury (DILI) caused by the Investigational 
Product (IP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safety reporting processes. 
2. DEFINITIONS 
Potential Hy’s Law (PHL) 
A Potential Hy’s Law (PHL) case is defined as a study subject with an increase in serum 
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Normal (ULN) together with Total Bilirubin (TBL) ≥ 2xULN irrespective of serum Alkaline 
Phosphatase (ALP), at any point during the study following the start of study medication. 
Hy’s Law (HL) 
A Hy’s Law (HL) case is defined as a study subject with an increase in serum AST or ALT 
≥ 3x ULN together with TBL ≥ 2xULN, where no other reason can be found to explain the 
combination of increases, eg, elevated serum ALP indicating cholestasis, viral hepatitis, 
another drug. 
For PHL and HL to be met the elevation in transaminases must precede or be coincident with 
(ie, on the same day) the elevation in TBL, but there is no specified timeframe within which 
the elevations in transaminases and TBL must occur. 
3. IDENTIFICATION OF POTENTIAL HY’S LAW CASES 
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any patient who meets any of the following identification criteria in 
isolation or in combination: 
• ALT ≥ 3xULN 
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• AST ≥ 3xULN 
• TBL ≥ 2xULN 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will: 
• Determine whether the patient meets PHL criteria (see Section 2 of this Appendix 
for definition) by reviewing laboratory reports from all previous visits 
• Promptly enter the laboratory data into the laboratory CRF. 
4. FOLLOW-UP 
4.1 Potential Hy’s Law Criteria not met 
If the patient does not meet PHL criteria the Investigator will: 
• Perform follow-up on subsequent laboratory results according to the guidance 
provided in the Clinical Study Protocol. 
4.2 Potential Hy’s Law Criteria met 
If the patient does meet PHL criteria the Investigator will: 
• Determine whether PHL criteria were met at any study visit prior to starting study 
treatment in the presence of liver metastases (See Section 6) 
• Notify the AstraZeneca representative who will then inform the central Study Team. 
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patient’s follow-up and the continuous review of data.  Subsequent to 
this contact the Investigator will: 
• Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated  
• Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician 
• Complete the 3 Liver CRF Modules as information becomes available 
• If at any time (in consultation with the Study Physician) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures. 
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5. REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW 
CASES 
The instructions in this section should be followed for all cases where PHL criteria were met. 
No later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the IP.  
The AstraZeneca Medical Science Director and Global Safety Physician will also be involved 
in this review together with other subject matter experts as appropriate. 
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below. 
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE: 
• If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF 
• If the alternative explanation is an AE/SAE, record the AE/SAE in the CRF 
accordingly and follow the AZ standard processes. 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IP: 
• Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes.  
− The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply 
− As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned. 
If there is an unavoidable delay of over 3 weeks in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation until such time as an informed decision can be made: 
• Report an SAE (report term ‘Potential Hy’s Law’) applying serious criteria and 
causality assessment as per above 
• Continue follow-up and review according to agreed plan.  Once the necessary 
supplementary information is obtained, repeat the review and assessment to 
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determine whether HL criteria are met.  Update the SAE report according to the 
outcome of the review. 
6. ACTIONS REQUIRED WHEN POTENTIAL HY’S LAW 
CRITERIA ARE MET BEFORE AND AFTER STARTING 
STUDY TREATMENT 
This section is applicable to patients who meet PHL criteria on study treatment having 
previously met PHL criteria at a study visit prior to starting study treatment.  
At the first on study treatment occurrence of PHL criteria being met (including the 30-day 
follow-up period) the Investigator will: 
• Determine if there has been a significant change in the patients’ condition# 
compared with the last visit where PHL criteria were met# 
− If there is no significant change no action is required 
− If there is a significant change, notify the AstraZeneca representative, who will 
inform the central Study Team, then follow the subsequent process described is 
Section 4.2 of this Appendix. 
# A ‘significant’ change in the patient’s condition refers to a subsequent clinically relevant 
change in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in 
isolation or in combination, or a clinically relevant change in associated symptoms such as 
fatigue, vomiting, rash, right upper quadrant pain, jaundice, eosinophilia.  The determination 
of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty. 
7. ACTIONS REQUIRED FOR REPEAT EPISODES OF 
POTENTIAL HY’S LAW 
This section is applicable when a patient meets PHL criteria on study treatment (including the 
30-day follow-up period) and has already met PHL criteria at a previous on study treatment 
visit. 
The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence. 
The investigator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the following question: 
• Was the alternative cause for the previous occurrence of PHL criteria being met 
chronic or progressing malignant disease or did the patient meet PHL criteria prior 
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to starting study treatment and at their first on study treatment visit as described in 
Section 6? 
If No: follow the process described in Section 4.2 of this Appendix 
If Yes: 
Determine if there has been a significant change in the patient’s condition# compared with 
when PHL criteria were previously met: 
• If there is no significant change no action is required 
• If there is a significant change follow the process described in Section 4.2 of this 
Appendix. 
# A ‘significant’ change in the patient’s condition refers to a subsequent clinically relevant 
change in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in 
isolation or in combination, or a clinically relevant change in associated symptoms, such as 
fatigue, vomiting, rash, right upper quadrant pain, jaundice, eosinophilia.  The determination 
of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty. 
8. REFERENCES 
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1. ACCEPTABLE BIRTH CONTROL METHODS 
Olaparib is regarded as a compound with medium/high foetal risk. 
Patients of childbearing potential and their partners, who are sexually active, must agree to the 
use of two highly effective forms of contraception in combination while they are receiving 
study treatment and for 3 months after last dose of study drug. 
Acceptable Non-hormonal birth control methods include 
• Total/True abstinence: when the subject refrains from any form of sexual 
intercourse and this is in line with their usual and/or preferred lifestyle; this must 
continue for the total duration of the study treatment and for 3 months after the last 
dose of study drug.  [Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods), and withdrawal are not acceptable methods of 
contraception] 
• Vasectomised sexual partner plus male condom. With participant assurance that 
partner received post-vasectomy confirmation of azoospermia 
• Tubal occlusion plus male condom 
• IUD plus male condom. Provided coils are copper-banded 
Acceptable hormonal methods   
• Etonogestrel implants (eg, Implanon, Norplan) + male condom 
• Normal and low dose combined oral pills + male condom 
• Norelgestromin / EE transdermal system + male condom 
• Intravaginal device + male condom (eg, EE and etonogestrel) 
• Cerazette (desogestrel) + male condom. Cerazette is currently the only highly 
efficacious progesterone based pill 
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1. INTRODUCTION 
This appendix details the implementation of modified RECIST (Response Evaluation Criteria 
in Solid Tumours) 1.1 guidelines (Eisenhauer et al 2009) for the study D081FC00001 with 
regards to investigator assessment of tumour burden including protocol-specific requirements 
for this study. 
2. DEFINITION OF MEASURABLE, NON-MEASURABLE, 
TARGET AND NON-TARGET LESIONS 
Patients with measurable disease and/or non measurable  disease or no evidence of disease 
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study. 
RECIST 1.1 has been modified to allow the assessment of progression due to new lesions in 
patients with no evidence of disease at base-line. 
Measurable lesions  
A lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10 mm in 
the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm with CT or 
MRI and which is suitable for accurate repeated measurements. 
Non-measurable lesions 
• All other lesions, including small lesions (longest diameter < 10 mm or pathological 
lymph nodes with ≥ 10 mm to < 15 mm short axis at baseline.  Nodes with < 10 mm 
short axis are considered non-pathological and should not be recorded as non-target 
lesions (NTLs) 
• Truly non-measurable lesions include the following: bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, abdominal masses/abdominal 
organomegaly identified by physical examination that are not measurable by CT or 
MRI 
• Previously irradiated lesions. Localised post-radiation changes which affect lesion 
size, may occur.  Therefore, lesions that have been previously irradiated will not be 
considered measurable and must be selected as NTLs at baseline and followed up as 
part of the NTL assessment 
• Skin lesions assessed by clinical examination  
• Brain metastasis 
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Special cases 
• Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue 
components, can be considered measurable if the soft tissue component meets the 
definition of measurability. Blastic lesions are considered non-measurable. 
• Cystic metastases can be considered measurable lesions if they meet the criteria for 
measurability from a radiological point of view, but if non-cystic lesions are present 
in the same patient; these non-cystic lesions should be selected as target lesions 
(TLs). 
Target lesions 
A maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), representative 
of all lesions involved suitable for accurate repeated measurement, should be identified as TLs 
at baseline. 
Non-target lesions 
All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline. 
3. METHODS OF MEASUREMENT 
The same method of assessment and the same technique should be used to characterise 
each identified and reported lesion at baseline and during follow-up. 
The methods to be used for RECIST assessment are summarised in Table 1 and those 
excluded for tumour assessments in this study are discussed below, with the rationale 
provided. 
Table 1 Summary of Methods of Assessment 





X-ray, Chest x-ray 
Clinical examination  
CT (preferred) 
MRI 





3.1 CT and MRI  
CT and MRI are generally considered to be the best currently available and reproducible 
methods to measure TLs selected for response assessment and to assess NTLs and 
identification of new lesions. 
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In study D081FC00001 it is recommended that CT examinations of the chest, abdomen and 
pelvis will be used to assess tumour burden at baseline and follow-up visits.  CT examination 
with intravenous contrast media administration is the preferred method.  MRI should be used 
where CT is not feasible or it is medically contra-indicated.  For assessment of brain lesions 
MRI is the preferred method. 
3.2 Clinical examination  
In study D081FC00001 clinical examination will not be used for assessment of TL. Clinically 
detected lesions can be selected as target lesions if they are assessed by CT or MRI scans. 
Clinical examination can be used to assess NTL and to identify the presence of new lesions. 
3.3 X-rays 
3.3.1 Chest X-ray 
Chest X-rays will not be used for assessment of TLs as they will be assessed by CT or MRI 
examination.  Chest X-rays can, however, be used to assess NTLs and to identify the presence 
of new lesions. 
3.3.2 Plain X-ray  
In study D081FC00001 plain X-rays may be used as a method of assessment for bone NTLs 
and to identify the presence of new bone lesions.  
3.4 Ultrasound  
Ultrasound examination will not be used for assessment of TLs and NTLs as it is not a 
reproducible method, does not provide an accurate assessment of tumour size and it is 
subjective and operator dependent. Ultrasound examination can, however, be used to identify 
the presence of new lesions.  If new clinical symptoms occur and an ultrasound is performed 
then new lesions should be confirmed by CT or MRI examination. 
3.5 Endoscopy and laparoscopy  
Endoscopy and laparoscopy will not be used for tumour assessments as they are not validated 
in the context of tumour measurements. 
3.6 Tumour markers  
Tumour markers will not be used for tumour response assessments per RECIST 1.1. 
3.7 Cytology and histology  
Histology will not be used as part of the tumour response assessment per RECIST 1.1.  
Cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment is required when the measurable tumour has met criteria for response or 
stable disease.  In such circumstances, the cytology is necessary to differentiate between 
response / stable disease (an effusion may be a side effect of the treatment) and progressive 
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disease (if the neoplastic origin of the fluid is confirmed).  Where cytology findings are not 
available, any effusion that significantly worsens (from trace to large) or the appearance of a 
clinically significant effusion (requiring change in drug therapy) during the study treatment 
will be considered to be progression of NTLs or disease progression due to new lesions. 
3.8 Isotopic bone scan  
Bone lesions identified on an isotopic bone scan at baseline and confirmed by CT, MRI or X-
ray at baseline should be recorded as NTLs and followed by the same method as per baseline 
assessment.   
In the D081FC00001 study isotopic bone scans may be used as a method of assessment to 
identify the presence of new bone lesions at follow-up visits.  New lesions will be recorded 
where a positive hot-spot that was not present on the baseline bone scan assessment is 
identified on a bone scan performed at any time during the study.  The Investigator should 
consider the positive hot-spot to be a significant new site of malignant disease and represent 
true disease progression in order to record the new lesion.  Confirmation by CT, MRI and X-
ray is recommended where bone scan findings are equivocal. 
3.9 FDG-PET scan  
In the D081FC00001 study FDG-PET (fluorodeoxyglucose positron emission tomography) 
scans may be used as a method for identifying new lesions, according with the following 
algorithm: New lesions will be recorded where there is positive FDG uptake (defined as when 
an uptake greater than twice that of the surrounding tissue is observed) not present on baseline 
FDG-PET scan or in a location corresponding to a new lesion on CT/MRI at the same follow-
up visit.  If there is no baseline FDG-PET scan available, and no evidence of new lesions on 
CT/MRI scans then follow-up CT/MRI assessments should be continued, scheduled as per 
protocol or clinical indicated, in order to confirm new lesions. 
4. TUMOUR RESPONSE EVALUATION  
4.1 Schedule of evaluation 
Baseline tumour assessments should encompass all areas of known predilection for metastases 
in the disease under evaluation and should additionally investigate areas that may be involved 
based on signs and symptoms of individual patients and should be performed no more than 28 
days before the start of study treatment.  Follow-up assessments should be performed every 8 
weeks (±1 week) for 40 weeks and then every 12 weeks ± 1 week relative to date of 
randomisation, until objective disease progression as defined by modified RECIST 1.1.  See 
Table 1: Study Schedule from Study Protocol for further information. Any other sites at which 
new disease is suspected should also be adequately imaged at follow-up. 
If an unscheduled assessment was performed and the patient has not progressed, every attempt 
should be made to perform the subsequent assessments at their scheduled visits. This schedule 
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is to be followed in order to minimise any unintentional bias caused by some patients being 
assessed at a different frequency than other patients. 
All patients will continue to be assessed for radiological tumour assessments according to the 
study schedule, until objective radiological disease progression, irrespective of reasons for 
discontinuation of treatment. 
4.2 Target lesions  
4.2.1 Documentation of target lesions 
A maximum of 5 measurable lesions, with a maximum of 2 lesions per organ (including 
lymph nodes), representative of all lesions involved, should be identified as TLs at baseline.  
Target lesions should be selected on the basis of their size (longest diameter for non-nodal 
lesions or short axis for nodal lesions) but in addition should be those that lend themselves to 
reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion 
does not lend itself to reproducible measurement in which circumstance the next largest lesion, 
which can be measured reproducibly, should be selected. 
The site and location of each TL should be documented as well as the longest diameter for 
non-nodal lesions (or short axis for lymph nodes).  All measurements should be recorded in 
millimetres.  At baseline, the sum of the diameters for all TLs will be calculated and reported 
as the baseline sum of diameters.  At follow-up visits the sum of diameters for all TLs will be 
calculated and reported as the follow-up sum of diameters. 
Special cases: 
• For TLs measurable in 2 or 3 dimensions, always report the longest diameter.  For 
pathological lymph nodes measurable in 2 or 3 dimensions, always report the short 
axis.  
• If the CT/MRI slice thickness used is > 5mm, the minimum size of measurable 
disease at baseline should be twice the slice thickness of the baseline scan. 
• If a lesion has completely disappeared, the longest diameter should be recorded as 0 
mm. 
• If a TL splits into two or more parts, then record the sum of the diameters of those 
parts. 
• If two or more TLs merge then the sum of the diameters of the combined lesion 
should be recorded for one of the lesions and 0 mm recorded for the other lesion(s). 
• If a TL is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned.  If an accurate measure can be given, this 
should be recorded, even if it is below 5 mm. 
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• If a TL cannot be measured accurately due to it being too large, provide an estimate 
of the size of the lesion. 
• When a TL has had any intervention eg, radiotherapy, embolisation, surgery etc, 
during the study, the size of the TL should still be provided where possible. 
4.2.2 Evaluation of target lesions 
Table 2 provides the definitions of the criteria used to determine objective tumour visit 
response for TLs. 
Table 2 Overall Visit Response for Target Lesions 
Complete Response (CR) Disappearance of all TLs since baseline. Any pathological lymph 
nodes selected as TLs must have a reduction in short axis to < 10 
mm. 
Partial Response (PR) At least a 30% decrease in the sum of diameters of TLs, taking as 
reference the baseline sum of diameters. 
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD 
Progressive Disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as 
reference the smallest sum on study (this includes the baseline 
sum if that is the smallest on study).  In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5mm. 
Not Evaluable (NE) Only relevant if any of the TLs were not assessed or not evaluable 
or had a lesion intervention at this visit. 
Note: If the sum of diameters meets the progressive disease 
criteria, progressive disease overrides not evaluable (NE) as a TL 
response 
4.3 Non-Target lesions  
4.3.1 Evaluation of non-target lesions 
All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline.  Measurements are not required for these lesions but their status should be followed 
at subsequent visits.  At each visit, an overall assessment of the NTL response should be 
recorded by the investigator.  This section provides the definitions of the criteria used to 
determine and record overall response for NTLs at the investigational site at each visit. 
Table 3 Overall Visit Response for Non-Target Lesions  
Complete Response (CR) Disappearance of all NTLs since baseline.  All lymph nodes must 
be non-pathological in size (< 10 mm short axis). 
Non-CR/Non PD Persistence of one or more NTLs. 
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Progressive Disease (PD) Unequivocal progression of existing NTLs.  Unequivocal 
progression may be due to an important progression in one lesion 
only or in several lesions.  In all cases the progression MUST 
clinically significant for the physician to consider changing or 
stopping therapy 
Not Evaluable (NE) Only relevant when one or some of the NTLs were not assessed 
and in the investigator’s opinion they are not able to provide an 
evaluable overall NTL assessment at this visit. 
Note: For patients without TLs at baseline, this is relevant if any 
of the NTLs were not assessed at this visit and the progression 
criteria have not been met. 
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficiently to merit discontinuation of therapy.  A 
modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status. 
4.4 New Lesions 
Details of any new lesions will also be recorded with the date of assessment.  The presence of 
one or more new lesions is assessed as progression. 
A lesion identified at a follow up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. 
The finding of a new lesion should be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumour. 
If a new lesion is equivocal, for example because of its small size, the treatment and tumour 
assessments should be continued until the new lesion has been confirmed.  If repeat scans 
confirm there is a new lesion, then the progression date should be declared using the date of 
the initial scan. 
4.5 Symptomatic deterioration 
Symptomatic deterioration is not a descriptor of an objective response: it is a reason for 
stopping study therapy. 
Patients with ‘symptomatic deterioration’ requiring discontinuation of treatment without 
objective evidence of disease progression at that time should continue to undergo tumour 
assessments where possible until objective disease progression is observed. 
4.6 Evaluation of Overall Visit Response and Best Overall Response  
The overall visit response will be derived using the algorithm shown in Table 4 
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Table 4 Overall Visit Response 
Target lesions Non-Target lesions New Lesions Overall response 
CR CR No CR 
CR NA No CR 
NA CR No CR 
CR Non-CR/Non PD No PR 
CR NE No PR 
PR Non PD or NE No PR 
SD  Non PD or NE No SD 
NA Non CR/Non PD No SD (Non CR/non PD) 
NE Non-PD or NE No NE 
NA NE No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
NA NA No NED 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease 
IR = incomplete response, NE = not evaluable, NED = no evidence of disease, NA = not applicable (relevant 
when no TLs/NTLs at baseline) 
5. CENTRAL REVIEW  
All CT/MRI scans will be sent to an AstraZeneca appointed Clinical Research Organisation 
(CRO) for blinded independent central review. After the final Progression Free Survival (PFS) 
analysis, central review of scans will no longer be required.  Patients should continue to 
receive study treatment until objective radiological disease progression as per modified 
RECIST 1.1 as assessed by the investigator, and as long as in the investigator’s opinion they 
are benefiting from treatment and they do not meet any other discontinuation criteria.  The 
CRO appointed by AstraZeneca to perform the independent central review for this study will 
provide specification for radiological imaging protocols in standard acquisition guidelines 
documentation. 
6. REFERENCES 
Eisenhauer et al 2009 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.  
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New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).  
European Journal of Cancer.  45 (2009) 228-247. 
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1. ECOG PERFORMANCE STATUS 
1.1 Example of Performance Status (ECOG SCALE) 
 
DESCRIPTION ECOG GRADE 
Fully active, able to carry on all pre-disease performance without 
restriction. 0 
Restricted in physically strenuous activity, but ambulatory and able 
to carry out work of a light or sedentary nature, ie light housework, 
office work. 
1 
Ambulatory and capable of self-care, but unable to carry out any 
work activities. Up and about more than 50% of waking hours. 2 
Capable of only limited self care, confined to bed or chair more than 
50% of waking hours. 3 
Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair. 4 
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GUIDANCE REGARDING POTENTIAL INTERACTIONS WITH 
CONCOMITANT MEDICATIONS 
NB. While this is not an exhaustive list, it covers the known potent inhibitors and inducers, 
which have most often previously been reported to be associated with clinically significant 
drug interactions.  Please contact the Medical Monitor or AstraZeneca physician if further 
clarification is required. 
1. POTENT INHIBITORS OF CYP3A4/5 
In vitro data has shown that the principal enzyme responsible for the formation of the 3 main 
metabolites of olaparib is CYP3A4/5 and consequently, to ensure patient safety, the following 
inhibitors of CYP3A4/5 must not be used during this study. 
Table 1 Competitive inhibitors of CYP3A4/5 









Table 2 Time dependent inhibitors of CYP3A4/5 




2. INDUCERS OF CYP 
In addition, to avoid potential reductions in exposure due to drug interactions, the following 
CYP3 inducers should be avoided: 
Table 3 Inducers of CYP 
Drug Minimum washout period prior to starting olaparib 
Carbamazepine 3 Weeks 
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Table 3 Inducers of CYP 







St John’s Wort (Hypericum perforatum) 
 
Phenobarbitone 5 Weeks 
 
After randomisation if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary for the patient’s safety and welfare, the investigator must contact the 
AstraZeneca Study Physician. A decision to allow the patient to continue in the study will be 
made on a case-by-case basis. 
3. NATURAL / HERBAL PRODUCTS 
The use of any natural/herbal products or other “folk remedies” should be discouraged but use 
of these products, as well as use of all vitamins, nutritional supplements and all other 
concomitant medications must be recorded in the appropriate eCRF. 
4. INTERACTIONS WITH P450 
Olaparib is an investigational drug for which no data on in vivo interactions is currently 
available.  Based on in vitro data and clinical exposure data, olaparib is considered unlikely to 
cause clinically significant drug interactions through inhibition or induction of cytochrome 
P450 enzyme activity. 
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Appendix I 
Patient Reported Outcomes EORTC QLQ-C30, QLQ-PAN26, EQ-5D-5L 
 
ENGLISH 
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
Please fill in your initials: bbbb
Your birthdate (Day, Month, Year): cececdde
Today's date (Day, Month, Year):  31 cececdde
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
5. Do you need help with eating, dressing, washing 
 yourself or using the toilet? 1 2 3 4 
During the past week: Not at A Quite Very 
  All Little a Bit Much 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
 Please go on to the next page
ENGLISH 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
29. How would you rate your overall health during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 
30. How would you rate your overall quality of life during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 


UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
2
Under each heading, please tick the ONE box that best describes your health TODAY
MOBILITY
I have no problems in walking about 
I have slight problems in walking about 
I have moderate problems in walking about 
I have severe problems in walking about 
I am unable to walk about 
SELF-CARE
I have no problems washing or dressing myself 
I have slight problems washing or dressing myself 
I have moderate problems washing or dressing myself 
I have severe problems washing or dressing myself 
I am unable to wash or dress myself 
USUAL ACTIVITIES (e.g. work, study, housework, 
family or leisure activities)
I have no problems doing my usual activities 
I have slight problems doing my usual activities 
I have moderate problems doing my usual activities 
I have severe problems doing my usual activities 
I am unable to do my usual activities 
PAIN / DISCOMFORT
I have no pain or discomfort 
I have slight pain or discomfort 
I have moderate pain or discomfort 
I have severe pain or discomfort 
I have extreme pain or discomfort 
ANXIETY / DEPRESSION
I am not anxious or depressed 
I am slightly anxious or depressed 
I am moderately anxious or depressed 
I am severely anxious or depressed 
I am extremely anxious or depressed 
UK (English) v.2 © 2009 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
3
 We would like to know how good or bad your health is 
TODAY.
 This scale is numbered from 0 to 100.
 100 means the best health you can imagine.
0 means the worst health you can imagine.
 Mark an X on the scale to indicate how your health is TODAY.
 Now, please write the number you marked on the scale in the 
box below. 
                    






















The best health     
you can imagine
The worst health   
you can imagine
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1. INTRODUCTION 
This document defines the primary responsibilities of the Independent Data Monitoring 
Committee (IDMC) for this olaparib phase III study, the purpose and timings of the meetings, 
and the relationship of the IDMC with the study Steering Committee (SC).  This document 
also defines the procedures for ensuring confidentiality, proper analysis, communication of 
interim data and a summary of the content of the Open and Closed Reports that will be 
provided to the IDMC. 
1.1 Description of Study 
This is a phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess 
the efficacy of olaparib maintenance monotherapy in metastatic pancreatic cancer patients 
with gBRCA mutations (documented mutation in gBRCA1 or gBRCA2) that is predicted to 
be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of 
function) and whose tumours have not progressed on at least 16 weeks of first line platinum 
based chemotherapy. 
 The study will be conducted in USA, UK, Canada, Korea, Israel, Netherlands, Belgium, 
Australia, Spain, France and Germany. 
1.2 Study Organisation 
In the execution of the study, AstraZeneca (as the sponsor) will take responsibility for 
logistics, including site monitoring, provision of study medication, data management, 
statistical analysis and financial support. 
The study execution is outsourced to PAREXEL under a Project Agreement between 
AstraZeneca and PAREXEL. 
Changes to the study protocol have to be agreed upon by AstraZeneca in writing before being 
submitted, as per local requirements, and implemented.  All contacts with regulatory 
authorities relating to the study should be channelled through AstraZeneca, unless specifically 
agreed and documented in writing between involved parties. 
1.3 Study Timings 
It is anticipated that the first patient to be recruited will be in Q4 2014, and the last patient to 
be recruited will be in Q4 2015.  A single interim efficacy analysis for superiority and futility 
will be performed when approximately 45 progression free survival (PFS) events have 
occurred.  The interim analysis is expected to occur approximately 13-14 months after the first 
patient is recruited and is therefore anticipated to be in Q1 2016.  AstraZeneca will inform the 
IDMC membership, in writing, of any changes in time schedule required for the services.  
1.4 AstraZeneca Responsibilities to the IDMC: 
AstraZeneca will have the following responsibilities; 
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• Overall responsibility for the operational work. 
• Overall responsibility for data collection and data management. 
• To provide reports on the progress of the olaparib study. 
• To organise the IDMC meetings (face-to-face, telephone or video conferences). 
• Making resources available to the IDMC as is required to carry out its designated 
functions. 
• Making resources available for creating and maintaining an independent Statistical 
Data Analysis Centre (SDAC) to receive data from the Data Management Centre at 
AstraZeneca.  The SDAC will then prepare reports for the IDMC. 
• Responsibility for generating randomisation schemes and providing these to the 
SDAC as required. This will be done by AstraZeneca personnel who are completely 
independent of the D081FC00001 study team, ensuring that the AstraZeneca study 
team remain blinded until the primary analysis of the trial. 
• For communicating the recommendations of the IDMC to the Regulatory 
Authorities as required. 
1.5 Reporting and Publications 
1.5.1 Reporting policy 
In accordance with ICH-GCP, AstraZeneca is obliged to analyse and report all study data as 
described in the Clinical Study Protocol.  On the basis of the data, AstraZeneca personnel, in 
co-operation with the SC, will write a Clinical Study Report intended for submission to 
Regulatory Authorities. 
1.5.2 Publication policy  
Principles 
AstraZeneca is committed to full publication of its clinical research and to ensure that the data 
are reported in a responsible and coherent manner.  AstraZeneca will manage the publication 
of the study results in partnership with the authors; the principal author will take a leading role 
in this process.  AstraZeneca will propose suitable journals and/or meetings and timelines for 
publication production for agreement with the authors.  
The results of the study will be submitted for publication in major scientific journals, once the 
final analyses have been performed and the manuscript authorised by AstraZeneca.  
AstraZeneca must approve the selection of journals prior to submission of the manuscript. 
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2. IDMC ROLE, REMIT AND COMPOSITION 
2.1 Role and Remit 
The IDMC is responsible for safeguarding the interests of study participants via review of 
accumulating safety and efficacy data.  The IDMC will provide the AstraZeneca Medical 
Science Director (MSD) or delegate with recommendations for action with respect to study 
conduct and the management of patients treated under the auspices of the study protocols. 
Additionally, the IDMC will be responsible for reviewing the results of the interim analyses, 
the results of which will not be revealed to any AstraZeneca personnel.  The IDMC will make 
a recommendation whether the study should be continued, amended or terminated.  Once the 
IDMC has reached its recommendation, notification will be provided to the SC.  This report 
will state only the recommendation of the IDMC on whether the study should be continued, 
amended or terminated (if the study may continue subject to a protocol amendment, the details 
of the proposed amendment may also be included). 
2.2 Composition 
The IDMC consists of 3 members.  Members have been restricted to individuals free of any 
personal or financial interest in the outcome of trial D081FC00001. 





And 1 independent biostatistician 
•  
These members are all voting members. 
The IDMC biostatistician will be supported by an independent statistician from the SDAC, 
who will not be a voting member.  Please see Section 3.1 for further details. 
IDMC membership is to be for the remaining duration of the study.  If any member/s leave the 
IDMC during the course of the study, the sponsor, in consultation with the IDMC chair, will 
appoint their replacements. 
2.3 Tasks and Responsibilities 
Each voting member of the IDMC will be responsible for the following (in addition to other 
responsibilities contained herein): 
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• To read and understand the clinical study protocols, all administrative 
changes/amendments and other study requirements communicated and/or provided 
by AstraZeneca. 
• To adhere to the guidelines contained herein, applicable for the full execution of the 
services. 
2.4 Conflicts of Interest 
Membership is restricted to individuals free of interest: the IDMC members are, therefore, 
neither study investigators, nor individuals who might have regulatory responsibilities for the 
study products.  
Any potential candidate for the IDMC needs to declare any potential conflict of interest that, 
according to regulatory requirements, may influence the decision-making process in olaparib 
study D081FC00001.  The Certification / Disclosure Form provided by AstraZeneca should be 
completed, signed and returned to AstraZeneca.  Conflicts of interest (COI) will be an agenda 
item for the start of each meeting and any relevant change in circumstances of any of the 
voting members should be raised and discussed.  The IDMC members will take the decision 
whether any COI precludes a member from continuing to form part of the IDMC. 
2.5 Meeting Attendance 
Safety review meetings: It is anticipated that there will be two safety review meetings and that 
these meetings will be conducted as teleconferences, when 50 patients are randomised and 
have received 3 months of treatment [expected Q3 2015] and at the time of the interim 
analysis. 
Interim efficacy analysis review meeting: This study incorporates a single interim analysis of 
efficacy to be conducted when 50% of the final number of progression events have been 
reached (approximately 45 PFS events based on blinded independent central review [BICR]), 
expected Q3 2015.  It is anticipated that the results of the interim analysis will be reviewed at 
a face-to-face meeting of the IDMC. 
All 3 voting members must be present in order for the committee to be considered quorate.   
3. STATISTICAL CONSIDERATIONS 
3.1 The Role of the Independent Biostatistician 
The independent SDAC biostatistician will be responsible for producing unblinded summaries 
of safety data for IDMC review.  In addition, for the interim efficacy analysis, the independent 
SDAC biostatistician will also be responsible for producing unblinded efficacy analysis 
outputs for IDMC review and for providing statistical expertise in the interpretation of these 
outputs.  The independent SDAC biostatistician will therefore be provided with the trial 
database, randomisation scheme and Statistical Analysis Plan (SAP).  The SDAC will author 
the programs required for the safety review meetings but will be provided with the programs 
required for the interim efficacy analysis. 
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If additional analyses are deemed to be required beyond the scope of the SAP, the nature of 
these analyses will be discussed with the MSD/SC. 
Unblinded interim data will be provided exclusively to the IDMC members.  The AstraZeneca 
independent randomiser will provide the random scheme to the SDAC biostatistician.  Apart 
from the IDMC biostatistician and the SDAC biostatistician(s) only the independent 
randomiser will have access to the randomisation schedule until the time of the final analysis. 
3.2 The Statistical Data Analysis Centre 
The SDAC is responsible for the overall data analysis preparation for review by the IDMC. 
The SDAC prepares reports for review by the IDMC based on data generated by the Data 
Management Centre at AstraZeneca. 
During the study, no unblinded analyses will be done by the SDAC on behalf of the SC or any 
investigator unless agreed to by the IDMC and AstraZeneca. 
AstraZeneca will (in close cooperation with the SDAC and SC) decide on the statistical 
methods and guidelines for interim analyses, which will be finalised and documented before 
database lock (DBL) for the interim analysis as specified in the SAP.  
4. RELATIONSHIP TO STEERING COMMITTEE 
The study SC comprises of study investigators and members of the AstraZeneca project team, 
who jointly have responsibility for the design, conduct and final analysis of the clinical study.  
The SC and the IDMC are responsible for safeguarding the interests of the participating 
patients and for the conduct of the study.  AstraZeneca, however, retains final accountability 
and may go beyond the recommendations made by the IDMC, to ensure patient safety. 
In order to execute their roles as described above, the SC will consider the recommendations 
made by the IDMC and act upon these recommendations as necessary, and help identify and 
address operational issues relating to study progress and conduct as they arise, referring issues 
related to patient safety to the IDMC as necessary. 
4.1 Communication between IDMC and SC 
The AstraZeneca MSD, Global Safety Physician (GSP) and Global Statistician, or their 
delegates, will act as liaison between the IDMC and the SC (see Appendix B Figure 1).  The 
AstraZeneca MSD or Global Statistician will communicate the recommendations of the IDMC 
to the SC.  However, the option of direct communication between the chair of the IDMC and 
the chair of the respective SC may be used if required.  Ultimately it is the prerogative of 
AstraZeneca and the SC to act as appropriate upon IDMC recommendations concerning safety 
or study conduct.  The IDMC will be informed by AstraZeneca in a timely manner of protocol 
amendments or other events, which impact on the conduct of the study (see Appendix B for a 
diagrammatic representation of the relationship between the IDMC and the SC). 
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5. PURPOSE OF THE IDMC MEETINGS 
5.1 Interim Efficacy Analysis 
The final analysis of the study will occur when approximately 89 PFS events have occurred.  
A single interim PFS analysis for superiority and futility will be performed when 50% of the 
final number of PFS events have been reached (approximately 45 PFS events).   
The timing and scope of the interim analysis may be modified and/or additional safety 
analyses added based on recommendation by the IDMC, SC, or AstraZeneca. 
The questions to be addressed by the IDMC following the interim efficacy and safety analyses 
are: 
1. Do the results of the interim analysis of efficacy and safety if appropriate raise any 
concerns with respect to the ongoing conduct of this study? 
2. Considering the response to question 1, should the study 
i) continue as planned 
ii) continue as planned with modification 
iii) early submission recommended (not applicable for safety IDMC review 
meeting) 
iv) terminate whole study for futility (not applicable for safety IDMC review 
meeting) 
v) terminate whole study for safety reasons 
5.1.1 Superiority interim analysis 
A multiple testing strategy will be employed for the analysis of PFS.  The test mass alpha for 
PFS (one-sided 2.5%) will be split between the final and the interim analysis using a bespoke 
spending function where a fixed significance level of 0.5% one-sided alpha will be assigned at 
the interim analysis and the remaining significance level assigned to the final analysis, taking 
account of correlation (Stone 2010).  Statistical significance will be declared at the interim 
analysis if the 1-sided p<0.005.   
The IDMC may recommend early termination due to overwhelming efficacy if the stopping 
boundary is crossed for PFS; i.e. 1-sided p-value is less than the nominal significance level of 
0.005.  As an example, if exactly 45 PFS events have occurred at the time of the interim 
analysis, a significant result would equate to a hazard ratio (HR) < 0.46. 
However, magnitude of PFS benefit, observed overall survival (OS) and safety data will form 
part of the superiority decision and the IDMC may make the decision to continue the study as 
planned for follow up on safety and secondary efficacy endpoints even if the statistical hurdle 
for superiority has been crossed. 
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If an early submission is recommended due to superiority, then analyses of all other endpoints 
would be performed and the results of these analyses will form the basis for submissions for 
regulatory approval. A further interim and final OS analysis is planned and irrespective of the 
PFS interim superiority outcome, patients would continue to be followed for survival until 106 
patients have died where an updated analysis would be performed based on more mature 
survival data. 
5.1.2 Futility interim analysis 
At the same time as the superiority analysis, consideration will also be given to stop the study 
early for futility, guided by calculation of conditional power.  The futility assessment will be 
based on the probability of eventually showing statistical significance for the primary 
endpoint when the final number of PFS events (n=89) is reached (Lachin 2005).  The 
determination of this probability will be conditional on the observed data at the time of the 
interim analysis for superiority and on the assumed hazard ratio for the alternative hypothesis 
(PFS HR=0.54).  If the probability is less than 20%, the IDMC will consider the option of 
declaring futility.  
The exact figure used for the futility boundary will be calculated by AZ and sent to the IDMC 
at the time of the interim analysis, based on the number of events which have occurred at that 
time. As an example, if exactly 50% of the final number of events have occurred at the time of 
the interim analysis (45 events), then the HR that corresponds to 20% conditional power for 
the interim analysis will be 1.00.  
If and only if the PFS results lead to a decision to stop for futility, then the patients will be 
unblinded and given the option to discontinue treatment. 
5.2 Review of Safety Data 
The reviews will take place when 50 patients are randomised and have received 3 months of 
treatment [expected Q3 2015] and at the time of the interim analysis [expected Q1 2016].  
They will involve review of baseline information and safety data including, all adverse events 
(AEs), serious adverse events (SAEs), AEs leading to discontinuation, AEs leading to death, 
exposure and laboratory data.  The date of the data cut-off (DCO) for the review of safety data 
should be no more than six weeks prior to the date of the corresponding meeting of the IDMC.  
Data will be cleaned in an ongoing manner as part of the overall data cleaning and validation 
process for each study.  However it should be recognised that the data supplied for use by the 
IDMC may not be fully cleaned or validated.  Any fatal SAEs or SAEs of special interest that 
have been obtained between the DCO and up to one week before the safety review meeting 
will be collated and presented to the IDMC. 
The questions to be addressed by the IDMC following the safety data review are: 
1. Do the results of the safety data raise any concerns with respect to the ongoing 
conduct of this study? 
2. Considering the response to question 1, should the study 
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i) continue as planned 
ii) continue as planned with modification 
iii) terminate whole study for safety reasons 
6. CONDUCT OF IDMC DATA REVIEW MEETINGS 
IDMC meetings will be conducted in open and closed sessions. 
6.1 Open Sessions 
In order to allow the IDMC to have adequate access to further relevant information SC 
members, and/or their delegates, may (with the majority consent of the voting members) 
attend open sessions, during which fully blinded data may be discussed.  Open session 
discussion of administrative/operational issues; e.g. updated information on enrolment and 
eligibility, will precede the closed session.  
Open session activities may include, but are not limited to the following: 
• Representatives of the AstraZeneca team present a summary of the program status, 
study enrolment and key safety findings 
• Communication of recommendations 
• Discussion of administrative/operational issues including requirements for 
additional data for future meetings 
6.2 Closed Sessions 
Attendance will be limited to the IDMC members, allowing discussion of confidential data 
from the study, including the safety and relative efficacy of interventions.  In order to ensure 
that the IDMC will be fully informed in its primary objective of safeguarding the interest of 
participating patients, the IDMC will be unblinded in its assessment of safety and efficacy 
data.  
Following such meetings the IDMC will formulate a list of recommendations regarding 
further conduct of the study. 
6.3 Meeting Minutes 
Two sets will be prepared: the Open and Closed minutes.  An AstraZeneca member of the SC 
will be responsible for preparing the Open Minutes, and the IDMC chair will be responsible 
for preparing the Closed Minutes. 
The Open Minutes will describe the proceedings in the open session of the IDMC meeting, 
and will summarise all recommendations by the IDMC.  Since these minutes will be circulated 
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immediately to the SC, it is important that they do not unblind the efficacy and safety data if 
the IDMC is not recommending early termination. 
The Closed Minutes will describe the proceedings from all sessions of the IDMC meeting, 
including the list of recommendations by the Committee.  As it is likely that these minutes 
will contain unblinded information, it is important that they are not made available to anyone 
outside the IDMC.  Copies will therefore be retained by the IDMC chair and by the IDMC 
biostatistician preparing the interim reports, for distribution to the sponsor at the time of study 
closure. The recommendation from each closed session will be shared with AstraZeneca 
verbally shortly  after the closed session has finished.  Formal written recommendation and 
minutes will be provided to the SC and AstraZeneca within seven calendar days. 
The AstraZeneca MSD, GSP and Global Statistician, or their delegates, will facilitate IDMC 
meetings and act as liaison between the IDMC and SC.  
If a joint meeting of the IDMC and SC is required, this will be conducted as per an open 
session data review. 
6.4 Open and Closed Reports 
Open reports/presentations, available to all who attend the IDMC meeting, will include data 
on general study progress such as recruitment updates and any issues with the study.  A 
representative from the AstraZeneca study team will prepare these open reports. 
Closed reports, available only to those attending the Closed Sessions of the IDMC meeting, 
will include unblinded data.  The independent biostatistician will prepare these Closed 
Reports.  The identity of study treatments will be fully visible, with no ‘masking’ of treatment 
identities, such as Treatment A, Treatment B. 
The Open and Closed Reports should provide information that is accurate with follow-up that 
is complete to a date no more than six weeks prior to the IDMC meeting.  The Reports should 
be provided to IDMC members approximately seven calendar days prior to the date of the 
meeting. 
6.5 Open Reports: An Outline 
The following information will be provided at each IDMC meeting in the form of an Open 
Report.  The summary data will be based on the overall population and will not be separated 
by treatment group.  
• General study progress including status of the development program 
• Actions taken as minuted in previous meetings where applicable 
• Patients screened and randomised according to country 
• Current patient accrual 
• Protocol amendments 
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• Issues and any major protocol deviations 
6.6 Closed Statistical Reports: An Outline  
6.6.1 Data to be provided to the IDMC for safety review and interim analysis 
The following outputs are proposed to be provided for the safety review and the interim 
analysis.  The IDMC will decide if they agree on the proposal or they may revise the proposal 
to add/delete the data to be provided prior to the data review. Only datasets which support 
these outputs will be provided to the IDMC. 
Demography 
• Summary of analysis sets  
• Summary of demographic characteristics (age, sex, race) 
• Summary of patient recruitment by country and centre 
• Summary of extent of disease 
• Summary of previous disease-related treatment modalities (including previous anti-
cancer chemotherapy, surgical history) 
• Summary of disease characteristics (including, but not limited to, history of 
pancreatectomy, tumour measurability, ECOG performance status, histology type, 
number and site of metastatic sites at baseline, biomarker status) 
• Summary of primary disease location on diagnosis (head, body, tail) 
• Summary of patient disposition 
Exposure 
• Summary of duration of exposure – olaparib/placebo 
• Summary of number of dose interruptions and reductions – olaparib/placebo 
Safety data 
Presented by treatment received: 
• Summary of AEs in any category - patient level 
• Summary of AEs by system organ class, preferred term and maximum reported 
CTC grade 
• Summary of AEs by system organ class, preferred term and maximum reported 
CTC grade, causally related to olaparib/placebo  
• Summary of AEs >= CTC grade 3  
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• Summary of AEs >= CTC grade 3 by system organ class, preferred term, causally 
related to olaparib/placebo  
• Summary of AEs leading to discontinuation, by system organ class and preferred 
term 
• Summary of AEs leading to discontinuation, by system organ class and preferred 
term, causally related to olaparib/placebo  
• Summary of AEs leading to death 
• Summary of AEs leading to death, causally related to olaparib/placebo  
• Summary of SAEs 
• Summary of SAEs, causally related to olaparib/placebo  
• Summary of clinically important changes in laboratory parameters identified by 
IDMC prior to the data review 
• Listing of SAEs (detailed case reports to be made available upon request) 
• Listing of SAEs leading to death (detailed case reports to be made available upon 
request) 
• Death rates (from the survival status eCRF) 
• Reasons for subject discontinuation of study therapy (including details of non-
compliance and loss to follow-up) 
• Patients receiving anti-cancer therapy following discontinuation of study therapy 
 
6.6.2 Additional data to be provided to the IDMC for interim analysis 
In addition to the outputs listed in Section 6.6.1, the following efficacy outputs will be 
provided to the IDMC for the interim analysis.  Results from the analysis of the secondary 
endpoint, OS, will be provided.  However, the option of early termination of the study due to 
overwhelming efficacy may only be considered if the stopping boundary for superiority of the 
primary endpoint, PFS, has been crossed. 
Efficacy 
• Summary of progression status 
• Summary of primary analysis of PFS  
• Summary of median overall PFS 
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• Summary of patients censored for PFS at more than 14 weeks before the DCO 
• Kaplan Meier plot of PFS 
• Summary of secondary analysis of OS 
• Summary of median OS 
• Kaplan Meier plot of OS 
6.6.3 Scheduled final analysis of the data 
After DBL and clean file has been declared, AstraZeneca will be responsible for providing the 
results of the final analysis.  The results of this analysis will be shared with the IDMC in a 
timely manner. 
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APPENDICES 
Appendix A: IDMC Voting Members Signature Pages 
IDMC Member A 
 
       
. 
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IDMC Member B 
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IDMC Member C 
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Appendix B:  IDMC & Steering Committee Members and Roles 
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Appendix C:  Communication from IDMC to Olaparib Project Team 
following Interim Analysis 
The following form will be completed by the IDMC to provide the olaparib team with a 
summary of their recommendations following the interim analysis meeting. 
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Recommendation of IDMC to Olaparib Project Team 
Meeting:  Study D081FC00001 Interim analysis, IDMC meeting 
Meeting date:  …………………….. 
   
Following review of the interim analysis data, the IDMC has the following recommendation 
for the olaparib project team regarding Study D081FC00001: 
 
Study should continue unchanged   
Study should continue as planned with modification   
Early submission recommended 
Terminate whole study for futility 
Terminate whole study for safety reasons 
 







Completed by: ………………………………. 
    
Date:   …………………………. 
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Appendix D:  Communication from IDMC to Olaparib Project Team 
following Safety Analysis 
The following form will be completed by the IDMC to provide the olaparib team with a 
summary of their recommendations following each safety analysis meeting. 
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Recommendation of IDMC to Olaparib Project Team 
Meeting:  Study D081FC00001 Safety analysis, IDMC meeting 
Meeting date:  …………………….. 
   
Following review of the safety data, the IDMC has the following recommendation for the 
olaparib project team regarding Study D081FC00001: 
Study should continue unchanged       
Study should continue as planned with modification 
Terminate whole study for safety reasons 
 







Completed by: ………………………………. 
    
Date:   …………………………. 
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Appendix E:   Documentation of Unblinded Personnel 
The following form will be completed to document exactly who had access to unblinded data 
for the interim analysis.   
Documentation of Unblinded Personnel 
Study D081FC00001 Interim analysis 
Date study was unblinded:  …………………….. 
The following people had access to unblinded data at the Study D081FC00001 interim 
analysis: 





   
    
Additional unblinded 
personnel 






IDDI     
 
 
Signed: ……………………………..…   ………………………. 
      Date: 
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 Amendment Number 1 
 Drug Substance Olaparib  
 Study Code D081FC00001 
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A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre 
Study of Maintenance Olaparib Monotherapy in Patients with gBRCA 
Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed 
on First Line Platinum Based Chemotherapy 
 
 
This submission /document contains trade secrets and confidential commercial information, disclosure of which 
is prohibited without providing advance notice to AstraZeneca and opportunity to object. 
Sponsor: 
AstraZeneca AB, 151 85 Södertälje, Sweden 
Centres affected by the Amendment: 
Affects all centres in the study. 
The protocol for the study is to be amended as follows:  
 
Section of protocol affected: 
1.4.1.1 Myelodysplastic syndrome/acute myeloid leukaemia 
Previous text: 
To ensure robust safety monitoring, patients in this clinical trial will have weekly safety 
assessments during the first cycle and then safety assessments every 3 weeks during the rest of 
the treatment period. Clinical guideline of managing bone marrow toxicity and use of G-CSF 
is implemented as the safety management plan. 
Revised text: 
To ensure robust safety monitoring, patients in this clinical trial will have weekly safety 
assessments during the first cycle and then safety assessments every 4 weeks during the rest of 
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the treatment period. Clinical guideline of managing bone marrow toxicity and use of G-CSF 
is implemented as the safety management plan. 
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Section of protocol affected: 
Table 1 Study Schedule – Screening, On Study Treatment, Discontinuation and Follow-up 
Previous text:  




















Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Haematology/clinical 
chemistry  
 X X  l    X X X  X  
l Haematology and clinical chemistry should be performed at screening and day 1 of every cycle.  Safety blood samples do not need to be repeated on Day 
1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study treatment, unless the 
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Revised text: 




















Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Haematology/clinical 
chemistry  
 X X  l X X X X X X  X  
l Haematology and clinical chemistry should be performed at screening, cycle 1 day 1, 8, 15,  22 and day 1 of every cycle.  Safety blood samples do not 
need to be repeated on Day 1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study 
treatment, unless the investigator believes that it is likely to have changed significantly 
 
Section of protocol affected: 
4.2  Treatment period 
Previous text: 
Haematology and clinical chemistry: Day 1 of every cycle. Safety blood samples do not need to be repeated on Day 1 of study 
treatment if there have been separate assessments within 7 days before starting study treatment and which must have been 3 weeks 
after last dose of chemotherapy based therapy, unless the investigator believes that it is likely to have changed significantly. 
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Revised text: 
Haematology and clinical chemistry: cycle 1 day 1, 8, 15, 22 and day 1 of every cycle. Safety 
blood samples do not need to be repeated on Day 1 of study treatment if there have been 
separate assessments within 7 days before starting study treatment and which must have been 
3 weeks after last dose of chemotherapy based therapy, unless the investigator believes that it 
is likely to have changed significantly 
 
 
Reason for Amendment:  
To ensure protocol consistency and correct typo. 
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Clinical Study Protocol Global Amendment
Amendment Number 2
Drug Substance Olaparib 
Study Code D081FC00001
Date 28 February 2015
Protocol Dated 31 March 2014
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre 
Study of Maintenance Olaparib Monotherapy in Patients with gBRCA
Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed 
on First Line Platinum Based Chemotherapy
This submission /document contains trade secrets and confidential commercial information, disclosure of which 
is prohibited without providing advance notice to AstraZeneca and opportunity to object.
Sponsor:
AstraZeneca AB, 151 85 Södertälje, Sweden
Centres affected by the Amendment:
Affects all centres in the study.
The protocol for the study is to be amended as follows: 
Section of protocol affected:
Synopsis, Statistical methods
Previous text:
Approximately 145 patients will be randomised (3:2 ratio of Olaparib:placebo) and the 
primary PFS analysis will occur once approximately 89 PFS events (confirmed via a central 
review) have occurred.   A single interim PFS analysis for superiority and futility will be 
performed when 50% of the final number of progressions has been reached (approximately 45 
PFS events).  The interim analysis will be performed by an Independent Data Management 
Committee (IDMC) and full details will be provided in the IDMC charter.  
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The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.26% alpha (1-sided) (accounting for a single interim PFS 
analysis), with 3:2 randomisation (Olaparib:placebo). Assuming PFS is exponentially 
distributed, a PFS HR of 0.54 equates to a 3.4 month improvement in median PFS over an 
assumed 4 month median PFS for placebo.  At the interim analyses, 0.5% of alpha (1-sided) 
will be spent, and controlling the type I error across the two time points, 89 PFS events will be 
required at the final analyses.  
Statistical significance will be declared at the interim analysis if the 1-sided p<0.005.  
Assuming 45 PFS events at the interim, a HR ≤ 0.46 would equate to a 1-sided p<0.005.  If 
the null hypothesis for PFS is not rejected at the interim analyses time point then PFS will be 
tested again when approximately 89 PFS events have occurred.  The final significance level 
will be determined accounting for the actual correlation between the interim and final PFS 
analyses. To ensure that the type I error will be controlled at 2.5% 1-sided level, if the interim 
occurs at exactly 50% of events and the number of PFS events at the final analysis is as 
expected then the 1-sided significance level to be applied for the final analysis would be 
2.26% (Stone 2010).  Assuming 89 PFS events, a HR ≤ 0.65 would equate to a 1-sided p-
value <0.0226.
Assuming that the study accrual period will be approximately 15 months, 89 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 45 PFS events will occur approximately 13 to 14 
months after the first patient enters the trial.
Revised text:
Approximately 145 patients will be randomised (3:2 ratio of Olaparib:placebo) and the 
primary PFS analysis will occur once approximately 87 PFS events (confirmed via a central 
review) have occurred.   A single interim PFS analysis for futility will be performed when 
50% of the final number of progression events needed for the primary PFS analysis has been 
reached (approximately 44 PFS events).  The interim analysis will be performed by an 
Independent Data Management Committee (IDMC) and full details will be provided in the 
IDMC charter.  
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.5% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median PFS for placebo.  
Assuming that the study accrual period will be approximately 15 months, 87 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 44 PFS events will occur approximately 13 to 14 
months after the first patient enters the trial.
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Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority 
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
Section of protocol affected:
Synopsis, Statistical methods
Previous text:
OS analyses will be performed at the same time as the interim (if PFS null hypothesis 
rejected) and final analysis of PFS and will use the same methodology and model as PFS.  A 
final analysis of OS will be performed when approximately 106 death events have occurred 
and a multiplicity adjustment will be made to account for the different analyses. At the time of 
the PFS analysis, a predicted treatment effect for OS at the final analysis will be derived using 
a weighted sum of the observed OS data and the predicted OS value using PFS data.
…
PFS2 analyses will be performed at the same time as the interim and final analyses of PFS, 
and at the time of the final analysis of OS.  PFS2 will be analysed using the same 
methodology and model as PFS. 
Revised text:
OS analyses will be performed at the same time as the primary analysis of PFS and will use 
the same methodology and model as PFS.  A final analysis of OS will be performed when 
approximately 106 death events have occurred and a multiplicity adjustment will be made to 
account for the different analyses. At the time of the PFS analysis, a predicted treatment effect 
for OS at the final analysis will be derived using a weighted sum of the observed OS data and 
the predicted OS value using PFS data.
…
PFS2 analyses will be performed at the same time as the primary analysis of PFS, and at the 
time of the final analysis of OS.  PFS2 will be analysed using the same methodology and 
model as PFS. 
Clinical Study Protocol Global Amendment 2
Drug Substance Olaparib
Study Code D081FC00001
Date 28 February 2015
4(39)
Reason for Amendment:
Removal of the superiority analysis at the time of the interim analysis as per FDA 
recommendation, therefore OS and PFS2 will not be analysed at this time.
Section of protocol affected:
Synopsis, Patient Reported Outcomes
Previous text:
The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales.  
Time to global QoL and pancreatic pain scale deterioration will be analysed using the same 
methodology and model as described for the primary analysis of PFS. Global QoL and PAN-
26 pain scale improvement rate will be analysed using a logistic regression model.
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group.
As supportive analyses, change from baseline in global QoL and pancreatic pain scale scores 
will be analysed using a mixed model for repeated measures (MMRM) analysis of all of the 
post-baseline scores for each visit.
Revised text:
The impact of olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC QLQ-C30 global quality of life (QoL) and QLQ-PAN26 pancreatic 
pain scales. Adjusted mean change from baseline in global QoL score will be analysed 
using a mixed model for repeated measures (MMRM) analysis of all of the post-baseline 
scores for each visit and will be presented by treatment group.  As a supportive analysis, 
global QoL improvement rate will be analysed using a logistic regression model.
An exploratory analysis will examine adjusted mean change from baseline on EORTC 
QLQ-C30 functioning domains (physical, role, cognitive, emotional, social) and on 
EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (including pancreatic pain, 
fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite), jaundice).
EORTC QLQ-C30 and QLQ-PAN26 compliance (overall compliance and by visit 
compliance) will be summarised for each treatment group.
Reason for Amendment:
To change the type of analysis used for EORTC QLQ-C30 global QoL score to MMRM 
analysis of adjusted mean change from baseline, which is independent of minimal important 
differences (MID) values that are not well-defined, and is suitable for analysing continuous 
responses measured repeatedly over time.  The MMRM statistical analysis will be based on 
Clinical Study Protocol Global Amendment 2
Drug Substance Olaparib
Study Code D081FC00001
Date 28 February 2015
5(39)
actual scores, rather than pre-selected MIDs, and will analyse data from all time points.  A 
supportive analysis of global HRQoL improvement rate will be conducted using the ‘generic’ 
cut off of 10% change from baseline as suggested in Osoba et al 2005.  An exploratory 
analysis will be performed to examine adjusted mean change from baseline on EORTC QLQ-
C30 and QLQ-PAN26 functioning domains and symptom scales/items.
Section of protocol affected:
Section 1.4 Benefit risk and ethical assessment
Previous text:
As of 2 October 2013, an estimated 2103 patients with ovarian, breast, gastric, pancreas, and a 
variety of other solid tumours are estimated to have received treatment with Olaparib across 
the dose range 10 mg qd to 600 mg bid in AstraZeneca-sponsored, investigator-sponsored, and 
collaborative group studies. Olaparib has been given as either monotherapy (18 studies, an 
estimated 1214 patients) or in combination with other chemotherapy/anticancer agents 
(25 studies, an estimated 889 patients). Many of these combinations studies are ongoing. The 
majority of patients to date have received the capsule formulation of Olaparib (an estimated 
1635 patients). Approximately 468 patients have received the tablet formulation to 
date. Approximately 304 patients have received comparator or placebo across the Olaparib 
development programme.
An analysis of monotherapy data across 12 AstraZeneca sponsored monotherapy studies in 
975 patients who have been given Olaparib capsule estimated that 16.1% (157/975) of patients 
had been exposed to Olaparib capsule for ≥12 months at the time of database closure for the 
12 studies.  Furthermore, 41/ 975 patients received treatment for >24 months (longest duration 
was 44 months).  From the available data to date, there is no evidence of any unexpected 
toxicity following long-term Olaparib (capsule) monotherapy exposure. 
Olaparib as monotherapy at doses up to 400 mg bid capsule is generally well tolerated, with 
most common AEs including nausea, fatigue, vomiting, anaemia mainly mild-to-moderate 
(CTCAE Grade ≤ 2) in severity.  In addition, in a small number of patients MDS/AML or 
pneumonitis have been observed and identified as important risks. 
Revised text:
As of 2 October 2013, an estimated 2103 patients with ovarian, breast, gastric, pancreas, and a 
variety of other solid tumours are estimated to have received treatment with Olaparib across 
the dose range 10 mg qd to 600 mg bid in AstraZeneca-sponsored, investigator-sponsored, and 
collaborative group studies. Olaparib has been given as either monotherapy (18 studies, an 
estimated 1214 patients) or in combination with other chemotherapy/anticancer agents 
(25 studies, an estimated 889 patients). Many of these combinations studies are ongoing. The 
majority of patients to date have received the capsule formulation of Olaparib (an estimated 
1635 patients). Approximately 468 patients have received the tablet formulation to 
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date. Approximately 304 patients have received comparator or placebo across the Olaparib 
development programme.
An analysis of monotherapy data across 12 AstraZeneca sponsored monotherapy studies in 
975 patients who have been given Olaparib capsule estimated that 16.1% (157/975) of patients 
had been exposed to Olaparib capsule for ≥12 months at the time of database closure for the 
12 studies.  Furthermore, 41/ 975 patients received treatment for >24 months (longest duration 
was 44 months).  From the available data to date, there is no evidence of any unexpected 
toxicity following long-term Olaparib (capsule) monotherapy exposure. 
Additionally statistical analysis of the pooled QT/QTc data from 2 studies in a total of 
109 patients for the primary multiple dose analysis and 119 patients for the supportive 
single dose analysis showed that following multiple dosing of olaparib (300 mg bd), the 
upper confidence limit of the 2-sided 90% confidence interval (CI) around the mean 
treatment effect for QT Fridericia Correction Formula (QTcF) was <10 ms at all time 
points. Furthermore, the supportive analysis showed that following a single dose of 
olaparib, of either 100mg or 300mg the upper confidence limit of the 2-sided 90%CI 
around the mean treatment effect for QTcF was also <10 ms at all time points.
In conclusion, there was no indication of a clinically relevant effect of olaparib on 
cardiac repolarisation (as determined by prolongation of QTcF) following multiple 
dosing (300 mg bd) or following single dosing.
As a further supporting analysis, concentration-effect modelling of the pooled QT/QTc 
data from the same patients was conducted. Predictions, from the concentration-effect 
relationship obtained of the likely magnitude of effect of olaparib on ΔQTcF, showed 
that at the range of plasma concentrations achieved following the 300 mg bd tablet dose, 
olaparib would not be expected to cause prolongation of QTc interval of a magnitude 
that would be of clinical concern or which would cross the threshold for regulatory 
concern as described in ICH E14.
Olaparib as monotherapy at doses up to 400 mg bid capsule is generally well tolerated, with 
most common AEs including nausea, fatigue, vomiting, anaemia mainly mild-to-moderate 
(CTCAE Grade ≤ 2) in severity.  In addition, in a small number of patients MDS/AML or 
pneumonitis have been observed and identified as important risks.
Reason for Amendment:
To provide additional data on the QT study that has been conducted.
Section of protocol affected:
1.5 Study Design
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Previous text:
The primary analysis of the study will occur when approximately 89 progression events have 
occurred, although an interim analysis for superiority will be done when 50% of the planned 
PFS events have occurred (see statistical Section 8).  
Revised text:
The primary analysis of the study will occur when approximately 87 progression events have 
occurred, although an interim analysis for futility will be done when 50% of the planned PFS 
events have occurred (see statistical Section 8).
Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority 
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
Section of protocol affected:
Table 1 Study Schedule – Screening, On Study Treatment, Discontinuation and 
Follow-up
Previous text:
i ECG assessments to be completed within 7 days before starting treatment if patient is 
eligible following completion of all other PART 2 assessments. After screening, ECGs 
will only be required if clinically indicated.
Revised text:
i ECG assessments to be completed within 14 days before starting treatment if patient is 
eligible following completion of all other PART 2 assessments. After screening, ECGs 
will only be required if clinically indicated.
Reason for Amendment:
To ensure that the patient can start treatment within 8 weeks of their last chemotherapy dose. 
Due to the screening period, the original text meant that patients would have had to start 
treatment within 7 weeks of their last chemotherapy dose, this was not the intention. 
Extending this window by 7 days makes it clearer for the investigators and reduces the risk of 
protocol deviations. 
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Section of protocol affected:
Table 2 Study Schedule – Screening, On Study Treatment, Discontinuation and 
Follow-up
Previous text:
r. Adverse events must be captured from time of consent. However, in Screening PART 1 of 
the study only SAEs related to study procedures will be collected.
Revised text:
r. Adverse events must be captured from time of consent. Only SAE’s related to blood 
sampling for the Myriad gBRCA test will be collected at this visit.
Reason for Amendment:
To clarify the SAE reporting requirements in the screening PART 1 phase
Section of protocol affected:
3.2 Exclusion criteria 9
Previous text:
Resting ECG with QTC > 470msec detected on 2 or more time points within a 24 hour period 
or family history of long QT syndrome. If ECG demonstrates QTC >470 msec, patient will 
only be eligible if repeat ECG demonstrates QTC ≤470 msec.
Revised text:
Resting ECG with QTC ≥450 msec detected on 2 or more time points within a 24 hour period 
or family history of long QT syndrome. If ECG demonstrates QTC ≥450 msec, patient will 
only be eligible if repeat ECG demonstrates QTC ≤ 450 msec.
Reason for Amendment:
To be consistent with the ICH E14 guideline as requested by the German Ethics committee. 
Of note the additional data added to section 1.4 of the protocol as part of this amendment 
summarises the clinical data on ECG and concludes that Olaparib does not affect QT interval.
Section of protocol affected:
4.1 Enrolment/screening period
Previous text:
 ECG (within 7 days prior to the start of the study treatment)
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Revised text:
 ECG (within 14 days prior to the start of the study treatment)
Reason for Amendment:  
To ensure that the patient can start treatment within 8 weeks of their last chemotherapy dose. 
Due to the screening period, the original text meant that patients would have had to start 
treatment within 7 weeks of their last chemotherapy dose, this was not the intention. 
Extending this window by 7 days makes it clearer for the investigators and reduces the risk of 
protocol deviations. 
Section of protocol affected:
4.3.7 Subsequent Treatment
Previous text:
The data cut-off date for the final statistical analysis for the primary objective of the study will 
be established when approximately 89 confirmed progression events are expected to have 
occurred.
Revised text:
The data cut-off date for the final statistical analysis for the primary objective of the study will 
be established when approximately 87 confirmed progression events are expected to have 
occurred.
Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
Section of protocol affected:
5.2.4 ECG
5.2.4.1 Resting 12-lead ECG
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Previous text:
ECGs are required during screening within 7 days prior to starting study treatment and when 
clinically indicated afterwards.
Revised text:
ECGs are required during screening within 14 days prior to starting study treatment and when 
clinically indicated afterwards.
Reason for Amendment:  
To ensure that the patient can start treatment within 8 weeks of their last chemotherapy dose. 
Due to the screening period, the original text meant that patients would have had to start 
treatment within 7 weeks of their last chemotherapy dose, this was not the intention. 
Extending this window by 7 days makes it clearer for the investigators and reduces the risk of 
protocol deviations. 
Section of protocol affected:
5.6.3 Handling, storage and destruction of biological samples
Previous text:
The samples will be used up or disposed of after analyses or retained for further use as 
described here.
Biological samples for future research will be retained at AstraZeneca or a CRO, on behalf of 
AstraZeneca for a maximum of 15 years following the Last Patient’s Last Visit in the study.  
The results from future analysis will not be reported in the Clinical Study Report but 
separately in a Scientific Report.
Revised text:
The samples will be used up or disposed of after analyses or retained for further use as 
described here.
Biological samples for future research will be retained at AstraZeneca or a CRO, on behalf of 
AstraZeneca for a maximum of 15 years following the Last Patient’s Last Visit in the study.  
The results from future analysis will not be reported in the Clinical Study Report but 
separately in a Scientific Report.
Reason for Amendment:
Deleted duplicate statements.
Section of protocol affected:
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5.6.4Labelling and shipment of biohazard samples
Previous text:
5.6.4Labelling and shipment of biohazard samples
Revised text:
5.6.3Labelling and shipment of biohazard samples
Reason for Amendment:
Changed the title number to ensure protocol consistency. 
Section of protocol affected:
5.6.5Chain of custody of biological samples
Previous text:
5.6.5 Chain of custody of biological samples
Revised text:
5.6.4 Chain of custody of biological samples 
Reason for Amendment:
Changed the title number to ensure protocol consistency. 
Section of protocol affected:
5.6.6 Withdrawal of informed consent for donated biological samples
Previous text:
5.6.6 Withdrawal of informed consent for donated biological samples
Revised text:
5.6.5 Withdrawal of informed consent for donated biological samples
Reason for Amendment:
Change the title number to ensure protocol consistency.
Section of protocol affected:
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Section 6.7.1 Management of haematological toxicity Olaparib 
Previous text:
6.7.1 Management of haematological toxicity Olaparib 
Table 3 Management of Haematological Toxicity Olaparib
Toxicity Study treatment dose adjustment
CTCAEa gr 1-2 Dose interruption as judged by the investigator; appropriate supportive 
treatment and causality investigation
Repeat CTCAE gr 1-2 Dose interruption until recovery to CTCAE gr 1 and dose reduction to 250 
mg bid as first step and 200 mg bid as second step
CTCAE gr 3-4 Dose interruption until recovered to CTCAE gr 1 for max of 4 weeks and 
dose reduction to 200 mg bid
Repeat CTCAE gr 3-4 Discontinue study treatment
a
CTCAE Version 4
6.7.1.1 Management of anaemia
Adverse events of anaemia CTCAE grade 1 or 2 (Hb > 8 g/dl) should be investigated and 
managed as deemed appropriate by the investigator with or without interruption of study drug 
or change in dose, taking into account previous history of anaemia.  Common treatable causes 
of anaemia (eg, iron, vitamin B12 or folate deficiencies and hypothyroidism) should be 
investigated and appropriately managed.  In some cases management of anaemia may require 
blood transfusions.  However, if a patient develops anaemia CTCAE grade 3 (Hb < 8g/dl) or 
worse, study treatment should be interrupted for up to maximum of 4 weeks.   Study treatment 
can be restarted at the same dose if Hb has recovered to > 9 g/dl.  Any subsequently required 
anaemia related interruptions, considered likely to be dose related, or coexistent with newly 
developed neutropenia, and or thrombocytopenia, will require study treatment dose reductions 
to 250 mg bid as a first step and to 200 mg bid as a second step. 
If a patient has been treated for anaemia with multiple blood transfusions without study 
treatment interruptions and becomes blood transfusion dependant as judged by investigator, 
study treatment should be interrupted for up to a maximum of 4 weeks to allow for bone 
marrow recovery.  Study treatment should be restarted at a reduced dose.
Revised text:
Table 6 Management of Haematological Toxicity Olaparib
Toxicity Study treatment dose adjustment
CTCAE gr 1-2 Dose interruption as judged by the investigator; appropriate supportive 
treatment and causality investigation
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Toxicity Study treatment dose adjustment
Repeat CTCAE gr 1-2 Dose interruption until recovery to CTCAE gr 1 and dose reduction to 250 
mg bid as first step and 200 mg bid as second step
CTCAE gr 3-4 Dose interruption until recovered to CTCAE gr 1 for max of 4 weeks and 
dose reduction to 250 mg bid as first step and 200 mg bid as second 
step




6.7.1.1 Management of anaemia
Patients can enter the study with a haemoglobin value of > 9g/dl, this should be taken 
into account when considering the management of anaemia. Adverse events of anaemia 
CTCAE grade 1 or 2 (Hb > 8 g/dl) should be investigated and managed as deemed appropriate 
by the investigator with or without interruption of study drug or change in dose, taking into 
account previous history of anaemia.  Common treatable causes of anaemia (eg, iron, vitamin 
B12 or folate deficiencies and hypothyroidism) should be investigated and appropriately 
managed.  In some cases management of anaemia may require blood transfusions.  However, 
if a patient develops anaemia CTCAE grade 3 (Hb < 8g/dl) or worse, study treatment should 
be interrupted for up to maximum of 4 weeks.   Study treatment can be restarted at a reduced 
dose (see Table 4) if Hb has recovered to > 9 g/dl.  Any subsequently required a further
anaemia related interruptions, considered likely to be dose related, or coexistent with newly 
developed neutropenia, and or thrombocytopenia, will require study treatment dose reduction 
to 200 mg bid..
If a patient has been treated for anaemia with multiple blood transfusions without study 
treatment interruptions and becomes blood transfusion dependant as judged by investigator, 
study treatment should be interrupted for up to a maximum of 4 weeks to allow for bone 
marrow recovery.  Study treatment should be restarted at a reduced dose if bone marrow 
recovers.
Reason for Amendment:
The management of haematological toxicity has been made clearer and this is reflected in the 
revised text. The text and table are better aligned and an additional dose reduction increment 
has been added.
Section of protocol affected:
6.8.1 Data Monitoring Committee
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Previous text:
This study will use an external independent data monitoring committee (IDMC) to perform 
interim reviews of accumulating study safety data and the interim analyses for superiority and 
futility based on PFS.  
Revised text:
This study will use an external independent data monitoring committee (IDMC) to perform 
interim reviews of accumulating study safety data and the interim analyses for futility based 
on PFS.  
Reason for Amendment:
Removal of the interim superiority analysis as per FDA recommendation.
Section of protocol affected:
8.2.3 PRO analysis set
Previous text:
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data.
Revised text:
The analysis population for PRO data will be the subset of the FAS (ITT) population; who
have evaluable baseline EORTC QLQ-C30 and QLQ-PAN26 forms.
Reason for Amendment:
To clarify the definition of the PRO analysis set.
Section of protocol affected:
Table 7 Summary of Outcome Variables and Analysis Populations
Previous text:
Table 4 Summary of Outcome Variables and Analysis Populations
Outcome Variable Populations
Efficacy Data
- Primary: PFS FAS (ITT), Myriad confirmed BRCAm subgroup 
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Outcome Variable Populations
- Secondary endpoints to be analysed: OS, PFS2, 
time to first subsequent therapy (TFST), time to 
second subsequent therapy (TSST), time to 
treatment discontinuation (TDT), time to 
deterioration and improvement rate of Global 
QoL and PAN-26 pain scale
- Secondary endpoints to be summarised: 
objective response rate, disease control rate
FAS (ITT), Myriad confirmed BRCAm subgroup




- Adverse Events Safety
- Lab measurements Safety
- Vital Signs Safety
Revised text:
Table 5 Summary of Outcome Variables and Analysis Populations
Outcome Variable Populations
Efficacy Data
- Primary: PFS FAS (ITT), Myriad confirmed BRCAm subgroup 
- Secondary endpoints to be analysed:
OS, PFS2, time to first subsequent therapy 
(TFST), time to second subsequent therapy 
(TSST), time to treatment discontinuation (TDT)
FAS (ITT), Myriad confirmed BRCAm subgroup
-Adjusted mean change from baseline in 
EORTC QLQ-C30 global QoL score
PRO (subset of the FAS (ITT) who have 
evaluable baseline EORTC QLQ-C30 and 
QLQ-PAN26 forms) 
-Secondary endpoints to be summarised:
-Objective response rate. FAS (ITT) (patients with measurable disease at 
baseline only), Myriad confirmed BRCAm
subgroup
-Disease control rate FAS (ITT), Myriad confirmed BRCAm
subgroup
Demography FAS (ITT)
Clinical Study Protocol Global Amendment 2
Drug Substance Olaparib
Study Code D081FC00001





- Adverse Events Safety
- Lab measurements Safety
- Vital Signs Safety
Reason for Amendment:
To change the health-related quality of life secondary endpoint from time to deterioration as 
assessed by the EORTC QLQ-C30 global QoL score to adjusted mean change from baseline 
in EORTC QLQ-C30 global QoL score.
To clarify the analysis sets used for the analysis of objective response rate, disease control rate 
and QoL endpoints.
Section of protocol affected:
8.3.1 Primary endpoint (PFS)
Previous text:
As a supportive summary to PFS, time to start of first subsequent chemotherapy or death will 
be assessed (see section 8.8.3). Time to first subsequent chemotherapy or death is defined as 
the time from the date of randomisation to the earlier of first subsequent chemotherapy start 
date, or death date. Any patient not known to have had a further subsequent therapy or death 




To remove repeated text detailing the time to first subsequent therapy endpoint.  This is a 
secondary endpoint detailed in Section 8.3.2.4.
Section of protocol affected:
8.3.2.2 Best overall RECIST response (BoR)
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Previous text:
Best overall RECIST response (BoR) is calculated based on the overall visit responses from 
each RECIST assessment, described in Appendix F. It is the best response a patient has had 
during their time in the study up until RECIST progression or the last evaluable assessment in 
the absence of RECIST progression.
…
Best overall response will be determined programmatically based on the RECIST criteria 
using BICR data.
Revised text:
Best overall RECIST response (BoR) is calculated based on the overall visit responses from 
each RECIST assessment, described in Appendix F. It is the best response a patient has had 
after randomisation but prior to starting any subsequent cancer therapy and prior to 
RECIST progression or the last evaluable assessment in the absence of RECIST progression.
…
Best overall response will be determined programmatically based on the RECIST criteria 
using BICR data.  In addition, this will also be reported using investigator-recorded 
assessment.
Reason for Amendment:
To bring text in line with current AstraZeneca oncology statistical guidance which states that 
objective response rate should only be calculated using data up to the point of any subsequent 
therapies being used.
Section of protocol affected:
8.3.2.4 Time to first subsequent therapy or death (TFST)
Previous text:
Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as 
the time from randomisation to the earlier of first subsequent therapy start date following 
study treatment discontinuation, or death. Subsequent therapies will be reviewed to assess
which represent clinically important treatments intended to control ovarian cancer. 
Revised text:
Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as 
the time from randomisation to the earlier of first subsequent cancer therapy start date 
following study treatment discontinuation, or death.
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Reason for amendment:
To specify that TFST is the time to first subsequent cancer therapy and to remove text copied 
from the ovarian cancer study which is not relevant to this study.
Section of protocol affected:
8.3.2.5 Time to second subsequent therapy or death (TSST)
Previous text:
Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined 
as the time from randomisation to the earlier of the second subsequent therapy start date 
following study treatment discontinuation, or death. 
Revised text:
Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined 
as the time from randomisation to the earlier of the second subsequent cancer therapy start 
date following study treatment discontinuation, or death. 
Reason for amendment:
To specify that TSST is the time to second subsequent cancer therapy.
Section of protocol affected:
8.5 Calculation or derivation of patient reported outcome variables
Previous text:
EORTC-QLQC30 and QLQ-PAN26
The EORTC QLQ-C30 will be scored according to the EORTC scoring manual (Fayers et al 
1999). Each scale will be transformed to a 100-point scale as per the manual.
Mean change from baseline in health related quality of life (HRQoL) will be assessed using 
the EORTC QLQ-C30 global QoL scale which includes two items from the QLQ-C30: “How 
would you rate your overall health during the past week?” (Item 29) and “How would you rate 
your overall quality of life during the past week?” (Item 30)
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data.
The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life (two items: “How would you rate your 
overall health during the past week?” (Item 29) and “How would you rate your overall quality 
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of life during the past week?” (Item 30)) and PAN-26 pancreatic pain (items 31, 33, 34, 35) 
scales . Time to global QoL and pancreatic pain scale worsening will be analysed using the 
same methodology and model as described for the primary analysis of PFS. However 
sensitivity analyses will not be performed (with the exception of attrition bias).
Global QoL and PAN-26 pain scale improvement rate will be analysed using a logistic 
regression model and using the same covariates as used in the PFS analyses. If the overall 
response rate is < 5%, no analysis will be performed. (Note that if the response rate in only 
one of the treatment groups is < 5% but ≥ 5% in the other treatment group then the analysis 
will still be performed.) If the expected response rate is low (< 20%) a Fisher’s exact test will 
be considered and mid p-values used. The results of the analysis will be presented in terms of 
an odds ratio together with its associated profile likelihood CIs and p-values (based on twice 
the change in log-likelihood resulting from the addition of a treatment factor to the model).
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group.
Revised text:
EORTC QLQ-C30 and QLQ-PAN26
The EORTC QLQ-C30 will be scored according to the EORTC scoring manual (Fayers et al 
2001).  Each scale will be transformed to a 100-point scale as per the manual.
Reason for Amendment:
To remove analysis details that are repeated in Section 8.8.4.6 Analysis of PRO endpoints.
Section of protocol affected:
8.5 Calculation or derivation of patient reported outcome variables
Previous text:
Higher scores represent more symptoms, except for health care satisfaction scale and sexuality 
scale where higher scores represent greater satisfaction and sexuality. For change scores, a 
score of +5 is considered deterioration (except for the two scales mentioned above) and a 
score of -5 is considered as improvement.
Revised text:
Higher scores represent more symptoms, except for health care satisfaction scale and sexuality 
scale where higher scores represent greater satisfaction and sexuality.
The threshold for a clinically important deterioration is outlined below (Table 8):
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Table 8 Visit Response in EORTC QLQ-C30 Global QoL Score
Score Change from baseline Visit response
EORTC QLQ-C30 global QoL 
score
≥ +10 Improved




Further detail will be provided in the SAP.
Best overall QoL response
A patient’s best overall QoL response will be derived as the best QoL response the 
patient achieved, based on evaluable QoL data collected from randomisation up to the 
earliest of starting any subsequent cancer therapy or death.  The criteria in Table 9 will 
be used to assign a best QoL response for HRQoL based on the 2-item global QoL score.  
Improvement rate will be defined as the proportion of patients whose best overall QoL 
response was “Improved”.
Table 9 Best QoL Response in EORTC QLQ-C30 Global QoL Score
Overall Score Response Criteria
Improved Two visit responses of “improved” a minimum of 21 days apart 
without an intervening visit response of “deterioration”
No Change Does not qualify for overall score response of “improved”.  Two visit 
responses of either “no change” or “improved” and “no change” a 
minimum of 21 days apart without an intervening visit response of 
“deterioration”
Deterioration Does not qualify for overall score response of “improved”.  A visit 
response of “deterioration” without response of “improved” or “no 
change” within 21 days.
Other Does not qualify for one of the above.
Compliance
Summary measures of overall compliance and compliance over time will be derived for 
the EORTC QLQ-C30 and QLQ-PAN26 questionnaires.  These will be based upon:
 Received forms = number of EORTC QLQ-C30 / QLQ-PAN26 questionnaire 
forms received back plus the number not received back where the reason was 
‘Subject too affected by symptoms of disease under investigation’.
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 Expected forms = number of patients still under QoL follow-up at the specified 
assessment time excluding patients in countries with no available translation.  
 Evaluable forms = subset of expected EORTC QLQ-C30 / QLQ-PAN26 
questionnaire forms with at least one subscale that can be determined; or 
where the reason questionnaire not completed is ticked as ‘Subject too affected 
by symptoms of disease under investigation’.
Thus the compliance rate for QLQ-C30 and for QLQ-PAN26 is defined as the number of 
patients with an evaluable baseline and at least one evaluable follow-up form (as defined 
above), divided by the number of patients expected to have completed at least a baseline 
EORTC QLQ-C30 / QLQ-PAN26 questionnaire form.  In addition, an overall 
compliance rate defined as number of patients with an evaluable baseline and at least 
one evaluable follow-up, divided by the number of patients expected to have completed 
at least a baseline for both, the EORTC QLQ-C30 AND QLQ-PAN26 questionnaire 
form, will be calculated.
Compliance over time will be calculated separately for each visit, including baseline, as 
the number of patients with an evaluable baseline form and a form at the time point (as 
defined above), divided by number of patients still expected to complete forms at that 
visit.  Similarly, the evaluability rate over time will be calculated separately for each 
visit, including baseline, as the number of evaluable forms (per definition above), divided 
by the number of received forms.
Reason for Amendment:
To provide additional detail of the derivation of best overall QoL response, improvement rate 
and compliance.
Section of protocol affected:
8.8 Methods for statistical analysis
Previous text:
A single interim PFS analysis for futility and superiority will be performed when 50% of the 
final number of progressions has been reached (approximately 45 PFS events).  The interim 
analysis will be performed by an Independent Data Monitoring Committee (IDMC) and full 
details will be provided in the IDMC charter.  A final PFS analysis will be performed when 
approximately 89 progression events have occurred (~60% maturity).  No further analyses of 
PFS are planned beyond this point unless requested by health authorities.
Timing of the statistical analyses are given in Section of protocol affected:
Table 8 Timing of statistical analyses
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A single interim PFS analysis for futility will be performed when 50% of the final number of 
progression events required for the primary PFS analysis has been reached (approximately 
44 PFS events).  The interim analysis will be performed by an Independent Data Monitoring 
Committee (IDMC) and full details will be provided in the IDMC charter.  A final PFS 
analysis will be performed when approximately 87 progression events have occurred (60%
maturity).  No further analyses of PFS are planned beyond this point unless requested by 
health authorities.
Timing of the statistical analyses are given in Table 10.
Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority 
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
Section of protocol affected:
Table 8 Timing of statistical analyses
Previous text:
Table 6 Timing of statistical analyses
7 Timing of analyses 8 Outcome Variable
Efficacy Data
Interim PFS analyses (~ 45 PFS events)
Final PFS (~ 89 PFS events) 
- PFS 
- PFS, PFS2, TDT, TFST, TSST, OS, time to 
deterioration of Global QoL and PAN-26 pain scale 
Final OS analyses (~ 106 OS events) - PFS2, TFST, TSST, OS, time to deterioration of 
Global QoL and PAN-26 pain scale
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** Only if superiority is met for PFS at the PFS interim analyses, will analyses of the following 
endpoints be performed: PFS2, TDT, TFST, TSST, OS, time to deterioration of Global QoL and PAN-
26 pancreatic pain scale.
Revised text:
Table 10 Timing of Statistical Analyses
Timing of analyses Outcome Variable
Efficacy Data
Interim PFS analyses (~ 44 PFS events) - PFS 
Final PFS (~ 87 PFS events) - PFS, PFS2, TDT, TFST, TSST, OS, adjusted mean 
change from baseline in global QoL score
Final OS analyses (~ 106 OS events) - PFS2, TFST, TSST, OS, adjusted mean change from 
baseline in global QoL score
Reason for Amendment:
To change the health-related quality of life secondary endpoint from time to deterioration as 
assessed by the EORTC QLQ-C30 global QoL score to adjusted mean change from baseline 
in EORTC QLQ-C30 global QoL score.
Removal of the superiority analysis at the time of the interim analysis as per FDA 
recommendation.
Section of protocol affected:
Table 9 Formal Statistical Analyses to be Conducted and Pre-Planned Sensitivity Analyses
Previous text:
Table 9 Formal Statistical Analyses to be Conducted and Pre-Planned Sensitivity 
Analyses
Endpoints Analysed Notes
PFS (Time from randomisation to first 
progression or death)
Primary analysis: log-rank test using BICR data
Key sensitivity analysis
a
: log rank test using 
BICR data in randomised patients confirmed as 
gBRCA mutation positive by central Myriad test 
(if subset of FAS) 
Additional sensitivity analyses:
1) Evaluation time bias analysis; log-rank test 
using BICR data
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Endpoints Analysed Notes
2) Attrition bias analysis (using alternative 
censoring rules); log-rank test using BICR data
3) Ascertainment bias analysis; log-rank test 
using investigator data
4) Deviation bias analysis (if meaningful to do);
log-rank test using BICR data
Overall Survival (Time from randomisation to 
death due to any cause)
Primary analysis: log-rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Supportive analysis: KM plot of time to censoring 
for OS
Second Progression Free Survival (PFS2) Primary analysis: log-rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to treatment discontinuation (TDT) Primary analysis: Stratified log rank test of time 
from randomisation to treatment discontinuation 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to first subsequent therapy (TFST) Primary analysis: Stratified log rank test of time 
from randomisation to first subsequent therapy or 
death 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to second subsequent therapy (TSST) Primary analysis: Stratified log rank test of time 
from randomisation to second subsequent therapy 
or death 
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Endpoints Analysed Notes
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to deterioration in global QoL (as measured 
by the global QOL score from the EORTC-QLQ-
C30 questionnaire)
Primary analysis: Stratified log rank test of time 
from randomisation to deterioration in global 
QOL 
a
See Section 8.8.3 for further details
Revised text:
Table 11 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses
Endpoints Analysed Notes
PFS (Time from randomisation to first 
progression or death)
Primary analysis: log-rank test using BICR data
Key sensitivity analysis
a
: log rank test using 
BICR data in randomised patients confirmed as 
gBRCA mutation positive by central Myriad test 
(if subset of FAS) 
Additional sensitivity analyses:
1) Evaluation time bias analysis; log-rank test 
using BICR data
2) Attrition bias analysis (using alternative 
censoring rules); log-rank test using BICR data
3) Ascertainment bias analysis; log-rank test 
using investigator data
4) Deviation bias analysis (if meaningful to do); 
log-rank test using BICR data
Overall Survival (Time from randomisation to 
death due to any cause)
Primary analysis: log-rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Supportive analysis: KM plot of time to censoring 
for OS
Second Progression Free Survival (PFS2) Primary analysis: log-rank test 
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Endpoints Analysed Notes
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to treatment discontinuation (TDT) Primary analysis: log rank test of time from 
randomisation to treatment discontinuation 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to first subsequent therapy (TFST) Primary analysis: log rank test of time from 
randomisation to first subsequent therapy or death 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Time to second subsequent therapy (TSST) Primary analysis: log rank test of time from 
randomisation to second subsequent therapy or 
death 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by central Myriad test (if subset 
of FAS)
Adjusted mean change from baseline in global 
QoL score from the EORTC QLQ-C30 
questionnaire
Primary analysis: mixed model for repeated 
measures (MMRM) analysis of all of the post-
baseline scores for each visit
Supportive analysis: logistic regression on 
global QoL score improvement rate.
a
See Section 8.8.3 for further details
Reason for Amendment:
To change the health-related quality of life secondary endpoint from time to deterioration as 
assessed by the EORTC QLQ-C30 global QoL score to adjusted mean change from baseline 
in EORTC QLQ-C30 global QoL score.
Correction to change ‘stratified log-rank test’ to ‘log-rank test’ as there is no stratification in 
this study.
Clinical Study Protocol Global Amendment 2
Drug Substance Olaparib
Study Code D081FC00001
Date 28 February 2015
27(39)
Section of protocol affected:
8.8.1 Multiplicity strategy for primary and key secondary endpoints
Previous text:
At the interim analyses for PFS, 1% of alpha will be spent; statistical significance will be 
declared at the interim analysis if the 1-sided p<0.005.  If the null hypothesis for PFS is not 
rejected at the interim analyses time point then PFS will be tested again when approximately 
89 PFS events have occurred. The final significance level will be determined accounting for 
the actual correlation between the interim and final PFS analyses. To ensure that the type I 
error will be controlled at 2.5% 1-sided level, if the interim occurs at exactly 50% of events 
and the number of PFS events at the final analysis is as expected then the 1-sided significance 
level to be applied for the final analysis would be 2.26%. (Stone 2010). If PFS is significant at 
either the interim or final analyses, the full test mass (alpha) will be carried forward to OS.
OS will only be tested if the null hypothesis (of no difference) is rejected for PFS.  Two 
interim analyses for OS will be performed; the first at the time of the interim PFS analysis 
(approximately 45 PFS events) and the second at the time of the final PFS analysis 
(approximately 89 PFS events).  A final analysis of OS will be performed when approximate 
106 death events have occurred. Statistical significance for OS will be declared the first at 
interim analyses for OS if the null hypothesis for PFS is rejected and the observed p-value for 
OS is p<0.005. If the null hypothesis for OS is not rejected at this time, then statistical 
significance for OS will be declared at the next interim analyses (final analysis of PFS) if the 
null hypothesis for PFS has been rejected and the observed 1-sided p-value for OS is < 
0.01499.  The final significance level will be determined accounting for the actual correlation 
between the interim and final OS analyses.  To ensure that the type I error will be controlled at 
the 2.5% 1-sided level, if the interim analyses occur at exactly 30% and 57% of events 
respectively and the number of OS events at the final analysis is approximately 106 then the 
1-sided significance level to be applied for the final analysis would be 1.53%
Revised text:
OS will only be tested if the null hypothesis (of no difference) is rejected for PFS.  One
interim analysis for OS will be performed; the time of the final PFS analysis (approximately 
87 PFS events).  A final analysis of OS will be performed when approximately 106 death 
events have occurred. The Lan and DeMets approach that approximates the O’Brien & 
Fleming spending function will be employed to preserve the overall 1-sided type I error 
rate of 2.5% (Lan and DeMets 1983).  If the interim analysis for OS occurs at exactly 
57% of the 106 OS events, statistical significance for OS will be declared if the null 
hypothesis for PFS is rejected and the observed p-value for OS is p<0.003, which equates to 
a HR ≤ 0.49. The significance level at the final analysis will be determined based on the 
exact number of events at the time of the interim and final analyses.  If the interim 
analysis for OS occurs at exactly 57% of events and the number of OS events at the final 
analysis is approximately 106 then the 1-sided significance level to be applied for the final 
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analysis will be 2.4%.  Statistical significance for OS will be declared if the observed p-
value for OS is p<0.024, which equates to a HR ≤ 0.68.
Reason for Amendment:
Removal of the interim superiority analysis as per FDA recommendation.  OS will be tested at 
the time of the primary PFS analysis and again after approximately 106 death events.  To 
ensure that the type I error is controlled at the 2.5% 1-sided level overall for OS, the 
significance level will be allocated between the two analyses based on the O’Brien & Fleming 
spending function.
Section of protocol affected:
8.8.2 Analysis of the primary variable (s)
Previous text:
A single interim PFS analysis for superiority will be performed when 50% of the final number 
of progressions has been reached (approximately 45 PFS events) based on the BICR.  A final 
PFS analysis will be performed when approximately 89 progression events have occurred 
(~60% maturity) based on the BICR.  No further analyses of PFS are planned beyond this 
point unless requested by Health Authorities.
Revised text:
The primary PFS analysis will be performed when approximately 87 progression events have 
occurred (60% maturity) based on the BICR.  No further analyses of PFS are planned beyond 
this point unless requested by Health Authorities.
Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority 
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
Section of protocol affected:
8.8.2 Analysis of the primary variable(s)
Previous text:
As patients will be randomised, imbalances in demographic factors between the treatment 
groups are not anticipated.  However if any imbalances should occur, the HR and associated 
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confidence interval calculated from a Cox Proportional Hazards model containing treatment 




To remove statistical assessment of balance at baseline.  If anything appeared quite strongly 
not to be balanced, this will be commented in the CSR and additional analysis requested to be 
produced.
Section of protocol affected:
8.8.2 Analysis of the primary variable(s)
Previous text:
The following subgroups of the full analysis set will be analysed for PFS:
 Type of chemotherapy (doublets vs triplets)
 Time on first line treatment till randomisation (≤6 months vs  >6 months)
 Best response on first line treatment (SD vs PR/CR)
 Measurable versus non measurable disease /no evidence of disease at baseline
 BRCA mutation type, eg BRCA1, BRCA2 or BRCA1/2 (both) 




The following subgroups of the full analysis set will be analysed for PFS:
 Previous chemotherapy (FOLFIRINOX variants vs gemcitabine/cisplatin)
 Presence or absence of biliary stent
 Type of previous chemotherapy (doublets vs triplets)
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 Time on first line treatment till randomisation (≤6 months vs  >6 months)
 Best response on first line treatment (SD vs PR/CR)
 Measurable versus non measurable disease /no evidence of disease at baseline
 BRCA mutation type, eg BRCA1, BRCA2 or BRCA1/2 (both) 




To include additional subgroup analyses of PFS; previous chemotherapy (FOLFIRINOX
variants versus gemcitabine/cisplatin), and presence/absence of biliary stent will be analysed 
in Cox proportional hazards models.
Section of protocol affected:
8.8.3.2 Attrition bias
Previous text:
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of subjects who progressed or died in the 
absence of progression immediately following two, or more, non-evaluable tumour 
assessments will be included. In addition, subjects who take subsequent therapy prior to 
progression or death will be censored at their last evaluable assessment prior to taking the 
subsequent therapy. 
Revised text:
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of subjects who progressed or died in the 
absence of progression immediately following two, or more, non-evaluable tumour 
assessments will be included. In addition, subjects who take subsequent therapy prior to their 
last evaluable RECIST assessment or progression or death will be censored at their last 
evaluable assessment prior to taking the subsequent therapy. 
Reason for amendment:
To clarify censoring rules for the attrition bias sensitivity analysis.
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Section of protocol affected:
8.8.4.1 Analysis of OS endpoint
Previous text:
OS data will be analysed at the time of the interim (if PFS null hypothesis rejected) and final 
analyses of PFS and will use the same methodology and model (provided there are sufficient 
events available for a meaningful analysis [> 20 deaths], if not descriptive summaries will be 
provided).  A further analysis of OS will be performed when approximately 106 deaths have 
occurred.
Revised text:
OS data will be analysed at the time of the final analyses of PFS and will use the same 
methodology and model (provided there are sufficient events available for a meaningful 
analysis [> 20 deaths], if not descriptive summaries will be provided).  A further analysis of 
OS will be performed when approximately 106 deaths have occurred.
Reason for Amendment:
Removal of the superiority analysis at the time of the interim analysis as per FDA 
recommendation, therefore OS will not be analysed at this time.
Section of protocol affected:
8.8.4.6 Analysis of PRO endpoints
Previous text:
The analysis population for PRO data will be the subset of the FAS (ITT) population; patients 
must have a baseline score to be included in the analysis of PRO data.
The impact of Olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales. 
Time to global QoL and pancreatic pain scale deterioration will be analysed using the same 
methodology and model as described for the primary analysis of PFS. However sensitivity 
analyses will not be performed (with the exception of attrition bias).
Global QoL and PAN-26 pain scale improvement rate will be analysed using a logistic 
regression model.  If the overall response rate is < 5%, no analysis will be performed (note 
that if the response rate in only one of the treatment groups is < 5% but ≥ 5% in the other 
treatment group then the analysis will still be performed). If the overall expected response 
rate is low (< 20%) a Fisher’s exact test will be considered and mid p-values used. The results 
of the analysis will be presented in terms of an odds ratio together with its associated profile 
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likelihood CIs and p-values (based on twice the change in log-likelihood resulting from the 
addition of a treatment factor to the model).
EORTC-QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will 
be summarised for each treatment group.
Supportive analyses (of time to deterioration and improvement rates) will be performed for the 
individual QLQC30 domains (physical, role, cognitive, emotional, social).  Treatment 
estimates and 95% CI for each domain will be presented on forest plots (one for Time to 
deterioration and one for improvement rate).  P-values will not be calculated for these 
supportive analyses. These additional sub-scales are considered exploratory to support the 
primary QLQC30 global QoL and will be used to assess whether any observed differences in 
the global measure are driven by particular domains of functioning, symptoms or group of 
symptoms.
Descriptive statistics and graphs will be reported for the Global QoL item and the pancreatic 
pain scale by visits as well as change in these scores from baseline. Summary tables of 
QLQC30 best change rates will be provided (improvement, worsening, no change).
As supportive analyses, change from baseline in global QoL and pancreatic pain scale scores 
will be analysed using a mixed model for repeated measures (MMRM) analysis of all of the 
post-baseline scores for each visit. The study discontinuation visit and the safety follow-up 
visit will be excluded from this analysis. Restricted maximum likelihood (REML) estimation 
will be used. The model will include treatment, pooled centre, visit and treatment by visit 
interaction as explanatory variables and the baseline score as a covariate. Treatment, visit and 
treatment by visit interaction will be fixed effects in the model; centre will be a random effect. 
The treatment by visit interaction will remain in the model regardless of significance.
An unstructured covariance matrix will be used to model the within-subject error and the 
Kenward-Roger approximation will be used to estimate the degrees of freedom. 
If the fit of the unstructured covariance structure fails to converge, the following covariance 
structures will be tried in order until convergence is reached: toeplitz with heterogeneity, 
autoregressive with heterogeneity, toeplitz, and autoregressive. If there are still issues with the 
fit of the model or estimation of the treatment effects, CENTRE will be treated as a fixed 
effect.
The adjusted mean estimates and corresponding 95% confidence intervals will be presented 
by visit for each treatment group.
No formal testing will be done on the global QoL and pancreatic pain scale data.  Data will be 
descriptive and plots will be used to visualise the adjusted mean global QoL score across time 
for each treatment arm.
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Compliance
Overall compliance will be defined as the number of patients who provided both a baseline 
and at least one post baseline assessment for which there were sufficient data recorded for the 
visit to be evaluable for the global QoL score, divided by the number of patients randomised.  
Compliance over time is calculated separately for each visit, including baseline, as the number 
of patients providing an evaluable assessment for the global QoL score at that visit divided by 
the number of patients expected to have provided an assessment.
QLQC30 and PAN-26 compliance (overall compliance and by visit compliance) will be 
summarised for each treatment group.
Revised text:
The analysis population for PRO data will be the PRO analysis set including patients with 
evaluable baseline EORTC QLQ-C30 and QLQ-PAN26 forms.
The impact of olaparib on health related quality of life and pain will be assessed through an 
analysis of the EORTC-QLQC30 global quality of life and PAN-26 pancreatic pain scales. 
Adjusted mean change from baseline in global QoL score will be analysed using a mixed 
model for repeated measures (MMRM) analysis of all of the post-baseline scores for each 
visit and will be presented by treatment group.  The study discontinuation visit and the 
safety follow-up visit will be excluded from this analysis. Restricted maximum likelihood 
(REML) estimation will be used. The model will include treatment, visit and treatment 
by visit interaction as explanatory variables and the baseline QoL score as a covariate. 
Treatment, visit and treatment by visit interaction will be fixed effects in the model.  The 
treatment by visit interaction will remain in the model regardless of significance.
An unstructured covariance matrix will be used to model the within-subject error and 
the Kenward-Roger approximation will be used to estimate the degrees of freedom. 
If the fit of the unstructured covariance structure fails to converge, the following 
covariance structures will be tried in order until convergence is reached: toeplitz with 
heterogeneity, autoregressive with heterogeneity, toeplitz, and autoregressive. 
The adjusted mean change from baseline estimates and corresponding 95% CIs will be 
presented by visit for each treatment group and corresponding plots over time will be 
presented.
As a supportive analysis, EORTC QLQ-C30 global QoL score  improvement rate will be 
analysed using a logistic regression model.  If the overall response rate is < 5%, no analysis 
will be performed (note that if the response rate in only one of the treatment groups is < 5% 
but ≥ 5% in the other treatment group then the analysis will still be performed). If the overall 
expected response rate is low (< 20%) a Fisher’s exact test will be considered and mid p-
values used. The results of the analysis will be presented in terms of an odds ratio together 
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with its associated profile likelihood CIs and p-values (based on twice the change in log-
likelihood resulting from the addition of a treatment factor to the model).
EORTC QLQ-C30 (overall compliance and by visit compliance) will be summarised for each 
treatment group.
Descriptive statistics and graphs will be reported for the global QoL score by visits as well as 
unadjusted change in these scores from baseline. Summary tables of EORTC QLQ-C30 
best overall QoL response as defined in Table 9 will be provided (improvement, 
deterioratio, no change).
An exploratory analysis will examine adjusted mean change from baseline on 
QLQ-PAN26 symptom scales/items (including pancreatic pain).  This is detailed in 
Section 8.8.5.1.
Reason for Amendment:
To change the health-related quality of life secondary endpoint from time to deterioration as 
assessed by the EORTC QLQ-C30 global QoL score to adjusted mean change from baseline 
in EORTC QLQ-C30 global QoL score, to be analysed in an MMRM model.
Section of protocol affected:
8.8.5.1 Exploratory analysis of PRO endpoints (PAN-26 symptom scales and items)
Previous text:
8.8.5.1 Exploratory analysis of PRO endpoints (PAN-26 symptom scales and items)
Exploratory analyses, examining improvement rates and time to worsening, will be performed 
for the individual PAN-26 symptom scales and items (with a particular focus on fatigue, 
nausea, weight loss (difficulty gaining weight/loss of appetite), jaundice), and presented on 
forest plots (showing treatment estimates and 95% CI for each domain). P-values will not be 
calculated for these exploratory analyses.
Descriptive statistics and graphs will be reported for the symptom scales and items 
(specifically fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite and 
jaundice). Summary tables of PAN26 best change rates will be provided (improvement, 
worsening, no change).
Change from baseline in QLQC30 functioning domain scores and PAN-26 scales and items 
may be analysed using the same MMRM model described in Section 8.8.4.6 for Global QoL 
score and the pancreatic pain score.
Descriptive summaries for individual symptom items within the PAN-26 will also be 
provided.
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Revised text:
8.8.5.1 Exploratory analysis of PRO endpoints (QLQ-PAN26 symptom scales and items)
Exploratory analyses examining adjusted mean change from baseline will be performed for 
EORTC QLQ-C30 functioning domains (physical, role, cognitive, emotional, social) and 
for the individual EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (with a 
particular focus on pancreatic pain, fatigue, nausea, weight loss (difficulty gaining 
weight/loss of appetite), jaundice), using the same MMRM model described in Section 
8.8.4.6 for the global QoL score.
Descriptive statistics and graphs will be reported for the EORTC QLQ-C30 functioning 
domains and EORTC QLQ-C30 and QLQ-PAN26 symptom scales/items (specifically 
pancreatic pain, fatigue, nausea, weight loss (difficulty gaining weight/loss of appetite) and 
jaundice). 
EORTC QLQ- PAN26 compliance (overall compliance and by visit compliance) will be 
summarised for each treatment group.
Reason for Amendment:
To change the exploratory analysis to MMRM to examine adjusted mean change from 
baseline on EORTC QLQ-C30 and QLQ-PAN26 functioning domains and symptom scales.
Section of protocol affected:
8.9 Sample Size Determination
Previous text:
The primary endpoint of the study is PFS.   Approximately 145 patients will be randomised 
(3:2 ratio of Olaparib:placebo) and the primary PFS analysis will occur once approximately 89 
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
superiority will be performed when 50% of the final number of progressions has been reached 
(approximately 45 PFS events) based on BICR.
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.26% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median OS for placebo.  At the interim 
analyses, 0.5% of alpha (1-sided) will be spent, and controlling the type I error across the two 
time points, 89 PFS events will be required at the final analyses.  
Statistical significance will be declared at the interim analysis if the 1-sided p<0.005.  
Assuming 45 PFS events at the interim, a HR ≤ 0.46 would equate to a 1-sided p<0.005.  If 
the null hypothesis for PFS is not rejected at the interim analyses time point then PFS will be 
tested again when approximately 89 PFS events have occurred.  The final significance level 
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will be determined accounting for the actual correlation between the interim and final PFS 
analyses. To ensure that the type I error will be controlled at 2.5% 1-sided level, if the interim 
occurs at exactly 50% of events and the number of PFS events at the final analysis is as 
expected then the 1-sided significance level to be applied for the final analysis would be 
2.26%. (Stone 2010).  Assuming 89 PFS events, a HR ≤ 0.65 would equate to a 1-sided p-
value <0.0226.
…
Assuming that the study accrual period will be approximately 15 months, 89 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 45 PFS events will occur approximately 13 to 14 
months after first patient in.  It is estimated that 106 death events will occur approximately 31 
months after first patient in.
Revised text:
The primary endpoint of the study is PFS.   Approximately 145 patients will be randomised 
(3:2 ratio of Olaparib:placebo) and the primary PFS analysis will occur once approximately 87
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
futility will be performed when 50% of the final number of progression events required for 
the primary PFS analysis has been reached (approximately 44 PFS events) based on BICR.
The study is sized assuming a true treatment effect is a PFS Hazard Ratio (HR) of 0.54, 
assuming 80% power and 2.5% alpha (1-sided), with 3:2 randomisation (Olaparib:placebo). 
Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 3.4 month 
improvement in median PFS over an assumed 4 month median OS for placebo.  87 PFS events 
will be required at the final analyses.  
…
Assuming that the study accrual period will be approximately 15 months, 87 progression 
events are anticipated to be observed approximately 18-19 months after the first patient is 
randomised in the study. It is estimated that 44 PFS events will occur approximately 13 to 14 
months after first patient in.  It is estimated that 106 death events will occur approximately 31 
months after first patient in.
Reason for Amendment:
The study is sized based on the number of events required to detect superiority at the time of 
the primary PFS analysis.  To ensure that the type I error is controlled at the 2.5% 1-sided 
level overall, the significance level was previously allocated between the interim and final 
PFS analyses, taking account of correlation between them.  Removal of the interim superiority 
analysis as per FDA recommendation means that a 2.5% significance level can be allocated to 
the primary PFS analysis and therefore the number of PFS events required at the time of the 
primary PFS analysis is slightly reduced.
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Section of protocol affected:
8.9.1 Interim analysis
Previous text:
A single interim PFS analysis for superiority and futility will be performed when 50% of the 
final number of progressions has been reached (approximately 45 PFS events) based on BICR.  
The interim analysis will be performed by an Independent Data Management Committee 
(IDMC) and full details will be provided in the IDMC charter.  
Section 8.8.1 details the spending function used to account for multiplicity introduced by 
including interim analyses for superiority.
Interim analyses of OS will be performed at the time of the interim analyses of PFS (~89 PFS 
events),and again at the final analyses at the final analyses of PFS (~89 events), and when 
approximately 106 OS events have occurred.
If the interim PFS results indicate superiority, then analyses of all other endpoints would be 
performed and the results of these analyses will form the basis for submissions for regulatory 
approval. Patients would continue to be followed for PFS and survival until ~89 PFS events 
had occurred, and then followed for survival until 106 patients had died.
Revised text:
A single interim PFS analysis for futility will be performed when 50% of the final number of 
progression events required for the primary PFS analysis has been reached (approximately 
44 PFS events) based on BICR.  The interim analysis will be performed by an Independent 
Data Management Committee (IDMC) and full details will be provided in the IDMC charter.  
Safety data including death rates will also be reviewed at this time.
The futility assessment will be based on the probability of eventually showing statistical 
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consider the option of declaring futility.
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LIST OF ABBREVIATIONS  





AE Adverse event 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
Baseline Refers to the most recent assessment of any variable prior to first dosing 
with study treatment 
BDRM Blind data review meeting 
bid Bis in die (Latin for 'twice a day') 
BICR Blinded independent central review 
BMI Body mass index 
BoR Best overall RECIST response 
BRCA Breast cancer susceptibility gene 
BRCA mutation or 
BRCAm 
Breast cancer susceptibility gene mutation (see gBRCA mutation or 
gBRCAm) 
CI Confidence interval  
CIF Cumulative incidence function 
CR Complete response 
CRF / eCRF  Case Report Form (electronic) 
CSP Clinical Study Protocol 
CSR Clinical Study Report 
CT Computed tomography 
CTC Common toxicity criteria 
CTCAE Common Terminology Criteria for Adverse Events 
DAE Discontinuation of investigational product due to adverse event 
DBP Diastolic blood pressure 
DCO Data cut-off 
DCR Disease control rate 
ECG Electrocardiogram  
ECOG Eastern Cooperative Oncology Group: A performance status using scales 
and criteria to assess how a patient’s disease is progressing. 
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EORTC European Organization for Research and Treatment of Cancer 
EQ-5D-5L EuroQoL five dimensions, five level (EQ-5D-5L) health state utility index 
FAS Full Analysis Set 
gBRCA Germline BRCA 
gBRCA mutation or 
gBRCAm 
The term "gBRCA mutation" is used to refer to a germline BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 
recommendations for standards for interpretation and reporting of sequence 
variants. 
HR Hazard ratio 
HRQoL Health-related quality of life 
ICU Intensive care unit 
IDMC Independent Data Monitoring Committee 
ITT Intention to treat 
KM Kaplan-Meier 
LD Longest diameter 
MedDRA Medical Dictionary for Regulatory Activities 
mg Milligram 
MMRM Mixed model for repeated measures 
MRI Magnetic resonance imaging 
MTP Multiple testing procedure 
NA Not applicable 
NE Not evaluable 
NED No evidence of disease 
NTL Non-target lesions 
OAE Other significant adverse event 
ORR Objective response rate 
OS Overall Survival 
PARP Polyadenosine 5’diphosphoribose [poly (ADP ribose)] polymerisation 
p.o. Per os (by mouth, orally) 
PD Progressive disease 
PFS Progression-free survival 
PFS2 Time from randomisation to second progression 
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PID  Percentage intended dose 
PR Partial response 
PRO Patient reported outcome 
PT Preferred term 
QoL Quality of life 
RDI Relative dose intensity 
RECIST Response Evaluation Criteria In Solid Tumours.  This study will use 
modified RECIST version 1.1. 
REML Restricted maximum likelihood 
RS Raw Score 
SAE Serious adverse event 
SAP Statistical Analysis Plan 
SBP Systolic blood pressure 
SD Stable disease 
SOC System organ class 
Study treatment Olaparib or matching placebo 
TDT Time from randomisation to study treatment discontinuation or death 
TFST Time from randomisation to first subsequent therapy or death 
TL Target lesions 
TSST Time from randomisation to second subsequent therapy or death 
ULN Upper limit of normal 
VAS Visual analogue scale 
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1 STUDY DETAILS 
As described in the protocol. 
1.1 Study Objectives 
Study objectives will be addressed in patients with deleterious or suspected deleterious 
germline mutation in breast cancer susceptibility gene 1 and/or 2 (BRCA1 and/or BRCA2) and 
metastatic pancreas cancer who have achieved disease control (absence of objective 




To determine the efficacy of olaparib maintenance monotherapy compared to placebo by 
progression-free survival (PFS), using blinded independent central review (BICR) according 
to modified Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1; in the 
following referred to as RECIST. 
Secondary: 
1. To determine the efficacy of olaparib maintenance monotherapy compared to placebo 
by assessment of  
• Overall Survival (OS). 
• Time from randomisation to second progression (PFS2). 
• Time from randomisation to first subsequent therapy or death (TFST). 
• Time from randomisation to second subsequent therapy or death (TSST). 
• Time from randomisation to study treatment (olaparib or matching placebo) 
discontinuation or death (TDT). 
• Objective response rate by BICR using modified RECIST criteria. 
• Disease control rate (DCR) at week 16 by BICR using modified RECIST criteria. 
2. To compare the effects of olaparib maintenance monotherapy compared to placebo on 
the health-related quality of life (HRQoL) as assessed by the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 global quality of life (QoL) 
scale.  
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To assess the safety and tolerability of olaparib maintenance monotherapy by assessment of 
adverse events (AEs), physical examination, vital signs including blood pressure, pulse, 
electrocardiogram (ECG) and laboratory findings including clinical chemistry and 
haematology. 
Exploratory: 
1. To explore the effect of olaparib on functioning as measured by the EORTC QLQ-C30 
functioning domains (physical, role, cognitive, emotional and social).  
2. To explore the effect of olaparib on pancreas cancer symptoms as measured by the 
EORTC QLQ-PAN26 items and scales. 
3. To assess clinically relevant symptoms as measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, weight loss (or difficulty gaining weight/loss of 
appetite), and jaundice. 
4. To assess the change in performance status as measured by the Eastern Cooperative 
Oncology Group (ECOG) performance status scale. 
5. To investigate the health economic impact of treatment and the disease on 
hospital-related resource use and health state utility. 
6. To explore methods of estimating OS adjusting for the impact of the control arm 
receiving subsequent Polyadenosine 5’diphosphoribose (poly [ADP ribose]) polymerise 
(PARP) inhibitors or imbalances between the treatment arms for other potentially active 
agents. 
7. To determine the frequency of and describe the nature of BRCA mutation/s in tumour 
samples and to compare this with germline BRCA mutation status. 
8. To identify tumour tissue-based biomarkers (including but not limited to somatic 
BRCA1/2 mutations, BRRCA methylation and/or other homologous recombination 
repair deficiencies biomarkers) that could be used to guide future patient segmentation 
approaches for development. 
9. Future exploratory research into factors that may influence development of cancer 
and/or response to treatment (where response is defined broadly to include efficacy, 
tolerability or safety) may be performed on the collected and stored archival tumour 
samples (if available), blood samples at day 1 and on disease progression or on residual 
tissue material collected as part of the study. 
Parts of the exploratory analyses may not be part of the analysis described in this statistical 
analysis plan (SAP) and as such, may not be reported in the Clinical Study Report (CSR).  If 
not, they will be reported separately by AstraZeneca. 
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1.2 Study Design 
This is a Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess 
the efficacy of olaparib maintenance monotherapy in metastatic pancreatic cancer patients 
with germline BRCA (gBRCA) mutations (documented mutation in gBRCA1 or gBRCA2) 
that is predicted to be deleterious or suspected deleterious (known or predicted to be 
detrimental/lead to loss of function) and whose tumours have not progressed on at least 
16-weeks of first-line platinum-based chemotherapy. 
Approximately 145 patients will be randomised (using an Interactive Voice Response 
System / Interactive Web Response System) in a 3:2 ratio to the treatments as specified below: 
• olaparib tablets per os (p.o.) 300 mg twice daily. 
• placebo tablets p.o. twice daily. 
Eligible patients will be those patients with pancreas cancer previously treated for metastatic 
disease gBRCA mutated, who have not progressed following completion of at least 16 weeks 
of first-line platinum-based chemotherapy before randomisation.  All patients must have a 
known deleterious or suspected deleterious germline BRCA mutation to be randomised.  
Determination of gBRCA mutation will be done before enrolment to the study at Myriad 
laboratories. 
Patients with known gBRCA mutation prior to randomisation will enter the study based on 
these results (by considering all other eligibility criteria as well), but undergo a confirmatory 
gBRCA test post-randomisation, while patients with unknown gBRCA mutation will enter the 
study after confirmation of gBRCA mutation.  
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is 
the day of last treatment) and study treatment will start as soon as possible but no less than 4 
and no more than 8 weeks after the last chemotherapy dose.  At the time of starting study 
treatment, all previous chemotherapy treatment should be discontinued. 
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of 
treatment (days 8, 15, 22 and 29).  Patients will then attend clinic visits every 4 weeks whilst 
on study treatment and will continue treatment until objective radiological disease progression 
as per RECIST as assessed by the investigator and as long as in the investigator’s opinion they 
are benefiting from treatment and they do not meet any other discontinuation criteria.  
Once a patient has discontinued study treatment, clinic visits will be reduced to every 8 weeks.  
Following discontinuation of study treatment, further treatment will be at the discretion of the 
investigator.  It is anticipated (but not required) that patients will be re-treated with their 
previous platinum-based regimen.  Details of any further systemic anti-cancer treatment will 
be collected until death, loss to follow-up, or withdrawal of consent.  In addition to their 
regular 8 weekly contacts, patients will be contacted in the 7 days following a specified day 
(data cut-off date [DCO]) to capture survival status.  
Statistical Analysis Plan 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1.0 
Date 22 September 2014 
 
14 
Patients will have tumour assessments according to RECIST at baseline and every 8 weeks 
(±1week) up to 40 weeks and then every 12 weeks (±1 week) relative to date of randomisation 
until objective radiological disease progression according to modified RECIST criteria.  
RECIST will be modified to assess patients with clinical CR at entry who will be assessed as 
having no evidence of disease (NED) until they have progressed based on the appearance of 
new lesions. 
Any patient who discontinues study treatment for reasons other than objective radiological 
progression should continue to undergo scheduled objective tumour assessments according to 
the study plan in order to assess objective radiological progression of disease.  Failure to do so 
may result in bias in the study results.  Once a patient has progressed, the patient will be 
followed for second progression every 8 weeks and then survival until the final analysis.  
Patients will be contacted in the week following last patient last visit for each analysis of 
survival. 
The final PFS analysis of the study will occur when approximately 89 PFS events have 
occurred, although an interim PFS analysis for superiority and futility will be performed when 
50% of the PFS events required for the final PFS analysis have occurred.  Both interim and 
final PFS analyses will be based on BICR of disease progression by modified RECIST version 
1.1; however, a sensitivity analysis will be performed using the investigator-recorded 
assessment. 
The study flow chart is in Appendix A while the study schedule is in Appendix B. 
1.3 Number of Patients 
The primary endpoint of the study is PFS.  Approximately 145 patients will be randomised 
(3:2 ratio of olaparib:placebo) and the final PFS analysis will occur once approximately 89 
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
superiority and futility will be performed when 50% of the PFS events required for the final 
analysis (approximately 45 PFS events) based on BICR have occurred. 
The study is sized assuming a true treatment effect that is a PFS Hazard Ratio (HR) of 0.54 at 
the final analysis, assuming 80% power and 2.26% alpha (1-sided), with 3:2 randomisation 
(olaparib:placebo).  Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 
3.4-month improvement in median PFS over an assumed 4-month median PFS for placebo.  
At the interim PFS analysis, 0.5% alpha (1-sided) will be spent, and controlling the type I 
error across the two time points, 89 PFS events will be required for the final PFS analysis. 
Statistical significance will be declared for PFS at the interim analysis if the 1-sided p<0.005.  
Assuming 45 PFS events at the interim, a HR ≤ 0.46 would equate to a 1-sided p<0.005.  If 
the null hypothesis for PFS is not rejected at the interim analysis time point then PFS will be 
tested again when approximately 89 PFS events have occurred.  The final significance level 
will be determined accounting for the actual correlation between the interim and final PFS 
analyses.  In order to ensure that the type I error will be controlled at 2.5% 1-sided level, if the 
interim occurs at exactly 45 PFS events and the number of PFS events at the final analysis is 
Statistical Analysis Plan 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1.0 
Date 22 September 2014 
 
15 
as planned (89 PFS events),  the 1-sided significance level to be applied for the final analysis 
would be 2.26% (Stone 2010).  Assuming 89 PFS events, a HR ≤ 0.65 would equate to a 
1-sided p-value<0.0226. 
Patients are to be followed for the final analysis of OS and PFS2 (when approximately 106 
death events have occurred).  With 106 OS events the study has 80% power to show a 
statistically significant difference in OS at the 1-sided 2.5% level if the assumed true treatment 
effect is a HR 0.57; this translates to an approximate 6-month improvement in median OS 
over an assumed 8 month median OS on placebo, assuming OS is exponentially distributed.   
Assuming that the study accrual period will be approximately 15 months, 89 PFS events are 
anticipated to be observed approximately 18 to 19 months after the first patient is randomised 
in the study.  It is estimated that 45 PFS events will occur approximately 13 to 14 months after 
first patient in.  It is estimated that 106 deaths will have occurred approximately 31 months 
after first patient in. 
2 ANALYSIS SETS 
2.1 Definition of Analysis Sets 
Full Analysis Set 
Intention to treat (ITT): The primary statistical analysis of the efficacy of olaparib will 
include all randomised patients and will compare the treatment groups on the basis of 
randomised treatment, regardless of the treatment actually received or discrepancy between 
local and Myriad gBRCA results.  Patients who were randomised but did not subsequently go 
on to receive study treatment are included in the Full Analysis Set (FAS).  Therefore, all 
efficacy endpoints will be summarised and analysed using the FAS on an ITT basis. 
In addition, key sensitivity analysis of efficacy endpoints will be performed in the subgroup of 
patients in the FAS that have a gBRCA mutation confirmed by the Myriad test. 
Safety Analysis Set  
All patients who received at least one dose of randomised investigational product, olaparib or 
placebo, will be included in the safety analysis set.  Throughout the safety results sections, all 
patients who received at least one dose of olaparib will be accounted for in the olaparib 
treatment group.  Erroneously treated placebo patients (those randomised to placebo but 
actually received at least one dose of olaparib) will be accounted for in the olaparib treatment 
group.  Any mis-randomisations will be discussed on an individual basis and decisions will be 
documented at the blind data review meeting (BDRM). 
Patient Reported Outcome Analysis Set 
The analysis population for patient reported outcome (PRO) data will be a subset of the FAS 
(ITT) population; patients must have a baseline score to be included in the analysis of PRO 
data. 
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Table 1 Summary of Outcome Variables and Analysis Populations 
Outcome Variable Populations 
Efficacy Data  
- Primary: PFS FAS (ITT), Myriad confirmed Breast 
cancer susceptibility gene mutation 
(BRCAm) subgroup 
- Secondary analysis: OS, PFS2, TFST, TSST, TDT  
- Secondary summary: objective response rate (ORR), 
disease control rate (DCR) 
 
PRO Data  
- Time to deterioration and improvement rate of global 
QoL and pancreatic cancer symptom scale 
PRO 
Demography FAS (ITT) 
Safety Data  
- Exposure, AEs, Laboratory measurements; ECGs, Vital 
signs, ECOG, Physical examinations 
Safety 
 
2.2 Violations and Deviations 
The important protocol deviations will be listed and summarised by randomised treatment 
group.  None of the deviations will lead to any patients being excluded from any of the 
analysis sets described in Section 2.1.  A per-protocol analysis excluding patients with 
significant protocol deviations is not planned; however, a ‘deviation bias’ sensitivity analysis 
will be performed excluding patients with deviations that may affect the efficacy of the trial 
therapy if > 10% of patients: 
• did not have the intended disease or indication or 
• did not receive any randomised therapy. 
The need for such a sensitivity analysis will be determined following review of the protocol 
deviations ahead of database lock or data freeze for interim and final analysis and will be 
documented prior to the analysis being conducted.   
The following general categories will be considered important deviations and be listed and 
discussed in the CSR as appropriate for study. 
• Patients randomised but who did not receive olaparib/matching placebo. 
• Patients who deviate from key entry criteria (to be determined at the BDRM), which 
will be documented ahead of database lock. 
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• Baseline RECIST scan > 28 days before start of study treatment. 
• Baseline RECIST scan after randomisation. 
The categorisation of these as important deviations is not automatic and will depend on 
duration and the perceived effect on efficacy. 
In addition to the programmatic determination of the deviations above, monitoring notes or 
summaries will be reviewed to determine any important post-entry deviations that are not 
identifiable via programming, and to check that those identified via programming are correctly 
classified. 
Mis-randomisations in terms of errors in treatment dispensing, will also be summarised and 
listed separately to the important protocol deviations.  A mis-randomisation is when a patient 
is not randomised or treated according to the randomisation schedule.  It is envisaged that 
there will be 2 subcategories of this: 
(a) Patients who receive no treatment whatsoever for a period of time due to errors in 
dispensing of medication.  Note, this is not due to tolerability issues where patients 
may stop taking drug. 
(b) The patient receives a treatment pack with a different code from their randomisation 
code.  However, the actual treatment may still match the randomised treatment.  For 
example, a patient is given randomisation code 0001, which according to the 
randomisation schedule is olaparib.  However, at the randomisation visit they are 
given treatment pack 0003, but this still contains olaparib. 
The summary will include all patients with a dispensing error but will also include 
information on how many of those patients received at least one dose of the wrong treatment 
(olaparib/placebo) at any time. 
Patients who receive the wrong treatment at any time will be included in the safety analysis 
set as described in Section 2.1.  During the study, decisions on how to handle mis-
randomisations will be made on an individual basis with written instruction from the study 
team leader and/or statistician. 
The final classification of deviations will be made at the BDRM prior to database lock or data 
freeze and all decisions will be made whilst blinded to study treatment allocation.  For 
example, details of disallowed concomitant medication use will be reviewed by a physician 
using blinded data and may be determined as key.  Decisions made at the BDRM will be 
documented and approved by AstraZeneca prior to analysis and unblinding. 
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3 PRIMARY AND SECONDARY VARIABLES 
At each visit patients will be assigned a RECIST visit response of complete response (CR), 
partial response (PR), stable disease (SD), progressive disease (PD), not evaluable (NE) or 
NED depending on the status of their disease compared to baseline and previous assessments, 
based on the BICR.  This will be repeated using the Investigator assessed RECIST data. 
3.1 Derivation of RECIST Visit Responses 
Patients with measurable or non-measurable disease or NED assessed at baseline by computed 
tomography (CT) / magnetic resonance imaging (MRI) will be entered in this study.  RECIST 
has been modified to allow the assessment of progression due to new lesions in patients with 
NED at baseline (inclusion criteria #4). 
For all patients, the RECIST tumour response data will be used to determine each patient’s 
visit response according to modified RECIST version 1.1.  It will also be used to determine if 
and when a patient has progressed in accordance with RECIST and also their best overall 
response.   
Baseline radiological tumour assessments are to be performed no more than 28 days before 
start of study treatment and as close as possible to randomisation.  Tumour assessments are 
then performed every 8 weeks (±1 week) up to 40 weeks and then every 12 weeks (±1 week) 
following randomisation until disease progression. 
If an unscheduled assessment was performed and the patient had not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits.  This 
schedule is to be followed in order to minimise any unintentional bias caused by some patients 
being assessed at a different frequency than other patients. 
At each visit, an overall visit response will be provided by the BICR and separately by the 
investigator - using the information from target lesions (TL), non-target lesions (NTL) and 
new lesions.   
3.1.1 Target lesions 
Measurable disease is defined as having at least one measurable lesion, not previously 
irradiated, which is ≥ 10 mm in the longest diameter (except lymph nodes which must have 
short axis ≥ 15 mm) with CT or MRI and which is suitable for accurate repeated 
measurements.  
A patient can have a maximum of 5 measurable lesions recorded at baseline with a maximum 
of 2 lesions per organ (representative of all lesions involved suitable for accurate repeated 
measurement) and these are referred to as TLs.  If more than one baseline scan is recorded, 
then measurements from the one that is closest to randomisation will be used to define the 
baseline sum of TLs.  It may be the case that, on occasion, the largest lesion does not lend 
itself to reproducible measurement in which circumstance the next largest lesion, which can 
be measured reproducibly, should be selected. 
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All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline.  Measurements are not required for these lesions, but their status should be followed 
at subsequent visits. 
Note: For patients who do not have measurable disease at entry (ie, no TLs) but have 
non-measurable disease, evaluation of overall visit responses will be based on the overall 
NTLs assessment and the absence/presence of new lesions (see Section 3.1.3 of the Clinical 
Study Protocol (CSP) for further details).  If a patient does not have measurable disease at 
baseline then the TL visit response will be not applicable (NA). 
For patients with NED at baseline (ie, no TLs and no NTLs), evaluation of overall visit 
responses will be based on absence/presence of new lesions.  If no TLs and no NTLs are 
recorded at a visit, both the TL and NTL visit response will be recorded as NA and the overall 
visit response will be NED. 
Table 2 TL Visit Responses 
Visit Responses Description 
CR Disappearance of all TLs since baseline.  Any pathological lymph nodes selected 
as TLs must have a reduction in short axis to <10 mm. 
PR At least a 30% decrease in the sum of diameters of TLs, taking as reference the 
baseline sum of diameters. 
SD Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD. 
PD At least a 20% increase in the sum of diameters of TLs, taking as reference the 
smallest sum on study (this includes the baseline sum if that is the smallest on 
study).  In addition to the relative increase of 20%, the sum must also indicate an 
absolute increase of at least 5 mm. 
NE Only relevant if any of the TLs were not assessed or not evaluable or had a lesion 
intervention at this visit. 
Note: If the sum of diameters meets the PD criteria, PD overrides NE as a TL 
response. 
NA No TLs are recorded at baseline. 
 
Rounding of TL data 
For calculation of PD and PR for TLs, percentage changes from baseline and previous 
minimum should be rounded to 1 decimal place before assigning a TL response.  For example 
19.95% should be rounded to 20.0% but 19.94% should be rounded to 19.9%. 
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Missing TL data  
For a visit to be evaluable, all TL measurements should be recorded.  However, a visit 
response of PD should still be assigned if any of the following occurred: 
• A new lesion is recorded. 
• A NTL visit response of PD is recorded. 
• The sum of TLs is sufficiently increased to result in a 20% increase, and an absolute 
increase of ≥ 5mm from nadir, even assuming the non-recorded TLs have 
disappeared.  Note: the nadir can only be taken from assessments where all the TLs 
had a longest diameter (LD) recorded. 
If there is at least one TL measurement missing and a visit response of PD cannot be assigned, 
the visit response is NE. 
Lymph nodes 
For lymph nodes, if the size reduces to < 10 mm then these are considered non-pathological.  
However, a size will still be given, and this size should still be used to determine the TL visit 
response as normal.  In the special case where all lymph nodes are < 10 mm and all other TLs 
are 0 mm, then although the sum may be > 0 mm the calculation of TL response should be 
over-written as a CR.  
TL visit responses subsequent to CR 
A CR can only be followed by CR, PD or NE.  If a CR has occurred then the following rules 
at the subsequent visits must be applied: 
• Step 1:  If all lesions meet the CR criteria (ie, 0 mm or < 10 mm for lymph nodes) 
then response will be set to CR irrespective of whether the criteria for PD of TL is 
also met ie, if a lymph node LD increases by 20% but remains < 10 mm.  
• Step 2:  If some lesion measurements are missing but all other lesions meet the CR 
criteria (ie, 0 mm or < 10 mm for lymph nodes), then response will be set to NE 
irrespective of whether when referencing the sum of TL diameters the criteria for 
PD is also met.  
• Step 3:  If not all lesions meet the CR criteria and the sum of lesions meets the 
criteria for PD, then response will be set to PD. 
• Step 4:  If after steps 1 – 3 a response can still not be determined, the response will 
be set to remain as CR. 
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TL too big to measure 
If a TL becomes too big to measure, this should be indicated in the database and a size (‘x’) 
above which it cannot be accurately measured should be recorded.  If using a value of x in the 
calculation of TL response would not give an overall visit response of PD, then this will be 
flagged and reviewed by the study team blinded to treatment assignment.  It is expected that a 
visit response of PD will remain in the vast majority of cases.   
TL too small to measure 
If a TL becomes too small to measure a value of 5 mm will be entered into the database and 
used in TL calculations, unless the radiologist has indicated and entered a smaller value that 
can be reliably measured.  If a TL response of PD results, then this will be reviewed by the 
study team blinded to treatment assignment. 
Irradiated lesions/lesion intervention 
Previously irradiated lesions (ie, lesion irradiated prior to entry into the study) should be 
recorded as NTLs and should not form part of the TL assessment. 
Any TL (including lymph nodes), which has had intervention during the study (for example, 
irradiation / palliative surgery / embolization), should be handled in the following way and 
once a lesion has had intervention then it should be treated as having had intervention for the 
remainder of the study, noting that an intervention will most likely shrink the size of tumours: 
• Step 1: the diameters of the TLs (including the lesions that have had intervention) will 
be summed and the calculation will be performed in the usual manner.  If the visit 
response is PD this will remain as a valid response category.  
• Step 2: If there was no evidence of progression after step 1, treat the lesion diameter (for 
those lesions with intervention) as missing and scale up as described below as long as 
there remain ≤ 1/3 of the TLs with missing measurements.  If the scaling results in a 
visit response of PD then the patient would be assigned a TL response of PD.   
Scaling will be based on the sizes at the nadir visit, to give an estimated sum of 
diameters and this will be used in calculations; this is equivalent to comparing the visit 
sum of diameters of the non-intervention lesions to the nadir sum of diameters excluding 
the lesions with interventions. 
Table 3 Example of scaling 
Lesion Longest diameter at nadir visit Longest diameter at follow-up visit 
1 7.2 7.1 
2 6.7 6.4 
3 4.3 4.0 
4 8.6 8.5 
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Table 3 Example of scaling 
Lesion Longest diameter at nadir visit Longest diameter at follow-up visit 
5 2.5 Intervention 
Sum 29.3 26 
 
Lesion 5 has had an intervention at the follow-up visit.  
The sum of lesions 1 to 4 at the follow-up is 26 cm.  The sum of the corresponding 
lesions at baseline visit is 26.8 cm. 





• Step 3: If after both steps PD has not been assigned, then if appropriate, a scaled sum of 
diameters will be calculated, treating the lesion with intervention as missing, and PR or 
SD, then assigned as the visit response.  Patients with intervention are evaluable for CR 
as long as all non-intervened lesions are 0 (or < 10 mm for lymph nodes) and the lesions 
that have been subject to intervention also have a value of 0 recorded.  If scaling-up is 
not appropriate due to too few non-missing sizes then the visit response will be set as 
NE. 
At subsequent visits the above steps will be repeated to determine the TL and overall visit 
response.  When calculating the previous minimum, lesions with intervention should be 
treated as missing and scaled up where appropriate (as per step 2 above). 
Lesions that split in two 
If a TL splits in two, then the LDs of the split lesions should be summed and reported as the 
LD for the lesion that split. 
Lesions that merge 
If two TLs merge, then the LD of the merged lesion should be recorded for one of the TL 
sizes and the other TL size should be recorded as 0 mm. 
Change in method of assessment of TLs 
Computed tomography and MRI are the only methods of assessment that can be used within 
the trial.  If a change in method of assessment occurs between CT and MRI, this will be 
considered acceptable and no adjustment within the programming is needed. 
If a change in method involves clinical examination (eg, CT changes to clinical examination), 
any affected lesions should be treated as missing. 
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3.1.2 NTLs and new lesions 
At each visit an overall assessment of the NTL response should be recorded.  This section 
provides the definitions of the criteria used to determine and record overall response for NTL 
at each visit. 
The NTL response will be derived based on the overall assessment of NTLs as follows: 
Table 4 NTL Visit Responses 
Visit Responses Description 
CR Disappearance of all NTLs present at baseline with all lymph nodes non-
pathological in size (<10 mm short axis). 
PD Unequivocal progression of existing NTLs.  Unequivocal progression may be due 
to an important progression in one lesion only or in several lesions.  In all cases 
the progression MUST be clinically significant for the physician to consider 
changing (or stopping) therapy. 
Non-CR/Non-PD Persistence of one or more NTLs with no evidence of progression. 
NE Only relevant when one or some of the NTLs were not assessed and, in the 
investigator's opinion, they are not able to provide an evaluable overall NTL 
assessment at this visit. 
Note: For patients without TLs at baseline, this is relevant if any of the NTLs 
were not assessed at this visit and the progression criteria have not been met. 
NA Only relevant if there are no NTLs at baseline. 
 
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficiently to merit discontinuation of therapy.  A 
modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status. 
The finding of a new lesion should be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumour. 
New lesions will be identified on the electronic case report form (eCRF).  The absence and 
presence of new lesions at each visit should be listed alongside the TL and NTL visit 
responses. 
A new lesion indicates progression so the overall visit response will be PD irrespective of the 
TL and NTL response. 
A lesion identified at a follow-up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. 
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If the question ‘Any new lesions since baseline’ has not been answered with Yes or No and 
the new lesion details are blank this is not evidence that no new lesions are present and should 
be treated as NE in the derivation of overall visit response. 
‘Symptomatic deterioration’ is not a descriptor for progression of NTLs: it is a reason for 
stopping study therapy and will not be included in any assessment of NTLs.  Patients with 
symptomatic deterioration requiring discontinuation of treatment without objective evidence 
of disease progression at that time should continue to undergo tumour assessments where 
possible until objective disease progression is observed. 
3.1.3 Overall visit response 
Table 5 defines how the previously defined TL and NTL visit responses will be combined 
with new lesion information to give an overall visit response.  
Table 5 Overall Visit Responses 
Target lesions Non-target lesions New lesions Overall response 
CR CR or NA No (or NE) CR 
NA CR No CR 
CR Non-CR/Non-PD or NE No (or NE) PR 
PR Non-PD or NE or NA No (or NE) PR 
SD Non-PD or NE or NA No (or NE) SD 
NA Non-CR/Non-PD No SD (Non-CR/Non-PD) 
NE Non-PD or NE or NA No (or NE) NE 
NA NE No (or NE) NE 
PD Any Any PD 
Any PD Any PD 
Any Any Yes PD 
NA NA No NED 
NA is only relevant if there were no TL/NTL at baseline. 
 
3.1.4 Independent review 
The BICR data will be used for the analysis of PFS. 
The independent review charter contains the details of the independent central review 
conducted by the AstraZeneca-appointed central Core Imaging Laboratory and will be 
developed in advance of the start of the study.  The independent data review will provide 
RECIST measurements for each visit for each patient at the time of DCO for the interim and 
final analyses of PFS.  After the final PFS analysis, BICR of scans will no longer be required.  
On an ongoing basis, patients who are determined to have progressed according to modified 
RECIST 1.1 criteria by the investigator will have scans centrally reviewed for confirmation of 
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objective disease progression.  If disease progression is not confirmed at BICR, an additional 
RECIST assessment will be requested at the next scheduled RECIST visit. 
For each patient, the independent reviewer will provide at each time point, TL and NTL 
responses with supporting dates, measurements and assessments, location of new lesions and 
comments (if applicable), overall visit responses and the relevant scan dates.  The overall visit 
response data as determined by the BICR will be used to derive PFS and best overall RECIST 
response (BoR) for the primary and secondary analyses. 
3.2 Outcome Variables 
At each visit patients will be assigned a RECIST visit response of CR, PR, SD, PD, NED, NE 
depending on the status of their disease compared to baseline and previous assessments, using 
the time point responses and relevant dates from the BICR.  Separately, the investigator will 
assign a RECIST visit response of CR, PR, SD, PD, NED, NE depending on the status of their 
disease compared to baseline and previous assessments. 
Where applicable, outcome variables, eg, PFS, OS, PFS2 etc., will be derived using time point 
responses and relevant dates from the BICR, unless otherwise stated. 
3.2.1 Progression-Free Survival 
Progression-free survival is defined as the time from randomisation until the date of objective 
radiological disease progression according to modified RECIST or death (by any cause in the 
absence of disease progression) regardless of whether the patient withdraws from randomised 
therapy or receives another anticancer therapy prior to disease progression.  Patients who have 
not progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment from their last evaluable RECIST assessment.  However, if the patient progresses 
or dies after two or more missed visits, the patient will be censored at the time of the latest 
evaluable RECIST assessment (prior to the missing visits).  Given the scheduled visit 
assessment scheme, for the first 40 weeks from randomisation, two missing visits will equate 
to more than 18 weeks since the previous RECIST assessment, allowing an extra two weeks 
for early and late visits.  After 40 weeks, two missing visits will equate to more than 26 weeks.  
If two missed visits occur over the period when the scheduled frequency of RECIST 
assessments changes (ie, from every 8 weeks to every 12 weeks), this will equate to more than 
22 weeks (allowing for an early assessment at Week 32 and a late assessment at Week 52).   
The baseline RECIST assessment should be performed prior to randomisation but if an 
evaluable RECIST assessment occurs after randomisation but before treatment then this 
assessment will be used as the baseline assessment.  If the patient has no evaluable visits or 
does not have a baseline assessment, they will be censored at day 1 unless they die within two 
tumour assessment visits of randomisation (16 weeks plus 1 week allowing for a late 
assessment within the visit window).   
If a patient has two missing visits between two evaluable RECIST assessments with outcome 
not equal to progression at the second evaluable RECIST assessment, but then subsequently 
progresses, the patient will not be censored when analysing for PFS.  For example, if RECIST 
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assessments were performed at week 8 with outcome SD, week 32 with outcome SD and 
week 40 with a progression event (weeks 16 and 24 were missed), the patient will be analysed 
from time of randomisation until progression event at week 40 without considering the 
interruptions. 
The PFS time will always be derived based on scan/assessment dates not visit dates. 
The RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates.  The following rules will be applied: 
(a) Date of progression will be determined based on the earliest of the RECIST 
assessment/scan dates of the component that triggered the progression. 
(b) When censoring a patient for PFS, the patient will be censored at the latest of the 
RECIST assessment/scan dates contributing to a particular overall visit assessment. 
Overall visit assessments will be determined by the investigator and BICR for each 
assessment (scheduled or unscheduled) and will contribute to the derivation of PFS. 
Objective progression is defined as at least a 20% increase in the sum of the diameters of the 
TLs (compared to previous minimum sum) and an absolute increase of > 5 mm, or an overall 
NTLs assessment of progression or a new lesion. 
The primary analysis will be based on the programmatically derived PFS based on the BICR 
of the radiological scans, and using all scans regardless of whether they were scheduled or not.  
A sensitivity analysis based on the derived PFS based on investigator-recorded assessments 
will be carried out. 
3.2.2 Overall Survival 
Overall Survival is defined as the time from the date of randomisation until death due to any 
cause.  Any patient not known to have died at the time of analysis will be censored based on 
the last recorded date on which the patient was known to be alive. 
Note: Survival calls will be made in the week following the date of DCO for the analysis, and 
if patients are confirmed to be alive or if the death date is not available these patients will be 
censored at the date of DCO.  Death dates may be found by checking publicly available death 
registries. 
3.2.3 Time from randomisation to second progression  
The PFS2 is defined as the time from the date of randomisation to the earliest of the 
progression event subsequent to that used for the primary variable PFS or death.  The date of 
second progression will be recorded by the investigator and defined according to local 
standard clinical practice and may involve any of objective radiological or symptomatic 
progression or death.  The RECIST assessments will not be collected for assessment of PFS2.  
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The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF. 
Second progression status will be reviewed every 8 weeks following the progression event 
used for the primary variable PFS (the first progression) and status recorded.  Patients alive 
and for whom a second disease progression has not been observed should be censored at the 
last time known to be alive and without a second disease progression, ie, censored at the latest 
of the PFS or PFS2 assessment date if the patient has not had a second progression or death. 
3.2.4 Time to first subsequent therapy or death 
As a supportive summary to PFS, TFST will be assessed at the 30-day follow-up visit 
following study treatment discontinuation and then every 8 weeks, in line with survival 
follow-up visits.  The TFST is defined as the time from randomisation to the earlier of first 
subsequent therapy start date following study treatment discontinuation, or death.  Any patient 
not known to have died at the time of the analysis and not known to have had a further 
intervention of this type will be censored at the last known time to have not received 
subsequent therapy, ie, the last follow-up visit where this was confirmed. 
3.2.5 Time to second subsequent therapy or death 
As a supportive summary to PFS2, TSST will be assessed at the 30-day follow-up visit 
following study treatment discontinuation and then every 8 weeks, in line with survival 
follow-up visits.  The TSST is defined as the time from randomisation to the earlier of the 
second subsequent therapy start date following study treatment discontinuation, or death.  Any 
patient not known to have died at the time of the analysis and not known to have had a further 
intervention of this type will be censored at the last known time to have not received second 
subsequent therapy, ie, the last follow-up visit where this was confirmed. 
3.2.6 Time to study treatment discontinuation or death 
The TDT is defined as the time from randomisation to the earlier of the date of study 
treatment discontinuation or death.  Any patient not known to have died at the time of analysis 
and not known to have discontinued study treatment will be censored based on the last 
recorded date on which the patient was known to be alive. 
3.2.7 Best overall RECIST response 
Best overall RECIST response is calculated based on the overall visit responses from each 
RECIST assessment (Table 5).  It is the best response a patient has had following 
randomisation but prior to starting any subsequent cancer therapy and prior to RECIST 
progression or the last evaluable assessment in the absence of RECIST progression. 
Categorization of BoR will be based on the RECIST criteria using the following order of 
response categories: CR, PR, SD, NED (applies only to those patients entering the study with 
no disease at baseline), PD and NE.  
BoR will be determined programmatically from the overall visit response using BICR data. 
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For determination of a best response of SD, the earliest of the dates contributing towards a 
particular overall visit assessment will be used.  SD should be recorded at least 7 weeks (ie, 8 
weeks minus 1 week to allow for an early assessment within the assessment window), after 
randomisation.  For CR/PR, the initial overall visit assessment which showed a response will 
use the latest of the dates contributing towards a particular overall visit assessment. 
For patients whose progression event is death, BoR will be calculated based on data up until 
the last evaluable RECIST assessment prior to death. 
For patients who die with no evaluable RECIST assessments, if the death occurred ≤ 17 weeks 
(ie, 16 weeks +1 week to allow for a late assessment within the assessment window) after 
randomisation then BoR will be assigned to the PD category.  For patients who die with no 
evaluable RECIST assessments, if the death occurred > 17 weeks (ie, 16 weeks +1 week) after 
randomisation then BoR will be assigned to the NE category. 
Progression events that have been censored due to them being more than two missed visits 
after the last evaluable assessment will not contribute to the BoR derivation. 
A patient will be classified as a responder if the RECIST criteria for a CR or PR are satisfied 
at any time following randomisation, prior to RECIST progression and prior to starting any 
subsequent cancer therapy.  
3.2.8 Objective response rate 
For each treatment group, the ORR is the number of CR and PR divided by the number of 
patients in the treatment group with measurable disease at baseline.  Only patients with PR 
and measurable disease at baseline can achieve an objective response of CR or PR. 
3.2.9 Disease control rate 
The DCR is defined as the percentage of patients who have at least one confirmed visit 
response of CR or PR or have demonstrated SD or NED for at least 15 weeks (ie, 16 weeks 
minus 1 week to allow for an early assessment within assessment window) prior to any 
evidence of progression.  In the case of SD and NED, follow-up assessments must have met 
the SD or NED criteria for a minimum interval of 15 weeks following randomisation. 
3.3 Patient Reported Outcome Variables 
Patient reported disease related symptoms and HRQOL will be evaluated using the validated 
EORTC QLQ-C30 and the EORTC QLQ-PAN26 questionnaire.  The EORTC QLQ-C30 was 
developed to assess HRQoL and functioning while the EORTC QLQ-PAN26 was developed 
specifically for patients with pancreas cancer.  
The EORTC QLQ-C30 comprises 30 questions designed for all cancer types.  Questions can 
be grouped into the following scales: 
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• 5 multi-item functional scales (physical, role, emotional, cognitive and social) 
• 3 multi-item symptom scales (fatigue, pain, nausea vomiting) 
• A 2-item global health status / QoL scale 
• 5 single items assessing the following common cancer symptoms: 
− dyspnoea 




• 1 item on the financial impact of the disease. 
The pancreas cancer module, PAN26, is intended for patients at all disease stages undergoing 
surgical resection, palliative surgical intervention, endoscopic palliation, or palliative 
chemotherapy.  The module comprises 26 questions assessing pain, dietary changes, jaundice, 
altered bowel habit, emotional problems related to pancreas cancer, and other symptoms 
(cachexia, indigestion, flatulence, dry mouth, taste changes). 
All the EORTC scales range from 0 to 100 (through transformation of scores as detailed 
below).  The EORTC QLQ-C30 scales can be interpreted as following: A high scale score 
represents a higher response level.  Thus a high score for a functional scale represents a high / 
healthy level of functioning, while a high score for a symptom scale / item represents a high 
level of symptomatology / problems.  The interpretation of the EORTC QLQ-PAN26 depends 
on the symptoms or problems.  For digestive symptoms, altered bowel habit, hepatic, sexuality 
and body image, a higher score represents worse QoL, while a lower score represents a good 
outcome.  For the health care satisfaction scale (items 53 and 54), a higher score represents 
good outcome while a less score represents worsening. 
Transformation of scores 
The EORTC QLQ-C30 / QLQ-PAN26 will be scored according to the EORTC scoring 
manual (Fayers et al 1999).  Each scale will be transformed to a 100-point scale as following: 
For all scales, the Raw Score (RS) is the mean of the component items: 
 
To obtain the score S, the following linear transformation will be applied: 
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Table 6 Linear Transformation of EORTC Scales 
Scale Item number  
QLQ-C30 
Item number  
QLQ-PAN26* 
Calculation of score 
Functional scale 1-7, 20-27 NA  
Symptom scales 8-19, 28 31, 33-37, 44-49  
Global Health Status / 
QoL 29, 30 NA  
Health care 
satisfaction scale NA 53, 54  
Sexuality NA 55, 56  
Range is the difference between the maximum possible value of RS and the minimum possible value.   
*A few items of the QLQ-PAN26 questionnaire are not part of the table as they are not part of a multi-item scale 
(ie, item number 32, 38, 39-43, 50-52).  Nevertheless, they need to be transformed in the same way as for 
symptom scales. 
 
The QLQ-C30 / PAN26 has been designed so that all items in any scale take the same range 
of values.  Therefore, the range of RS equals the range of the item values.  Most items are 
scored 1 to 4, giving range = 3.  The exceptions are the items contributing to the global health 
status / QoL, which are 7-point questions with range = 6. 
HRQoL visit responses 
A change of at least 10 points in the global QoL score will be considered as a clinically 
relevant or a minimally important difference (Osoba D et al 1998).  A change of at least 
10 points in the pancreas cancer module will be considered as a clinically relevant or a 
minimally important difference, too (Serrano et al 2014). 
Table 7 Mean Change and Visit Response in Health-Related QoL 
Score Change from baseline Visit response 
EORTC QLQ-C30 symptom scales ≥ +10 or patient too ill to complete measure Deterioration  
 ≤ -10 Improved 
 Otherwise No change 
≥ +10 Improved 
≤ -10 or patient too ill to complete measure Deterioration 
EORTC QLQ-C30 Global QoL 
score and functional scales: 
physical, role, emotional, cognitive 
and social Otherwise No change 
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Table 7 Mean Change and Visit Response in Health-Related QoL 
Score Change from baseline Visit response 
≥ +10 or patient too ill to complete measure Deterioration 
≤ -10 Improved 
EORTC QLQ-PAN26 scales*: 
pancreatic pain, digestive 
symptoms, altered bowel habit, 
hepatic, sexuality and body image 
multi item scales and single item 
measures 
Otherwise No change 
≥ +10 Improved 
≤ -10 or patient too ill to complete measure Deterioration 
EORTC QLQ-PAN26 scales*: 
Satisfaction with health care 
Otherwise No change 
*The change from baseline of 10 points for detecting a deterioration or improvement in the pancreas cancer 
module is based on recent investigations by Serrano et al 2014. 
 
Note for some patients it will not be immediately possible to obtain a visit response for a 
particular subscale, for example: 
• Patients with no baseline score for a particular subscale, or no baseline data at all 
• Patients whose baseline subscale score is too close to the maximum or minimum 
possible score to allow an increase or decrease of the specific size to be observed. 
− For patients whose baseline score is greater than the maximum possible score 
for that subscale minus the score needed to satisfy improvement, the best visit 
response possible will be “No Change”. 
− For patients whose baseline score is less than the threshold needed for 
worsening all post-baseline visit responses will be considered not-calculable. 
Time to deterioration of HRQoL 
Time to deterioration of HRQoL, as measured by the EORTC QLQ-C30 (global QoL) and 
EORTC QLQ-PAN26 (pancreas cancer symptom) scores, will be defined as the time from 
date of randomisation to the date of a clinically important deterioration in the EORTC 
QLQ-C30 / PAN26 score (Table 7) or death (by any cause) in the absence of a clinically 
important deterioration, provided death occurs within two HRQoL assessment visits of the last 
evaluable assessment, and regardless of whether the patient withdraws from randomised 
therapy or receives another anti-cancer therapy prior to deterioration.  “Subject Too Affected 
by Symptoms of Disease Under Investigation” answered as the reason for not completing 
HRQoL at a post-baseline visit will also signify a clinically important deterioration in 
HRQoL. 
Patients whose HRQoL has not shown a clinically important deterioration and who are alive at 
the time of the analysis will be censored at the time of their last evaluable HRQoL assessment.  
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Also, if HRQoL deteriorates after two or more missed HRQoL assessment visits or the patient 
dies after two or more missed HRQoL assessment visits, the patient will be censored at the 
time of the last evaluable HRQoL assessment. 
A patient’s best overall QoL response will be derived as the best QoL response the patient 
achieved, based on evaluable QoL data collected from randomisation up to the earliest of 
starting any subsequent cancer therapy, date of HRQoL deterioration or death.  The criteria in 
Table 8 will be used to assign a best QoL response for HRQoL based on the 2-item global 
QoL score.  Improvement rate will be defined as the proportion of patients whose best overall 
QoL response was “Improved”. 
Table 8 Best Response in EORTC QLQ-C30 Scores 
Overall Score Response Criteria 
Improved Two visit responses of “improved” a minimum of 21 days apart without 
an intervening visit response of “deterioration” 
No Change Does not qualify for overall score response of “improved”.  Two visit 
responses of either “no change” or “improved” and “no change” a 
minimum of 21 days apart without an intervening visit response of 
“deterioration” 
Deterioration Does not qualify for overall score response of “improved”.  A visit 
response of “deterioration” without response of “improved” or “no 
change” within 21 days. 
Other Does not qualify for one of the above. 
 
For each subscale, if less than 50% of the subscale items are missing, then the subscale score 
will be divided by the number of non-missing items and multiplied by the total number of 
items on the subscales.  If at least 50% of the items are missing, then that subscale will be 
treated as missing.  Missing single items are treated as missing.  The reason for any missing 
questionnaire items will be identified and recorded.  If there is evidence that the missing data 
are systematic, missing values will be handled to ensure that any possible bias is minimised. 
3.3.1 Compliance 
Summary measures of overall compliance and compliance over time will be derived for the 
global QoL score.  These will be based upon: 
• Received forms = number of EORTC QLQ-C30 / EORTC QLQ-PAN26 
questionnaire forms received back plus the number not received back where the 
reason was ‘Subject too affected by symptoms of disease under investigation’. 
• Expected forms = number of patients still under QoL follow-up at the specified 
assessment time excluding patients in countries with no available translation.   
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• Evaluable forms = subset of expected EORTC QLQ-C30 / EORTC QLQ-PAN26 
questionnaire forms with at least one subscale that can be determined; or where the 
reason questionnaire not completed is ticked as ‘Subject too affected by symptoms 
of disease under investigation’. 
Thus the compliance rate for QLQ-C30 and for QLQ-PAN26 is defined as number of patients 
with an evaluable baseline and at least one evaluable follow-up form (as defined above), 
divided by the number of patients expected to have completed at least a baseline EORTC 
QLQ-C30 / EORTC QLQ-PAN26 questionnaire form.  In addition, an overall compliance rate 
defined as number of patients with an evaluable baseline and at least one evaluable follow-up, 
divided by the number of patients expected to have completed at least a baseline for both, the 
EORTC QLQ-C30 AND EORTC QLQ-PAN26 questionnaire form, will be calculated. 
Compliance over time will be calculated separately for each visit, including baseline, as the 
number of patients with an evaluable baseline form and a form at the time point (as defined 
above), divided by number of patients still expected to complete forms at that visit.  Similarly, 
the evaluability rate over time will be calculated separately for each visit, including baseline, 
as the number of evaluable forms (per definition above), divided by the number of received 
forms. 
3.4 Safety 
Safety and tolerability will be assessed in terms of AEs (including serious AEs [SAEs]), 
deaths, laboratory data, vital signs, ECGs, physical examination, ECOG performance status, 
and exposure.  These will be collected for all patients. 
3.4.1 Adverse events 
Adverse events and SAEs will be collected throughout the study, from informed consent until 
30 days after the last dose of olaparib/placebo.  Any untoward event occurring subsequent to 
the 30-day follow-up AE reporting period that the investigator assesses as possibly related to 
the study treatment should also be reported as an AE. 
Other significant adverse events 
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs and ‘Discontinuation of Investigational Product 
due to Adverse Events’ (DAEs).  Based on the expert’s judgement, significant AEs of 
particular clinical importance may, after consultation with the Global Patient Safety Physician, 
be considered other significant adverse events (OAEs) and reported as such in the CSR.  A 
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3.4.2 Treatment exposure 
Exposure will be defined as follows: 
Total (or intended) exposure of olaparib/placebo: 
• Total (or intended) exposure in days = last dose date - first dose date + 1  
Actual exposure of olaparib/placebo: 
• Actual exposure = intended exposure – total duration of dose interruptions, where 
intended exposure will be calculated as above.  Dose interruptions are any periods 
when the patient does not take any treatment. 
To calculate actual exposure, dose interruptions will include those where a patient forgot to 
take a dose.  
Number of days on 300 mg olaparib/placebo bis in die (bid) 
• Number of days on 300 mg olaparib/placebo bd = actual exposure for the dose 
assigned.  Any days with changes in doses will not be counted. 
Compliance will be assessed by calculating the actual administration days (total planned days 
- days of interruption) divided by the total planned administration days (last dose date - first 
dose date + 1) in percent.  In addition, patient’s individual drug accountability will be listed. 
3.4.3 Dose intensity  
Relative dose intensity (RDI) is the percentage of the actual dose intensity delivered relative 
to the intended dose intensity through to treatment discontinuation.  Percentage intended dose 
(PID) is the percentage of the actual dose delivered relative to the intended dose through to 
progression.  Both will be derived using study treatment data up to the date of objective 
disease progression as defined by RECIST using the investigator site assessments.  If the 
investigator considered that it was in the patient’s best interest to continue study treatment 
past this time, this will not be included in the derivation of dose intensity.   
RDI and PID will be defined as follows: 
• RDI = 100% * d/D, where d is the actual cumulative dose delivered up to the earlier 
of progression (or a censoring event) or the actual last day of dosing and D is the 
intended (or planned) cumulative dose up to the earlier of progression (or a 
censoring event) or the actual last day of dosing. 
• PID = 100% * d/D, where d is the actual cumulative dose delivered up to 
progression (or a censoring event) and D is the intended (or planned) cumulative 
dose up to progression (or a censoring event).  D is the total dose that would be 
delivered, if there were no modification to dose or schedule. 
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3.4.4 Laboratory data  
Laboratory data will be collected throughout the study, from screening to 30-day follow-up 
visit as described in Appendix B.  Blood and urine samples for determination of pregnancy, 
haematology, clinical chemistry, and urinalysis will be collected as described in Section 5.2.1 
of the CSP.  For derivation of post baseline visit values considering visit window and how to 
handle multiple records, derivation rules as described in Section 3.4.9 below will be used. 
3.4.5 Electrocardiograms 
Electrocardiogram data will be collected during screening within 7 days prior to starting study 
treatment and when clinically indicated afterwards.  For derivation of post baseline visit 
values considering visit window and how to handle multiple records present in any visit 
window, derivation rules as described in Section 3.4.9 below will be used. 
3.4.6 Vital signs 
Vital signs data including body temperature, height, weight, pulse and blood pressure will be 
collected as described in Appendix B.  For derivation of post baseline visit values considering 
visit window and how to handle multiple records, derivation rules as described in Section 
3.4.9 below will be used. 
3.4.7 Physical examination 
Physical examination data including the following: general appearance, respiratory, 
cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose and throat), lymph 
nodes, thyroid, abdomen, musculo-skeletal (including spine and extremities), and neurological 
systems will be collected as described in Appendix B.   
3.4.8 ECOG performance status 
ECOG data will be collected as described in Appendix B.  For derivation of post baseline visit 
values considering visit window, derivation rules as described in Section 3.4.9 below will be 
used. 
3.4.9 General consideration for safety assessments 
Time windows will need defining for any presentations that summarise values by visit.  The 
following conventions should also apply: 
• The time windows should be exhaustive so that data recorded at any time point has 
the potential to be summarised.  Inclusion within the time window should be based 
on the actual date and not the intended date of the visit. 
• All unscheduled visit data should have the potential to be included in the 
summaries. 
• The window for the visits following baseline will be constructed in such a way that 
the upper limit of the interval falls half way between the two visits (the lower limit 
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of the first post-baseline visit will be Day 2).  The equation to be used to calculate 
the time windows for each post-baseline visit is: 
Lower limit of interval=Upper limit of previous visit’s time window +1 
Upper limit of interval=Nominal day at visit + ([nominal day at visiti+1 - nominal 
day at visiti]/2), where i = 3, 4, 5, 5.1, 5.2..., etc. 
If an even number of days exists between two consecutive visits then the upper limit 
will be taken as the midpoint value minus 1 day.   
For example, the visit windows for vital signs data with 28 days between scheduled 
assessments are: 
− Day 29, visit window 2 – 42 
− Day 57, visit window 43 – 70 
− Day 85, visit window 71 – 98 
− Day 113, visit window 99 – 126 
− ... 
• For summaries showing the maximum or minimum values, the maximum/minimum 
value recorded on treatment will be used (regardless of where it falls in an interval). 
• Listings should display all values contributing to a time point for a patient. 
• For visit-based summaries: 
− If there is more than one value per patient within a time window, then the 
closest value should be summarised, or the earlier in the event the values are 
equidistant from the nominal visit date.  The listings should highlight the value 
for that patient that went into the summary table, wherever feasible. 
− To prevent very large tables or plots being produced that contain many cells 
with meaningless data, for each treatment group visit data should only be 
summarised if the number of observations is greater than the minimum of 20 
and > 1/3 of patients dosed.  For example, if 150 patients were dosed in the 
study (1/3*150 = 50), data at a particular visit would be summarised if the 
number of observations is greater than min (20, 50).  This would be in each 
treatment group.  Eg, if olaparib arm at Visit 6 has > 20 observations and 
placebo arm has < 20 observations, the visit data will be summarised for the 
olaparib arm but not the placebo arm.  If both had < 20 patients, the data for 
that visit will be presented as ‘NC’ (Not Calculated). 
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• For summaries at a patient level, all values should be included, regardless of 
whether they appear in a corresponding visit based summary, when deriving a 
patient level statistic such as a maximum.  
• Baseline will be defined as the last non-missing measurement prior to dosing with 
study treatment (olaparib or placebo).  For laboratory data and vital signs data, any 
assessments made on day 1 will be considered pre-dose.  Where safety data are 
summarised over time, study day will be calculated in relation to date of first 
treatment (olaparib or placebo). 
Missing safety data will generally not be imputed.  However, safety assessment values of the 
form of “< x” (ie, below the lower limit of quantification) or “> x” (ie, above the upper limit 
of quantification) will be imputed as “x” in the calculation of summary statistics but displayed 
as “< x” or “> x” in the listings. 
3.5 Resource Use 
Resource use outcome variables include the following: 
• Total number of hospitalisations 
• Length of hospital stay 
• Reasons for hospitalisation 
• Total number of ICU admissions 
• Length of any time spent in an intensive care unit (ICU)  
• Reasons for ICU admission 
The length of hospital stay will be calculated as the difference between the date of hospital 
discharge (or death date when occurred during hospital stay) and the start date of 
hospitalisation or start of study drug if the start of study drug is after start date of 
hospitalisation (length of hospital stay = end date of hospitalisation – start date of 
hospitalisation + 1).  Patients with missing discharge dates will be calculated as the difference 
between the last day with available data (if possible, the very first confirmed date outside 
hospital will be used as discharge date) and the start date of hospitalisation. 
Sum of total duration of hospital stay will be considered for analysis if patient was admitted to 
hospital more than one time during study period.  
Hospital and ICU admissions will be counted as a single event if a patient is re-admitted 
within 24 hours.  
The length of ICU stay will be calculated using the same method as detailed above for the 
length of hospital stay. 
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4 ANALYSIS METHODS 
4.1 General Principles 
Efficacy data will be summarised and analysed using the FAS on an ITT basis while HRQoL 
data will be analysed using the PRO analysis set (see Section 2.1).  In addition, as sensitivity 
to the main analyses of PFS, PFS2, OS, TDT, TFST and TSST, analyses of these endpoints 
will be repeated in those patients whose gBRCAm status is confirmed by the Myriad test. 
Results of all statistical analysis will be presented using a 95% confidence interval (CI) and 
2-sided p-value, unless specified otherwise.  
When assessing safety and tolerability, summaries will be produced based on the safety 
analysis set.  The safety data will be summarised descriptively and will not be formally 
analysed. 
4.1.1 Presentation of results in summary tables 
If not stated otherwise, tabulations will be presented by treatment group as follows: 
• Olaparib 300 mg bd 
• Placebo bd 
• Total 
Data listings will include at least the following details: 
• Patient identifier 
• Centre identifier 
• Actual / randomised treatment group 
Data listings will be sorted by actual treatment group and patient ID, if not stated otherwise. 
4.2 Analysis Methods 
A single interim PFS analysis for futility and superiority will be performed when 50% of the 
final number of progressions has been reached (approximately 45 PFS events).  A final PFS 
analysis will be performed when approximately 89 progression events have occurred (~60% 
maturity).  No further analyses of PFS are planned beyond this point. 
Two interim analyses for OS will be performed; the first at the time of the interim PFS 
analysis (approximately 45 PFS events) and the second at the time of the final PFS analysis 
(approximately 89 PFS events).  A final analysis of OS will be performed when approximate 
106 death events have occurred. 
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Individual efficacy response data will be listed in a by-patient listing. 
Timing of the statistical analysis is given in Table 9. 
Table 9 Timing of Statistical Analyses 
Timing of analysis Outcome Variable 
Interim PFS when ~45 
PFS events reported 
PFS 
PFS2, TDT, TFST, TSST, OS, and time to deterioration and improvement 
rate of global health status / QoL and pancreatic cancer symptom scale. 
Final PFS when ~89 
PFS events reported 
PFS, PFS2, TDT, TFST, TSST, OS, and time to deterioration and 
improvement rate of global health status / QoL and pancreatic cancer 
symptom scale. 
Final OS when ~106 
OS events reported 
PFS2, TFST, TSST, OS, and - time to deterioration and improvement rate of 
global health status / QoL and pancreatic cancer symptom scale. 
Safety variables will be analysed at each analysis time point.  
 
The treatment comparison is olaparib 300 mg bid versus placebo. 
The following table details which efficacy endpoints are to be subject to formal statistical 
analysis, together with pre-planned sensitivity analyses making clear which analysis is 
regarded as primary for that endpoint.  
Table 10 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses 
Endpoints Analysed Notes 
Primary analysis: log-rank test using BICR data 
Key sensitivity analyses: log-rank test using BICR data in randomised 
patients confirmed as gBRCA mutation positive by the Myriad test (if 
subset of FAS) 
Additional sensitivity analyses:  
1) Evaluation time bias analysis; log-rank test using BICR data 
2) Attrition bias analysis (using alternative censoring rules); log-rank test 
using BICR data 
3) Ascertainment bias analysis; log-rank test using investigator data 
PFS 
4) Deviation bias analysis; log-rank test using BICR data 
Primary analysis: log-rank test  OS 
Key sensitivity analysis: log-rank test data in randomised patients 
confirmed as gBRCA mutation positive by the Myriad test (if subset of 
FAS) 
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Table 10 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses 
Endpoints Analysed Notes 
 Supportive analysis: Kaplan-Meier (KM) plot of time to censoring for OS 
Primary analysis: log-rank test using investigator assessment of second 
progression 
PFS2 
Key sensitivity analysis: log-rank test in randomised patients confirmed as 
gBRCA mutation positive by the Myriad test (if subset of FAS) 
Primary analysis: log-rank test  TDT 
Key sensitivity analysis: log-rank test in randomised patients confirmed as 
gBRCA mutation positive by the Myriad test (if subset of FAS) 
Primary analysis: log-rank test  TFST 
Key sensitivity analysis: log-rank test in randomised patients confirmed as 
gBRCA mutation positive by the Myriad test (if subset of FAS) 
Primary analysis: log-rank test  TSST 
Key sensitivity analysis: log-rank test in randomised patients confirmed as 
gBRCA mutation positive by the Myriad test (if subset of FAS) 
Primary analysis: log-rank test Time to deterioration in 
global QoL (as measured 
by the global QoL score 
from the EORTC QLQ-
C30 questionnaire) and 
in pancreatic symptoms 
(EORTC QLQ-PAN26 
Sensitivity analysis: Attrition bias analysis (using alternative censoring 
rules); log rank test 
Improvement rate in 
global QoL and in 
pancreatic symptoms 
(EORTC QLQ-PAN26 
Primary analysis: Logistic regression model 
 
Statistical Analysis Plan 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1.0 




4.2.1 Multiplicity  
In order to describe the nature of the benefits of olaparib maintenance treatment, PFS and OS 
will be tested at a 1-sided significance level of 2.5%. 
In addition to these planned analyses, which will be performed and reported in the CSR, in 
order to strongly control the type I error at 2.5% 1-sided for key label claims, a multiple 
testing procedure (MTP) will be employed across the primary endpoint (PFS) and key 
secondary endpoint (OS). 
A hierarchical testing strategy will be employed where PFS is tested first using the full test 
mass (full test mass = alpha 2.5% 1-sided) and key secondary endpoints of OS will then be 
tested using a MTP with a recycling strategy (ie, the MTP will recycle the test mass to the 
endpoint not yet rejected in the hierarchy outlined in Figure 1). 
The MTP is detailed below. 
Figure 1  Multiple Testing Procedure 
 
 
One interim efficacy analysis for PFS is planned at the time when approximately 45 PFS 
events (50% of the total 89 PFS events required for the final analysis) have occurred.  The test 
mass alpha for PFS (1-sided 2.5%) will be split between the final and interim analysis using a 
bespoke spending function where a fixed significance level of 0.5% 1-sided alpha will be 
assigned at the interim and the remaining significance level assigned to the final analysis, 
taking into account of correlation (Stone 2010).  Statistical significance will be declared at the 
interim analysis if the 1-sided p<0.005.  If the null hypothesis for PFS is not rejected at the 
interim analyses time point then PFS will be tested again when approximately 89 PFS events 
have occurred.  To ensure that the type I error will be controlled at 2.5% 1-sided level, if the 
interim occurs at exactly 45 PFS events and the final analysis at 89 PFS events accounting for 
the actual correlation between the interim and final PFS analyses, then the 1-sided 
significance level to be applied for the final analysis would be 2.26% (Stone 2010).  If PFS is 
significant at either the interim or final analyses, the full test mass (alpha) will be carried 
forward to OS. 
The OS will only be tested if the null hypothesis (of no difference) is rejected for PFS.  Two 
interim analyses for OS will be performed; the first at the time of the interim PFS analysis 
(approximately 45 PFS events) and the second at the time of the final PFS analysis 
(approximately 89 PFS events).  A final analysis of OS will be performed when approximately 
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106 death events have occurred.  Statistical significance for OS will be declared at the first 
interim analysis for OS if the null hypothesis for PFS is rejected and the observed p-value for 
OS is p<0.00005.  If the null hypothesis for OS is not rejected at this first interim analysis, 
then statistical significance for OS will be declared at the next interim analysis (final analysis 
of PFS) if the null hypothesis for PFS has been rejected and the observed 1-sided p-value for 
OS is <0.01499.  The final significance level will be determined accounting for the actual 
correlation between the interim and final OS analyses.  For example, to ensure that the type I 
error will be controlled at the 2.5% 1-sided level, if the interim analyses occur at exactly 30% 
and 57% of events respectively and the number of OS events at the final analysis is 
approximately 106 then the 1-sided significance level to be applied for the final analysis 
would be 1.53%. 
Table 11 shows the expected nominal p-values required to produce a significant result at each 
of the planned analyses.  Note that the actual nominal significance level at final analysis will 
depend on the exact number of patients analysed (information fraction). 
Table 11 1-Sided Significance Levels and Critical Values for PFS and OS to 
Control Type-I Error at 2.5% Across Multiple Time Points 















1 0.005 ~45 0.46 0.00005 ~32 0.22 
2 0.0226 ~89 0.65 0.01499 ~60 0.56 
3 ---   0.0153 ~106 0.65 
Assumes: 50% of final PFS events at k=1 for PFS; 30% and 57% of final OS events at k=1 and 2 for OS.  Note, 
the null hypothesis for OS could not be rejected if PFS hurdle is not met.  The significance levels at k=2 for 
PFS and k=3 for OS will be adjusted to account for the correlation between final and interim analysis while 
the significance levels at k=1 for PFS and k=1, 2 for OS will be fixed and does not account for patient 
accrual.   
 
Summary tables of hierarchical testing after approximately 50% progression events and 57% 
death events will be provided. 
 
4.2.2 Primary variable - progression free survival 
A summary of PFS will be prepared to present the number of patients with progression and no 
progression.  Tabulation will detail the total number of progressions and no progressions, the 
number of patients with progression identified by RECIST (separately for TLs, NTLs, and 
new lesions) and death as well as details about non-progressed patients including the number 
of patients progression-free at time of DCO, lost to follow-up, withdrawn consent, and 
prematurely censored (RECIST or death) if they did not progress and if the latest scan prior to 
DCO was more than one scheduled tumour assessment interval (+ 2 weeks) prior to the DCO 
date.  The summary will be presented by treatment group. 
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The PFS as defined in Section 3.2.1 will be analysed using a log-rank test for generation of the 
p-value and using the Breslow approach for handling ties in the following manner: 
PROC LIFETEST DATA=...; 
  TIME pfsTime*censor(1); 
  TEST trtn; 
RUN; 
By using the TEST-Statement within LIFETEST procedure the test statistics U and the 
covariance matrix will be averaged over the possible orderings of the tied failure times (SAS 
Lifetest 2008). 
The HR and its CI will be estimated from the log-rank (U and V statistics) follows directly 
from the LIFETEST model as used above for calculation of p-values (Berry et al 1999 and 
Sellke et al 1983) 
 
 
Where  is the log-rank test statistic (with  and  the observed and 
expected events in group 1); and  the variance of the log-rank test statistic.   and  will be 
obtained directly from LIFETEST procedure;  will be taken from the table “Rank Statistics” 
while  will be taken from the table “Covariance Matrix for the Log-Rank Statistics”. 
The log-rank test statistic, the HR (olaparib vs. placebo) together with its corresponding 95% 
CI and p-value will be presented (a HR less than 1 will favour olaparib). 
The median and 95%-CI of PFS and the proportion of patients progression-free at 6 months, 
12 months will be summarised and presented by treatment group. 
In addition, duration of follow-up will be summarised using median time from randomisation 
to date of censoring (date last known to be non-progressor) in censored (not progressed) 
patients only, presented by treatment group. 
The following KM plots of PFS will be presented by treatment group.  The KM plot will be 
prepared using LIFETEST procedure and selecting ODS graphics.  The plot will identify 
censored patients using a different symbol and include patients at risk at specific time points: 
• PFS 
• PFS with censoring and event flags reversed 
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The assumption of proportionality will be assessed.  Note that in the presence of non-
proportionality, the HR will be interpreted as an average HR over the observed extent of 
follow-up.  Proportionality will be tested firstly by producing plots of complementary log-log 
(event times) versus log (time) and, if these raise concerns, a time dependent covariate would 
be fitted to assess the extent to which this represents random variation.  The complementary 
log-log plot will be directly produced in SAS LIFETEST procedure using ODS graphics 
option PLOTS=(LLS) in the PROC-Statement.  The graph will be assessed visually.  Two 
parallel lines favour the proportionality assumption.  To support the proportionality 
assessment a Cox proportional hazard’s model will be constructed containing the interaction 
of treatment and the logarithm of PFS (treatment*log(PFS)).  The p-value obtained from the 
Wald Chi-squared test for the time dependent covariate will be presented.  The following 
SAS-code may be used: 
PROC PHREG DATA=...; 
  CLASS trtn (REF='placebo') / PARAM=REFERENCE; 
  MODEL pfs*censor(1)=trtn timeDependent / TIES=EFRON; 
  timeDependent = trtn*LOG(pfs); 
  proportionality_test: TEST timeDependent; 
RUN; 
A further analysis of PFS (using investigator assessed RECIST) may be performed at the time 
of the final OS analyses, if requested by health authorities.  A final decision will be made at 
the BDRM for the final OS analysis. 
4.2.2.1 Progression-free survival sensitivity analyses 
As a sensitivity analysis to the primary endpoint of PFS, the primary analysis will be repeated 
excluding any patients who did not have a gBRCA mutation status confirmed by the central 
Myriad test.  The same methodology and model will be used as for the primary analysis and 
the HR and associated 95% CI will be reported.  A KM plot of PFS in this subset of patients 
will be presented by treatment group.  
Summary statistics for the number of weeks between the time of progression and the last 
evaluable RECIST assessment prior to progression will be presented for each treatment group. 
(a) Attrition bias 
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of patients who progressed or died in the 
absence of progression immediately following two, or more, non-evaluable tumour 
assessments will be included.  In addition, patients who take subsequent therapy prior to their 
last evaluable RECIST assessment or progression or death will be censored at their last 
evaluable assessment prior to taking the subsequent therapy.  
A KM plot of the time to censoring where the censoring indicator of the primary PFS analysis 
is reversed will be produced (called median time to follow-up where events will be censored 
and previously censored patients will be treated as events). 
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A by-patient listing will be produced similar to the PFS listing but including only patients who 
progressed but were censored for the primary analysis due to missing of two, or more, non-
evaluable tumour assessments.  The actual PFS times will be reported. 
(b) Evaluation-time bias 
A sensitivity analysis will be performed to assess possible evaluation-time bias that may be 
introduced if scans are not performed at the protocol-scheduled time points.  The log-rank test, 
as described for the primary analysis of PFS, will be repeated using the midpoint between the 
time of progression and the previous evaluable RECIST assessment to derive PFS time for 
patients with RECIST progression events.  For patients whose death was treated as a PFS 
event, the date of death will be used to derive the PFS time used in the analysis.  This 
approach has been shown to be robust to even highly asymmetric assessment schedules (Chen 
and Sun 2010).  This approach will use the BICR RECIST assessments.   
To support this analysis, the individual mean time difference between RECIST assessments 
(patient inter-assessment times) will be calculated and summarised using descriptive statistics. 
(c) Ascertainment bias 
The primary analysis of PFS (log-rank test) will be repeated using investigator assessed 
RECIST data.  The HR and 95% CI will be presented. 
Disagreements between investigator and central reviews of RECIST progression will be 
presented for each treatment group.  The summary will include the early discrepancy rate 
which is the frequency of central review declared progressions before the investigator review 
as a proportion of all central review progressions and the late discrepancy rate which is the 
frequency of central review declared progressions after the investigator review as a proportion 
of all discrepancies. 
If there is an important discrepancy between the primary analysis using BICR assessments and 
this sensitivity analysis using investigator assessments, the proportion of patients with site but 
no central confirmation of progression will be summarised by treatment group and the primary 
analysis will be repeated for this subset of patients.  The approach of imputing an event at the 
next visit in the central review analysis may help inform the most likely HR value, but only if 
an important discrepancy exists.  Discrepancy between the primary analysis using BICR 
assessments and investigator assessments of progression will be discussed at the BDRM.  The 
study team will decide whether the discrepancy between assessments is of importance and 
whether or not additional analyses are required.  
A by-patient listing will be produced to present patients where at least one assessment differs 
between investigator and central reviews of RECIST progression. 
 
 
Statistical Analysis Plan 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1.0 
Date 22 September 2014 
 
46 
(d) Deviation bias 
As a sensitivity analysis to the primary endpoint of PFS, an analysis excluding patients with 
“important” deviations that may affect the efficacy of the trial therapy will be performed if the 
following deviations were reported for > 10% of patients: 
• did not have the intended disease or indication or 
• did not receive any randomised therapy 
A log-rank test will be repeated using the BICR RECIST data, using the same method as 
described for the primary analysis of PFS.  The HR and 95% CI will be presented. 
The treatment status at progression by patients who have progressed / censored including the 
number of patients and percentage of on-treatment or discontinued will be tabulated.  The 
number of days from treatment discontinuation to progression for patients who have 
discontinued treatment will be summarised descriptively.  Data will be presented by treatment 
group. 
Patients censored for progression at more than 14 weeks before the DCO (‘censored > 14 
weeks before DCO’, ‘censored <= 14 weeks before DCO’) will be tabulated and presented by 
treatment group. 
A by-patient listing will be produced including patients with an important deviation only. 
4.2.2.2 Progression-free survival subgroup analyses 
Subgroup analyses will be conducted comparing PFS between treatments.  The purpose of the 
subgroup analyses is to assess the consistency of treatment effect across potential or expected 
prognostic factors.  If there are too few events available for a meaningful analysis of a 
particular subgroup (it is not considered appropriate to present analyses where there are less 
than 20 events in a subgroup), the relationship between that subgroup and PFS will not be 
formally analysed.  In this case, only descriptive summaries will be provided. 
The following subgroups will be analysed for PFS: 
• Type of previous chemotherapy (doublets vs. triplets); Reference=doublets 
• Time on first-line treatment till randomisation (≤ 6 months vs > 6 months); 
Reference=≤6 months 
• Best response on first-line treatment (SD vs PR/CR); Reference=SD 
These will be determined from the “Previous Cancer Therapy” (CAPRX) module of the eCRF 
at screening. 
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• Measurable versus non measurable disease / NED at baseline; Reference=non 
measurable disease / NED at baseline 
This will be determined from the “Tumour Evaluation Target Lesions RECIST1.1 - Baseline” 
(RECIST11) module of the eCRF at screening. 
• BRCA mutation type, eg, BRCA1, BRCA2 or BRCA1/2 (both); 
Reference=BRCA1 
This will be determined from the Myriad central laboratory test data transfer.  If there are less 
than 20 events in the “BRCA1/2 both” category, these patients will be excluded from this 
analysis. 
• Age at randomisation (>= 65 vs. < 65); Reference=< 65 
• Race; Reference=White 
• Sex; Reference=Male 
These will be determined from the “Demography” (DEM) module of the eCRF at screening. 
Other baseline variables may also be assessed if there is clinical justification.  A final decision 
will be made at the BDRM. 
For each subgroup, the HRs (olaparib: placebo) and associated CIs will be calculated from a 
Cox proportional hazards model (TIES = Efron) that contains the treatment group, factor 
(subgroup) and treatment-by-factor interaction term.  Reference cell coding will be used 
introduced by the PARAM=REFERENCE option in the CLASS-Statement.  Individual 
reference levels will be defined using the REF= option within the CLASS-Statement for each 
subgroup.  The treatment effect HRs for each treatment comparison along with their CIs will 
be obtained for each level of the subgroup from this single model.  Analysis will be carried 
out using PHREG procedure in SAS in the following manner: 
PROC PHREG DATA=...; 
  CLASS trtn (REF='placebo') chemoType (REF='doublets') 
    / PARAM=REFERENCE; 
  MODEL pfs*censor(1)=trtn chemoType trtn*chemoType  
    / TIES=EFRON; 
RUN; 
The HRs and 95% CIs will be presented in an overview table as well as on a forest plot 
including the HR and 95% CI from the overall population (using the HR and 95% CIs from 
the primary analysis). 
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No adjustment to the significance level for testing will be made since all these subgroup 
analyses will be considered exploratory and may only be supportive of the primary analysis of 
PFS. 
A by-patient listing will be produced for presenting individual PFS data. 
4.2.3 Overall Survival 
A summary of survival status at the time of analysis will be produced.  This will summarise 
the number of patients who have died, who are still in survival follow-up, who are lost to 
follow-up or who have withdrawn consent.  Results will be presented by treatment group.   
Overall Survival as defined in Section 3.2.2 will be analysed at the time of the interim and 
final analysis for PFS and will use the same methodology and model (provided there are 
sufficient events available for a meaningful analysis [> 20 deaths], if not descriptive 
summaries only will be provided).  A further analysis of OS will be performed when 
approximately 106 deaths have occurred. 
Median Overall Survival will be summarised including the number of deaths, and survival at 
month 6 and 12.  Results will be presented by treatment group. 
The sensitivity analyses outlined for PFS in Section 4.2.2 will not be repeated for OS with the 
exception of a KM plot.  Two KM plots will be produced.  The first KM plot will show time 
to censoring of OS and the second KM plot will show will show time to censoring where the 
censoring indicator is reversed (median time to follow-up where events will be censored and 
previously censored patients will be treated as events). 
Overall Survival data will be listed in a by-patient listing. 
Overall Survival effect at the final analysis  
A predicted treatment effect for OS at the final OS analysis will be calculated in a supportive 
analysis to assist in quantifying the treatment effect for PFS in terms of a clinical benefit at the 
time of the PFS analysis (interim and final) when the OS analysis would still be 
underpowered.  This predicted OS effect,  ,will be derived using a weighted sum of the 
observed OS effect and an estimate of the OS effect using observed PFS data at the time of the 
PFS analyses (interim and final) in the following way (see Chen and Sun 2011): 
 
    (1) 
with 
    (2) 
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    (3) 
 
    (4) 
where 
•  is the predicted OS treatment effect at the final analysis.  This will be referred to 
as the predicted OS effect (average weighting). 
•  is the weight, based on the inverse of the variance (ie, those studies included in 
the assessment of the relationship between PFS and OS based on historical data 
with more uncertainty will be given less weight). 
•  is the observed treatment effect (ln HR) for OS (see Section 4.2.3). 
•  is the natural estimate of the OS effect (ln HR) based on the historical 
relationship in effect size. 
•  represents the estimated slope relating PFS to OS from historical data (ratio of OS 
effect to PFS effect on natural log scale), and  (> 0) is the corresponding standard 
error. 
Historical data from Phase III studies and large Phase II studies (>40 patients per arm) 
comparing treatments for metastatic pancreatic cancer will be included.  A simple linear 
regression model weighted by the size of the trial (where size = number of OS events [Sabin et 
al 2014]) will be constructed with the intercept assumed to be zero to obtain estimates of the 
slope and standard error.  Full details including a list of studies to be included and all relevant 
model specifications and derivations will be described in a separate plan, which will include 
the details of the correlation between PFS and OS in historical advanced pancreatic cancer 
data under the responsibility of AstraZeneca. 
•  is the observed treatment effect (ln HR) for PFS (see Section 4.2.3). 
•  is the variance estimate for observed OS treatment effect (on natural log scale). 
•  is the variance estimate for observed PFS treatment effect (on natural log 
scale). 
In addition, a predicted OS effect using a more conservative weighting which will take into 
account any residual variability from the linear regression model on historical data, will also 
be calculated.  The variance of  will include a term, , to incorporate this:   
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    (4’) 
The predicted OS effect based on a more conservative weighting using the variance (4’) will 
be referred to as the predicted OS effect (alternative weighting). 
Assume asymptotic normality for the test-statistic , each predicted OS effect, , will be 




where  is an estimate of the correlation between  and  (the observed treatment effects 
for OS and PFS) and will be estimated via a bootstrapping method performed on the observed 
data.  Datasets with the same number of patients as the overall study will be created from 
sampling pairs of PFS and OS data.  For each dataset, the PFS and OS treatment effects 
(ln HRs) will be calculated.  This will be repeated 10,000 times and a linear regression 
analysis performed to estimate the correlation between PFS and OS, ie, . 
The estimates of both the predicted OS effect (average weighting) and the predicted OS effect 
(alternative weighting), together with 95% CIs and p-values will be presented. 
4.2.4 Time from randomisation to second progression 
The status of PFS2 as defined in Section 3.2.3 will be summarised by the number and 
percentage of patients experiencing a PFS2 event and the type of progression (objective 
progression by RECIST, symptomatic progression or death).  Results will be presented by 
treatment group.   
The analysis of PFS2 will use the same methodology and model as the primary analysis of 
PFS.  No multiplicity adjustment will be applied as this is viewed as a supportive endpoint. 
A KM plot of PFS2 will be provided by treatment group.  A KM plot of the time to censoring 
where the censoring indicator of the PFS2 analysis is reversed will be produced (called 
median time to follow-up where events will be censored and previously censored patients will 
be treated as events). 
As a key sensitivity, the analysis of PFS2 will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of PFS2 in this subset of patients will be 
presented by treatment group. 
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The median and 95%-CI of time to PFS2 and the proportion of patients progression-free at 
6 months, 12 months will be summarised and presented by treatment group. 
Median time and 95% CI from PFS2 to previous investigator assessment will be summarised 
by treatment group. 
A by-patient listing will be produced including details about time of second progression. 
4.2.5 Time to first subsequent therapy or death  
The TFST will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HRs for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group.   
As a key sensitivity, the analyses of TFST will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of TFST in this subset of patients will be 
presented by treatment group. 
The time between progression and starting subsequent therapy will be summarised. 
In addition, best overall RECIST response to first subsequent therapy by treatment group will 
be provided. 
Individual TFST will be presented in a by-patient listing. 
4.2.6 Time to second subsequent therapy or death  
The TSST will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HRs for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group.   
As a key sensitivity, the analyses of TSST will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  KM plots of TSST in this subset of patients will be 
presented by treatment group. 
In addition, best overall RECIST response to second subsequent therapy by treatment group 
will be provided. 
Individual TSST will be presented in a by-patient listing. 
4.2.7 Time to study treatment discontinuation or death 
The TDT will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HR for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group. 
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As sensitivity, the analyses of TDT will be repeated in those patients whose gBRCAm status 
is confirmed by the Myriad test.  A KM plot of TDT in this subset of patients will be 
presented by treatment group. 
Individual TDT will be presented in a by-patient listing. 
4.2.8 Best overall RECIST response and objective response rate 
For each treatment group, BoR as defined in Section 3.2.7 will be summarised by n (%) for 
each category (CR, PR, SD, NED, PD, NE).  No formal statistical analyses are planned.   
The ORR as defined in Section 3.2.8 will be summarised and analysed (ie, number of patients 
[%]) by treatment group, in patients in the FAS (ITT population) with measurable disease at 
baseline.  Any patients who experienced CR or PR which was first observed whilst receiving 
subsequent therapy after discontinuation of olaparib will be identified.  The denominator for 
the response rate will be measurable disease at baseline as defined by the BICR data.  The 
ORR will be analysed using a logistic regression model.  The model will include a binary 
variable as response (response=1; no response =0) and treatment group as explanatory 
variable in the MODEL-Statement together with the option CLPARM=PL to compute profile 
likelihood CIs and p-values.  Explanatory variables will be introduced using a reference cell 
coding (option PARAM=REFERENCE) while the option REF= will be used to identify the 
reference.  The following provides sample SAS code for implementing the analysis: 
PROC LOGISTIC DATA=… ALPHA=0.05; 
   CLASS trt(REF=’PLACEBO’) / PARAM=REFERENCE; 
   MODEL improvement (EVENT=’1’) = trt / CLPARM=PL; 
   EXACT trt / ESTIMATE; 
RUN; 
If the overall response rate is < 5%, no analysis will be performed (note that if the response 
rate in only one of the treatment groups is < 5% but ≥ 5% in the other treatment group then the 
analysis will still be performed).  If the overall response rate is low (< 20%) a Fisher’s exact 
test (for an example SAS code see below) will be considered and mid p-values used.  The 
results of the analysis will be presented in terms of an odds ratio together with its associated 
profile likelihood CIs and p-values (based on twice the change in log-likelihood resulting from 
the addition of a treatment factor to the model). 
PROC FREQ DATA=…; 
   TABLE improvement * trt / FISHER; 
   EXACT OR / ALPHA=0.05; 
RUN; 
In addition, the duration and onset of objective response in patients with objective response 
will be summarised by treatment group.  Duration and onset of objective response is defined 
as time from the first documentation of CR/PR until the date of progression, or the last 
evaluable RECIST assessment for patients that do not progress. 
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BoR will be presented in a by-patient listing.  In addition, a listing will be prepared including 
objective responders (confirmed CR or PR) only. 
4.2.9 Disease control rate 
The DCR as defined in Section 3.2.9 will be summarised (ie, n, %) by treatment group.  The 
DCR will be presented based on the BICR data and also the investigator recorded data.  
4.2.10 Target lesion summary and other efficacy 
Target lesion size, and percentage change from baseline will be summarised by treatment 
group and time point using descriptive statistics.  The best change in TL will be presented in a 
waterfall plot for each treatment group separately.  The best change in TL size is the 
maximum reduction from baseline or the minimum increase from in the absence of a 
reduction.  Lesion data will be listed in a by-patient listing. 
Subsequent cancer therapy relative to progression will be summarised using frequency counts 
and percentages.  The tabulation will detail any patients receiving any further therapy for 
cancer by time of therapy (‘After progression’, ‘Before progression’, ‘No progression’).  
Tabulation will include the number of patients where no subsequent cancer therapy was 
recorded as well.  Data will be presented by treatment group. 
4.2.11 Patient reported outcomes 
The analysis population for PRO data will be the PRO analysis set as defined in Section 2.1.  
Derivations and rules for transformation of PRO data are defined in Section 3.3. 
Impact of olaparib on HRQOL 
The impact of olaparib on HRQOL will be assessed through an analysis of the global health 
status / QoL gathered from items 29 and 30 of EORTC QLQ-C30 while pancreatic pain will 
be assessed through items 31, 33, 34, 35 of EORTC QLQ-PAN26.  
Descriptive statistics including change from baseline score will be produced by time point for 
the EORTC QLQ-C30 global health status / QoL and EORTC QLQ-PAN26 pancreatic pain 
scores.  Results will be presented by treatment group.  Arithmetic mean (± standard deviation) 
plots of scores versus time point will be produced in linear scale.  
Frequency tables will be prepared to present the number of patients (and percentages) with a 
deterioration and improvement in global health status / QoL and pancreatic cancer symptoms 
scores.  Results will be presented by treatment group. 
Time from randomisation to first global health status / QoL and pancreatic cancer symptoms 
scale deterioration will be analysed using the same methodology and model as described for 
the primary analysis of PFS including a KM-Plot.  However, sensitivity analyses will not be 
performed (with the exception of attrition bias).  Results will be presented by treatment group. 
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Global health status / QoL and pancreatic pain scores improvement rate will be analysed using 
a logistic regression model.  The model includes a binary variable as response 
(improvement=1; no improvement=0) and treatment group as an explanatory variable in the 
MODEL-Statement together with the option CLPARM=PL to compute profile likelihood CIs 
and p-values.  Explanatory variables will be introduced using a reference cell coding (option 
PARAM=REFERENCE) while the option REF= will be used to identify the reference.  The 
following provides sample SAS code for implementing the analysis: 
PROC LOGISTIC DATA=… ALPHA=0.05; 
   CLASS trt(REF=’PLACEBO’) / PARAM=REFERENCE; 
   MODEL improvement(EVENT=’1’) = trt / CLPARM=PL; 
   EXACT trt / ESTIMATE; 
RUN; 
If the overall improvement rate is < 5%, no analysis will be performed (note that if the 
response rate in only one of the treatment groups is < 5% but ≥ 5% in the other treatment 
group then the analysis will still be performed).  If the overall response rate is low (< 20%) a 
Fisher’s exact test (for an example SAS code see below) will be considered and mid p-values 
used.  The results of the analysis will be presented in terms of an odds ratio together with its 
associated profile likelihood CIs and p-values (based on twice the change in log-likelihood 
resulting from the addition of a treatment factor to the model). 
PROC FREQ DATA=…; 
   TABLE improvement * trt / FISHER; 
   EXACT OR / ALPHA=0.05; 
RUN; 
In addition, a summary table of global health status / QoL and pancreatic pain best change 
rates will be provided (improvement, worsening, no change). 
As supportive analyses, change from baseline in global health status / QoL and pancreatic 
symptoms scale scores will be analysed using a mixed model for repeated measures (MMRM) 
analysis of all of the post-baseline scores for each visit.  The study discontinuation visit and 
the safety follow-up visit will be excluded from this analysis.  Restricted maximum likelihood 
(REML) estimation will be used.  The model will include treatment, centre, visit and treatment 
by visit interaction as explanatory variables and the baseline score as a covariate.  Treatment, 
visit and treatment by visit interaction will be fixed effects in the model; centre will be a 
random effect.  The treatment by visit interaction will remain in the model regardless of 
significance. 
An unstructured covariance matrix will be used to model the within-patient error and the 
Kenward-Roger approximation will be used to estimate the degrees of freedom.  The 
following provides sample SAS code for implementing the MMRM analysis: 
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PROC MIXED DATA=… METHOD=REML; 
   CLASS trt centre visit patient; 
   MODEL cfb = trt visit centre trt*visit base / S DDFM=KR; 
   REPEATED visit / TYPE=UN SUBJECT=patient; 
   RANDOM intercept / SUBJECT=centre; 
   LSMEANS trt*visit / SLICE=visit PDIFF ALPHA=0.05 CL; 
RUN; 
where TRT is the treatment group, CENTRE is the centre, VISIT is the visit, CFB is the 
change from baseline in the global health status / QoL (separately the PAN26) score, and 
BASE is the baseline score. 
If the fit of the unstructured covariance structure fails to converge, the following covariance 
structures will be tried in order until convergence is reached: Toeplitz with heterogeneity, 
autoregressive with heterogeneity, Toeplitz, and autoregressive.  If there are still issues with 
the fit of the model or estimation of the treatment effects, CENTRE will be treated as a fixed 
effect and the RANDOM-Statement removed. 
The adjusted mean estimates (obtained from LSMEANS-Statement as the calculated least 
square means are adjusted for the random component of the model) and corresponding 95% 
CIs will be presented by visit for each treatment group. 
A by-patient listing will be produced presenting the EORTC QLQ-C30 global health status / 
QoL scale.  A separate by-patient listing will be produced for EORTC QLQ-PAN26 scales.  
Listings will include the items of interest and the transformed scales by time point. 
Compliance 
The EORTC QLQ-C30 and EORTC QLQ-PAN26 compliance (overall compliance and by 
visit compliance) will be summarised and presented by treatment group. 
4.2.12 Exploratory analyses 
EORTC QLQ-C30 functional and symptom scales and EORTC QLQ-PAN26 scales 
The analysis as described above to assess the impact of olaparib on HRQoL will be repeated 
for EORTC QLQ-C30 functional and symptom scales as well as for EORTC QLQ-PAN26 
scales.  This involves the following analysis: 
• Descriptive statistics including change from baseline 
• Frequency table of deterioration and improvement 
• Arithmetic mean (±standard deviation) plots of scores versus time point 
• Analyses of time to deterioration 
• Analyses of improvement rate 
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• Analyses of compliance 
Supportive analyses (of time to first deterioration and improvement rates) will be performed 
for the individual EORTC QLQ-C30 functional scales (physical, role, cognitive, emotional, 
social).  Treatment estimates and 95% CI for each domain will be presented on forest plots 
(one for HRs of time to deterioration and one for odds ratios of improvement rate).  P-values 
will not be calculated for these supportive analyses.  These additional sub-scales are 
considered exploratory to support the primary EORTC QLQ-C30 global QoL and will be used 
to assess whether any observed differences in the global measure are driven by particular 
domains of functioning, symptoms, or group of symptoms. 
A by-patient listing will be produced presenting the EORTC QLQ-C30 functional and 
symptom scales.  A separate by-patient listing will be produced for EORTC QLQ-PAN26 
scales.  Listings will include the items and the transformed scales by time point. 
EuroQoL five dimensions, five level health state utility index 
EuroQoL five dimensions, five level health state utility index (EQ-5D-5L) and visual 
analogue scale data will be analysed using the PRO analysis set. 
Five level health state utility index will be tabulated by presenting the baseline and the worst 
status during treatment.  Visual analogue scale (VAS) for health status will be summarised 
using descriptive statistics.  The change from baseline and the percentage change from 
baseline will be calculated for each time point and presented by actual treatment group.  The 
VAS will be presented graphically using arithmetic mean (±standard deviation) plot. 
By-patient listings will be produced presenting the individual EQ-5D-5L raw scores and 
review assessments. 
Resource use 
Total length of hospital stay and total length of ICU stay (number of days) will be summarised 
by randomised treatment group.  Total number of nights spent in hospital and in ICU, the 
number of hospitalisations and reasons for hospitalisation will also be summarised by 
randomised treatment group. 
A by-patient listing will be produced presenting details of hospital and ICU stay. 
ECOG 
A by-patient listing will be produced presenting details of ECOG performance status. 
Impact of Switching to PARP inhibitors (or other potentially active investigational 
agents) on Overall Survival Analysis 
Exploratory analyses of OS adjusting for impact of subsequent PARP inhibitor trial or 
treatment may be performed if a sufficient proportion of patients receive the therapies of 
interest.  Decision will be made at the BDRM.   
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Methods such as Rank Preserving Structural Failure Time (RPSFT) (Robins et al 1991), 
Inverse Probability of Censoring Weighting (IPCW) (Robins 1993) and other methods in 
development will be explored.  The decision to adjust and final choice of methods will be 
based on a blinded review of the data and the plausibility of the underlying assumptions.   
Baseline and time-dependent characteristics will be explored, and summaries of baseline 
characteristics will be summarised for patients receiving physician’s choice of chemotherapy, 
splitting between those that have and haven’t received a PARP inhibitor at the time of the 
analyses.  Further detail will be provided in the Payer Analysis Plan under the responsibility 
of AstraZeneca.  These analyses are intended to support reimbursement appraisals. 
Biomarkers 
If available, individual biomarker will be listed in a by-patient listing. 
4.2.13 Safety 
Safety data will be summarised and listed only.  No formal statistical analyses will be 
performed on the safety data.  All safety data will be summarised by actual treatment group 
(olaparib or placebo).  However, some listings such as AEs listings will display the actual 
dose the patient received at onset of an AE. 
Adverse events 
All AEs, both in terms of Medical Dictionary for Regulatory Activities (MedDRA) preferred 
term (PT) and Common Toxicity Criteria for Adverse Events (CTCAE) grade, will be listed 
and summarised descriptively by count (n) and percentage (%) for each treatment group.  
MedDRA dictionary will be used for coding.  Any AE occurring before olaparib/placebo 
treatment (ie, before Study Day 1) will be included in the AE listings, but will not be included 
in the summary tables (unless otherwise stated).  These will be referred to as ‘pre-treatment’. 
The summary tables will include all AEs that occurred after the start of treatment up until the 
end of the 30 day follow-up period.  The 30 day follow-up period will be defined as 30 days 
following discontinuation of olaparib/placebo treatment.  Any untoward event occurring 
subsequent to the 30-day follow-up AE reporting period that the investigator assesses as 
possibly related to the study treatment will also be included in the AE listings, but not in the 
summary tables. 
All reported AEs will be listed along with the date of onset, date of resolution (if AE is 
resolved), investigator’s assessment of severity and relationship to study drug.  Frequencies 
and percentages of patients reporting each PT will be presented (ie, multiple events per patient 
will not be accounted for apart from on the episode level summaries).  
Summary information (the number and percent of patients by actual treatment) will be 
tabulated for: 
• All AEs  
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• All AEs causally related to study medication 
• AEs with CTCAE grade 3 or higher 
• AEs with CTCAE grade 3 or higher, causally related to study medication 
• AEs with outcome of death 
• AEs with outcome of death causally related to study medication 
• All SAEs 
• All SAEs causally related to study medication  
• DAEs 
• AEs leading to discontinuation of olaparib/placebo, causally related to study 
medication 
• OAEs 
• Other significant AEs causally related to study medication  
An overall summary of the number and percentage of patients in each category will be 
presented, as will an overall summary of the number of episodes in each category. 
In addition, a truncated AE table of most common AEs, showing all events that occur in at 
least 5% of patients overall will be summarised by PT, by decreasing frequency.  This cut-off 
may be modified after review of the data. 
Each AE event rate (per 1000 patient years) will also be summarised by PT within each 
system organ class (SOC).  The event rate will be calculated as the number of patients with 
that AE divided by the sum of the duration of therapy (for patients without the event) and the 
time to the AE (for patients with the event) in each group multiplied by 1000.  The 
denominator defines the time at risk for an event with:  
• Duration of therapy (days) calculated as:  
MINIMUM([date of last dose + 30-day safety follow-up period], OS date, DCO) – 
date of first dose + 1 
• Time to the AE (days) calculated as date of first occurrence of the AE – date of first 
dose + 1 (in days) 
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PT =Patients with the event reported; eg, all patients with an AE where PT equals to 
‘Headache’. 
 =Patients without the event; eg, all patients who never experienced an AE where PT is 
equal to ‘Headache’. 
AEs will be assigned CTCAE grades (National Cancer Institute CTCAE version 4.0) and 
summaries of the number and percentage of patients will be provided by maximum reported 
CTCAE grade, SOC, PT and actual treatment group.  Tabulation will be repeated to present 
AEs with a CTCAE grade 3 or higher and separately those AEs, causally related to study 
treatment by SOC and PT.  Fluctuations observed in CTCAE grades within the same PTs 
during study will be listed. 
Tabulation of AEs causally related to study treatment will be summarised by SOC and PT and 
presented by treatment group. 
Summaries of the number and percentage of patients with AEs leading to dose change of 
olaparib/placebo and also dose interruptions of olaparib/placebo will be presented by PT and 
treatment group.   
A summary table will be prepared presenting AEs which started prior to first dose or > 30 
days following date of last dose by SOC and PT.  Data will be presented by treatment group. 
Death 
A summary of all AEs resulting in deaths will be provided with number and percentage of 
patients by actual treatment group, categorised as: 
• Related to disease under investigation  
• AE outcome=death 
• Both related to disease under investigation and with AE outcome=death  
• AE with outcome=death ≥30 days after last treatment dose  
• Deaths ≥ 30 days after last treatment dose, unrelated to AE or disease under 
investigation 
• Patients with unknown reason for death  
In addition, AEs with outcome of death will be summarised.  The following summary tables 
will be prepared and presented by treatment group: 
• By SOC and PT 
• Causally related to study treatment by SOC and PT 
Statistical Analysis Plan 
Drug Substance Olaparib  
Study Code D081FC00001 
Edition Number 1.0 
Date 22 September 2014 
 
60 
• Death will be listed as part of TLFs for part 11 of the CSR 
Serious AEs 
The following SAE summaries and listings will be prepared.  Summaries will be presented by 
treatment group: 
• By SOC and PT 
• Causally related to study treatment by SOC and PT 
• Listing of key information 
Discontinuation 
AEs leading to discontinuation of study treatment will be summarised by SOC and PT.  In 
addition, AEs leading to discontinuation of study treatment, causally related to study treatment 
will be summarised by SOC and PT.  Details of AEs leading to discontinuation will be 
presented in a by-patient table. 
Listings 
By-patient listings will be produced as following: 
• A by-patient listing of AEs 
• A by-patient listing of AEs causally related to olaparib 
• A by-patient listing of SAEs 
• A by-patient listing of AEs with CTCAE grade 3 or higher (separately for causally 
related to olaparib) 
• A by-patient listing of AEs leading to dose reduction or dose interruption 
• A by-patient listing of AEs presenting any events that occur prior to dosing or 
starting more than 30 days after discontinuing therapy 
Summary of Long Term Tolerability 
To assess long term tolerability, prevalence plots, life table plots and cumulative incidence 
plots will be presented for: 
• Nausea 
• Vomiting 
• Any other events considered important after review of the safety data, provided 
there are ≥ 5% events overall. 
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Data for nausea and vomiting will be listed in a by-patient listing. 
For each AE, median time from randomisation to first onset of the AE (in days) will be 
presented by treatment group.  Calculation will be done using the KM-technique.  Patients 
who did not experience the AE will be censored at the end of their safety follow-up or DCO.  
Summary tables of time to first onset for each AE will also be produced (eg, 1-28 days, 29-56 
days, 57-84 days, 85-112 days, >112 days).  Median duration of the AE where each patient is 
represented for the first occurrence of a PT only will be presented in patients who experienced 
each AE.  The end date of an AE should be defined as: MINIMUM(AE end date, [date of last 
dose + 30-day safety follow-up period], OS date, DCO). 
Prevalence Plot 
A prevalence plot provides information on the extent to which the events may be an ongoing 
burden to patients.  The prevalence at time t after first dose of study treatment is calculated as 
the number of patients experiencing the event divided by the number of patients receiving 
study treatment or in safety follow-up at time t; generally, t is categorised by each day after 
dosing (t=0 at Day 1, which is the day of first dosing).  Presented as formula: 
 
 =Patients with the event reported at time t; eg, all patients with an AE where PT equals to 
‘Headache’ at study day 11 (study day is relative to first dosing). 
 =All patients receiving study treatment or are in safety follow-up at time t. 
The prevalence is plotted over time (in months) split by treatment group.  Multiple 
occurrences of the same event are considered for each patient but a patient is only counted 
once in the numerator whilst they are experiencing one of the occurrences of the event.  
Life-Table Plot 
A life table plot can be used to describe the time to onset of the event and specifically when 
patients are at most risk of first experiencing the event.  The hazard, or in other words, the 
probability of having an AE in a specified time period (eg, 0-1 months, 1-3 months, 3-6 
months, etc.) given that the patient reaches that time period without having an event is plotted 
for each time period split by treatment group.  The event rate is derived as the number of 
patients who had a first occurrence in that time period divided by the total number of patients 
receiving study treatment or are in safety follow-up who were event free at that time point.  
Presented as formula: 
 
 =Patients with the event reported at time t; eg, all patients with an AE where PT equals to 
‘Headache’ with first occurrence in time category ‘3-6’ months. 
 =All patients event-free and receiving study treatment or are in safety follow-up at time t. 
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Cumulative Incidence Plot 
A cumulative incidence plot is a plot of the raw cumulative incidence and cumulative 
incidence function (CIF) over time.  Treatment groups will be presented on separate plots.  
The raw cumulative incidence is the actual probability that a patient will have experienced 
their first occurrence of the event by a given time point.  The cumulative incidence function 
estimates the raw cumulative incidence if the DCO had not been imposed and all patients had 
completed safety follow-up.  The CIF represents the probability that an individual will 
experience an event of type i by time t and can be calculated as following: (Pintilie M. 2006). 
 
  = to be the empirical estimate of the CIF for the event of type i 
  = to be the number of events of type i that occur at time  
  = to be the number at risk at time  
  = to be the KM-estimator of the probability of being free of any event by time  
 can be obtained using PROC LIFETEST in SAS®.   and  are time j and event i 
specific and can be calculated directly in SAS®. 
 
Laboratory assessments 
For all continuous laboratory assessments, absolute value, change from baseline and 
percentage change from baseline will be summarised using descriptive statistics at each 
scheduled assessment time by actual treatment group. 
Shift tables for laboratory values by worst common toxicity criteria (CTC) grade will be 
produced, and for electrolytes separate shift tables indicating hyper- and hypo- directionality 
of change will be produced. 
For parameters with no CTCAE grading, shift tables from baseline to worst value on-
treatment will be provided (ie, on-treatment is defined as data collected up until the last dose 
of olaparib/placebo). 
Shift tables for urinalysis values by worst grade will be provided.  
Box-plots of absolute values and change from baseline for continuous laboratory assessments 
will be presented. 
A scatter plot of alanine aminotransferase (ALT) versus total bilirubin, both expressed as 
multiples of upper limit of normal (ULN) (calculated as ULN divided by maximum observed 
post-baseline result), will be produced in log-scale.  The scatter plot will be repeated for 
Aspartate aminotransferase (AST) versus total bilirubin. 
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Liver biochemistry test results over time for patients with elevated ALT or aspartate 
aminotransferase (AST) (AST or ALT ≥3xULN), and elevated total bilirubin (at any time ≥ 
2xULN) will be tabulated and plotted. 
Clinically significant laboratory results will be flagged and listed.  Reference ranges will also 
be listed.  All laboratory summaries and listings will be presented by actual treatment group. 
By-patient listings of laboratory assessments will be provided showing at least: laboratory 
parameters, scheduled time point, measurements/results, CTC grade (if available), and the 
change from baseline value (for continuous data) (if appropriate).  In addition a flag will 
indicate if the value was out of normal range, if appropriate: 
• Laboratory reference ranges 
• Hematology  
• Serum chemistry 
• Urinalysis 
• Individual patient data with elevated ALT or AST plus total bilirubin 
• Pregnancy report data 
Electrocardiagrams 
If available, overall evaluation of ECG will be summarised by visit as normal, abnormal or 
borderline.  
All ECG data will be listed by actual treatment group. 
Vital signs 
Vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate, body 
temperature and weight) will be summarised by time point in terms of absolute values, 
changes from baseline and percentage changes from baseline at each scheduled measurement 
by actual treatment group.  A shift table comparing baseline to maximum value on treatment 
will be summarised for each vital sign by actual treatment group. 
Box plots for absolute values and change from baseline in SBP, DBP, pulse rate, body 
temperature, and weight will be presented. 
Vital signs data will be listed. 
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• Any concomitant procedures patients experiencing during the study will be listed in 
a by-patient listing 
• Patients experiencing a Hy’s Law incident will be tabulated and details will be 
included in by-patient listings.  Hy’s Law incidents are those cases where a patient 
shows an AST or ALT ≥ 3xULN or total bilirubin ≥ 2xULN.  Please refer to 
Appendix D of the CSP for further instructions. 
4.2.14 Demographic and baseline characteristics data 
The following will be listed and summarised by randomised treatment group using the FAS 
analysis set: 
• Listing of patients receiving the various batches of investigational product 
• Listing of randomisation scheme and codes 
• Patient disposition (including screening failures and reason for screening failure, 
reasons for patients prematurely withdrawing from study, patients with a mis-
randomisation [treatment dispensing error] and patients who were unblinded, 
discontinuation of study treatment) 
• Important deviations including patients with a dispensing error and the number of 
patients received at least one dose of the wrong study treatment (see Section 2.2) 
• Inclusion and exclusion from analysis populations; exclusions from full, safety and 
PRO analysis set 
• Demographics (age in years, age group in years (‘< 33’, ‘>= 33 - < 50’, ‘>= 50 - 
< 65’, ‘>= 65 - < 88’ and ‘> 88’), sex, race, and ethnicity) 
• Patient characteristics (baseline height [cm], baseline weight [kg], baseline body 
mass index [BMI] [kg/m²], weight group [< 70 kg, 70 kg to 90 kg, > 90 kg], BMI 
group [‘Normal (< 25)’, ‘Overweight (25 - 30)’, ‘Obesity (> 30)’]) 
• Patient recruitment by country and centre 
• All (allowed) concomitant medications on entry and during the study 
• Disallowed concomitant medications on entry and during the study (defined at the 
BDRM) 
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• Disease characteristics at baseline including BRCA testing (local and Myriad) and 
pathology at time of diagnosis  
• Extent of disease 
• Disease related medical history per CRF 
• Relevant surgical history per CRF 
• Pregnancy at baseline (entry) 
• Physical examination at baseline (entry) 
• Archival paraffin embedded tumour tissue or cytology sample 
• Blood transfusion 
• Previous radiotherapy and radiotherapy post randomisation 
• Post-discontinuation cancer therapy, defined as any therapy received after 
discontinuation of study treatment 
• Patients who subsequently received a PARP inhibitor or entered a PARP inhibitor 
trial will be summarised and listed by treatment group according to line of 
subsequent therapy, ie, immediately after olaparib or as a later line, in addition to 
patients in the placebo arm who subsequently received olaparib 
• Previous disease-related treatment modalities (metastatic pancreas cancer therapy) 
• Previous non-disease-related treatment modalities 
• Initial vomiting and nausea data will be listed only 
AstraZeneca drug dictionary will be used for concomitant medication coding. 
Patients who were unblinded (a) prior to disease progression and (b) prior to or on the day of 
treatment discontinuation will be listed. 
4.2.15 Treatment exposure 
The following summaries related to study treatment will be produced for the Safety Analysis 
Set by actual treatment group: 
• Total exposure of olaparib/placebo 
• Actual exposure of olaparib/placebo 
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• Number of days on 300 mg olaparib/placebo bd = actual exposure for the dose 
assigned 
• Reasons for dose reductions, dose interruptions, and dose modifications of 
olaparib/placebo.  Dose reductions and dose interruptions will be based on 
investigator initiated dosing decisions.  Dose interruptions/reductions due to 
“Subject Forgot to Take Dose” will be omitted from these summaries 
• Number of dose reductions, dose interruptions, and dose modifications of 
olaparib/placebo that last for a period of three days or more 
• PID and RDI of olaparib/placebo (entire intended treatment period) 
For patients on study treatment at the time of the PFS analysis, the DCO date will be used to 
calculate exposure. 
Treatment compliance will be summarised by treatment group using descriptive statistics.  
Tabulation will be presented by actual treatment group. 
All treatment information data will be listed:  
• Study treatment compliance 
• Administration of investigational product 
• Duration of exposure 
• Overdose report 
5 INTERIM ANALYSES 
A single interim PFS analysis for superiority and futility will be performed when 50% of the 
PFS events required for the final analysis have occurred (approximately 45 PFS events) based 
on BICR.  The interim analysis will be performed by an Independent Data Management 
Committee (IDMC) and full details will be provided in the IDMC charter.   
Section 4.2.1 details the spending function used to account for multiplicity introduced by 
including interim analyses for superiority. 
Interim analyses of OS will be performed at the time of the interim analyses of PFS (~45 PFS 
events), and again at the final analyses of PFS (~89 PFS events).  A final analysis of OS will 
be performed when approximately 106 OS events have occurred. 
If the interim PFS results indicate superiority, then analyses of all other endpoints would be 
performed and the results of these analyses will form the basis for submissions for regulatory 
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approval.  Patients would continue to be followed for PFS and survival until ~89 PFS events 
had occurred, and then followed for survival until 106 patients had died. 
The futility analyses on PFS will be used to guide decisions on stopping the study for futility 
or continuing the study.  Safety data will form part of this decision.  The predictive power will 
be calculated and used to guide the decision on stopping for futility.  A predictive power of 
20% or higher is considered to be sufficiently high to warrant continuing the study.  The 
predictive power is the probability of a statistically significant result at the final OS analysis, 
given the observed treatment effect at the interim analysis and using that as the best estimate 
of the true treatment effect in the remainder of the study.  Details will be documented in the 
IDMC charter. 
6 CHANGES OF ANALYSIS FROM PROTOCOL 
• Section 8.2.1 of the CSP says: “[…] Therefore, all efficacy and health-related QoL 
data will be summarised and analysed using the FAS on an intention-to-treat (ITT) 
basis.”.  
Efficacy data will be summarised and analysed using FAS on an ITT basis while 
HRQoL data will be summarised and analysed using the PRO analysis set. 
• Page 102, last paragraph of the CSP states the following: “As patients will be 
randomised, imbalances in demographic factors between the treatment groups are 
not anticipated.  However if any imbalances should occur, the HR and associated 
confidence interval calculated from a Cox Proportional Hazards model containing 
treatment and these additional demographic variables, may be reported.”.  
AstraZeneca do not normally carry out statistical assessment of balance at baseline 
so do not suggest it for this study as well.  If anything appeared quite strongly not to 
be balanced, this will be commented in the CSR and additional analysis requested to 
be produced. 
• Section 8.8.1 of the CSP details for OS that the “[…] Statistical significance for OS 
will be declared the first at interim analysis for OS if the null hypothesis for PFS is 
rejected and the observed p-value for OS is p>0.005. […]”.  
AstraZeneca corrected the typographic error of the significance level for OS.  
Statistical significance for OS will be declared the first at interim analysis for PFS, 
if the null hypothesis for PFS is rejected and the observed p-value for OS is 
p>0.00005. 
• Section 8.2.1 of the CSP defines the Full Analysis Set as following: “The primary 
statistical analysis of the efficacy of Olaparib will include all randomised patients 
and will compare the treatment groups on the basis of randomised treatment, 
regardless of the treatment actually received.[…]”  
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Clarification for ITT population with respect to gBRCA testing added, resulting in 
the following definition for the full analysis population: “The primary statistical 
analysis of the efficacy of olaparib will include all randomised patients and will 
compare the treatment groups on the basis of randomised treatment, regardless of 
the treatment actually received or discrepancy between local and Myriad gBRCA 
results.” 
• Section 8.5 of the CSP defines deterioration and improvement for pancreas cancer 
quality of life questionnaire as following: “[…] For change scores, a score of +5 is 
considered deterioration (except for the two scales mentioned above) and a score of 
-5 is considered as improvement. […]”.  
When the protocol was written, minimal interpretive data was available for quality 
of life assessment in pancreas cancer.  Serrano et al 2014 suggest using a change of 
10 points for detecting a deterioration or improvement for investigation of pancreas 
cancer.  This SAP defines a change of 10 points as a notable change instead of a 
change of 5 points as defined by the CSP to be in line with recent investigations. 
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Appendix A: Study Flow Chart 
Figure 2 Study Flow Chart 
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Appendix B: Study Schedule 
 





















Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Informed consent  X X          
Randomisation f   X f         
Demographics X X          
Medical and surgical history, 
including blood transfusions a 
 X          
Prior cancer therapies 
including radiotherapy 
 X          
Inclusion/exclusion criteria X (all * 
criteria) b 
X          
Blood samples for gBRCA 
status c 
X   X d         
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Archival paraffin embedded 
tumour tissue or cytology 
sample e 
X X          
Concomitant medications   X X X X X X X X X  
ECOG performance status   X     X X X X  
Vital signs   X g X  
g 
   X X X X  
Physical examination h   X     X X X X  
ECG i  X As clinically indicated    
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Tumour assessment (modified 
RECIST) j 








Every 8 weeks (± 1 week) until week 40 
then every 12 weeks (±1 week), relative to 
the date of randomisation j 
If patient 
does not have 
disease 
progression 












 X X  
l 
   X X X  X  
Coagulation m  X As clinically indicated    
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 
Urinalysis n  X As clinically indicated    
Pregnancy test  o X X X         




   
EORTC QLQ-C30 q  X     X X X X  
EORTC QLQ-PAN26 q  X  X X X X X X X  
Euro QoL EQ5D   X X    X X X X  
Hospital Resource Use   X X X X X X X X  
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Cycle/ Visit    1 (28 days) 2 3+ 
(every 
28 days) 
   
Day  -28 to 0 1 8 15 22 29 57+   Every 8 
weeks 
Visit window    ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d 





X X X X X X X X X  
Study drug dispensing s   X    X X     
Study drug return        X X X X  
Subsequent cancer treatment t          X  X 
Second progression 
assessment u 
          X u 
Survival status v           X v 
 
a Include history of blood transfusion within previous 120 days from start of study treatment and the reasons eg, bleeding or myelosuppression. 
b These screening assessments do not need capturing on the eCRF, but they must be recorded in the patient’s notes. 
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c Patients must have a known deleterious or suspected deleterious BRCA mutation to be randomised to the study; this can be either a local lab result or a 
Myriad test result.  Patients for whom their gBRCA status is already known, should be consented to the study within 28 days prior to day 1 of study 
treatment.  Any patient who consents to study related Myriad gBRCA status testing, must also have a blood sample taken at the same time for the 
purpose of developing and validating a future diagnostic test(s) for gBRCA mutations. 
d Samples to be taken on Day 1 only for patients with known gBRCA mutation who have not completed PART 1 Screening.  The screening gBRCA test 
and method performed at site must be recorded in the eCRF. 
e Collection of an archival tumour sample is requested, if available, for all patients.  These samples will be collected from the site pathologist during the 
screening Part 1 for patients with unknown gBRCA status and screening Part 2 for patients with known local gBRCA test. 
f Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last treatment) and treatment started as soon 
as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose.  At the time of starting protocol treatment, all previous 
chemotherapy treatment should be discontinued. 
g Vital signs performed on day 1 before every cycle.  If vital signs assessed within 7 days before starting study treatment, it does not need to be repeated 
on Day 1 of study treatment unless investigator believes that it is likely to have changed significantly.  
h Physical examination should be performed according to the schedule.  After the baseline assessment it is not necessary to record the details on the eCRF, 
any clinically significant changes not unequivocally related to disease progression, should be reported as adverse events. 
i ECG assessments to be completed within 7 days before starting treatment if patient is eligible following completion of all other PART 2 assessments.  
After screening, ECGs will only be required if clinically indicated. 
j Baseline RECIST assessments will be performed using CT scans of the chest, abdomen and pelvis (or MRI where CT is contraindicated) and should be 
performed no more than 28 days before start of study treatment and as close as possible to randomisation.  A randomisation must be within 6 weeks of 
last chemotherapy.  Treatment should be started as soon as possible but no less than 4 weeks and no more than 8 weeks after their last dose of 
chemotherapy.  RECIST follow-up assessments will be performed every 8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) 
irrespective of treatment decisions.  Follow-up assessment will include CT assessments of chest, abdomen and pelvis (or MRI where CT is 
contraindicated) for all patients.  Any other sites at which new disease is suspected should also be appropriately imaged.  Patients must be followed until 
disease progression assessed using modified RECIST criteria.  If an unscheduled assessment was performed and the patient has not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits.  Prior to primary analysis for PFS, all scans will be submitted 
for independent review.  If progression is not confirmed at central review an additional RECIST assessment will be requested at the next scheduled visit. 
k For patients who discontinue study treatment prior to disease progression, RECIST assessments will continue until objective disease progression (every 
8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) relative to date of randomisation, until objective disease progression as defined 
by modified RECIST.). 
l Haematology and clinical chemistry should be performed at screening and day 1 of every cycle.  Safety blood samples do not need to be repeated on Day 
1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study treatment, unless the 
investigator believes that it is likely to have changed significantly.    
m Coagulation test should be performed at screening and if clinically indicated.  
n Urinalysis should be performed at screening.  After screening, urinalysis will only be required if clinically indicated.  
o In the event of suspected pregnancy during the study, the test should be repeated and, if positive, the patient discontinued from study treatment 
immediately. 
p Mandatory blood samples for biomarker analysis to be taken prior to dosing on Cycle 1 Day 1 and at disease progression. 
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q Questionnaires to be completed prior to randomisation once eligibility has been confirmed and then until objective radiological disease progression, at 
discontinuation of study treatment visit and then 30 days post last dose.  Questionnaires should be completed prior to dosing on all administrations. 
r Adverse events must be captured from time of consent.  However, in Screening PART 1 of the study only SAEs related to study procedures will be 
collected. 
s Continuous Olaparib 300mg/ placebo twice daily dosing.  Sufficient study treatment should be dispensed for at least each treatment period plus overage, 
however additional treatment can be dispensed to patients to last longer in accordance with local practice.  
t All anti-cancer treatments (including, but not limited to, chemotherapy and targeted agents), and the Investigator’s opinion of response to them, plus the 
date of progression post discontinuation of study treatment, need to be recorded.  
 
u Second disease progression (PFS2) assessment will be performed by the Investigator and defined according to local standard clinical practice and may 
involve any of; objective radiological or symptomatic progression or death.  Subsequent therapy will be collected for these patients from the time of 
treatment discontinuation. 
v The status of ongoing, withdrawn (from the study) and ‘lost to follow-up’ patients at the time of an OS analysis should be obtained by the site  personnel 
by checking the patients notes, hospital records, contacting the patient’s general practitioner and checking publicly available death registries.  In the 
event that the patient has actively withdrawn consent to the processing of their personal data the vital status of the patient can be obtained by site 
personnel from publicly available resources where it is possible to do so under applicable local laws (see Section 3.10 of the CSP).  In addition to their 
regular 8 weekly contact, patients will be contacted in the 7 days following a specified date (data cut-off date) for each survival analysis. 
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LIST OF ABBREVIATIONS 






AML Acute myeloid leukemia
AST Aspartate aminotransferase
Baseline Refers to the most recent assessment of any variable prior to first dosing 
with study treatment
BDRM Blind data review meeting
bid Bis in die (Latin for 'twice a day')
BICR Blinded independent central review
BMI Body mass index
BoR Best overall RECIST response
BRCA Breast cancer susceptibility gene
BRCA mutation Breast cancer susceptibility gene mutation (see gBRCA mutation or 
gBRCAm)
CI Confidence interval 
CIF Cumulative incidence function
CR Complete response
CRF / eCRF Case Report Form (electronic)
CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed tomography
CTC Common toxicity criteria
CTCAE Common Terminology Criteria for Adverse Events
DAE Discontinuation of investigational product due to adverse event
DBP Diastolic blood pressure
DCO Data cut-off
DCR Disease control rate











ECOG Eastern Cooperative Oncology Group: A performance status using scales 
and criteria to assess how a patient’s disease is progressing.
EORTC European Organization for Research and Treatment of Cancer
EQ-5D-5L EuroQoL five dimensions, five level (EQ-5D-5L) health state utility index
FAS Full Analysis Set
gBRCA Germline BRCA
gBRCA mutation or 
gBRCAm
The term "gBRCA mutation" is used to refer to a germline BRCA1 or 
BRCA2 mutation classified as "deleterious" or "suspected deleterious" in 
accordance with the American College of Medical Genetics and Genomics 
recommendations for standards for interpretation and reporting of sequence 
variants.
HR Hazard ratio
HRQoL Health-related quality of life
ICU Intensive care unit
IDMC Independent Data Monitoring Committee




MedDRA Medical Dictionary for Regulatory Activities
mg Milligram
MMRM Mixed model for repeated measures
MRI Magnetic resonance imaging
MTP Multiple testing procedure
NA Not applicable
NE Not evaluable
NED No evidence of disease
NTL Non-target lesions
ORR Objective response rate
OS Overall Survival
PARP Polyadenosine 5’diphosphoribose [poly (ADP ribose)] polymerisation












PFS2 Time from randomisation to second progression
PID Percentage intended dose
PR Partial response
PRO Patient reported outcome
PT Preferred term
QoL Quality of life
RDI Relative dose intensity
RECIST Response Evaluation Criteria In Solid Tumours.  This study will use 
modified RECIST version 1.1.
REML Restricted maximum likelihood
RS Raw Score
SAE Serious adverse event
SAP Statistical Analysis Plan
SBP Systolic blood pressure
SD Stable disease
SOC System organ class
Study treatment Olaparib or matching placebo
TCMD Time to sustained clinically meaningful deterioration (in HRQoL)
TDT Time from randomisation to study treatment discontinuation or death
TFST Time from randomisation to first subsequent therapy or death
TL Target lesions
TSST Time from randomisation to second subsequent therapy or death
ULN Upper limit of normal
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AMENDMENT HISTORY 
Date Brief description of change
14 Dec 2018  Change in definition for best response in HRQoL.
 Additional exposure calculation for mean total daily dose
 Analysis population for EQ-5D-5L changed from Safety Set to Full 
Analysis Set
 Additional statistics for treatment difference estimates in the change 
from baseline HRQoL analysis
02 Aug 2018  Added analysis of time to sustained clinically meaningful deterioration 
in HRQoL.
06 Nov 2017  Changes in line with changes and reductions to the TFL shells.
 Update to the PRO analysis set definition.
 Additional specification of important protocol deviations.
 Logistic regression analysis for Objective Response Rate (ORR) added.
 Remove selected OS analysis
 Updated time to second progression (PFS2) analysis section to confirm 
that PFS2 is based on investigator assessment. Censoring rules in case 
of two or more missed visits also added.
29 May 2015 In line with the Clinical Study Protocol (CSP) Amendment: 
 Removal of the interim superiority analysis (change to futility only) as 
per Regulatory Agency recommendation.  This included recalculation of 
the number of events needed for the primary PFS analysis.
 Change to the method used for Type 1 error adjustment for the interim 
and final analyses of overall survival as per Regulatory Agency 
recommendation.
 Inclusion of additional subgroup analyses as per Regulatory Agency 
recommendation.
 Standardisation of the analysis of patient reported outcomes to be in line 
with other studies in the olaparib programme and to ensure consistency 
within the protocol.
 Minor clarifications for the derivation of statistical endpoints in line 
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Date Brief description of change
Further updates:
 Additional detail to clarify the independent central review process for 
tumour scans.
 Clarification of programming of time-to-event endpoints in line with AZ
oncology statistical guidance, i.e. to add one day to avoid issues with 
censoring at Day 1.
 Clarification that best objective response, objective response rate and 
disease control rate will be repeated using investigator-recorded 
assessment as well as blinded independent central review data.
 Additional detail to describe summaries of duration of response and 
time to onset of response.
 Further detail on EQ-5D-5L questionnaire.
 Further clarification of dose intensity calculations for olaparib.
 Inclusion of interaction testing for progression-free survival.
 Inclusion of overall survival subgroup analyses.
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1. STUDY DETAILS
As described in the protocol.
1.1 Study Objectives
Study objectives will be addressed in patients with deleterious or suspected deleterious 
germline mutation in breast cancer susceptibility gene 1 and/or 2 (BRCA1 and/or BRCA2) and 
metastatic pancreas cancer who have achieved disease control (absence of objective 
progression) after receiving a minimum of 16 weeks of first-line platinum-based 
chemotherapy.
Primary:
To determine the efficacy of olaparib maintenance monotherapy compared to placebo by 
progression-free survival (PFS), using blinded independent central review (BICR) according 
to modified Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1; in the 
following referred to as RECIST.
Secondary:
1. To determine the efficacy of olaparib maintenance monotherapy compared to placebo 
by assessment of 
 Overall survival (OS).
 Time from randomisation to second progression (PFS2).
 Time from randomisation to first subsequent therapy or death (TFST).
 Time from randomisation to second subsequent therapy or death (TSST).
 Time from randomisation to study treatment (olaparib or matching placebo) 
discontinuation or death (TDT).
 Objective response rate by BICR using modified RECIST criteria.
 Disease control rate (DCR) at week 16 by BICR using modified RECIST criteria.
2. To compare the effects of olaparib maintenance monotherapy compared to placebo on 
the health-related quality of life (HRQoL) as assessed by the European Organization for 
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Safety:
To assess the safety and tolerability of olaparib maintenance monotherapy by assessment of 
adverse events (AEs), physical examination, vital signs including blood pressure, pulse, 
electrocardiogram (ECG) and laboratory findings including clinical chemistry and 
haematology.
Exploratory:
1. To explore the effect of olaparib on functioning as measured by the EORTC QLQ-C30 
functioning domains (physical, role, cognitive, emotional and social). 
2. To explore the effect of olaparib on pancreas cancer symptoms as measured by the 
EORTC QLQ-PAN26 items and scales.
3. To assess clinically relevant symptoms as measured by the EORTC QLQ-C30 and 
PAN26, including pain, fatigue, nausea, weight loss (or difficulty gaining weight/loss of 
appetite), and jaundice.
4. To assess the change in performance status as measured by the Eastern Cooperative 
Oncology Group (ECOG) performance status scale.
5. To investigate the health economic impact of treatment and the disease on 
hospital-related resource use and health state utility.
6. To explore methods of estimating OS adjusting for the impact of the control arm 
receiving subsequent Polyadenosine 5’diphosphoribose (poly [ADP ribose]) polymerise 
(PARP) inhibitors or imbalances between the treatment arms for other potentially active 
agents.
7. To determine the frequency of and describe the nature of BRCA mutation/s in tumour 
samples and to compare this with germline BRCA mutation status.
8. To identify tumour tissue-based biomarkers (including but not limited to somatic 
BRCA1/2 mutations, BRRCA methylation and/or other homologous recombination 
repair deficiencies biomarkers) that could be used to guide future patient segmentation 
approaches for development.
9. Future exploratory research into factors that may influence development of cancer 
and/or response to treatment (where response is defined broadly to include efficacy, 
tolerability or safety) may be performed on the collected and stored archival tumour 
samples (if available), blood samples at day 1 and on disease progression or on residual 
tissue material collected as part of the study.
Parts of the exploratory analyses may not be part of the analysis described in this statistical 
analysis plan (SAP) and as such, may not be reported in the Clinical Study Report (CSR). If 
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1.2 Study Design
This is a Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess 
the efficacy of olaparib maintenance monotherapy in metastatic pancreatic cancer patients
with germline BRCA (gBRCA) mutations (documented mutation in gBRCA1 or gBRCA2) 
that is predicted to be deleterious or suspected deleterious (known or predicted to be 
detrimental/lead to loss of function) and whose tumours have not progressed on at least 
16-weeks of first-line platinum-based chemotherapy.
Approximately 145 patients will be randomised (using an Interactive Voice Response 
System / Interactive Web Response System) in a 3:2 ratio to the treatments as specified below:
 olaparib tablets per os (p.o.) 300 mg twice daily.
 placebo tablets p.o. twice daily.
Eligible patients will be those patients with pancreas cancer previously treated for metastatic 
disease gBRCA mutated, who have not progressed following completion of at least 16 weeks 
of first-line platinum-based chemotherapy before randomisation.  All patients must have a 
known deleterious or suspected deleterious germline BRCA mutation to be randomised.  
Determination of gBRCA mutation will be done before enrolment to the study at Myriad 
laboratories.
Patients with known gBRCA mutation prior to randomisation will enter the study based on 
these results (by considering all other eligibility criteria as well), but undergo a confirmatory 
gBRCA test post-randomisation, while patients with unknown gBRCA mutation will enter the 
study after confirmation of gBRCA mutation. 
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is 
the day of last treatment) and study treatment will start as soon as possible but no less than 4 
and no more than 8 weeks after the last chemotherapy dose.  At the time of starting study 
treatment, all previous chemotherapy treatment should be discontinued.
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of 
treatment (days 8, 15, 22 and 29).  Patients will then attend clinic visits every 4 weeks whilst 
on study treatment and will continue treatment until objective radiological disease progression 
as per RECIST as assessed by the investigator and as long as in the investigator’s opinion they 
are benefiting from treatment and they do not meet any other discontinuation criteria. 
Once a patient has discontinued study treatment, clinic visits will be reduced to every 8 weeks.  
Following discontinuation of study treatment, further treatment will be at the discretion of the 
investigator.  It is anticipated (but not required) that patients will be re-treated with their 
previous platinum-based regimen.  Details of any further systemic anti-cancer treatment will 
be collected until death, loss to follow-up, or withdrawal of consent.  In addition to their 
regular 8 weekly contacts, patients will be contacted in the 7 days following a specified day 
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Patients will have tumour assessments according to RECIST at baseline and every 8 weeks 
(±1week) up to 40 weeks and then every 12 weeks (±1 week) relative to date of randomisation 
until objective radiological disease progression according to modified RECIST criteria.  
RECIST will be modified to assess patients with clinical complete response (CR) at entry who 
will be assessed as having no evidence of disease (NED) until they have progressed based on 
the appearance of new lesions.
Any patient who discontinues study treatment for reasons other than objective radiological 
progression should continue to undergo scheduled objective tumour assessments according to 
the study plan in order to assess objective radiological progression of disease.  Failure to do so 
may result in bias in the study results.  Once a patient has progressed, the patient will be 
followed for second progression every 8 weeks and then survival until the final analysis.  
Patients will be contacted in the week following DCO for each analysis of survival.
The final PFS analysis of the study will occur when approximately 87 PFS events have 
occurred, although an interim PFS analysis for futility will be performed when 50% of the 
PFS events required for the final PFS analysis have occurred.  Both interim and final PFS 
analyses will be based on BICR of disease progression by modified RECIST version 1.1; 
however, a sensitivity analysis will be performed using the investigator-recorded assessment.
An interim analysis of OS will be performed at the time of the final analyses of PFS. A final 
analysis of OS will be performed when approximately 106 OS events have occurred.
Unblinded outputs for the interim analysis of PFS will be prepared by the International Drug 
Development Institute (IDDI). For the combined analysis of final PFS and interim OS, the 
study will be unblinded at PAREXEL. No measures for keeping team members blinded for the 
subsequent final OS analysis are required. 
The study flow chart is in Appendix A: Study Flow Chart while the study schedule is in 
Appendix C: Study Schedule. 
1.3 Number of Patients
The primary endpoint of the study is PFS.  Approximately 145 patients will be randomised 
(3:2 ratio of olaparib:placebo) and the final PFS analysis will occur once approximately 87 
PFS events (confirmed via a central review) have occurred.  A single interim PFS analysis for 
futility will be performed when 50% of the PFS events required for the final analysis 
(approximately 44 PFS events) based on BICR have occurred.
The study is sized assuming a true treatment effect that is a PFS hazard ratio (HR) of 0.54 at 
the final analysis, assuming 80% power and 2.5% alpha (1-sided), with 3:2 randomisation 
(olaparib:placebo).  Assuming PFS is exponentially distributed, a PFS HR of 0.54 equates to a 
3.4 month improvement in median PFS over an assumed 4 month median PFS for placebo.  
Patients are to be followed for the final analysis of OS and PFS2 (when approximately 106 
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statistically significant difference in OS at the 1-sided 2.5% level if the assumed true treatment 
effect is a HR 0.57; this translates to an approximate 6-month improvement in median OS 
over an assumed 8 month median OS on placebo, assuming OS is exponentially distributed.  
Assuming that the study accrual period will be approximately 15 months, 87 PFS events are 
anticipated to be observed approximately 18 to 19 months after the first patient is randomised 
in the study.  It is estimated that 44 PFS events will occur approximately 13 to 14 months after 
first patient in.  It is estimated that 106 deaths will have occurred approximately 31 months 
after first patient in.
2. ANALYSIS SETS
2.1 Definition of Analysis Sets
Full Analysis Set
Intention to treat (ITT): The primary statistical analysis of the efficacy of olaparib will 
include all randomised patients and will compare the treatment groups on the basis of 
randomised treatment, regardless of the treatment actually received or discrepancy between 
local and Myriad gBRCA results.  Patients who were randomised but did not subsequently go 
on to receive study treatment are included in the Full Analysis Set (FAS).  Therefore, all 
efficacy endpoints will be summarised and analysed using the FAS on an ITT basis.
In addition, key sensitivity analysis of efficacy endpoints will be performed in the subgroup of 
patients in the FAS that have a gBRCA mutation confirmed by the Myriad test.
Safety Analysis Set 
All patients who received at least one dose of randomised investigational product, olaparib or 
placebo, will be included in the safety analysis set.  Throughout the safety results sections, all 
patients who received at least one dose of olaparib will be accounted for in the olaparib 
treatment group.  Erroneously treated placebo patients (those randomised to placebo but 
actually received at least one dose of olaparib) will be accounted for in the olaparib treatment 
group.  Any mis-randomisations will be discussed on an individual basis and decisions will be 
documented at the blind data review meeting (BDRM) for the final analysis of PFS and at the 
data review meeting (DRM) for the final analysis of OS and PFS2.
Patient Reported Outcome Analysis Set
The analysis population for patient reported outcome (PRO) data will be a subset of the FAS 
(ITT) population who have evaluable baseline EORTC QLQ-C30 or QLQ-PAN26 forms
where evaluable means that at least one sub-scale baseline score can be determined from at 
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Table 1 Summary of Outcome Variables and Analysis Populations
Outcome Variable Populations
Efficacy Data
Primary analysis: PFS FAS (ITT), Myriad confirmed Breast 
cancer susceptibility gene mutation 
(gBRCAm) subgroup
Secondary analysis: 
OS, PFS2, TFST, TSST, TDT 
Objective response rate (ORR) 
Disease control rate (DCR), Duration of response (DoR)
FAS (ITT), Myriad confirmed gBRCAm 
subgroup




PRO Data (EORTC QLQ-C30/PAN26)
Adjusted mean change from baseline in global HRQoL 
score





Exposure, AEs, Laboratory measurements; ECGs, Vital 
signs, ECOG, Physical examinations
Safety
2.2 Violations and Deviations
Important protocol deviations are those that could have a heavy influence on the interpretation 
of any analysis based on addressing the primary efficacy and secondary safety objectives of 
the trial. This section will define important protocol deviations so that instances can be 
identified and reported in the CSR.
Major protocol deviations are deviations from the protocol that are likely to have an impact on 
the subject’s rights, safety, well-being, and/or on the validity of the data for analysis. This will 
include all important deviations to be reported in the CSR.
Major and important protocol deviations will be listed for the FAS analysis set. Important 
protocol deviations will be summarised by randomised treatment group for the FAS analysis 
set.  None of the deviations will lead to any patients being excluded from any of the analysis 
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A per-protocol analysis excluding patients with important protocol deviations is not planned; 
however, a ‘deviation bias’ sensitivity analysis will be performed excluding patients with 
those important deviations that may affect the efficacy of the trial therapy if >10% of patients:
 did not have the intended disease or indication or
 did not receive any randomised therapy.
The need for such a sensitivity analysis will be determined following review of the protocol 
deviations ahead of database lock or data freeze for the final analysis on PFS and will be 
documented prior to the study being unblinded and the analysis being conducted.  
The full definition of important protocol deviations and any action to be taken regarding the 
exclusion of subjects (for the sensitivity analysis) are defined in the project-specific Protocol 
Deviation Specification. The dataset of protocol deviations that is received from the protocol 
deviation system will contain a variable DVACTION that can be used to identify patients to 
be excluded from the sensitivity analysis.
The following general categories will be considered important deviations from a statistical 
perspective and will be summarized, listed and discussed in the CSR as appropriate:
 Patients randomised but who did not receive olaparib/matching placebo.
 Patients who deviate from key study entry criteria (to be determined at the BDRM), 
which will be documented ahead of database lock.
 Baseline RECIST scan missing or > 28 days before start of study treatment.
 Baseline RECIST scan after randomisation.
 RECIST scan not performed according to protocol.
The categorisation of these as important deviations is not automatic and will depend on 
duration and the perceived effect on efficacy.
In addition to the programmatic determination of the deviations above, monitoring notes or 
summaries will be reviewed to determine any important post-entry deviations that are not 
identifiable via programming, and to check that those identified via programming are correctly 
classified.
Mis-randomisations in terms of errors in treatment dispensing, will also be considered as 
important protocol deviations.  A mis-randomisation is when a patient is not randomised or 
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(a) Patients who receive no treatment whatsoever for a period of time due to errors in 
dispensing of medication.  Note, this is not due to tolerability issues where patients 
may stop taking drug.
(b) The patient receives a treatment pack with a different code from their randomisation 
code.  However, the actual treatment may still match the randomised treatment.  For 
example, a patient is given randomisation code 0001, which according to the 
randomisation schedule is olaparib.  However, at the randomisation visit they are 
given treatment pack 0003, but this still contains olaparib.
The summary will include all patients with a dispensing error but will also include 
information on how many of those patients received at least one dose of the wrong treatment 
(olaparib/placebo) at any time.
Patients who receive the wrong treatment at any time will be included in the safety analysis 
set as described in Section 2.1.  During the study, decisions on how to handle mis-
randomisations will be made on an individual basis with written instruction from the study 
team leader and/or statistician.
The following table summarizes the important deviations discussed above. The last column 
flags the deviations that if observed in >10% of FAS patients would lead to a sensitivity 
analysis. For the full specification please refer to the project-specific Protocol Deviation 
Specification.
Table 2 Important protocol deviations
PD term Criteria to identify PD Sensitivity 
analysis
Not the intended disease 
or indication
Relevant in- or exclusion criteria are not fulfilled. Yes
Did not receive any 
randomised therapy
Patient was randomised and did not receive any study 
treatment.
Yes
Deviation from other key 
entry criteria
Patients who deviate from key entry criteria other than 
the intended disease or indication. 
Baseline RECIST missing RECIST scan on or before first dose of study treatment 
is missing.
Baseline RECIST scan 
too early
Baseline RECIST scan taken more than 28 days before 
start of study treatment.
Baseline RECIST scan 
too late
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RECIST scan not 
performed according to 
protocol
RECIST scan not in scheduled visit window on >2 
occasions post-baseline regardless of whether visits 
were consecutive or not.
Wrong treatment kit but
correct study drug
The patient receives a wrong treatment pack. Actual 
treatment matches the randomised treatment.  
Wrong treatment kit with
incorrect study drug
The patient receives a wrong treatment pack. Actual 
treatment does not match the randomised treatment.  
Treatment interrupted Subject did not receive study treatment for a period of 
28 consecutive days or more due to errors in 
dispensing of medication or non-compliance. This 
excludes drug interruptions due to adverse events or 
due to tolerability issues.
Subject took concomitant 




Subject took disallowed medications or therapies 
starting on or after first dose of treatment. Refer to 
details of medication types in section 7.7 of the CSP.
Non-compliance with 
study treatment
Severe non-compliance with treatment reported by site 
monitor in IMPACT.
Deviation from ICH-GCP Deviation of ICH Good Clinical Practice (GCP) 
reported by site monitor in IMPACT
The categories listed in the table can be identified using the protocol deviation reference IDs 
that are defined for each type of protocol deviation in the project-specific specification.
For the final analysis of PFS / interim analysis of OS, the final classification of deviations will 
be made at the BDRM prior to database lock or data freeze and all decisions including the 
requirement of a sensitivity analysis will be made whilst blinded to study treatment allocation 
Decisions made at the BDRM for the final analysis of PFS will be documented and approved 
by AstraZeneca prior to analysis and unblinding.
For the final analysis of OS, new protocol deviations will be reviewed and classified at a
DRM prior to DB lock. The study will be unblinded by that time, however, there is not 
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3. PRIMARY AND SECONDARY VARIABLES
At each visit patients will be assigned a RECIST visit response of complete response (CR), 
partial response (PR), stable disease (SD), progressive disease (PD), not evaluable (NE) or 
NED depending on the status of their disease compared to baseline and previous assessments, 
based on the BICR.  This will be repeated using the Investigator assessed RECIST data.
3.1 Derivation of RECIST Visit Responses
Patients with measurable or non-measurable disease or NED assessed at baseline by computed 
tomography (CT) / magnetic resonance imaging (MRI) will be entered in this study.  RECIST 
has been modified to allow the assessment of progression due to new lesions in patients with 
NED at baseline (inclusion criteria #4).
For all patients, the RECIST tumour response data will be used to determine each patient’s 
visit response according to modified RECIST version 1.1.  It will also be used to determine if 
and when a patient has progressed in accordance with RECIST and also their best overall 
response.  
Baseline radiological tumour assessments are to be performed no more than 28 days before 
start of study treatment and ideally as close as possible to the start of study treatment and prior
to randomisation.  Tumour assessments are then performed every 8 weeks (±1 week) up to 40 
weeks and then every 12 weeks (±1 week) following randomisation until disease progression.
If an unscheduled assessment was performed and the patient had not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits.  This 
schedule is to be followed in order to minimise any unintentional bias caused by some patients 
being assessed at a different frequency than other patients.
At each visit, an overall visit response will be provided by the BICR and separately by the 
investigator - using the information from target lesions (TL), non-target lesions (NTL) and 
new lesions.  
3.1.1 Target lesions
Measurable disease is defined as having at least one measurable lesion, not previously 
irradiated, which is ≥ 10 mm in the longest diameter (except lymph nodes which must have 
short axis ≥ 15 mm) with CT or MRI and which is suitable for accurate repeated 
measurements. 
A patient can have a maximum of 5 measurable lesions recorded at baseline with a maximum 
of 2 lesions per organ (representative of all lesions involved suitable for accurate repeated 
measurement) and these are referred to as TLs.  If more than one baseline scan is recorded, 
then measurements from the one that is closest to and prior to randomisation will be used to 
define the baseline sum of TLs.  It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest lesion, 
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All other lesions (or sites of disease) not recorded as TLs should be identified as NTLs at 
baseline.  Measurements are not required for these lesions, but their status should be followed 
at subsequent visits.
Note: For patients who do not have measurable disease at entry (ie, no TLs) but have 
non-measurable disease, evaluation of overall visit responses will be based on the overall 
NTLs assessment and the absence/presence of new lesions (see Section 3.1.3 of the Clinical 
Study Protocol (CSP) for further details).  If a patient does not have measurable disease at 
baseline, then the TL visit response will be not applicable (NA).
For patients with NED at baseline (ie, no TLs and no NTLs), evaluation of overall visit 
responses will be based on absence/presence of new lesions.  If no TLs and no NTLs are 
recorded at a visit, both the TL and NTL visit response will be recorded as NA and the overall 
visit response will be NED.
Table 3 TL Visit Responses
Visit Responses Description
CR Disappearance of all TLs since baseline.  Any pathological lymph nodes selected 
as TLs must have a reduction in short axis to <10 mm.
PR At least a 30% decrease in the sum of diameters of TLs, taking as reference the 
baseline sum of diameters.
SD Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD.
PD At least a 20% increase in the sum of diameters of TLs, taking as reference the 
smallest sum on study (this includes the baseline sum if that is the smallest on 
study).  In addition to the relative increase of 20%, the sum must also indicate an 
absolute increase of at least 5 mm.
NE Only relevant if any of the TLs were not assessed or not evaluable or had a lesion 
intervention at this visit.
Note: If the sum of diameters meets the PD criteria, PD overrides NE as a TL 
response.
NA No TLs are recorded at baseline.
Rounding of TL data
For calculation of PD and PR for TLs, percentage changes from baseline and previous 
minimum should be rounded to 1 decimal place before assigning a TL response.  For example 
19.95% should be rounded to 20.0% but 19.94% should be rounded to 19.9%.
Missing TL data 
For a visit to be evaluable, all TL measurements should be recorded.  However, a visit 
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 A new lesion is recorded.
 A NTL visit response of PD is recorded.
 The sum of TLs is sufficiently increased to result in a 20% increase, and an absolute 
increase of ≥ 5mm from nadir, even assuming the non-recorded TLs have 
disappeared.  Note: the nadir can only be taken from assessments where all the TLs 
had a longest diameter (LD) recorded, including non-missing TLs which have had 
intervention during the study and prior to any scaling of the measurements.
If there is at least one TL measurement missing and a visit response of PD cannot be assigned, 
the visit response is NE.
Lymph nodes
For lymph nodes, if the size reduces to < 10 mm then these are considered non-pathological.  
However, a size will still be given, and this size should still be used to determine the TL visit 
response as normal.  In the special case where all lymph nodes are < 10 mm and all other TLs 
are 0 mm, then although the sum may be > 0 mm the calculation of TL response should be 
over-written as a CR. 
TL visit responses subsequent to CR
A CR can only be followed by CR, PD or NE.  If a CR has occurred then the following rules 
at the subsequent visits must be applied:
 Step 1:  If all lesions meet the CR criteria (ie, 0 mm or < 10 mm for lymph nodes) 
then response will be set to CR irrespective of whether the criteria for PD of TL is 
also met ie, if a lymph node LD increases by 20% but remains < 10 mm. 
 Step 2:  If some lesion measurements are missing but all other lesions meet the CR 
criteria (ie, 0 mm or < 10 mm for lymph nodes), then response will be set to NE 
irrespective of whether when referencing the sum of TL diameters the criteria for 
PD is also met. 
 Step 3:  If not all lesions meet the CR criteria and the sum of lesions meets the 
criteria for PD, then response will be set to PD.
 Step 4:  If after steps 1 – 3 a response can still not be determined, the response will 
be set to remain as CR.
TL too big to measure
If a TL becomes too big to measure, this should be indicated in the database and a size (‘x’) 
above which it cannot be accurately measured should be recorded.  If using a value of x in the 
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flagged and reviewed by the study team blinded to treatment assignment.  It is expected that a 
visit response of PD will remain in the vast majority of cases.  
TL too small to measure
If a TL becomes too small to measure a value of 5 mm will be entered into the database and 
used in TL calculations, unless the radiologist has indicated and entered a smaller value that 
can be reliably measured.  If a TL response of PD results, then this will be reviewed by the 
study team blinded to treatment assignment.
Irradiated lesions/lesion intervention
Previously irradiated lesions (ie, lesion irradiated prior to entry into the study) should be 
recorded as NTLs and should not form part of the TL assessment.
Any TL (including lymph nodes), which has had intervention during the study (for example, 
irradiation / palliative surgery / embolization), should be handled in the following way and 
once a lesion has had intervention then it should be treated as having had intervention for the 
remainder of the study, noting that an intervention will most likely shrink the size of tumours:
 Step 1: the diameters of the TLs (including the lesions that have had intervention) will 
be summed and the calculation will be performed in the usual manner.  If the visit 
response is PD this will remain as a valid response category. 
 Step 2: If there was no evidence of progression after step 1, treat the lesion diameter (for 
those lesions with intervention) as missing and if  1/3 of the TLs have missing 
measurements, then scale up as described below.  If the scaling results in a visit 
response of PD then the patient would be assigned a TL response of PD.  
Scaling will be based on the measurements at the nadir visit, to give an estimated sum of 
diameters and this will be used in calculations; this is equivalent to comparing the visit 
sum of diameters of the non-intervention lesions to the nadir sum of diameters excluding 
the lesions with interventions.
Table 4 Example of scaling











Date 14 December 2018
26
Lesion 5 has had an intervention at the follow-up visit. 
The sum of lesions 1 to 4 at the follow-up is 26 cm.  The sum of the corresponding 
lesions at baseline visit is 26.8 cm.





 Step 3: If after both steps PD has not been assigned, then if appropriate, a scaled sum of 
diameters will be calculated (as long as  1/3 of the TLs have missing measurements), 
treating the lesion with intervention as missing, and PR or SD, then assigned as the visit 
response.  Patients with intervention are evaluable for CR as long as all non-intervened 
lesions are 0 (or < 10 mm for lymph nodes) and the lesions that have been subject to 
intervention also have a value of 0 recorded.  If scaling-up is not appropriate due to too 
few non-missing measurements then the visit response will be set as NE.
At subsequent visits the above steps will be repeated to determine the TL and overall visit 
response.  When calculating the previous minimum, lesions with intervention should be 
treated as missing and scaled up where appropriate (as per step 2 above).
Lesions that split in two
If a TL splits in two, then the LDs of the split lesions should be summed and reported as the 
LD for the lesion that split.
Lesions that merge
If two TLs merge, then the LD of the merged lesion should be recorded for one of the TL 
sizes and the other TL size should be recorded as 0 mm.
Change in method of assessment of TLs
Computed tomography (CT) and MRI are the only methods of assessment that can be used 
within the trial.  If a change in method of assessment occurs between CT and MRI, this will be 
considered acceptable and no adjustment within the programming is needed.
If a change in method involves clinical examination (eg, CT changes to clinical examination), 
any affected lesions should be treated as missing.
3.1.2 NTLs and new lesions
At each visit an overall assessment of the NTL response should be recorded.  This section 
provides the definitions of the criteria used to determine and record overall response for NTL 
at each visit.
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Table 5 NTL Visit Responses
Visit Responses Description
CR Disappearance of all NTLs present at baseline with all lymph nodes non-
pathological in size (<10 mm short axis).
PD Unequivocal progression of existing NTLs.  Unequivocal progression may be due 
to an important progression in one lesion only or in several lesions.  In all cases 
the progression MUST be clinically significant for the physician to consider 
changing (or stopping) therapy.
Non-CR/Non-PD Persistence of one or more NTLs with no evidence of progression.
NE Only relevant when one or some of the NTLs were not assessed and, in the 
investigator's opinion, they are not able to provide an evaluable overall NTL 
assessment at this visit.
Note: For patients without TLs at baseline, this is relevant if any of the NTLs 
were not assessed at this visit and the progression criteria have not been met.
NA Only relevant if there are no NTLs at baseline.
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficiently to merit discontinuation of therapy.  A 
modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status.
The finding of a new lesion should be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumour.
New lesions will be identified on the electronic case report form (eCRF).  The absence and 
presence of new lesions at each visit should be listed alongside the TL and NTL visit 
responses.
A new lesion indicates progression so the overall visit response will be PD irrespective of the 
TL and NTL response.
A lesion identified at a follow-up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.
If the question ‘Any new lesions since baseline’ has not been answered with Yes or No and 
the new lesion details are blank this is not evidence that no new lesions are present and should 
be treated as NE in the derivation of overall visit response.
‘Symptomatic deterioration’ is not a descriptor for progression of NTLs: it is a reason for 
stopping study therapy and will not be included in any assessment of NTLs.  Patients with 
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of disease progression at that time should continue to undergo tumour assessments where 
possible until objective disease progression is observed.
3.1.3 Overall visit response
Table 6 defines how the previously defined TL and NTL visit responses will be combined 
with new lesion information to give an overall visit response. 
Table 6 Overall Visit Responses
Target lesions Non-target lesions New lesions Overall response
CR CR or NA No (or NE) CR
NA CR No (or NE) CR
CR Non-CR/Non-PD or NE No (or NE) PR
PR Non-PD or NE or NA No (or NE) PR
SD Non-PD or NE or NA No (or NE) SD
NA Non-CR/Non-PD No (or NE) SD
NE Non-PD or NE or NA No (or NE) NE
NA NE No (or NE) NE
PD Any Any PD
Any PD Any PD
Any Any Yes PD
NA NA No (or NE) NED
NA is only relevant if there were no TL/NTL at baseline.
3.1.4 Independent review
A planned BICR of all radiological imaging data will be carried out using modified RECIST 
version 1.1 and these data will be used for the interim and primary analyses of PFS. All 
radiological scans for all patients (including those at unscheduled visits, or outside visit 
windows) will be collected on an ongoing basis and sent to an AstraZeneca appointed 
Contract Research Organisation (PAREXEL Imaging) for central analysis. Prior radiotherapy 
and location of screening biopsy lesion reports will also be provided to the BICR to allow the 
selection of appropriate TLs. The imaging scans will be reviewed by 2 independent 
radiologists using modified RECIST 1.1 and will be adjudicated, if required. For each patient, 
the BICR will define the overall visit response (ie, the response obtained overall at each visit 
by assessing TLs, NTLs and new lesions) data (for patients with TLs at baseline: CR, PR, SD, 
PD, NE; for patients with NTLs only: CR, SD, PD or NE; for patients with no disease 
identified at baseline: PD, NED, NE). If a patient has had a tumour assessment that cannot be 
evaluated then the patient will be assigned a visit response of NE (unless there is evidence of 





Date 14 December 2018
29
RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates and for the central review the date of progression will be determined based on 
the earliest of the scan dates of the component that triggered the progression, either for the 
adjudicated reviewer selecting PD or of the first reviewer where both select PD as time-point 
response and there is no adjudication.
Results of this independent review will not be communicated to Investigators and the 
management of patients will be based solely upon the results of the modified RECIST 1.1 
assessment conducted by the Investigator.
On an ongoing basis, patients who are determined to have progressed according to modified 
RECIST 1.1 criteria by the investigator will have scans centrally reviewed for confirmation of 
objective disease progression.  Radiological scans will only be sent for BICR up until the date 
of RECIST progression determined by the investigator.  However, if disease progression is not 
confirmed at BICR, an additional RECIST assessment will be requested at the next scheduled 
RECIST visit.  After the final PFS analysis, BICR of scans will no longer be required, 
regardless of progression status.  
Further details of the BICR will be documented in the BICR Charter.
3.2 Outcome Variables
For each patient, an overall RECIST visit response of CR, PR, SD, PD, NED, NE, will be 
determined from the BICR as described in Section 3.1.4 above.  The outcome variables 
involving RECIST data, i.e. PFS, best overall response, ORR and DCR, will be derived using 
overall visit responses and relevant dates from the BICR (which is considered to be the 
primary RECIST dataset), unless otherwise stated.
Separately, investigator-assessed site measurements/assessments (TLs, NTLs, new lesions) 
will be used to programmatically derive an investigator assessment of overall visit response.
3.2.1 Progression-Free Survival
Progression-free survival is defined as the time from randomisation until the date of objective 
radiological disease progression according to modified RECIST or death (by any cause in the 
absence of disease progression) regardless of whether the patient withdraws from randomised 
therapy or receives another anticancer therapy prior to disease progression (i.e. date of 
RECIST progression/death or censoring – date of randomisation + 1).  Patients who have not 
progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment from their last evaluable RECIST assessment.  However, if the patient progresses 
or dies after two or more missed visits, the patient will be censored at the time of the latest 
evaluable RECIST assessment (prior to the missing visits).  Given the scheduled visit 
assessment scheme, for the first 40 weeks from randomisation, two missing visits will equate 
to more than 18 weeks since the previous RECIST assessment, allowing an extra two weeks 
for early and late visits. After 40 weeks, two missing visits will equate to more than 26 weeks.  
If two missed visits occur over the period when the scheduled frequency of RECIST 
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22 weeks (allowing for an early assessment at Week 32 and a late assessment at Week 52). 
Please refer to the appendix for a graphical display of the allowed time gap in RECIST 
assessments (Appendix D: Visualisation of Censoring Rule for Progression Free Survival).
The baseline RECIST assessment should be performed prior to randomisation but if an 
evaluable RECIST assessment occurs after randomisation but before treatment then this 
assessment will be used as the baseline assessment. If the patient has no evaluable visits or 
does not have a baseline assessment, they will be censored at day 1 unless they die within two 
tumour assessment visits of randomisation (16 weeks plus 1 week allowing for a late 
assessment within the visit window).  
If a patient has two missing visits between two evaluable RECIST assessments with outcome 
not equal to progression at the second evaluable RECIST assessment, but then subsequently 
progresses, the patient will not be censored when analysing for PFS.  For example, if RECIST 
assessments were performed at week 8 with outcome SD, week 32 with outcome SD and 
week 40 with a progression event (weeks 16 and 24 were missed), the patient will be analysed 
from time of randomisation until progression event at week 40 without considering the 
interruptions.
The PFS time will always be derived based on scan/assessment dates not visit dates.
The RECIST assessments/scans contributing towards a particular visit may be performed on 
different dates.  The following rules will be applied:
(a) For BICR data, the date of progression will be determined based on the earliest of 
the scan dates of the component that triggered the progression for the adjudicated 
reviewer selecting PD or of either reviewer where both select PD as a time point 
response and there is no adjudication.
(b) For investigational site assessments, date of progression will be determined based 
on the earliest of the RECIST assessment/scan dates of the component that triggered 
the progression.
(c) For both BICR data and investigational site assessments, when censoring a patient 
for PFS, the patient will be censored at the latest of the RECIST assessment/scan 
dates contributing to a particular overall visit assessment.
Overall visit assessments will be determined by the investigator and BICR for each 
assessment (scheduled or unscheduled) and will contribute to the derivation of PFS.
Objective progression is defined as at least a 20% increase in the sum of the diameters of the 
TLs (compared to previous minimum sum) and an absolute increase of > 5 mm, or an overall 
NTLs assessment of progression or a new lesion.
The primary analysis will be based on the programmatically derived PFS based on the BICR 
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A sensitivity analysis based on the derived PFS based on investigator-recorded assessments 
will be carried out.
3.2.2 Overall Survival
Overall Survival is defined as the time from the date of randomisation until death due to any 
cause (i.e. date of death or censoring – date of randomisation + 1).  Any patient not known to 
have died at the time of analysis will be censored based on the last recorded date on which the 
patient was known to be alive. This analysis will be based on the “date subject last known to 
be alive” variable which is recorded within the survival status module of the eCRF 
(SURVIVE module).
Note: Survival calls will be made in the week following the date of DCO for the analysis, and 
if patients are confirmed to be alive or if the death date is post the DCO date these patients 
will be censored at the date of DCO.  If a patient has died but the date of death cannot be 
determined, then the patient will be censored based on the last recorded date on which the 
patient was known to be alive (although every effort needs to be made to determine the date of 
death). The status of ongoing, withdrawn (from the study) and “lost to follow-up” patients at 
the time of the final OS analysis should be obtained by the site personnel by checking the 
patient’s notes, hospital records, contacting the patient’s general practitioner and checking 
publicly-available death registries. If the patient has actively withdrawn consent to the 
processing of their personal data, the vital status of the patient can be obtained by site 
personnel from publicly-available resources where it is possible to do so under applicable 
local laws.
3.2.3 Time from randomisation to second progression 
The time from randomisation to second progression (PFS2) is defined as the time from the 
date of randomisation to the earliest of the second progression event as assessed by the 
investigator or death (ie date of PFS2 event or censoring – date of randomisation + 1). The 
date of second progression will be recorded by the investigator and defined according to local 
standard clinical practice and may involve any of objective radiological or symptomatic 
progression or death. The RECIST assessments will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and investigator opinion of progression status (progressed or 
non-progressed) at each assessment will be recorded in the eCRF.
Second progression status will be reviewed every 8 weeks following the investigator 
assessment of the first objective progression and status recorded. Patients alive and for whom 
a second disease progression has not been observed should be censored at the last time known 
to be alive and without a second disease progression, ie, censored at the latest of the RECIST 
assessment or PFS2 assessment dates. If a patient progresses for the second time or dies after 
two or more missed visits, the patient will be censored for PFS2 at the time of the latest 
evaluable investigator – recorded assessment.
Censoring will need to be applied for some patients prior to the first progression and for others 
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analysis or not. The duration of two missed visits is depending on the respective visit 
schedule:
 If the patient was progression-free at the time of analysis, then patients will be censored as 
described for PFS (Section 3.2.1), i.e. using the latest RECIST scan.
 If the patient died in the absence of any progression after two or more missed visits, then 
the censoring visit rule as described for PFS (Section 3.2.1) needs to be applied.
 If a patient is alive and had only the first progression assessed at the time of analysis, then 
the censoring will be based on the latest investigator assessment of no progression in the 
follow-up phase. If there are no follow-up results recorded, then the date of the latest scan 
contributing to the investigator assessment of first progression will be used for censoring.
 If the patient had progressed once and then died or progressed for the second time after
two or more visits, then those two or more missed visits equate to more than 18 weeks, 
since the patient is in the follow-up phase (16 weeks plus allowing an extra two weeks for 
early and late visits), i.e., if the latest follow-up assessment prior to second progression or 
death was are more than 18 weeks ago, then the patient is censored with the date of this 
last investigator assessment. If no follow-up results are recorded, and the investigator 
assessment of first progression is more than 18 weeks ago, then the date of the latest scan 
contributing to this first progression assessment will be used for censoring.
3.2.4 Time to first subsequent therapy or death
As a supportive summary to PFS, TFST will be assessed at the 30-day follow-up visit 
following study treatment discontinuation and then every 8 weeks, in line with survival 
follow-up visits.  The TFST is defined as the time from randomisation to the earlier of first 
subsequent cancer therapy start date following study treatment discontinuation, or death (i.e. 
date of first subsequent cancer therapy/death or censoring – date of randomisation + 1).  Any 
patient not known to have died at the time of the analysis and not known to have had a further 
intervention of this type will be censored at the last known time to have not received 
subsequent cancer therapy, ie, the last follow-up visit where this was confirmed.
3.2.5 Time to second subsequent therapy or death
As a supportive summary to PFS2, TSST will be assessed at the 30-day follow-up visit 
following study treatment discontinuation and then every 8 weeks, in line with survival 
follow-up visits.  The TSST is defined as the time from randomisation to the earlier of the 
second subsequent cancer therapy start date following study treatment discontinuation, or 
death (i.e. date of second subsequent cancer therapy/death or censoring – date of 
randomisation + 1).  Any patient not known to have died at the time of the analysis and not 
known to have had a further intervention of this type will be censored at the last known time 






Date 14 December 2018
33
3.2.6 Time to study treatment discontinuation or death
The TDT is defined as the time from randomisation to the earlier of the date of study 
treatment discontinuation or death (i.e. date of study treatment (olaparib/placebo) 
discontinuation/death or censoring – date of randomisation + 1).  Any patient not known to 
have died at the time of analysis and not known to have discontinued study treatment will be 
censored based on the last recorded date on which the patient was known to be alive. Patients 
who were randomised but never exposed to study treatment will be censored at day 1.
3.2.7 Best objective response
Best objective response (BoR) is calculated based on the overall visit responses from each 
RECIST assessment (Table 6).  It is the best response a patient has had following 
randomisation but prior to starting any subsequent cancer therapy and prior to RECIST 
progression or the last evaluable assessment in the absence of RECIST progression.
Categorization of BoR will be based on the RECIST criteria using the following order of 
response categories: CR, PR, SD, NED (applies only to those patients entering the study with 
no disease at baseline), PD and NE. Patients entering the study with no measurable disease at 
baseline who would qualify for CR are considered as SD and summarized separately as 
“stable disease (complete response without measurable disease)”.
BoR will be determined programmatically from the overall visit response using BICR data.
In addition, this will also be reported using investigator-recorded assessment.
For determination of a best response of SD, the earliest of the dates contributing towards a 
particular overall visit assessment will be used.  SD should be recorded at least 7 weeks (ie, 8 
weeks minus 1 week to allow for an early assessment within the assessment window), after 
randomisation.  For CR/PR, the initial overall visit assessment which showed a response will 
use the latest of the dates contributing towards a particular overall visit assessment.
For patients whose progression event is death, BoR will be calculated based on data up until 
the last evaluable RECIST assessment prior to death.
For patients who die with no evaluable RECIST assessments, if the death occurred ≤ 17 weeks 
(ie, 16 weeks +1 week to allow for a late assessment within the assessment window) after 
randomisation then BoR will be assigned to the PD category.  For patients who die with no 
evaluable RECIST assessments, if the death occurred 17 weeks (ie, 16 weeks +1 week) after 
randomisation then BoR will be assigned to the NE category.
Progression events that have been censored due to them being more than two missed visits 
after the last evaluable assessment will not contribute to the BoR derivation.
A patient will be classified as a responder if the RECIST criteria for a CR or PR are satisfied 
at any time following randomisation, prior to RECIST progression and prior to starting any 
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3.2.8 Objective response rate
For each treatment group, the ORR is the number of patients with a BoR of CR and PR
according to the BICR data divided by the number of patients in the treatment group with 
measurable disease at baseline where ‘measurable’ is defined by the BICR data.  Only patients 
with measurable disease at baseline can achieve an objective response of CR or PR.
As supportive summaries, duration and time to onset of objective response in patients with an 
objective response (derived using BICR data) will be calculated using a Kaplan-Meier 
technique.
Duration of response will be defined as the time from the date of first documented response 
until date of documented progression or death in the absence of disease progression.  The end 
of response should coincide with the date of progression or death from any cause used for the 
PFS endpoint (using BICR data).  The time of the initial response will be defined as the latest 
of the dates contributing towards the first visit response of PR or CR.  If a subject does not 
progress following a response, then the patient will be censored at the same timepoint that was 
used for the censored PFS analysis.
Time to onset of objective response will be defined as the time from randomisation to the date 
of first documented response.
ORR, duration of response and time to onset of objective response will also be calculated
using investigator-recorded assessment, with ‘measurable’ disease at baseline defined 
according to investigator assessment.  
3.2.9 Disease control rate
The DCR is defined as the percentage of patients who have at least one visit response of CR 
or PR or have demonstrated SD or NED for at least 15 weeks (ie, 16 weeks minus 1 week to 
allow for an early assessment within assessment window) prior to any evidence of 
progression.  In the case of SD and NED, follow-up assessments must have met the SD or 
NED criteria for a minimum interval of 15 weeks following randomisation.  This will be 
calculated using BICR data, in addition to investigator-recorded assessment.
3.3 Patient Reported Outcome Variables
3.3.1 EORTC QLQ-C30 (Version 3) and EORTC QLQ-PAN26
The EORTC QLQ-C30/PAN26, validated PRO questionnaires in the target patient population, 
will be used to evaluate disease symptoms, functional impacts (e.g., physical functioning), and 
HRQoL and characterise clinical benefit from the patient perspective. The EORTC QLQ-C30 
was developed to assess general cancer related symptoms, functional impacts (e.g., physical 
functioning) and HRQoL while the EORTC QLQ-PAN26 was developed specifically to 
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The EORTC QLQ-C30 comprises 30 questions designed for all cancer types.  Questions can 
be grouped into the following scales:
 5 multi-item functional scales (physical, role, emotional, cognitive and social)
 3 multi-item symptom scales (fatigue, pain, nausea vomiting)
 A 2-item global health status / QoL scale
 5 single items assessing the following common cancer symptoms:
 dyspnoea




 1 item on the financial impact of the disease.
The pancreas cancer module, EORTC QLQ-PAN26, is intended for patients at all disease 
stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation, or 
palliative chemotherapy.  The module comprises 26 questions assessing pain, dietary changes, 
jaundice, altered bowel habit, emotional problems related to pancreas cancer, and other 
symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes).
Data from these questionnaires will be analysed according to the visit as collected, ie no visit 
remapping will take place. Baseline is defined as the last result on or before the first day of 
study drug. For patients who are randomised but not treated, baseline is defined as the last 
result on or before the date of randomisation.
EORTC QLQ-C30/PAN26 scoring:
The EORTC QLQ-C30 / QLQ-PAN26 will be scored according to the EORTC scoring 
manual (Fayers et al 2001) and the draft scoring procedure for QLQ-PAN26 (Johnson 2007).  
All the EORTC scales range from 0 to 100 (through transformation of scores as detailed 
below).  The EORTC QLQ-C30 scales can be interpreted as following: A high scale score 
represents a higher response level. Thus, a high score for a functional scale represents a high / 
healthy level of functioning, while a high score for a symptom scale / item represents a high 
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on the symptoms or problems.  For digestive symptoms, altered bowel habit, hepatic, sexuality 
and body image, a higher score represents worse QoL, while a lower score represents a better 
outcome.  For the health care satisfaction scale (items 53 and 54), a higher score represents 
better outcome while a lower score represents worsening.
Transformation of scores
Each scale will be transformed to a 100-point scale as follows:
For all scales, the Raw Score (RS) is the mean of the component items:
To obtain the score S, the following linear transformation will be applied:
Table 7 Linear Transformation of EORTC Scales





Functional scale 1-7, 20-27 NA
Symptom scales 8-19, 28 31, 33-37, 44-49
Global Health Status / 
QoL 29, 30 NA
Health care 
satisfaction scale NA 53, 54
Sexuality NA 55, 56
Range is the difference between the maximum possible value of RS and the minimum possible value.  
*A few items of the QLQ-PAN26 questionnaire are not part of the table as they are not part of a multi-item scale 
(ie, item number 32, 38, 39-43, 50-52).  Nevertheless, they need to be transformed in the same way as for 
symptom scales.
The QLQ-C30 / QLQ-PAN26 has been designed so that all items in any scale take the same 
range of values.  Therefore, the range of RS equals the range of the item values.  Most items 
are scored 1 to 4, giving range = 3.  The exceptions are the items contributing to the global 
health status / QoL, which are 7-point questions with range = 6.
For each subscale, if less than 50% of the subscale items are missing, then the subscale score 
will be divided by the number of non-missing items and multiplied by the total number of 
items on the subscales.  If at least 50% of the items are missing, then that subscale will be 
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questionnaire items will be identified and recorded.  If there is evidence that the missing data 
are systematic, missing values will be handled to ensure that any possible bias is minimised.
EORTC QLQ-C30/PAN26 Score Interpretation - Clinically Meaningful Change & Best 
Overall Response:
Clinically Meaningful Change
Definition of clinically meaningful changes in score compared with baseline will be evaluated. A 
clinically meaningful change is defined as an absolute change in the score from baseline of ≥10 
for scales from the EORTC QLQ-C30 (Osoba et al 1998) (Table 8). For example, a clinically 
meaningful improvement in physical function (as assessed by EORTC QLQ-C30) is defined as an 
increase in the score from baseline of ≥10, whereas a clinically meaningful deterioration is defined 
as a decrease in the score from baseline of ≥10.  At each postbaseline assessment, the change in 
global health status/QoL, symptoms, and functioning score from baseline will be categorized as 
improvement, no change, or deterioration as shown in Table 8. Similarly, a change of at least 
10 points in the QLQ-PAN26 will be considered as a clinically meaningful (Serrano et al 
2014).
Table 8 EORTC QLQ-C30/PAN26 Clinically Meaningful Visit Response
Score Change from baseline Visit response
EORTC QLQ-C30 symptom scales ≥ +10 or patient too ill to complete measure Deterioration 
≤ -10 Improved
Otherwise No change
EORTC QLQ-C30 Global QoL 
score and functional scales: 
physical, role, emotional, cognitive 
and social
≥ +10 Improved
≤ -10 or patient too ill to complete measure Deterioration
Otherwise No change
EORTC QLQ-PAN26 scales*: 
pancreatic pain, digestive 
symptoms, altered bowel habit, 
hepatic, sexuality and body image 
multi item scales and single item 
measures
≥ +10 or patient too ill to complete measure Deterioration
≤ -10 Improved
Otherwise No change
EORTC QLQ-PAN26 scales*: 
Satisfaction with health care
≥ +10 Improved
≤ -10 or patient too ill to complete measure Deterioration
Otherwise No change
*The change from baseline of 10 points for detecting a deterioration or improvement in the pancreas cancer 
module is based on recent investigations by Serrano et al 2014.
Note for some patients it will not be immediately possible to obtain a visit response for a 
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 Patients with no baseline score for a particular subscale, or no baseline data at all
 Patients whose baseline subscale score is too close to the maximum or minimum 
possible score to allow an increase or decrease of the specific size to be observed.
 For patients whose baseline score is greater than the maximum possible score 
for that subscale minus the score needed to satisfy improvement, the best visit 
response possible will be “No Change”.
 For patients whose baseline score is less than the threshold needed for 
worsening all post-baseline visit responses will be considered not-calculable.
Best overall response in HRQoL
A patient’s best overall QoL response will be derived as the best QoL response the patient 
achieved, based on evaluable QoL data collected from randomisation up to the earliest of 
starting any subsequent cancer therapy or death.  The criteria in Table 9 will be used to assign 
a best QoL response for HRQoL based on each QoL score.  Improvement rate will be defined 
as the proportion of patients whose best overall QoL response was “Improved”.




Missing Patient has no evaluable baseline or post-baseline PRO assessments.
Improved Patient meets one of the following criteria:
1. Has 2 consecutive visit responses of “improvement” at least 21 days apart.
2. Has 1 visit response of “improvement” and no further assessments and did 
not die within 2 PRO assessment visits.
No Change Patient does not qualify for an overall score response of “improved” and meets 1 
of the following criteria:
1. Has 2 consecutive visit responses of “no change” at least 21 days apart.
2. Has 1 visit response of “no change” and no further assessments and did not 
die within 2 PRO assessment visits. 
Deterioration Patient does not qualify for an overall score response of “improved” or “no 
change” and meets 1 of the following criteria:
1. Has 2 consecutive visit responses of “deterioration” at least 21 days apart.
2. Has 1 visit response of “deterioration” and no further assessments.
3. Has 1 visit response of “improvement” or “no change” followed by death 
within 2 PRO assessment visits.
Other Patient does not qualify for one of the above.
Visit responses are considered consecutive and at least 21 days apart if the next response is within a 
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3.3.2 EORTC QLQ-C30/PAN26 time to sustained clinically meaningful 
deterioration
Time to sustained clinically meaningful deterioration of HRQoL will be calculated for the 
EORTC QLQ-C30 Global QoL score, the QLQ-C30 symptom and functional scales, the 
QLQ-PAN26 multi-item scales and the QLQ-PAN26 single item scales.
It will be defined as the time from date of randomisation until the earliest of the date of a 
sustained clinically meaningful deterioration in the respective score or death (by any cause in 
the absence of a sustained clinically meaningful deterioration), provided death occurs within 
two HRQoL assessment visits of the last HRQoL assessment where the respective score could 
be evaluated, and regardless of whether the patient withdraws from randomised therapy or 
receives another anti-cancer therapy prior to deterioration in HRQoL (i.e. date of 
deterioration/death or censoring – date of randomisation + 1).
A sustained clinically meaningful deterioration will be defined as a deterioration per definition 
in Table 8, which must be sustained at the next scheduled visit and there must be no response 
of “improved” or “no change” between the two visit responses of “deterioration”.
Patients whose respective score has not shown a sustained clinically meaningful deterioration 
and who are alive at the time of the analysis will be censored at the time of their last HRQoL
assessment where the respective score could be evaluated. Also, if the respective score shows 
a sustained clinically meaningful deterioration after two or more missed HRQoL assessments
or the patient dies after two or more missed HRQoL assessment visits, the patient will be 
censored at the time of the last HRQoL assessment where the respective score could be
evaluated. However, if a patient has two missing visits between two evaluable QoL 
assessments with outcome not equal to deterioration at the second assessment, but then 
subsequently shows sustained clinically meaningful deterioration, the patient will not be 
censored.
Time to sustained clinically meaningful deterioration for a respective score will only be 
evaluated if a patient has a baseline score that is far enough from the maximum or minimum 
possible score to allow for such a deterioration to occur.  
3.3.3 EORTC QLQ-C30/PAN26 compliance
Summary measures of overall compliance and compliance over time will be derived 
separately for the EORTC QLQ-C30/PAN26 questionnaire forms.  These will be based upon:
 Received forms = number of EORTC QLQ-C30/PAN26 questionnaire forms 
received back plus the number not received back where the reason was ‘Subject too 
affected by symptoms of disease under investigation’.
 Expected forms = number of patients still under QoL follow-up at the specified 
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 Evaluable forms = subset of expected EORTC QLQ-C30/PAN26 questionnaire 
forms with at least one subscale that can be determined; or where the reason 
questionnaire not completed is ticked as ‘Subject too affected by symptoms of 
disease under investigation’.
For each form, compliance over time will be calculated separately for each visit, including 
baseline, as the number of patients with an evaluable baseline form and a form at the time 
point (as defined above), divided by number of patients still expected to complete forms at 
that visit.  Similarly, the evaluability rate over time will be calculated separately for each visit, 
including baseline, as the number of evaluable forms (per definition above), divided by the 
number of received forms.
For each form, the overall compliance rate is defined as number of patients with an evaluable 
baseline and at least one evaluable follow-up form (as defined above), divided by the number 
of patients expected to have completed at least a baseline form.
3.3.4 EQ-5D-5L
The EuroQoL five dimensions five level (EQ-5D-5L) is a standardised measure of health 
status developed by the EuroQol Group in order to provide a simple, generic measure of 
health for clinical and economic appraisal. Applicable to a wide range of health conditions and 
treatments, it provides a simple descriptive profile and a single index value for health status 
that can be used in the clinical and economic evaluation of health care. 
The EQ-5D-5L index comprises five dimensions of health (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression). For each dimension, respondents select 
which statement best describes their health on that day from a possible five options of 
increasing levels of severity (no problems, slight problems, moderate problems, severe 
problems and unable to/ extreme problems).  A unique EQ-5D health state is referred to by a 
five digit code allowing for a total of 3125 health states.  For example, state 11111 indicates 
no problems on any of the five dimensions. This data will be converted into a weighted health 
state index by applying scores from EQ-5D value sets elicited from general population 
samples (the base case will be the UK valuation set, with other country value sets applied in 
scenario analyses). Where values sets are not available, the EQ-5D-5L to EQ-5D-3L 
crosswalk will be applied. In addition to the descriptive system, respondents also assess their 
health today on a visual analogue scale, ranging from 0 (worst imaginable health) to 100 (best 
imaginable health). This score is reported separately.
The evaluable population will comprise all patients in the FAS.
3.4 Safety
Safety and tolerability will be assessed in terms of AEs (including serious AEs [SAEs]), 
deaths, laboratory data, vital signs, ECGs, physical examination, ECOG performance status, 
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3.4.1 Adverse events
Adverse events and SAEs will be collected throughout the study, from informed consent until 
30 days after the last dose of olaparib/placebo.  Any untoward event occurring subsequent to 
the 30-day follow-up AE reporting period that the investigator assesses as possibly related to 
the study treatment should also be reported as an AE.
Adverse Event of special interest
Some AEs that follow clinical concepts are considered as adverse events of special interest 
(AESIs). They are grouped into the following three categories: Myelodysplastic syndrome / 
acute myeloid leukemia (MDS/AML), new primary malignancies and pneumonitis. An 
AstraZeneca medically qualified expert after consultation with the Global Patient Safety 
Physician will confirm the list of AEs of special interest (group terms and the specific 
preferred terms) and provide them for analysis. They will be confirmed at the BDRM prior to 
the final analysis for PFS and at the DRM prior to the final analysis of OS and PFS2.
3.4.2 Treatment exposure
Exposure will be defined as follows:
Total (or intended) exposure of olaparib/placebo:
 Total (or intended) exposure in days = last dose date - first dose date + 1 
Actual exposure of olaparib/placebo:
 Actual exposure = intended exposure – total duration of dose interruptions, where 
intended exposure will be calculated as above.  Dose interruptions are any periods 
when the patient does not take any treatment.
To calculate actual exposure, dose interruptions will include those where a patient forgot to 
take a dose. 
Number of days on 300 mg olaparib/placebo bis in die (bid)
 Number of days on 300 mg olaparib/placebo bid = actual exposure for the dose 
assigned.  Any days with changes in doses will not be counted.
Mean total daily dose per time period
 Sum of the total dose actually received in the time period of interest (considering 
interruptions and dose reductions) divided by number of days patient on dose for 
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Compliance will be assessed by calculating the actual exposure in days (total planned days -
days of interruption) divided by the total exposure in days (last dose date - first dose date + 1) 
in percent.  In addition, patient’s individual drug accountability will be listed.
3.4.3 Dose intensity 
Relative dose intensity (RDI) is the percentage of the actual dose intensity delivered relative 
to the intended dose intensity through to treatment discontinuation.  Percentage intended dose 
(PID) is the percentage of the actual dose delivered relative to the intended dose through to 
progression.  Both will be derived using study treatment data up to the date of objective 
disease progression as defined by RECIST using the investigator site assessments.  If the 
investigator considered that it was in the patient’s best interest to continue study treatment 
past this time, this will not be included in the derivation of dose intensity.  
RDI and PID will be defined as follows:
 RDI = 100% * d/D, where d is the actual cumulative dose delivered up to the earlier 
of progression (or a censoring event) or the actual last day of dosing and D is the 
intended (or planned) cumulative dose up to the earlier of progression (or a 
censoring event) or the actual last day of dosing.
 PID = 100% * d/D, where d is the actual cumulative dose delivered up to 
progression (or a censoring event) and D is the intended (or planned) cumulative 
dose up to progression (or a censoring event).  D is the total dose that would be 
delivered, if there were no modification to dose or schedule.
For olaparib administered daily for the first two weeks of the cycle, the intended cumulative 
dose, D, will include all doses received up to midnight on the day of the last non-zero dose.
Figure 1 provides examples of how dose intensity is calculated for olaparib.
Figure 1 Example of dose intensity calculations for olaparib
In this example, patients 1-4 progressed or were censored on Day 15.  All four patients 
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 Missed/forgotten doses (Patient 1)
 Dose reduction and early stopping (Patient 2)
 Dose interruption (Patient 3)
 Progression whilst on dose interruption (Patient 4) 
 Early stopping (Patient 5)
Patient 1: RDI = PID = ((12 * 300 mg * 2) + (2 * 300 mg)) / (14 * 300 mg * 2) = 93%
Patient 2: RDI = ((7 * 300 mg * 2) + (4 * 250 mg * 2)) / (11 * 300 mg * 2) = 94%
PID = ((7 * 300 mg * 2) + (4 * 250 mg * 2)) / (14 * 300 mg * 2) = 74%
Patient 3: RDI = PID = (9 * 300 mg * 2) / (14 * 300 mg * 2) = 64%
Patient 4: RDI = (12 * 300 mg * 2) / (12 * 300 mg * 2) = 100%
PID = (12 * 300 mg * 2) / (14 * 300 mg * 2) = 86% 
Patient 5: RDI = ((5 * 300 mg * 2) + (1 * 300 mg)) / (6 * 300 mg * 2) = 92%
PID = ((5 * 300 mg * 2) + (1 * 300 mg)) / (14 * 300 mg * 2) = 39% 
3.4.4 Laboratory data 
Laboratory data will be collected throughout the study, from screening to 30-day follow-up 
visit as described in Appendix C.  Blood and urine samples for determination of pregnancy, 
haematology, clinical chemistry, and urinalysis will be collected as described in Section 5.2.1 
of the CSP.  For derivation of post baseline visit values considering visit window and how to 
handle multiple records, derivation rules as described in Section 3.4.9 below will be used.
3.4.5 Electrocardiograms
Electrocardiogram data will be collected during screening within 7 days prior to starting study 
treatment and when clinically indicated afterwards.  For derivation of post baseline visit 
values considering visit window and how to handle multiple records present in any visit 
window, derivation rules as described in Section 3.4.9 below will be used.
3.4.6 Vital signs
Vital signs data including body temperature, height, weight, pulse and blood pressure will be 
collected as described in Appendix C.  For derivation of post baseline visit values considering 
visit window and how to handle multiple records, derivation rules as described in Section 
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3.4.7 Physical examination
Physical examination data including the following: general appearance, respiratory, 
cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose and throat), lymph 
nodes, thyroid, abdomen, musculo-skeletal (including spine and extremities), and neurological 
systems will be collected as described in Appendix C.  
3.4.8 ECOG performance status
ECOG data will be collected as described in Appendix C.  For derivation of post baseline visit 
values considering visit window, derivation rules as described in Section 3.4.9 below will be 
used.
3.4.9 General consideration for safety assessments
Time windows
Time windows will need defining for any presentations that summarise safety values by visit
(ie. vital signs [incl weight and height], ECG, laboratory, and ECOG).  The following 
conventions should also apply:
 The time windows should be exhaustive so that data recorded at any time point has the 
potential to be summarised.  Inclusion within the time window should be based on the 
actual date and not the intended date of the visit.
 All unscheduled visit data should have the potential to be included in the summaries.
 The window for the visits following baseline will be constructed in such a way that the 
upper limit of the interval falls half way between the two visits (the lower limit of the first 
post-baseline visit will be Day 2, ie. the day after the first dose of study drug).  The visits 
Screening, Cycle 1 Day 1, Treatment Discontinuation, 30-Day Follow-up and Survival 
Follow-up visits will be excluded from remapping. The equation to be used to calculate 
the time windows for each post-baseline visit is:
Lower limit of interval=Upper limit of previous visit’s time window +1
Upper limit of interval=Nominal day at visit + ([nominal day at visiti+1 - nominal day at 
visiti]/2), where i = 3, 4, 5, 5.1, 5.2..., etc.
If an even number of days exists between two consecutive visits then the upper limit will 
be taken as the midpoint value minus 1 day.  
For example, the visit windows for vital signs data with 28 days between scheduled 
assessments are:
 Day 29, visit window 2 – 42
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 Day 85, visit window 71 – 98
 Day 113, visit window 99 – 126
 ...
 For summaries showing the maximum or minimum values, the maximum/minimum value 
recorded on treatment will be used (regardless of where it falls in an interval).
 Listings should display all values contributing to a time point for a patient.
 For visit-based summaries:
 If there is more than one value per patient within a time window, then the closest 
value should be summarised, or the earlier in the event the values are equidistant 
from the nominal visit date.  The listings should highlight the value for that patient 
that went into the summary table, wherever feasible.
 To prevent very large tables or plots being produced that contain many cells with 
meaningless data, for each treatment group visit data should only be summarised if 
the number of observations is greater than the minimum of 20 and > 1/3 of patients 
dosed.  For example, if 150 patients were dosed in the study (1/3*150 = 50), data at 
a particular visit would be summarised if the number of observations is greater than 
min (20, 50).  This would be in each treatment group.  Eg, if olaparib arm at Visit 6 
has > 20 observations and placebo arm has < 20 observations, the visit data will be 
summarised for the olaparib arm but not the placebo arm.  If both had < 20 patients, 
the data for that visit will be presented as ‘NC’ (Not Calculated).
 For summaries at a patient level, all values should be included, regardless of whether they 
appear in a corresponding visit based summary, when deriving a patient level statistic 
such as a maximum. 
 Baseline will be defined as the last non-missing measurement prior to dosing with study 
treatment (olaparib or placebo).  Any assessments made on day 1 will be considered pre-
dose. If an assessment on day 1 is identified as baseline, then it will not be considered as 
“on treatment”.  Where safety data are summarised over time, study day will be 
calculated in relation to date of first treatment (olaparib or placebo).
Imputation of missing safety data
Missing safety data will generally not be imputed.  However, safety assessment values of the 
form of “< x” (ie, below the lower limit of quantification) or “> x” (ie, above the upper limit 
of quantification) will be imputed as “x” in the calculation of summary statistics but displayed 
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Imputation of missing age
 Age at randomisation: Age at randomisation (baseline) will be calculated from the date of 
birth. Due to country specific regulations the full date of birth will not be available for all 
patients. In this case the “age as collected” from the demographics CRF will be used 
instead.
 Age calculation after randomisation: If order to identify reference ranges for laboratory 
parameters during the study, the age of a patient needs to be calculated at the timepoint of 
the collection of the sample. If the date of birth of a patient is only partially collected, then 
the following rule will be applied: (a) if only day is missing, then calculate age using the 
first day of the month; (b) if day and month are missing, then calculate age using the first 
of July. Then use the maximum of this calculated age and of the age as collected at 
screening for identification of reference ranges. If the date of birth is completely missing, 
then age as collected will be used.
Imputation of missing dates
For AEs, imputation methods will be used on completely missing start dates. Missing AE stop 
dates are not imputed. Imputation for partial dates is not applicable because partial adverse 
event dates are not collected in this study. Imputed start dates are used to decide if an 
observation is treatment emergent and for calculation of the AE event rates. Data listings will 
show actual date values. Missing AE start dates will be imputed with the first dose date unless 
the end date indicates it started prior to first dose date, in which case impute the 1st January of 
the year where the AE stopped as the start date.
For concomitant medications, start and stop dates are captured on the CRF with no partial 
dates being entered in the CRF. If the drug started prior to study start, then this is indicated by 
a flag “Yes” and the start date is missing. If the treatment with the medication continues, then 
this is indicated by a flag “Yes” and the stop date is missing. For the analysis of medications,
it is required to decide if the medication was taken during the time of study treatment. Such a 
medication may have started before, on or after the first dose of study drug and was taken in 
the time frame up to and including 30 days following the last dose of study drug. For patients 
on study treatment at the time of the PFS analysis, the DCO date will be used as the last dose 
of study drug.
Therefore, medications are considered as treatment emergent (taken during study treatment) if 
they:
- started on or before first dose and (stopped on or after first dose or are ongoing) OR
- started after first dose but prior to or on date of last dose plus 30 days.
The following conservative imputation rules will be applied:
 Start and stop date of medication present: apply the rules above
 Start date present but no stop date of medication: assume that medication is ongoing and 
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 Start date missing and stop date is not missing and “treatment prior to study start” is 
“Yes”: Temporarily set start date to the earliest of (date of first dose of study drug, stop 
date of medication) and apply the rules above
 Start date missing and stop date is missing and “treatment prior to study start” is “Yes”: 
Temporarily set start date to the date of first dose of study drug, assume the medication is 
ongoing and apply the rules above
 Start date missing and stop date is not missing and “treatment prior to study start” is 
missing: Temporarily set start date to the earliest of (date of first dose of study drug, stop 
date of medication) and apply the rules above
 Start date missing and stop date is missing and “treatment prior to study start” is missing: 
Temporarily set start date to the date of first dose of study drug, assume the medication is 
ongoing and apply the rules above
3.5 Resource Use
Resource use outcome variables include the following:
 Total number of hospitalisations
 Length of hospital stay
 Reasons for hospitalisation
 Total number of ICU admissions
 Length of any time spent in an intensive care unit (ICU) 
 Reasons for ICU admission
The length of hospital stay will be calculated as the difference between the date of hospital 
discharge (or death date when occurred during hospital stay) and the start date of 
hospitalisation (length of hospital stay = end date of hospitalisation – start date of 
hospitalisation + 1). If the start of study drug is after the start of hospitalisation, then the start 
of study drug will be used instead (length of hospital stay = end date of hospitalisation – start 
date of study drug + 1). If a patient was never treated with study drug and the date of 
randomisation is after the start date of hospitalisation, then the date of randomisation will be 
used instead (length of hospital stay = end date of hospitalisation – date of randomisation + 1).
For patients without an end date at the time of the PFS analysis, the date of death will be used 
if available; otherwise the DCO date will be used.
Sum of total duration of hospital stay will be considered for analysis if patient was admitted to 
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Hospital and ICU admissions will be counted as a single event if a patient is re-admitted on 
the same day. 
The length of ICU stay will be calculated using the same method as detailed above for the 
length of hospital stay. However, if the end date of the ICU stay is not available, but the end 
date of the corresponding hospitalisation period is given, then the end of the ICU stay will be 
imputed using this date, instead of using the DCO date.
4. ANALYSIS METHODS
4.1 General Principles
Efficacy data will be summarised and analysed using the FAS on an ITT basis while HRQoL 
data will be analysed using the PRO analysis set (see Section 2.1) and will compare the 
treatment groups on the basis of randomised treatment, regardless of the treatment actually 
received.  In addition, as sensitivity to the main analyses of PFS, PFS2, OS, TDT, TFST and 
TSST, analyses of these endpoints will be repeated in those patients whose gBRCAm status is 
confirmed by the Myriad test.
Results of all statistical analysis will be presented using a 95% confidence interval (CI) and 
2-sided p-value, unless specified otherwise. Median and corresponding 95% CI of time to 
event data (PFS, OS, PFS2, TFST, TSST, TDT) will be calculated using a Kaplan-Meier 
technique. 
When assessing safety and tolerability, summaries will be produced based on the safety 
analysis set and will compare the treatment groups on the basis of treatment actually received.  
The safety data will be summarised descriptively and will not be formally analysed.
4.1.1 Presentation of results in summary tables
If not stated otherwise, tabulations will be presented by treatment group as follows:
 Olaparib 300 mg bid
 Placebo bid
 Total
Data listings will include at least the following details:
 Patient identifier
 Centre identifier
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Data listings will be sorted by treatment group (planned or actual) and patient ID, if not stated 
otherwise.
4.2 Analysis Methods
A single interim PFS analysis for futility will be performed when 50% of the final number of 
progression events has been reached (approximately 44 PFS events).  A final PFS analysis 
will be performed when approximately 87 progression events have occurred (60% maturity).  
No further analyses of PFS are planned beyond this point.
One interim analysis for OS will be performed at the time of the final PFS analysis 
(approximately 87 PFS events).  A final analysis of OS will be performed when approximate 
106 death events have occurred.
Individual efficacy response data will be listed in a by-patient listing.
Timing of the statistical analysis is given in Table 10.
Table 10 Timing of Statistical Analyses
Timing of analysis Outcome Variable
Interim PFS when ~44 
PFS events reported
PFS
Final PFS when ~87 
PFS events reported
PFS, PFS2, TDT, TFST, TSST, OS, ORR, BoR, DoR and adjusted mean 
change from baseline in global HRQoL score.
Final OS when ~106 
OS events reported
OS, PFS2, TDT, TFST, TSST, and adjusted mean change from baseline in 
global HRQoL score.
Safety variables will be analysed at each analysis time point. 
The treatment comparison is olaparib 300 mg bid versus placebo.
The following table details which efficacy endpoints are to be subject to formal statistical 
analysis, together with pre-planned sensitivity analyses making clear which analysis is 
regarded as primary for that endpoint. 
Table 11 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses
Endpoints Analysed Notes
PFS Primary analysis: log-rank test using BICR data
Key sensitivity analyses: log-rank test using BICR data in randomised 
patients confirmed as gBRCA mutation positive by the Myriad test (if 
subset of FAS)
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Table 11 Formal Statistical Analyses to be Conducted and Pre-Planned 
Sensitivity Analyses
Endpoints Analysed Notes
1) Evaluation time bias analysis; log-rank test using BICR data
2) Attrition bias analysis (using alternative censoring rules); log-rank test 
using BICR data
3) Ascertainment bias analysis; log-rank test using investigator data
4) Deviation bias analysis (if meaningful to do); log-rank test using BICR 
data
OS Primary analysis: log-rank test 
Key sensitivity analysis: log-rank test data in randomised patients 
confirmed as gBRCA mutation positive by the Myriad test (if subset of 
FAS)
Supportive analysis: Kaplan-Meier (KM) plot of time to censoring for 
OS
PFS2 Primary analysis: log-rank test using investigator assessment of second 
progression
Key sensitivity analysis: log-rank test in randomised patients confirmed 
as gBRCA mutation positive by the Myriad test (if subset of FAS)
TDT Primary analysis: log-rank test 
Key sensitivity analysis: log-rank test in randomised patients confirmed 
as gBRCA mutation positive by the Myriad test (if subset of FAS)
TFST Primary analysis: log-rank test 
Key sensitivity analysis: log-rank test in randomised patients confirmed 
as gBRCA mutation positive by the Myriad test (if subset of FAS)
TSST Primary analysis: log-rank test 
Key sensitivity analysis: log-rank test in randomised patients confirmed 
as gBRCA mutation positive by the Myriad test (if subset of FAS)
ORR Primary analysis: logistic regression using BICR data 
Sensitivity analysis: logistic regression using investigator data
Adjusted mean change 
from baseline in global 
HRQoL score
Primary analysis: mixed model for repeated measures (MMRM) analysis
of all of the post-baseline scores for each visit
Supportive analysis: logistic regression on global HRQoL score 
improvement rate.
Time to sustained 
clinically meaningful
deterioration in HRQoL
Primary analysis: log-rank test
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4.2.1 Multiplicity 
In order to describe the nature of the benefits of olaparib maintenance treatment, PFS and OS 
will be tested at a 1-sided significance level of 2.5%.
In addition to these planned analyses, which will be performed and reported in the CSR, in 
order to strongly control the type I error at 2.5% 1-sided for key label claims, a multiple 
testing procedure (MTP) will be employed across the primary endpoint (PFS) and key 
secondary endpoint (OS).
A hierarchical testing strategy will be employed where PFS is tested first using the full test 
mass (full test mass = alpha 2.5% 1-sided) and the key secondary endpoint of OS will then be 
tested using a MTP with a recycling strategy (ie, the MTP will recycle the test mass to the 
endpoint not yet rejected in the hierarchy outlined in Figure 2).
The MTP is detailed below.
Figure 2 Multiple Testing Procedure
The OS will only be tested if the null hypothesis (of no difference) is rejected for PFS.  One 
interim analysis for OS will be performed at the time of the final PFS analysis (approximately 
87 PFS events).  The Lan and DeMets approach that approximates the O’Brien & Fleming
spending function will be employed to preserve the overall 1-sided type-I error rate of 2.5% 
(Lan and DeMets 1983).  If the interim analysis for OS occurs at exactly 57% of the 106 OS 
events (60 OS events), statistical significance for OS will be declared if the null hypothesis for 
PFS is rejected and the observed p-value for OS is p<0.003, which equates to a HR ≤ 0.49.  
The significance level at the interim and the final analysis will be determined based on the 
exact number of events at the time of the interim and final analyses and documented in the 
minutes of the blind data review meeting prior to DB lock.  If the interim analysis for OS 
occurs at exactly 57% of OS events and the number of OS events at the final analysis is 
approximately 106 then the 1-sided significance level to be applied for the final analysis will 
be 2.4%.  Statistical significance for OS will be declared if the observed p-value for OS is 
p<0.024, which equates to a HR ≤ 0.68.
4.2.2 Primary variable - progression free survival
A summary of PFS will be prepared to present the number of patients with progression and no 
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number of patients with progression identified by RECIST (separately for TLs, NTLs, and 
new lesions) and death as well as details about non-progressed patients including the number 
of patients progression-free at time of DCO, lost to follow-up, withdrawn consent, and 
prematurely censored (RECIST or death) if they did not progress and if the latest scan prior to 
DCO was more than one scheduled tumour assessment interval (+ 2 weeks) prior to the DCO 
date.  The summary will be presented by treatment group.
The PFS as defined in Section 3.2.1 will be analysed using a log-rank test for generation of the 
p-value and using the Breslow approach for handling ties in the following manner:
PROC LIFETEST DATA=...;
  TIME pfsTime*censor(1);
  TEST trtn;
RUN;
By using the TEST-Statement within LIFETEST procedure the test statistics U and the 
covariance matrix will be averaged over the possible orderings of the tied failure times (SAS 
Lifetest 2008).
The HR and its CI will be estimated from the log-rank (U and V statistics) follows directly 
from the LIFETEST model as used above for calculation of p-values (Berry et al 1999 and 
Sellke et al 1983)
Where is the log-rank test statistic (with and the observed and 
expected events in group 1); and the variance of the log-rank test statistic.  and will be 
obtained directly from LIFETEST procedure; will be taken from the table “Rank Statistics” 
while will be taken from the table “Covariance Matrix for the Log-Rank Statistics”.
The log-rank test statistic, the HR (olaparib vs. placebo) together with its corresponding 95% 
CI and p-value will be presented (a HR less than 1 will favour olaparib).
The median and 95%-CI of PFS and the proportion of patients progression-free at 6 months, 
12 months, 18 months, 24 months, 36 months and 48 months will be summarised and 
presented by treatment group.
In addition, duration of follow-up will be summarised using median time from randomisation 
to date of censoring (date last known to be non-progressor) in censored (not progressed) 
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The following KM plots of PFS will be presented by treatment group.  The KM plot will be 
prepared using LIFETEST procedure and selecting ODS graphics.  The plot will identify 
censored patients using a different symbol and include patients at risk at specific time points:
 PFS
 PFS with censoring and event flags reversed
The assumption of proportionality will be assessed.  The results of these model checks will
not be presented in the CSR as part of the formal outputs; however, any deviation from this 
assumption will be considered in the interpretation. Note that in the presence of non-
proportionality, the HR will be interpreted as an average HR over the observed extent of 
follow-up.  Proportionality will be tested firstly by producing plots of complementary log-log
(event times) versus log (time) and, if these raise concerns, a time dependent covariate would 
be fitted to assess the extent to which this represents random variation.  The complementary 
log-log plot will be directly produced in SAS LIFETEST procedure using ODS graphics 
option PLOTS=(LLS) in the PROC-Statement.  The graph will be assessed visually.  Two 
parallel lines favour the proportionality assumption.  To support the proportionality 
assessment a Cox proportional hazard’s model will be constructed containing the interaction 
of treatment and the logarithm of PFS_time (treatment*log(PFS_time)).  The p-value obtained 
from the Wald Chi-squared test for the time dependent covariate will be presented.  The 
following SAS-code may be used:
PROC PHREG DATA=...;
  CLASS trtn (REF='placebo') / PARAM=REFERENCE;
  MODEL pfs_Time *censor(1)=trtn timeDependent / TIES=EFRON;
  timeDependent = trtn*LOG(pfs_Time);
  proportionality_test: TEST timeDependent;
RUN;
A further analysis of PFS (using investigator assessed RECIST) may be performed at the time 
of the final OS analyses, if requested by health authorities.  A final decision will be made at 
the BDRM for the final OS analysis.
4.2.2.1 Progression-free survival sensitivity analyses
As a sensitivity analysis to the primary endpoint of PFS, the primary analysis will be repeated 
excluding any patients who did not have a gBRCA mutation status confirmed by the central 
Myriad test.  The same methodology and model will be used as for the primary analysis and 
the HR and associated 95% CI will be reported.  A KM plot of PFS in this subset of patients 
will be presented by treatment group. 
(a) Attrition bias
Attrition bias will be assessed by repeating the primary PFS analysis except that the actual 
PFS event times, rather than the censored times, of patients who progressed or died in the 
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assessments will be included.  In addition, patients who take subsequent therapy prior to their 
last evaluable RECIST assessment or progression or death will be censored at their last 
evaluable assessment prior to taking the subsequent therapy. 
A by-patient listing will be produced similar to the PFS listing but including only patients who 
progressed but were censored for the primary analysis due to missing of two, or more, non-
evaluable tumour assessments.  The actual PFS times will be reported.
(b) Evaluation-time bias
A sensitivity analysis will be performed to assess possible evaluation-time bias that may be 
introduced if scans are not performed at the protocol-scheduled time points.  The log-rank test, 
as described for the primary analysis of PFS, will be repeated using the midpoint between the 
time of progression and the previous evaluable RECIST assessment to derive PFS time for 
patients with RECIST progression events.  For patients whose death was treated as a PFS 
event, the date of death will be used to derive the PFS time used in the analysis.  This 
approach has been shown to be robust to even highly asymmetric assessment schedules (Chen 
and Sun 2010).  This approach will use the BICR RECIST assessments.  
To support this analysis, the individual mean time difference between RECIST assessments 
(patient inter-assessment times) will be calculated and summarised using descriptive statistics.
(c) Ascertainment bias
The primary analysis of PFS (log-rank test) will be repeated using investigator assessed 
RECIST data.  The HR and 95% CI will be presented.  A KM plot of PFS based on the 
investigator assessed RECIST data will be presented by treatment group.
Ascertainment bias will be assessed through the use of two measures proposed by Amit (Amit, 
et al., 2011): the early discrepancy rate (EDR) and late discrepancy rate (LDR).  The EDR 
represents the positive predictive value of Investigator assessment and quantifies the 
frequency with which the Investigators declare progression early relative to BICR within each 
arm as a proportion of the total number of Investigator assessed PD’s.  The LDR quantifies the 
frequency that the Investigators declare progression later than BICR as a proportion of the 
total number of discrepancies within the arm.  If the distribution of discrepancies is similar 
between the arms, then this suggests the absence of evaluation bias favouring a particular arm.
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The EDR and LDR will be calculated for each treatment arm and the differential discordance 
around each measure will be defined as the rate on the experimental arm minus the rate on the 
control arm.  
If there is an important discrepancy between the primary analysis using BICR assessments and 
this sensitivity analysis using investigator assessments, the proportion of patients with site but 
no central confirmation of progression will be summarised by treatment group and the primary 
analysis will be repeated for this subset of patients.  The approach of imputing an event at the 
next visit in the central review analysis may help inform the most likely HR value, but only if 
an important discrepancy exists.  Discrepancy between the primary analysis using BICR 
assessments and investigator assessments of progression will be discussed at the BDRM.  The 
study team will decide whether the discrepancy between assessments is of importance and 
whether or not additional analyses are required. 
A by-patient listing will be produced to present patients where at least one assessment differs 
between investigator and central reviews of RECIST progression.
(d) Deviation bias
As a sensitivity analysis to the primary endpoint of PFS, an analysis excluding patients with 
“important” deviations that may affect the efficacy of the trial therapy will be performed if the 
following deviations were reported for > 10% of patients:
 did not have the intended disease or indication or
 did not receive any randomised therapy
A log-rank test will be repeated using the BICR RECIST data, using the same method as 
described for the primary analysis of PFS.  The HR and 95% CI will be presented.
The treatment status at progression by patients who have progressed / censored including the 
number of patients and percentage of on-treatment or discontinued will be tabulated.  The 
number of days from treatment discontinuation to progression for patients who have 
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Patients censored for progression at more than 14 weeks before the DCO (‘censored > 14 
weeks before DCO’, ‘censored <= 14 weeks before DCO’) will be tabulated and presented by 
treatment group.
A by-patient listing will be produced including patients with an important deviation only.
4.2.2.2 Progression-free survival subgroup analyses
Subgroup analyses will be conducted comparing PFS between treatments.  The purpose of the 
subgroup analyses is to assess the consistency of treatment effect across potential or expected 
prognostic factors.  KM plots will be produced for each subgroup according to treatment 
group.  
If there are too few events available for a meaningful analysis of a particular subgroup (it is 
not considered appropriate to present analyses where there are less than 5 events in a subgroup 
in at least one treatment group), the results of the subgroup analysis (HR and 95% CI) will not 
be presented, however, all patients with non-missing subgroup data will be included in the 
Cox model used for the analysis (see below).
The following subgroups will be analysed for PFS:
 Previous chemotherapy (FOLFORINOX variants, gemcitabine/cisplatin, other); 
Reference=FOLFORINOX variants
 Type of previous chemotherapy (doublets, triplets, other); Reference=doublets
 Time on first-line treatment till randomisation (≤ 6 months vs > 6 months); 
Reference=≤6 months
 Best response on first-line treatment (SD vs PR/CR); Reference=SD
These will be determined from the “Metastatic Pancreas Cancer Therapy” (CAPRX2) module 
of the eCRF at screening by medical review.
 Presence or absence of biliary stent; Reference=Presence of biliary stent
This will be determined from the “Surgical History” (HISS) module of the eCRF at screening
by medical review.
 Measurable versus non measurable disease / NED at baseline; Reference=non 
measurable disease / NED at baseline
This will be determined programmatically from the baseline BICR results.
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This will be determined programmatically from the Myriad central laboratory test results.
 Age at randomisation (>= 65 vs < 65); Reference=< 65
 Race (White vs Other); Reference=White
 Sex (Male vs Female); Reference=Male
These will be determined programmatically from the “Demography” (DEM) module of the 
eCRF at screening.
Other baseline variables may also be assessed if there is clinical justification.  A final decision 
will be made at the BDRM.
For each subgroup, the HRs (olaparib: placebo) and associated CIs will be calculated from a 
Cox proportional hazards model (TIES = Efron) that contains the treatment group, factor 
(subgroup) and treatment-by-factor interaction term. All patients with non-missing subgroup 
category data will be included in the Cox model. Statistics produced by the Cox model, i.e. 
HR/CI will only be displayed in subgroup categories with a sufficient number of events 
available (at least 5 events in both treatment groups), otherwise, only the total number of 
patients and events will be displayed. Reference cell coding will be used introduced by the 
PARAM=REFERENCE option in the CLASS-Statement.  Individual reference levels will be 
defined using the REF= option within the CLASS-Statement for each subgroup.  The 
treatment effect HRs for each treatment comparison along with their CIs will be obtained for 
each level of the subgroup from this single model.  Analysis will be carried out using PHREG 
procedure in SAS in the following manner:
PROC PHREG DATA=...;
  CLASS trtn (REF='placebo') chemoType (REF='doublets')
    / PARAM=REFERENCE;
  MODEL pfs*censor(1)=trtn chemoType trtn*chemoType 
    / TIES=EFRON;
RUN;
The HRs and 95% CIs will be presented in an overview table as well as on a forest plot 
including the HR and 95% CI from the overall population (using the HR and 95% CIs from 
the primary analysis).
No adjustment to the significance level for testing will be made since all these subgroup 
analyses will be considered exploratory and may only be supportive of the primary analysis of 
PFS.
The presence of quantitative interactions will be assessed by means of an overall global 
interaction test.  This will be performed in the overall population by comparing the fit of a 
Cox proportional hazards model including treatment, all covariates, and all 
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be assessed at the two-sided 10% significance level.  If a covariate does not have more than 5
events per level in both treatment groups (of the covariate) it will be included as a covariate in 
the model but the covariate-by-treatment interaction term will be omitted.  If the fit of the 
model is not significantly improved then it will be concluded that overall the treatment effect 
is consistent across the subgroups.
If the global interaction test is found to be statistically significant, an attempt to determine the 
cause and type of interaction will be made. Stepwise backwards selection will be performed 
on the saturated model, whereby (using a 10% level throughout) the least significant 
interaction terms are removed one-by-one and any newly significant interactions re-included 
until a final model is reached where all included interactions are significant and all excluded 
interactions are non-significant.  Throughout this process all main effects will be included in 
the model regardless of whether the corresponding interaction term is still present.  This 
approach will identify the factors that independently alter the treatment effect and prevent 
identification of multiple correlated interactions. 
Any quantitative interactions identified using this procedure will then be tested to rule out any 
qualitative interaction using the approach of Gail and Simon 1985.
A by-patient listing will be produced for presenting individual PFS data.
4.2.3 Overall Survival
A summary of survival status at the time of analysis will be produced.  This will summarise 
the number of patients who have died, who are still in survival follow-up, who are lost to 
follow-up or who have withdrawn consent.  Results will be presented by treatment group.  
Overall survival as defined in Section 3.2.2 will be analysed at the time of the final analysis 
for PFS and will use the same methodology and model (provided there are sufficient events 
available for a meaningful analysis [> 5 deaths in both treatment groups], if not descriptive 
summaries only will be provided).  A further analysis of OS will be performed when 
approximately 106 deaths have occurred.
Median OS and corresponding 95% CI will be summarised including the number of deaths, 
and survival at month 6, 12, 18, 24, 36 and 48.  Results will be presented by treatment group.
The analysis will be repeated excluding any patients who did not have a gBRCA mutation 
status confirmed by the central Myriad test.
The sensitivity analyses outlined for PFS in Section 4.2.2 will not be repeated for OS with the 
exception of a KM plot.  Two KM plots will be produced.  The first KM plot will show time 
to censoring of OS and the second KM plot will show will show time to censoring where the 
censoring indicator is reversed (median time to follow-up where events will be censored and 
previously censored patients will be treated as events). The first KM plot will be repeated 
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OS data will be listed in a by-patient listing.
Similar subgroup analyses (except the interaction test) will be conducted comparing OS 
between treatments as detailed for PFS in Section 4.2.2.2, using the same methodology and 
model.  KM plots will be produced for each subgroup according to treatment group.  If there 
are too few events available for a meaningful analysis of a particular subgroup (it is not 
considered appropriate to present analyses where there are less than 5 events in a subgroup in 
at least one treatment group), the relationship between that subgroup and OS will not be 
formally analysed. In this case, only descriptive summaries (number of patients, number (%) 
of events, and KM plots) will be provided.
4.2.4 Time from randomisation to second progression
The status of PFS2 as defined in Section 3.2.3 will be summarised by the number and 
percentage of patients experiencing a PFS2 event and the type of progression (objective 
progression by RECIST, symptomatic progression or death).  Results will be presented by 
treatment group.  
The analysis of PFS2 will use the same methodology and model as the primary analysis of 
PFS.  No multiplicity adjustment will be applied as this is viewed as a supportive endpoint.
A KM plot of PFS2 will be provided by treatment group.  A KM plot of the time to censoring 
where the censoring indicator of the PFS2 analysis is reversed will be produced (called 
median time to follow-up where events will be censored and previously censored patients will 
be treated as events).
As a key sensitivity, the analysis of PFS2 will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  A KM plot of PFS2 in this subset of patients will be 
presented by treatment group.
The median and 95%-CI of PFS2 and the proportion of patients with no second progression at 
6, 12, 18, 24, 36 and 48 months will be summarised and presented by treatment group.
Days between second progression and last assessment prior to second progression will be 
summarised descriptively by treatment group.
A by-patient listing will be produced including details about time of second progression.
4.2.5 Time to first subsequent therapy or death 
The TFST will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HRs for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group, together with status, median TFST and 95% CI for each 
treatment group.  
As a key sensitivity, the analyses of TFST will be repeated in those patients whose gBRCAm 
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will be reported by treatment group. In addition, a KM plot of TFST will be presented by 
treatment group.
The time between progression and starting subsequent cancer therapy will be summarised.
In addition, best overall RECIST response to first subsequent cancer therapy by treatment 
group will be provided.
Individual TFST will be presented in a by-patient listing.
4.2.6 Time to second subsequent therapy or death 
The TSST will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HRs for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group, together with status, median TSST and 95% CI for each 
treatment group.  
As a key sensitivity, the analyses of TSST will be repeated in those patients whose gBRCAm 
status is confirmed by the Myriad test.  In this subset of patients, median TSST and 95% CI
will be reported by treatment group.  In addition, a KM plot of TSST will be presented by 
treatment group.
In addition, best overall RECIST response to second subsequent cancer therapy by treatment 
group will be provided.
Individual TSST will be presented in a by-patient listing.
4.2.7 Time to study treatment discontinuation or death
The TDT will be analysed using the same methodology and model as the primary analysis of 
PFS.  The HR for the treatment effect together with 95% CIs will be presented.  A KM plot 
will be presented by treatment group, together with status, median TDT and 95% CI for each 
treatment group.
As sensitivity, the analyses of TDT will be repeated in those patients whose gBRCAm status 
is confirmed by the Myriad test.  In this subset of patients, median TDT and 95% CI will be 
reported by treatment group.  In addition, a KM plot of TDT will be presented by treatment 
group.
Individual TDT will be presented in a by-patient listing.
4.2.8 Best objective response and objective response rate
For each treatment group, BoR as defined in Section 3.2.7 will be summarised by n (%) for 
each category (CR, PR, SD, NED, PD, NE) based on the BICR data.  This will also be 
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ORR as defined in Section 3.2.8 will be summarised descriptively, ie, number of patients (%)
by treatment group, and using logistic regression, based on the BICR data, in patients in the 
FAS (ITT population) with measurable disease at baseline defined according to BICR. The 
results of the analysis will be presented in terms of an odds ratio together with its associated 
profile likelihood 95% CI and p-value (based on twice the change in log-likelihood resulting 
from the addition of a treatment factor to the model). If there are not enough responses for a 
meaningful analysis using logistic regression then a Fisher’s exact test will be presented.  
ORR will also be summarised based on the investigator-assessed data in the FAS (ITT 
population) with measurable disease at baseline defined according to investigator assessment
using the same methods as for the BICR data. Any patients who experienced CR or PR which 
was first observed whilst receiving subsequent therapy after discontinuation of olaparib will 
be identified and not treated as responders per definition of BoR in Section 3.2.7.  
In addition, the duration and time to onset of objective response in patients with objective 
response (by BICR and by investigator assessment) will be summarised by treatment group.  
BoR will be presented in a by-patient listing.  In addition, a listing will be prepared including 
objective responders (confirmed CR or PR) only.
4.2.9 Disease control rate
The DCR as defined in Section 3.2.9 will be summarised (ie, n, %) by treatment group.  The 
DCR will be presented based on the BICR data and also the investigator recorded data. 
4.2.10 Target lesion summary and other efficacy
Target lesion size, and percentage change from baseline will be summarised by treatment 
group and time point using descriptive statistics.  Lesion data according to BICR and also by 
investigator assessment will be listed in by-patient listings.
Subsequent cancer therapy relative to progression will be summarised using frequency counts 
and percentages.  The tabulation will detail any patients receiving any further therapy for 
cancer by time of therapy (‘After progression’, ‘Before progression’, ‘No progression’).  
Tabulation will include the number of patients where no subsequent cancer therapy was 
recorded as well.  Data will be presented by treatment group.
4.2.11 Patient reported outcomes
The analysis population for PRO data will be the PRO analysis set as defined in Section 2.1.  
Derivations and rules for transformation of PRO data are defined in Section 3.3.
Impact of olaparib on HRQoL
The impact of olaparib on HRQoL will be assessed through an analysis of the global health 
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Descriptive statistics including change from baseline score will be produced by time point for 
the EORTC QLQ-C30 global health status / QoL score.  Results will be presented by 
treatment group.  Arithmetic mean (± standard deviation) plots of scores versus time point will 
be produced in linear scale. 
Adjusted mean change from baseline in global QoL score will be analysed using a mixed 
model for repeated measures (MMRM) analysis of all of the post-baseline scores for each visit 
and will be presented by treatment group.  Only visits with at least 25% of non-missing values 
in both treatment arms (calculated separately by treatment arm) are included in the model.  
The study treatment discontinuation visit and the safety follow-up visit will be excluded from 
this analysis. Restricted maximum likelihood (REML) estimation will be used. The model will 
include randomised treatment group, visit and treatment by visit interaction as explanatory 
variables and the baseline QoL score as a covariate along with a baseline QoL score by visit 
interaction. Treatment, visit and treatment by visit interaction will be fixed effects in the 
model.  The treatment by visit interaction will remain in the model regardless of significance.
An unstructured covariance matrix will be used to model the within-subject error and the 
Kenward-Roger approximation will be used to estimate the degrees of freedom.  The 
following provides sample code for implementing the MMRM analysis: 
* Model 1 (adjusted means by treatment and visit);
PROC MIXED DATA=… METHOD=REML;
   CLASS trt visit patient;
   MODEL cfb = trt visit trt*visit base base*visit / S DDFM=KR;
   REPEATED visit / TYPE=UN SUBJECT=patient;
   LSMEANS trt*visit / SLICE=visit AT MEANS DIFF PDIFF ALPHA=0.05 CL;
RUN;
* Model 2 (adjusted means by treatment, averaging over all visits);
PROC MIXED DATA=… METHOD=REML;
   CLASS trt visit patient;
   MODEL cfb = trt visit trt*visit base base*visit / S DDFM=KR;
   REPEATED visit / TYPE=UN SUBJECT=patient;
LSMEANS trt / AT MEANS PDIFF ALPHA=0.05 CL;
RUN;
where TRT is the randomised treatment group, VISIT is the visit, CFB is the change from 
baseline in the global QoL score, and BASE is the baseline global QoL score.
If the fit of the unstructured covariance structure fails to converge, the following covariance 
structures will be tried in order until convergence is reached: Toeplitz with heterogeneity, 
autoregressive with heterogeneity, Toeplitz, and autoregressive. 
The adjusted mean change from baseline estimates (obtained from LSMEANS-Statement as 
the calculated least square means adjusted for the random component of the model), standard 
error, and corresponding 95% CIs will be presented by visit for each treatment group.  
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An overall adjusted mean estimate will also be derived that will estimate the average 
treatment effect over all visits giving each visit equal weight. For this overall treatment 
comparison, adjusted mean estimates per treatment group and corresponding 95% confidence 
intervals will be presented along with an estimate of the treatment difference, 95% confidence 
interval and p-value. Also, for each visit, an estimate of the treatment difference and a 95% 
confidence interval will be presented.
A by-patient listing will be produced for the EORTC QLQ-C30 global QoL scale presenting 
raw scores (overall health and overall quality of life items) and the transformed score by time 
point.
As a supportive analysis, EORTC QLQ-C30 global QoL score improvement rate will be 
analysed using a logistic regression model.  The model will include a binary variable as 
response (improvement=1; no improvement=0) and treatment group as an explanatory 
variable in the MODEL-Statement together with the option CLPARM=PL to compute profile 
likelihood CIs and p-values.  Explanatory variables will be introduced using a reference cell 
coding (option PARAM=REFERENCE) while the option REF= will be used to identify the 
reference.  The following provides sample SAS code for implementing the analysis:
PROC LOGISTIC DATA=… ALPHA=0.05;
   CLASS trt(REF=’PLACEBO’) / PARAM=REFERENCE;
   MODEL improvement(EVENT=’1’) = trt / CLPARM=PL;
   EXACT trt / ESTIMATE;
RUN;
If the overall improvement rate is < 5%, no analysis will be performed (note that if the 
response rate in only one of the treatment groups is < 5% but ≥ 5% in the other treatment 
group then the analysis will still be performed).  If the overall response rate is low (< 20%) a 
Fisher’s exact test (for an example SAS code see below) will be considered and mid p-values 
used.  The results of the analysis will be presented in terms of an odds ratio together with its 
associated profile likelihood CIs and p-values (based on twice the change in log-likelihood 
resulting from the addition of a treatment factor to the model).
PROC FREQ DATA=…;
   TABLE improvement * trt / FISHER;
   EXACT OR / ALPHA=0.05;
RUN;
In addition, a summary table of EORTC QLQ-C30 global QoL score best overall QoL 
response will be provided (improvement, deterioration, no change).
Compliance
The EORTC QLQ-C30 and EORTC QLQ-PAN26 compliance (overall compliance and by 
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4.2.12 Exploratory analyses
EORTC QLQ-C30 functional and symptom scales and EORTC QLQ-PAN26 scales
The analysis as described above to assess the impact of olaparib on HRQoL will be repeated 
for selected EORTC QLQ-C30 functional and symptom scales as well as for selected EORTC 
QLQ-PAN26 scales.  This involves the following, presented by treatment group:
 Descriptive statistics including change from baseline
 Arithmetic mean (±standard deviation) plots of scores versus time point
 Adjusted mean change from baseline (95% CI) over time (summary tables and 
plots)
 Frequency tables of best overall QoL response (improvement, deterioration, no 
change)
The following scores will be analysed in the exploratory analysis:
 QLQ-C30 Functional scale: Physical score (items 1-5), role score (items 6, 7), 
emotional score (items 21-24), cognitive score (items 20, 25), social score (items 26, 
27)
 QLQ-C30 Multi-item symptom scale: Pain score (items 9, 19), fatigue score (items 10, 
12, 18), nausea/vomiting score (items 14, 15)
 QLQ-C30 Single-item symptom scale: Loss of appetite (item 13), insomnia (item 11)
 QLQ-PAN26 Multi item scale: Pancreatic pain score (items 31, 33-35), digestive 
symptoms score (items 36, 37), hepatic score (items 44, 45)
 QLQ-PAN26 Single item scale: Worried about low weight (item 41)
These additional sub-scales are considered exploratory to support the primary EORTC QLQ-
C30 global QoL and will be used to assess whether any observed differences in the global 
measure are driven by particular domains of functioning, symptoms, or group of symptoms.  
P-values will not be calculated for these supportive analyses.
A by-patient listing will be produced presenting the EORTC QLQ-C30 functional and 
symptom scales.  A separate by-patient listing will be produced for EORTC QLQ-PAN26 
scales.  Listings will include the raw scores for each item and the transformed scores by time 
point.
Time to sustained clinically meaningful deterioration in HRQoL
A supportive analysis of time to sustained clinically meaningful deterioration will be 
performed, using the same methodology and model as described for the primary analysis of 
PFS (log-rank test). For each type of score, the analysis will be carried out for a subset of 
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meaningful deterioration to occur. The following scores will be analysed (requirement for 
baseline score):
 QLQ-C30 Global Health Status / QoL score (baseline score ≥ 10)
 QLQ-C30 Functional scale: Physical score (baseline score ≥ 10)
 QLQ-C30 Multi-item symptom scale: Pain score, fatigue score, nausea/vomiting score
(baseline score ≤ 90)
 QLQ-C30 Single-item symptom scale: Loss of appetite (baseline score ≤ 90)
 QLQ-PAN26 Multi item scale: pancreatic pain (baseline score ≤ 90)
 QLQ-PAN26 Single item scale: worried about low weight (baseline score ≤ 90)
A KM plot of time to sustained clinically meaningful deterioration will be presented by 
treatment group. Summaries of the median time to sustained clinically meaningful
deterioration of HRQoL for each treatment will be produced.
A sensitivity analysis will be performed to assess the impact of attrition bias. This will be 
assessed by repeating the time to sustained clinically meaningful deterioration analysis except 
that the actual times to deterioration of HRQoL, rather than the censored times, of patients 
who experienced sustained clinically meaningful deterioration or died immediately following 
two, or more, non-evaluable assessments will be included. In addition, patients who take 
subsequent therapy prior to their last evaluable HRQoL assessment or prior to sustained 
clinically meaningful deterioration of HRQoL or death will be censored at their last evaluable
HRQoL assessment prior to taking the subsequent therapy.
EQ-5D-5L health state utility index
The evaluable population will comprise all patients in the FAS.
Health state utility index and visual analogue scale (VAS) for health status will be 
summarised using descriptive statistics.  The change from baseline and the percentage change 
from baseline will be calculated for each time point and presented by randomised treatment 
group, and both will be presented graphically using arithmetic mean (±standard deviation) 
plots.  EQ-5D-5L five-point dimension scales will also be summarised over time by 
randomised treatment group.
By-patient listings will be produced presenting the individual EQ-5D-5L raw scores and 
review assessments.
Resource use
Total length of hospital stay and total length of ICU stay (number of days) will be summarised 
by randomised treatment group.  Total number of days spent in hospital and in ICU, the 
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A by-patient listing will be produced presenting details of hospital and ICU stay.
ECOG
A by-patient listing will be produced presenting details of ECOG performance status.
Impact of Switching to PARP inhibitors (or other potentially active investigational 
agents) on Overall Survival Analysis
Exploratory analyses of OS adjusting for impact of subsequent PARP inhibitor trial or 
treatment may be performed if a sufficient proportion of patients receive the therapies of 
interest.  Decision will be made at the BDRM.  
Methods such as Rank Preserving Structural Failure Time (RPSFT) (Robins et al 1991), 
Inverse Probability of Censoring Weighting (IPCW) (Robins 1993) and other methods in 
development will be explored.  The decision to adjust and final choice of methods will be 
based on a blinded review of the data and the plausibility of the underlying assumptions.  
Baseline and time-dependent characteristics will be explored, and summaries of baseline 
characteristics will be summarised for patients receiving physician’s choice of chemotherapy, 
splitting between those that have and haven’t received a PARP inhibitor at the time of the 
analyses.  Further detail will be provided in the Payer Analysis Plan under the responsibility 
of AstraZeneca.  These analyses are intended to support reimbursement appraisals.
Biomarkers
Collection details for biomarker samples will be listed in a by-patient listing.
4.2.13 Safety
Safety data will be summarised and listed only.  No formal statistical analyses will be 
performed on the safety data.  All safety data will be summarised by actual treatment group 
(olaparib or placebo).  However, some listings such as AEs listings will display the actual 
dose the patient received at onset of an AE.
Adverse events
All AEs, both in terms of Medical Dictionary for Regulatory Activities (MedDRA) preferred 
term (PT) and Common Toxicity Criteria for Adverse Events (CTCAE) grade, will be listed 
and summarised descriptively by count (n) and percentage (%) for each treatment group.  
MedDRA dictionary will be used for coding.  Any AE occurring before olaparib/placebo 
treatment (ie, before Study Day 1) will be included in the AE listings, but will not be included 
in the summary tables (unless otherwise stated).  These will be referred to as ‘pre-treatment’.
The summary tables will include all AEs that occurred after the start of treatment up until the 
end of the 30 day follow-up period.  The 30 day follow-up period will be defined as 30 days 
following discontinuation of olaparib/placebo treatment.  Any untoward event occurring 
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possibly related to the study treatment will also be included in the AE listings, but not in the 
summary tables.
All reported AEs will be listed along with the date of onset, date of resolution (if AE is 
resolved), investigator’s assessment of severity and relationship to study drug.  Frequencies 
and percentages of patients reporting each PT will be presented (ie, multiple events per patient 
will not be accounted for apart from on the episode level summaries). 
Summary information (the number and percent of patients by actual treatment) will be 
tabulated for:
 All AEs 
 All AEs causally related to study medication
 AEs with CTCAE grade 3 or higher
 AEs with CTCAE grade 3 or higher, causally related to study medication
 AEs leading to dose modification of olaparib/placebo
 AEs leading to dose interruption of olaparib/placebo
 AEs leading to dose reduction of olaparib/placebo
 AEs with outcome of death
 AEs with outcome of death causally related to study medication
 All SAEs
 All SAEs causally related to study medication 
 DAEs
 AEs leading to discontinuation of olaparib/placebo, causally related to study 
medication
An overall summary of the number and percentage of patients in each category will be 
presented.
In addition, a truncated AE table of most common AEs, showing all events that occur in at 
least 5% of patients overall will be summarised by PT, by decreasing frequency.  This cut-off 
may be modified after review of the data.
Each AE event rate (per 1000 patient years) will be summarised by system organ class (SOC) 
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with an AE in that SOC or with that PT divided by the sum of the duration of therapy (for 
patients without such an event) and the time to the AE (for patients with such an event) in 
each group multiplied by 1000.  The denominator defines the time at risk for an event with: 
 Duration of therapy (days) calculated as: 
MINIMUM([date of last dose + 30-day safety follow-up period], OS date, DCO) –
date of first dose + 1
 Time to the AE (days) calculated as date of first occurrence of the AE – date of first 
dose + 1 (in days), imputed AE start dates can be used in case of missing start dates.
The formula for calculating the event rate for a specific PT is as follows:
PT = Patients with the event reported; eg, all patients with an AE where PT equals to 
‘Headache’.
= Patients without the event; eg, all patients who never experienced an AE where PT is 
equal to ‘Headache’.
Similarly, the formula for calculating the event rate in as SOC is as shown below:
PT in SOC = Patients with any reported event in the respective SOC
= Patients who did not report any event in the respective SOC
AEs will be assigned CTCAE grades (National Cancer Institute CTCAE version 4.0) and 
summaries of the number and percentage of patients will be provided by maximum reported 
CTCAE grade, SOC, PT and actual treatment group.  Tabulation will be repeated to present 
AEs with a CTCAE grade 3 or higher and separately those AEs, causally related to study 
treatment by SOC and PT.  Fluctuations observed in CTCAE grades within the same PTs 
during study will be listed.
Tabulation of AEs causally related to study treatment will be summarised by SOC and PT and 
presented by treatment group.
Summaries of the number and percentage of patients with AEs leading to dose modification of 
olaparib/placebo and also separately with AEs leading to dose reductions and drug 
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A summary table will be prepared presenting AEs which started prior to first dose or > 30 
days following date of last dose by SOC and PT.  Data will be presented by treatment group.
Death
A summary of all AEs resulting in deaths will be provided with number and percentage of 
patients by actual treatment group, categorised as:
 Related to disease under investigation 
 AE outcome=death
 Both related to disease under investigation and with AE outcome=death 
 AE with outcome=death ≥30 days after last treatment dose 
 Deaths ≥ 30 days after last treatment dose, unrelated to AE or disease under 
investigation
 Patients with unknown reason for death 
In addition, AEs with outcome of death will be summarised.  The following summary tables 
will be prepared and presented by treatment group:
 By SOC and PT
 Causally related to study treatment by SOC and PT
 Death will be listed as part of TLFs for part 11 of the CSR
Serious AEs
The following SAE summaries and listings will be prepared.  Summaries will be presented by 
treatment group:
 By SOC and PT
 Causally related to study treatment by SOC and PT
 Listing of key information
Discontinuation
AEs leading to discontinuation of study treatment will be summarised by SOC and PT.  In 
addition, AEs leading to discontinuation of study treatment, causally related to study treatment 
will be summarised by SOC and PT.  Details of AEs leading to discontinuation will be 
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Listings
By-patient listings will be produced as following:
 A by-patient listing of AEs, including flags for AESIs
 A by-patient listing of AEs causally related to olaparib
 A by-patient listing of SAEs
 A by-patient listing of AEs with CTCAE grade 3 or higher (separately for causally 
related to olaparib)
 A by-patient listing of AEs leading to dose reduction or dose interruption
 A by-patient listing of AEs presenting any events that occur prior to dosing or 
starting more than 30 days after discontinuing therapy
Laboratory assessments
Laboratory data is collected by local laboratories. Results will be converted to standard units 
for reporting purposes. Reference ranges from the local laboratories are collected in the CRF 
and will be used to determine reference range indicators (low, normal, high). If the same 
parameter is found as measured in serum and in plasma, then the summaries will not 
distinguish between them (e.g. values from plasma Albumin and serum Albumin will be 
summarised under Albumin). If the same parameter is found as measured in serum and in
plasma within the same patient, which would be a rare case, then the change from baseline 
will only be calculated for those post-baseline values using the same source, i.e. only within 
plasma or serum. If one patient has multiple toxicity grades, because they are derived 
separately from serum and plasma, then the maximum value of the two will be considered.
For all continuous laboratory assessments, absolute value, change from baseline and 
percentage change from baseline will be summarised using descriptive statistics at each 
scheduled assessment time by actual treatment group.
Shift tables for laboratory values (excluding electrolytes) from baseline to worst value on-
treatment categorized using the common toxicity criteria (CTC) grading based on local 
reference ranges will be produced. On-treatment is defined as data collected up until the last 
dose of olaparib/placebo. For parameters with no CTC grading, shift tables from baseline to 
worst value on-treatment will be provided using normal ranges for categorization. Shift tables 
for urinalysis values from baseline to worst grade on-treatment will also be provided. 
Box-plots of absolute values for continuous laboratory assessments will be presented, with AZ 
project defined reference ranges indicated.
A scatter plot of alanine aminotransferase (ALT) versus total bilirubin, both expressed as 





Date 14 December 2018
71
for ALT, and 2×ULN for total bilirubin. The scatter plot will be repeated for aspartate 
aminotransferase (AST) versus total bilirubin with reference lines at 3×ULN for AST, and 
2×ULN for total bilirubin. In each plot, total bilirubin will be in the vertical axis.
Liver biochemistry test results over time for patients who show elevated ALT or aspartate 
aminotransferase (AST) (≥3xULN) and elevated total bilirubin (≥ 2xULN) (elevated results 
do not need to be present at the same visit), or a total bilirubin of ≥ 5xULN will be tabulated 
and plotted.
All laboratory summaries and listings will be presented by actual treatment group.
By-patient listings of laboratory assessments will be provided showing at least: laboratory 
parameters, actual time point, measurements/results, CTC grade (if available), and the change 
from baseline value (for continuous data) (if appropriate).  In addition a flag will indicate if 
the value was out of normal range, if appropriate:




 Individual patient data with elevated ALT or AST plus total bilirubin
 Pregnancy report data
Electrocardiograms
If available, overall evaluation of ECG will be summarised by visit as normal, abnormal or 
borderline. 
All ECG data will be listed by actual treatment group.
Vital signs
Vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate, body 
temperature and weight) will be summarised by time point in terms of absolute values, 
changes from baseline and percentage changes from baseline at each scheduled measurement 
by actual treatment group.  A shift table comparing baseline to maximum value on treatment 
will be summarised for SBP, DBP and pulse rate by actual treatment group, using the 
following normal ranges: SBP = 100 - 160 mmHg; DBP = 60 - 95 mmHg; pulse rate = 55 - 95 
bpm.
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Vital signs data will be listed.
Other
 Any concomitant procedures patients experiencing during the study will be listed in 
a by-patient listing
 Patients experiencing a Hy’s Law incident will be tabulated and details will be 
included in by-patient listings.  Hy’s Law incidents are those cases where a patient 
shows an AST or ALT ≥ 3xULN or total bilirubin ≥ 2xULN.  Please refer to 
Appendix D of the CSP for further instructions.
4.2.14 Demographic and baseline characteristics data
The following will be listed and summarised by randomised treatment group using the FAS 
analysis set:
 Listing of patients receiving the various batches of investigational product
 Listing of randomisation scheme and codes
 Patient disposition (including screening failures and reason for screening failure, 
reasons for patients prematurely withdrawing from study, patients with a mis-
randomisation [treatment dispensing error] and patients who were unblinded, 
discontinuation of study treatment), to be repeated also for Myriad confirmed 
gBRCAm subgroup
 Important deviations including patients with a dispensing error and the number of 
patients received at least one dose of the wrong study treatment (see Section 2.2)
 Inclusion and exclusion from analysis populations; exclusions from full, safety and 
PRO analysis set
 Demographics (age in years, age group in years (<35, 35 to 44, 45 to 54, 55 to 64, 
65 to 74, 75 to 84, >= 85), sex, race, and ethnicity), to be repeated also for Myriad 
confirmed gBRCAm subgroup
 Patient characteristics (baseline height [cm], baseline weight [kg], baseline body 
mass index [BMI] [kg/m²], weight group [< 70 kg, 70 kg to 90 kg, > 90 kg], BMI 
group [Normal (< 25), Overweight (25 - 30), Obesity (> 30)]), to be repeated also 
for Myriad confirmed gBRCAm subgroup
 Patient recruitment by country and centre
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 Disallowed concomitant medications on entry and during the study (defined at the 
BDRM)
 Disease characteristics at baseline including BRCA testing (local and Myriad, 
including a comparison of local versus Myriad results) and pathology at time of 
diagnosis, to be repeated also for Myriad confirmed gBRCAm subgroup
 Extent of disease
 Disease related medical history per CRF
 Relevant surgical history per CRF
 Pregnancy at baseline (entry)
 Physical examination at baseline (entry)
 Archival paraffin embedded tumour tissue or cytology sample
 Blood transfusion
 Previous radiotherapy and radiotherapy post randomisation (including current and 
subsequent radiotherapy)
 Post-discontinuation cancer therapy, defined as any therapy received after 
discontinuation of study treatment
 Patients who subsequently received a PARP inhibitor or entered a PARP inhibitor 
trial will be summarised and listed by treatment group according to line of 
subsequent therapy, ie, immediately after olaparib or as a later line, in addition to 
patients in the placebo arm who subsequently received olaparib
 Previous disease-related treatment modalities (metastatic pancreas cancer therapy)
 Previous non-disease-related treatment modalities
 Initial vomiting and nausea data will be listed only
WHO drug dictionary will be used for concomitant medication coding.
Patients who were unblinded (a) prior to disease progression and (b) prior to or on the day of 
treatment discontinuation will be listed.
4.2.15 Treatment exposure
The following summaries related to study treatment will be produced for the Safety Analysis 





Date 14 December 2018
74
 Total exposure of olaparib/placebo
 Actual exposure of olaparib/placebo
 Number of days on 300 mg olaparib/placebo bid = actual exposure for the dose 
assigned
 Reasons for dose reductions, dose interruptions, and dose modifications of 
olaparib/placebo.  Dose reductions and dose interruptions will be based on 
investigator initiated dosing decisions.  Dose interruptions/reductions due to 
“Subject Forgot to Take Dose” will be omitted from these summaries
 Number of dose reductions, dose interruptions, and dose modifications of 
olaparib/placebo that last for a period of three days or more
 PID and RDI of olaparib/placebo (entire intended treatment period)
 Mean total daily dose per time period
For patients on study treatment at the time of the PFS analysis, the DCO date will be used to 
calculate exposure.
Treatment compliance will be summarised by treatment group using descriptive statistics.  
Tabulation will be presented by actual treatment group.
All treatment information data will be listed:
 Study treatment compliance
 Administration of investigational product
 Duration of exposure
 Overdose report
5. INTERIM ANALYSES
A single interim PFS analysis for futility will be performed when 50% of the PFS events 
required for the final PFS analysis have occurred (approximately 44 PFS events) based on 
BICR.  The interim analysis will be performed by an Independent Data Management 
Committee (IDMC) and full details will be provided in the IDMC charter.  Safety data 
including death rates will also be reviewed at this time.
The futility assessment will be based on the probability of eventually showing statistical 
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(Lachin 2005).  The determination of this probability will be conditional on the observed data 
at the time of the interim analysis and on the assumed hazard ratio for the alternative 
hypothesis (PFS HR=0.54).  If the probability is less than 20%, the IDMC will consider the 
option of declaring futility.
The exact figure used for the futility boundary will be calculated by AstraZeneca and sent to 
the IDMC at the time of the interim analysis, based on the number of events which have 
occurred at that time.  As an example, if exactly 50% of the PFS events required for the 
primary PFS analysis have occurred at the time of the interim analysis (44 events), then the 
HR that corresponds to 20% conditional power for the interim analysis will be 1.02.  
Therefore, if the observed HR for PFS at the interim is more than 1.02, the IDMC will 
consider the option of declaring futility.
An interim analysis of OS will be performed at the time of the final analyses of PFS (~87 PFS 
events).  A final analysis of OS will be performed when approximately 106 OS events have 
occurred.
6. CHANGES OF ANALYSIS FROM PROTOCOL
The definition of the Patient Reported Outcome analysis set has been changed in order to add 
clarification. The previous definition required a patient to have “evaluable baseline EORTC 
QLQ-C30 and QLQ-PAN26 forms”. Now it has been decided to specify this in more detail by 
saying that it must be possible to determine at least one sub-scale baseline score from at least 
one of the two forms.
Analysis of time to sustained clinically meaningful deterioration in HRQoL has been added.
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APPENDIX
Appendix A: Study Flow Chart
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Appendix C: Study Schedule






















Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d
Informed consent X X
Randomisation f X f
Demographics X X
Medical and surgical history, 
including blood transfusions a
X
Prior cancer therapies 
including radiotherapy
X
Inclusion/exclusion criteria X (all * 
criteria) b
X
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d
Archival paraffin embedded 
tumour tissue or cytology 
sample e
X X
Concomitant medications X X X X X X X X X
ECOG performance status X X X X X
Vital signs X g X  
g
X X X X
Physical examination h X X X X X
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Cycle/ Visit 1 (28 days) 2 3+ 
(every 
28 days)
Day -28 to 0 1 8 15 22 29 57+ Every 8 
weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d










Every 8 weeks (± 1 week) until week 40 
then every 12 weeks (±1 week), relative to 
the date of randomisation j
If patient 
does not have 
disease 
progression 











X X  
l
X X X X
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a Include history of blood transfusion within previous 120 days from start of study treatment and the reasons eg, bleeding or myelosuppression.
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c Patients must have a known deleterious or suspected deleterious BRCA mutation to be randomised to the study; this can be either a local lab result or a 
Myriad test result.  Patients for whom their gBRCA status is already known, should be consented to the study within 28 days prior to day 1 of study 
treatment.  Any patient who consents to study related Myriad gBRCA status testing, must also have a blood sample taken at the same time for the 
purpose of developing and validating a future diagnostic test(s) for gBRCA mutations.
d Samples to be taken on Day 1 only for patients with known gBRCA mutation who have not completed PART 1 Screening.  The screening gBRCA test 
and method performed at site must be recorded in the eCRF.
e Collection of an archival tumour sample is requested, if available, for all patients.  These samples will be collected from the site pathologist during the 
screening Part 1 for patients with unknown gBRCA status and screening Part 2 for patients with known local gBRCA test.
f Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last treatment) and treatment started as soon 
as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous 
chemotherapy treatment should be discontinued.
g Vital signs performed on day 1 before every cycle.  If vital signs assessed within 7 days before starting study treatment, it does not need to be repeated 
on Day 1 of study treatment unless investigator believes that it is likely to have changed significantly. 
h Physical examination should be performed according to the schedule.  After the baseline assessment it is not necessary to record the details on the eCRF, 
any clinically significant changes not unequivocally related to disease progression, should be reported as adverse events.
i ECG assessments to be completed within 14 days before starting treatment if patient is eligible following completion of all other PART 2 assessments.  
After screening, ECGs will only be required if clinically indicated.
j Baseline RECIST assessments will be performed using CT scans of the chest, abdomen and pelvis (or MRI where CT is contraindicated) and should be 
performed no more than 28 days before start of study treatment and as close as possible to randomisation.  A randomisation must be within 6 weeks of 
last chemotherapy.  Treatment should be started as soon as possible but no less than 4 weeks and no more than 8 weeks after their last dose of 
chemotherapy.  RECIST follow-up assessments will be performed every 8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) 
irrespective of treatment decisions.  Follow-up assessment will include CT assessments of chest, abdomen and pelvis (or MRI where CT is 
contraindicated) for all patients.  Any other sites at which new disease is suspected should also be appropriately imaged.  Patients must be followed until 
disease progression assessed using modified RECIST criteria.  If an unscheduled assessment was performed and the patient has not progressed, every 
attempt should be made to perform the subsequent assessments at their scheduled visits.  Prior to primary analysis for PFS, all scans will be submitted 
for independent review.  If progression is not confirmed at central review an additional RECIST assessment will be requested at the next scheduled visit.
k For patients who discontinue study treatment prior to disease progression, RECIST assessments will continue until objective disease progression (every 
8 weeks (±1 week) for the first 40 weeks, then every 12 weeks (±1 week) relative to date of randomisation, until objective disease progression as defined 
by modified RECIST.).
l Haematology and clinical chemistry should be performed at screening and day 1 of every cycle.  Safety blood samples do not need to be repeated on Day 
1 of study treatment if assessed at least 3 weeks after the last dose of chemotherapy but within 7 days before starting study treatment, unless the 
investigator believes that it is likely to have changed significantly.  
m Coagulation test should be performed at screening and if clinically indicated. 
n Urinalysis should be performed at screening.  After screening, urinalysis will only be required if clinically indicated. 
o In the event of suspected pregnancy during the study, the test should be repeated and, if positive, the patient discontinued from study treatment 
immediately.
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q Questionnaires to be completed prior to randomisation once eligibility has been confirmed and then until objective radiological disease progression, at 
discontinuation of study treatment visit and then 30 days post last dose.  Questionnaires should be completed prior to dosing on all administrations.
r Adverse events must be captured from time of consent. Only SAE’s related to blood sampling for the Myriad gBRCA test will be collected at this visit.
s Continuous Olaparib 300mg/ placebo twice daily dosing.  Sufficient study treatment should be dispensed for at least each treatment period plus overage, 
however additional treatment can be dispensed to patients to last longer in accordance with local practice. 
t All anti-cancer treatments (including, but not limited to, chemotherapy and targeted agents), and the Investigator’s opinion of response to them, plus the 
date of progression post discontinuation of study treatment, need to be recorded. 
u Second disease progression (PFS2) assessment will be performed by the Investigator and defined according to local standard clinical practice and may 
involve any of; objective radiological or symptomatic progression or death.  Subsequent therapy will be collected for these patients from the time of 
treatment discontinuation.
v The status of ongoing, withdrawn (from the study) and ‘lost to follow-up’ patients at the time of an OS analysis should be obtained by the site  personnel 
by checking the patients notes, hospital records, contacting the patient’s general practitioner and checking publicly available death registries.  In the 
event that the patient has actively withdrawn consent to the processing of their personal data the vital status of the patient can be obtained by site 
personnel from publicly available resources where it is possible to do so under applicable local laws (see Section 3.10 of the CSP).  In addition to their 
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Appendix D: Visualisation of Censoring Rule for Progression Free Survival
